<SEC-DOCUMENT>0001104659-24-071811.txt : 20240614
<SEC-HEADER>0001104659-24-071811.hdr.sgml : 20240614
<ACCEPTANCE-DATETIME>20240614164930
ACCESSION NUMBER:		0001104659-24-071811
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		6
FILED AS OF DATE:		20240614
DATE AS OF CHANGE:		20240614

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Rezolute, Inc.
		CENTRAL INDEX KEY:			0001509261
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				273440894
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-275562
		FILM NUMBER:		241045614

	BUSINESS ADDRESS:	
		STREET 1:		275 SHORELINE DRIVE, SUITE 500
		CITY:			REDWOOD CITY
		STATE:			CA
		ZIP:			94065
		BUSINESS PHONE:		650-206-4507

	MAIL ADDRESS:	
		STREET 1:		275 SHORELINE DRIVE, SUITE 500
		CITY:			REDWOOD CITY
		STATE:			CA
		ZIP:			94065

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AntriaBio, Inc.
		DATE OF NAME CHANGE:	20130114

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	FITS MY STYLE INC
		DATE OF NAME CHANGE:	20110104
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>tm2416818-4_424b5.htm
<DESCRIPTION>424B5
<TEXT>
<html>
  <head>
    <title>tm2416818-4_424b5 - none - 7.3906642s</title>
  </head>
  <body style="margin-left:auto;margin-right:auto;width:595.31pt;">
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:27.85pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:right; width:456pt; line-height:9.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;">
          <font style="letter-spacing:0.475pt;">&#8202;Filed Pursuant to Rule&#160;424(b)(5)</font>&#8203;</div>
        <div style="text-align:right; width:456pt; line-height:9.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;">
          <font style="letter-spacing:0.475pt;">&#8202;Registration No. 333-275562</font>&#8203;</div>
        <div style="margin-top:7.2pt; width:456pt; line-height:11.5pt;font-family:Arial Narrow, Helvetica, sans-serif;">
          <font style="font-weight:bold;letter-spacing:0.475pt;">PROSPECTUS SUPPLEMENT</font> <br ><font style="font-family:Arial, Helvetica, sans-serif;">(To Prospectus dated November&#160;29, 2023)</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="position:relative;margin-top:9.7pt; text-align:center; width:456pt;">
          <img src="lg_rezolute-4clr.jpg" alt="[MISSING IMAGE: lg_rezolute-4clr.jpg]" height="48" width="259" >
        </div>
        <div style="margin-top:11.2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.361pt;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;</font>
        </div>
        <div style="margin-top:3pt; text-align:center; width:456pt; line-height:18pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:16pt;">
          <font style="letter-spacing:0.8pt;">11,250,000 Shares of Common Stock</font>
          <br >
          <font style="letter-spacing:0.8pt;">and</font>
          <br >
          <font style="letter-spacing:0.8pt;">3,750,000 Pre-Funded Warrants to Purchase Shares of </font>
          <br >
          <font style="letter-spacing:0.8pt;">Common Stock</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.32pt;"> </font>
        </div>
        <div style="margin-top:3pt; width:456pt; line-height:11.5pt;">We are offering <font style="letter-spacing:-0.361pt;">11,250,000 </font>shares of our common stock, par value $0.001 per share (&#8220;<font style="font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;letter-spacing:0.475pt;">common stock</font>&#8221;) and in lieu of common stock to certain investors that choose, <font style="letter-spacing:-0.361pt;">3,750,000 </font>pre-funded warrants (the &#8220;<font style="font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;letter-spacing:0.475pt;">Pre-Funded Warrants</font>&#8221;) to purchase shares of common stock, pursuant to this prospectus supplement and the accompanying prospectus. The purchase price of each Pre-Funded Warrant will equal the price per share of common stock being sold to the public in this offering, minus $0.001, and the exercise price of each Pre-Funded Warrant will be $0.001. This prospectus supplement also relates to the offering of shares of our common stock issuable upon the exercise of the Pre-Funded Warrants (the &#8220;<font style="font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;letter-spacing:0.475pt;">Pre-Funded Warrant Shares</font><font style="letter-spacing:-0.361pt;">&#8221;).</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">Our common stock is traded on the Nasdaq Capital Market, or Nasdaq, under the symbol &#8220;RZLT.&#8221; On June&#160;<font style="letter-spacing:-0.361pt;">13, </font>2024, the last reported sale price of our common stock on Nasdaq was $5.<font style="letter-spacing:-0.361pt;">16</font>. We do not intend to list the Pre-Funded Warrants on Nasdaq or any other national securities exchange or any other nationally recognized trading system.<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="margin-top:8pt; width:456pt; line-height:11.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;">
          <font style="letter-spacing:0.475pt;">Investing in our securities involves substantial risks. See &#8220;</font><font style="font-style:italic;letter-spacing:0.475pt;">Risk Factors</font><font style="letter-spacing:0.475pt;">&#8221; beginning on page <a href="#sRIFA">S-13</a>, and under similar headings in the other documents that are incorporated by reference into this prospectus supplement and the accompanying prospectus.</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <table style="width:456pt;margin-top:5.5pt;border-collapse: collapse;border-top:0.75pt solid #000000; border-bottom:0.75pt solid #000000; font-style:normal;font-weight:bold;font-variant:normal;text-transform:uppercase;color:#000000;font-family:Arial Narrow, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial Narrow, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:24pt;">&#8203;</td>
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:231.83pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:4.833pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="text-transform:uppercase;letter-spacing:0.4pt;">PER SHARE </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:4.833pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="text-transform:uppercase;letter-spacing:0.4pt;">PER </font>
                <br >
                <font style="text-transform:uppercase;letter-spacing:0.4pt;">PRE-FUNDED</font>
                <br >
                <font style="text-transform:uppercase;letter-spacing:0.4pt;">WARRANT </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:4.833pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="text-transform:uppercase;letter-spacing:0.4pt;">TOTAL </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:24pt;">&#8203;</td>
          </tr>
          <tr style="line-height:7.97999999999996pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt; width:24pt;">&#8203;</td>
            <td style="padding:2.763pt 0pt 1.597pt 0pt; width:231.83pt;text-align:left;">
              <div style="white-space:nowrap;">Public offering price </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.68pt;width:0pt;">&#8203;</td>
            <td style="padding:2.763pt 0pt 1.597pt 0pt; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:2.763pt 0pt 1.597pt 0pt; min-width:12.75pt; text-align:right; white-space:nowrap;">4.00 </td>
            <td style="padding:0pt;padding-left:7.68pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.565pt;width:0pt;">&#8203;</td>
            <td style="padding:2.763pt 0pt 1.597pt 0pt; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:2.763pt 0pt 1.597pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">3.999</td>
            <td style="padding:0pt;padding-left:2.565pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.763pt 0pt 1.597pt 0pt; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:2.763pt 0pt 1.597pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">59,996,250.00</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:24pt;">&#8203;</td>
          </tr>
          <tr style="line-height:7.97999999999996pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt; width:24pt;">&#8203;</td>
            <td style="padding:2.013pt 0pt 1.597pt 0pt; width:231.83pt;text-align:left;">
              <div style="white-space:nowrap;">Underwriting discounts and commissions paid by us </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.68pt;width:0pt;">&#8203;</td>
            <td style="padding:2.013pt 0pt 1.597pt 0pt; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:2.013pt 0pt 1.597pt 0pt; min-width:12.75pt; text-align:right; white-space:nowrap;">0.24 </td>
            <td style="padding:0pt;padding-left:7.68pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.565pt;width:0pt;">&#8203;</td>
            <td style="padding:2.013pt 0pt 1.597pt 0pt; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:2.013pt 0pt 1.597pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">0.23994</td>
            <td style="padding:0pt;padding-left:2.565pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.013pt 0pt 1.597pt 0pt; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:2.013pt 0pt 1.597pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">3,599,775.00</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:24pt;">&#8203;</td>
          </tr>
          <tr style="line-height:7.97999999999996pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt;border-bottom:0.75pt solid #000000; ; width:24pt;">&#8203;</td>
            <td style="border-bottom:0.75pt solid #000000; ;padding:2.013pt 0pt 12pt 0pt; width:231.83pt;text-align:left;">
              <div style="white-space:nowrap;">Proceeds to us, before expenses </div>
            </td>
            <td style="padding:0pt;border-bottom:0.75pt solid #000000; ; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:0.75pt solid #000000; ; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.68pt;width:0pt;border-bottom:0.75pt solid #000000; ;">&#8203;</td>
            <td style="padding:2.013pt 0pt 12pt 0pt;border-bottom:0.75pt solid #000000; ; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:2.013pt 0pt 12pt 0pt;border-bottom:0.75pt solid #000000; ; min-width:12.75pt; text-align:right; white-space:nowrap;">3.76 </td>
            <td style="padding:0pt;padding-left:7.68pt;width:0pt;border-bottom:0.75pt solid #000000; ;">&#8203;</td>
            <td style="padding:0pt;border-bottom:0.75pt solid #000000; ; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:0.75pt solid #000000; ; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.565pt;width:0pt;border-bottom:0.75pt solid #000000; ;">&#8203;</td>
            <td style="padding:2.013pt 0pt 12pt 0pt;border-bottom:0.75pt solid #000000; ; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:2.013pt 0pt 12pt 0pt;border-bottom:0.75pt solid #000000; ; min-width:19.5pt; text-align:right; white-space:nowrap;">3.759</td>
            <td style="padding:0pt;padding-left:2.565pt;width:0pt;border-bottom:0.75pt solid #000000; ;">&#8203;</td>
            <td style="padding:0pt;border-bottom:0.75pt solid #000000; ; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:0.75pt solid #000000; ; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:0.75pt solid #000000; ;">&#8203;</td>
            <td style="padding:2.013pt 0pt 12pt 0pt;border-bottom:0.75pt solid #000000; ; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:2.013pt 0pt 12pt 0pt;border-bottom:0.75pt solid #000000; ; min-width:34.5pt; text-align:right; white-space:nowrap;">56,396,475.00</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:0.75pt solid #000000; ;">&#8203;</td>
            <td style="padding:0pt;border-bottom:0.75pt solid #000000; ; width:24pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:-0.44pt; width:456pt;">
          <div style="margin-left: 0pt; width: 456pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-size:7pt;">
          <font style=" position:relative; bottom:2.75pt;font-size:5.5pt;letter-spacing:-0.209pt;">(1)</font>
          <br >
        </div>
        <div style=" margin-top:4.7pt; margin-bottom:0pt; line-height:8.3pt; text-align:left; margin-left:20pt;font-size:7pt;">
          <!--blacklining:none;-->See &#8220;<font style="font-style:italic;">Underwriting</font>&#8221; for a full description of compensation payable to the underwriters in connection with this offering and estimated offering expenses.<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.14pt;"> </font></div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">We have granted the underwriters an option for a period of 30&#160;days from the date of this prospectus supplement to purchase up to an additional <font style="letter-spacing:-0.361pt;">2,250,000</font> shares of common stock at the public offering price set forth above, less the underwriting discount and commissions paid by us.<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">The underwriters expect to deliver the securities against payment on or about June&#160;<font style="letter-spacing:-0.361pt;">17</font>, 2024 through the book-entry facilities of The Depository Trust Company.<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="margin-top:8pt; width:456pt; line-height:11.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;">
          <font style="letter-spacing:0.475pt;">Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus supplement or the accompanying prospectus. Any representation to the contrary is a criminal offense.</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:4pt; text-align:center; width:456pt; line-height:12pt;font-style:italic;">Lead Bookrunning Managers<font style="font-style:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="margin-top:4pt; width:456pt; line-height:18.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:16pt;">
          <font style="letter-spacing:0.8pt;">&#8199;</font><font style="margin-left:113.48pt;letter-spacing:0.8pt;">Jefferies</font><font style="margin-left:113.48pt;letter-spacing:0.8pt;">Cantor&#8199;</font><font style="float:right;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.32pt;"> </font>
        </div>
        <div style="margin-top:4pt; text-align:center; width:456pt; line-height:12pt;font-style:italic;">Co-Managers<font style="font-style:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="margin-top:8pt; width:456pt; line-height:14.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:12pt;">
          <font style="letter-spacing:0.6pt;">BTIG</font><font style="margin-left:36.39pt;"><font style="letter-spacing:0.6pt;">Craig-Hallum</font>
          </font><font style="margin-left:36.39pt;"><font style="letter-spacing:0.6pt;">H.C. Wainwright &amp; Co.</font>
          </font><font style="margin-left:36.39pt;"><font style="letter-spacing:0.6pt;">Jones</font>
          </font><font style="float:right;"><font style="letter-spacing:0.6pt;">Maxim Group LLC</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.24pt;"> </font>
          </font>
        </div>
        <div style="margin-top:51.03pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;">
          <font style="letter-spacing:0.475pt;">The date of this prospectus supplement is June 13, 2024</font>
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="TOC">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:12.5pt;">
          <font style="letter-spacing:0.625pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:140pt;margin-left:69.66pt;width:456pt;">
        <table style="width:456pt;margin-top:0pt;border-collapse: collapse;border-top:0.75pt solid #000000; border-bottom:0.75pt solid #000000; font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial Narrow, Helvetica, sans-serif;font-size:10pt;">
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial Narrow, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:11.5pt 0pt 0.5pt 0pt; width:423pt;">
              <font style="letter-spacing:0.5pt;">Table of Contents</font><font style="font-size:9.5pt;">&#8203;</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial Narrow, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:9pt 0pt 1.5pt 0pt; width:423pt;">
              <font style="letter-spacing:0.475pt;">Prospectus Supplement </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; width:423pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#sATPS"><font style="letter-spacing:-0.361pt;">ABOUT THIS PROSPECTUS SUPPLEMENT </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.215pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.361pt;"><a href="#sATPS">S-1</a></font> <a href="#sATPS"></a></td>
            <td style="padding:0pt;padding-left:0.215pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; width:423pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#sFOST"><font style="letter-spacing:-0.361pt;">FORWARD-LOOKING STATEMENTS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.215pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.361pt;"><a href="#sFOST">S-2</a></font> <a href="#sFOST"></a></td>
            <td style="padding:0pt;padding-left:0.215pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; width:423pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#sPSS"><font style="letter-spacing:-0.361pt;">PROSPECTUS SUPPLEMENT SUMMARY </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.215pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.361pt;"><a href="#sPSS">S-3</a></font> <a href="#sPSS"></a></td>
            <td style="padding:0pt;padding-left:0.215pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; width:423pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#sTHOF"><font style="letter-spacing:-0.361pt;">THE OFFERING </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.215pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.361pt;"><a href="#sTHOF">S-11</a></font> <a href="#sTHOF"></a></td>
            <td style="padding:0pt;padding-left:0.215pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; width:423pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#sRIFA"><font style="letter-spacing:-0.361pt;">RISK FACTORS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.215pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.361pt;"><a href="#sRIFA">S-13</a></font> <a href="#sRIFA"></a></td>
            <td style="padding:0pt;padding-left:0.215pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; width:423pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#sUOP"><font style="letter-spacing:-0.361pt;">USE OF PROCEEDS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.215pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.361pt;"><a href="#sUOP">S-16</a></font> <a href="#sUOP"></a></td>
            <td style="padding:0pt;padding-left:0.215pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; width:423pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#sDIF1"><font style="letter-spacing:-0.361pt;">DILUTION </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.215pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.361pt;"><a href="#sDIF1">S-17</a></font> <a href="#sDIF1"></a></td>
            <td style="padding:0pt;padding-left:0.215pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; width:423pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#sDOS"><font style="letter-spacing:-0.361pt;">DESCRIPTION OF SECURITIES </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.215pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.361pt;"><a href="#sDOS">S-19</a></font> <a href="#sDOS"></a></td>
            <td style="padding:0pt;padding-left:0.215pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:1.333pt 0pt 0.667pt 0pt; width:423pt;white-space:normal;text-align:left;">
              <div style="margin-left:9.5pt; text-indent:-9.5pt;">
                <a href="#sMUTC"><font style="letter-spacing:-0.361pt;">MATERIAL U.S. TAX CONSIDERATIONS FOR NON-U.S. HOLDERS OF COMMON STOCK AND PRE-FUNDED WARRANTS. </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.215pt;width:0pt;">&#8203;</td>
            <td style="padding:1.333pt 0pt 0.667pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.333pt 0pt 0.667pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.361pt;"><a href="#sMUTC">S-21</a></font> <a href="#sMUTC"></a></td>
            <td style="padding:0pt;padding-left:0.215pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; width:423pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#sUNF1"><font style="letter-spacing:-0.361pt;">UNDERWRITING </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.215pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.361pt;"><a href="#sUNF1">S-26</a></font> <a href="#sUNF1"></a></td>
            <td style="padding:0pt;padding-left:0.215pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; width:423pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#sLEMA"><font style="letter-spacing:-0.361pt;">LEGAL MATTERS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.215pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.361pt;"><a href="#sLEMA">S-34</a></font> <a href="#sLEMA"></a></td>
            <td style="padding:0pt;padding-left:0.215pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; width:423pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#sEXF1"><font style="letter-spacing:-0.361pt;">EXPERTS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.215pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.361pt;"><a href="#sEXF1">S-34</a></font> <a href="#sEXF1"></a></td>
            <td style="padding:0pt;padding-left:0.215pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; width:423pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#sWYCF"><font style="letter-spacing:-0.361pt;">WHERE YOU CAN FIND ADDITIONAL INFORMATION </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.215pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.361pt;"><a href="#sWYCF">S-35</a></font>
            </td>
            <td style="padding:0pt;padding-left:0.215pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial Narrow, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:9pt 0pt 1.5pt 0pt; width:423pt;">
              <font style="letter-spacing:0.475pt;">Base Prospectus </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; width:423pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tATP"><font style="letter-spacing:-0.361pt;">ABOUT THIS PROSPECTUS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.215pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.361pt;"><a href="#tATP">1</a></font> <a href="#tATP"></a></td>
            <td style="padding:0pt;padding-left:0.215pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; width:423pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tSNRF"><font style="letter-spacing:-0.361pt;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.215pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.361pt;"><a href="#tSNRF">2</a></font> <a href="#tSNRF"></a></td>
            <td style="padding:0pt;padding-left:0.215pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; width:423pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tTHCO"><font style="letter-spacing:-0.361pt;">THE COMPANY </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.215pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.361pt;"><a href="#tTHCO">3</a></font> <a href="#tTHCO"></a></td>
            <td style="padding:0pt;padding-left:0.215pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; width:423pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tRIFA"><font style="letter-spacing:-0.361pt;">RISK FACTORS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.215pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.361pt;"><a href="#tRIFA">7</a></font> <a href="#tRIFA"></a></td>
            <td style="padding:0pt;padding-left:0.215pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; width:423pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tUOP"><font style="letter-spacing:-0.361pt;">USE OF PROCEEDS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.215pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.361pt;"><a href="#tUOP">10</a></font> <a href="#tUOP"></a></td>
            <td style="padding:0pt;padding-left:0.215pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; width:423pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tDODS"><font style="letter-spacing:-0.361pt;">DESCRIPTION OF DEBT SECURITIES </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.215pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.361pt;"><a href="#tDODS">11</a></font> <a href="#tDODS"></a></td>
            <td style="padding:0pt;padding-left:0.215pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; width:423pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tDOCS"><font style="letter-spacing:-0.361pt;">DESCRIPTION OF CAPITAL STOCK </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.215pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.361pt;"><a href="#tDOCS">18</a></font> <a href="#tDOCS"></a></td>
            <td style="padding:0pt;padding-left:0.215pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; width:423pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tDOW"><font style="letter-spacing:-0.361pt;">DESCRIPTION OF WARRANTS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.215pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.361pt;"><a href="#tDOW">20</a></font> <a href="#tDOW"></a></td>
            <td style="padding:0pt;padding-left:0.215pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; width:423pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tDOPC"><font style="letter-spacing:-0.361pt;">DESCRIPTION OF PURCHASE CONTRACTS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.215pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.361pt;"><a href="#tDOPC">26</a></font> <a href="#tDOPC"></a></td>
            <td style="padding:0pt;padding-left:0.215pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; width:423pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tDODS1"><font style="letter-spacing:-0.361pt;">DESCRIPTION OF DEPOSITARY SHARES </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.215pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.361pt;"><a href="#tDODS1">27</a></font> <a href="#tDODS1"></a></td>
            <td style="padding:0pt;padding-left:0.215pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; width:423pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tPOD"><font style="letter-spacing:-0.361pt;">PLAN OF DISTRIBUTION </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.215pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.361pt;"><a href="#tPOD">31</a></font> <a href="#tPOD"></a></td>
            <td style="padding:0pt;padding-left:0.215pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; width:423pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tWYCF"><font style="letter-spacing:-0.361pt;">WHERE YOU CAN FIND MORE INFORMATION </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.215pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.361pt;"><a href="#tWYCF">35</a></font> <a href="#tWYCF"></a></td>
            <td style="padding:0pt;padding-left:0.215pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; width:423pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tIBR"><font style="letter-spacing:-0.361pt;">INCORPORATION BY REFERENCE </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.215pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.361pt;"><a href="#tIBR">35</a></font> <a href="#tIBR"></a></td>
            <td style="padding:0pt;padding-left:0.215pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; width:423pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tLEMA"><font style="letter-spacing:-0.361pt;">LEGAL MATTERS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.215pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.361pt;"><a href="#tLEMA">37</a></font> <a href="#tLEMA"></a></td>
            <td style="padding:0pt;padding-left:0.215pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:0pt;border-bottom:0.75pt solid #000000; ; width:0pt;">&#8203;</td>
            <td style="border-bottom:0.75pt solid #000000; ;padding:3pt 0pt 12pt 0pt; width:423pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tEXP"><font style="letter-spacing:-0.361pt;">EXPERTS </font></a>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:0.75pt solid #000000; ; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:0.75pt solid #000000; ; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.215pt;width:0pt;border-bottom:0.75pt solid #000000; ;">&#8203;</td>
            <td style="padding:3pt 0pt 12pt 0pt;border-bottom:0.75pt solid #000000; ; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 12pt 0pt;border-bottom:0.75pt solid #000000; ; min-width:22.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.361pt;"><a href="#tEXP">37</a></font>
            </td>
            <td style="padding:0pt;padding-left:0.215pt;width:0pt;border-bottom:0.75pt solid #000000; ;">&#8203;</td>
            <td style="padding:0pt;border-bottom:0.75pt solid #000000; ; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.361pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11pt;font-size:9pt;">S-i<br ></div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="sATPS">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:12.5pt;">
          <font style="letter-spacing:0.625pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:10pt;">
          <font style="text-transform:uppercase;letter-spacing:0.5pt;">ABOUT THIS PROSPECTUS SUPPLEMENT</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:18pt; width:456pt; line-height:12pt;">This prospectus supplement relates to the offering of our common stock and Pre-Funded Warrants. Before buying any of the common stock or Pre-Funded Warrants that we are offering, we urge you to carefully read this prospectus supplement, together with the information incorporated by reference as described under the headings &#8220;<font style="font-style:italic;">Where You Can Find Additional Information</font>&#8221; in the accompanying prospectus, and any free writing prospectus that we have authorized for use in connection with this offering. These documents contain important information that you should consider when making your investment decision.<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">This prospectus supplement describes the terms of this offering of common stock and Pre-Funded Warrants and also adds to and updates information contained in the documents incorporated by reference into this prospectus supplement. To the extent there is a conflict between the information contained in this prospectus supplement, on the one hand, and the information contained in any document incorporated by reference into this prospectus supplement that was filed with the Securities and Exchange Commission, or SEC, before the date of this prospectus supplement, on the other hand, or the information contained in any free writing prospectus prepared by us or on our behalf that we have authorized for use in connection with this offering, you should rely on the information in this prospectus supplement. If any statement in one of these documents is inconsistent with a statement in another document having a later date for example, a document incorporated by reference into this prospectus supplement- the statement in the document having the later date modifies or supersedes the earlier statement.<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">We further note that the representations, warranties and covenants made by us in any agreement that is filed as an exhibit to any document that is incorporated by reference into this prospectus supplement were made solely for the benefit of the parties to such agreement, including, in some cases, for the purpose of allocating risk among the parties to such agreement, and should not be deemed to be a representation, warranty or covenant to you. Moreover, such representations, warranties or covenants were accurate only as of the date when made. Accordingly, such representations, warranties and covenants should not be relied on as accurately representing the current state of our affairs.<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">You should rely only on the information contained in or incorporated by reference into this prospectus supplement and any free writing prospectus prepared by or on our behalf that we have authorized for use in connection with this offering. We have not, and the underwriters have not, authorized any dealer, salesperson or other person to provide any information or to make any representation other than those contained or incorporated by reference into this prospectus supplement or into any free writing prospectus prepared by or on our behalf or to which we have referred you. If anyone provides you with additional, different or inconsistent information, you should not rely on it. We and the underwriters take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. You should assume that the information appearing or incorporated by reference into this prospectus supplement and in any free writing prospectus prepared by or on our behalf that we have authorized for use in connection with this offering is accurate only as of the date of each such respective document. Our business, financial condition, results of operations and prospects may have changed since those dates.<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">The securities offered by this prospectus supplement may not be offered or sold, directly or indirectly, nor may this prospectus supplement or any other offering material in connection with the offer and sale of the securities be distributed or published in any jurisdiction, except under circumstances that will result in compliance with the applicable rules and regulations of that jurisdiction. Persons into whose possession this prospectus supplement comes are advised to inform themselves about and to observe any restrictions relating to this offering and the distribution of this prospectus supplement. This prospectus supplement does not constitute an offer to sell or a solicitation of an offer to buy the securities offered by this prospectus supplement in any jurisdiction in which such an offer or a solicitation is unlawful.<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">Unless stated otherwise or the context otherwise requires, references in this prospectus supplement to &#8220;Rezolute,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; or &#8220;our&#8221; refer to Rezolute, Inc. and our wholly-owned subsidiaries through which we conduct our business. </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.361pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11pt;font-size:9pt;">
          <font style="letter-spacing:-0.342pt;">S-1</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="sFOST">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:12.5pt;">
          <font style="letter-spacing:0.625pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:114pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:10pt;">
          <font style="text-transform:uppercase;letter-spacing:0.5pt;">FORWARD-LOOKING STATEMENTS</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:18pt; width:456pt; line-height:12pt;">This prospectus, and the documents incorporated by reference herein, contain certain &#8220;forward-looking statements&#8221; within the meaning of Section&#160;27A of the Securities Act, Section&#160;21E of the Securities and Exchange Act of 1934, as amended, (the &#8220;<font style="font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;letter-spacing:0.475pt;">Exchange Act</font>&#8221;) and the Private Securities Litigation Reform Act of 1995, and are based on management&#8217;s current expectations. These forward-looking statements can be identified by the use of forward-looking terminology, including, but not limited to, &#8220;believes,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;seek,&#8221; &#8220;see,&#8221; &#8220;confidence,&#8221; &#8220;trends,&#8221; &#8220;intend,&#8221; &#8220;estimate,&#8221; &#8220;on track,&#8221; &#8220;are positioned to,&#8221; &#8220;on course,&#8221; &#8220;opportunity,&#8221; &#8220;continue,&#8221; &#8220;project,&#8221; &#8220;guidance,&#8221; &#8220;target,&#8221; &#8220;forecast,&#8221; &#8220;anticipated,&#8221; &#8220;plan,&#8221; &#8220;potential&#8221; and the negative of these terms or comparable terms. In particular, these include, but are not limited to, statements relating to the following:<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->our ability to obtain regulatory approvals or remove regulatory holds for clinical trials and our drug candidates;</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->expectations regarding clinical development and the timing of clinical trials in the United States and outside the United States;<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->our projected operating or financial results, including anticipated cash flows used in our operating activities;<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->our expectations regarding capital expenditures, research and development expense and other payments;<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->our beliefs and assumptions relating to our liquidity position, including our ability to obtain additional financing;<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->our future dependence on third party manufacturers or strategic partners to manufacture any of our pharmaceutical drugs and diagnostics that receive regulatory approval, and our ability to identify strategic partners and enter into license, co-development, collaboration or similar arrangements; and</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->our anticipated use of proceeds from this offering.</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">Various factors could adversely affect our operations, business or financial results in the future and cause our actual results to differ materially from those contained in the forward-looking statements, including those factors discussed under &#8220;<font style="font-style:italic;">Risk Factors</font>&#8221; on page <font style="letter-spacing:-0.361pt;"><a href="#sRIFA">S-13</a></font> of this prospectus supplement, or otherwise discussed in our Annual Report on Form 10-K for the fiscal year ended June&#160;30, 2023 and in our other filings made from time to time with the SEC after the date of this prospectus.<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">For additional information about factors that could cause actual results to differ materially from those described in the forward-looking statements, please see the documents that we have filed with the SEC, including our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other documents and reports filed from time to time with the SEC.<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">All subsequent forward-looking statements attributable to us or any person acting on our behalf are expressly qualified in their entirety by the cautionary statements contained or referred to in this section. We are not under any obligation to, and expressly disclaim any obligation to, update or alter any forward-looking statements whether as a result of such changes, new information, subsequent events or otherwise.</div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.361pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11pt;font-size:9pt;">
          <font style="letter-spacing:-0.342pt;">S-2</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="sPSS">&#8203;</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:4pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:12.5pt;">
          <font style="letter-spacing:0.625pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;min-height:660pt;margin-left:12pt;width:456pt;">
          <div style="text-align:center; width:456pt; line-height:12.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:10pt;">
            <font style="text-transform:uppercase;letter-spacing:0.5pt;">PROSPECTUS SUPPLEMENT SUMMARY</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="margin-top:18pt; width:456pt; line-height:12.5pt;font-style:italic;">This summary highlights certain information about us, this offering and selected information contained elsewhere in or incorporated by reference into this prospectus supplement. This summary is not complete and does not contain all of the information that you should consider before deciding to invest in our securities. For a more complete understanding of our company and this offering, you should read carefully this entire prospectus supplement, including the information incorporated by reference into this prospectus supplement, and any free writing prospectus prepared by or on our behalf that we have authorized for use in connection with this offering, including the &#8220;Risk Factors&#8221; section beginning on page <a href="#sRIFA">S-13</a> of this prospectus supplement and the other information included in, or incorporated by reference into, this prospectus supplement.<font style="font-style:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
          <div style="margin-top:8pt; width:456pt; line-height:12.5pt;">We are developing transformative therapies for devastating rare and chronic metabolic diseases. Our lead compound, RZ358, is a fully human monoclonal antibody for the treatment of hypoglycemia resulting from excessive secretion of insulin or insulin-like substances such as IGF-2 (&#8220;<font style="font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;letter-spacing:0.475pt;">hyperinsulinism</font>&#8221; or &#8220;<font style="font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;letter-spacing:0.475pt;">HI</font>&#8221;). The antibody counteracts excess insulin receptor activation thereby improving hypoglycemia. We have commenced a global Phase 3 study (&#8220;<font style="font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;letter-spacing:0.475pt;">sunRIZE</font>&#8221;) for congenital HI, an ultra-rare pediatric and genetic form of HI. In addition, through our expanded access program (&#8220;<font style="font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;letter-spacing:0.475pt;">EAP</font>&#8221;), U.S. physician-investigators have been administering RZ358 on a compassionate use basis for the management of hypoglycemia resulting from hyperinsulinism associated with tumors (&#8220;<font style="font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;letter-spacing:0.475pt;">tumor HI</font>&#8221;). We are also developing RZ402, a small molecule selective and potent plasma kallikrein inhibitor (&#8220;<font style="font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;letter-spacing:0.475pt;">PKI</font>&#8221;), as a potential oral therapy for the chronic treatment of diabetic macular edema <font style="letter-spacing:-0.361pt;">(&#8220;</font><font style="font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;letter-spacing:0.475pt;">DME</font><font style="letter-spacing:-0.361pt;">&#8221;).</font></div>
          <div style="margin-top:8pt; width:456pt; line-height:12.5pt;">Our primary objectives for the first half of 2024 are to complete the Phase 2 study for RZ402 to enable announcement of topline results in May 2024, as well as to continue site activation and increase patient enrollment for sunRIZE to enable completion of enrollment by the end of this calendar year.</div>
          <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;">
            <font style="letter-spacing:0.475pt;">RZ358 for congenital hyperinsulinism (&#8220;cHI&#8221;)</font>
          </div>
          <div style="margin-top:6pt; width:456pt; line-height:11.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;">
            <font style="letter-spacing:0.475pt;">cHI</font>
          </div>
          <div style="margin-top:2pt; width:456pt; line-height:12.5pt;">cHI is the most common cause of recurrent and persistent hypoglycemia in children. Individuals with cHI typically present with signs or symptoms of hypoglycemia shortly after birth. Hypoglycemia can result in significant brain injury and death if not recognized and managed appropriately. Additionally, recurrent, or cumulative, hypoglycemia can lead to progressive and irreversible damage over time, including serious and devastating brain injury, seizures, neuro-developmental problems, feeding difficulties, and significant impact on patient and family quality of life. Treatment options for individuals include treatment with diazoxide or glucagon, carbohydrate supplements or off label administration of somatostatin analogues. In cases that are unresponsive to medical management, surgical removal of the pancreas may be required. In those with diffuse disease where the whole pancreas is affected, a near-total pancreatectomy can be undertaken, although ongoing medical treatment of hypoglycemia is generally required for several years after surgery, and patients will eventually develop insulin-dependent diabetes. cHI occurs in one in 28,000 live births in the U.S., and we estimate that in the U.S. alone the addressable market for cHI is more than 1,500 individuals.</div>
          <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;">
            <font style="letter-spacing:0.475pt;">sunRIZE Phase 2b Study</font>
          </div>
          <div style="margin-top:2pt; width:456pt; line-height:12.5pt;">In our Phase 2 RIZE study of RZ358 in patients with cHI ages two and older, nearly all participants achieved significant improvement in hypoglycemia across multiple endpoints, including the primary and key secondary endpoints planned for the sunRIZE study. At doses and exposures planned for sunRIZE, RZ358 was generally safe and well-tolerated, and resulted in median improvements in hypoglycemia of up to ~90% at top doses. Furthermore, a clinically-relevant threshold of <font style="letter-spacing:-0.361pt;">&ge;</font>25% hypoglycemia correction was observed.</div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:-0.361pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11pt;font-size:9pt;">
          <font style="letter-spacing:-0.342pt;">S-3</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:4pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:12.5pt;">
          <font style="letter-spacing:0.625pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:18pt;margin-left:12pt;width:456pt;">
          <div style="position:relative;margin-top:8pt; text-align:center; width:456pt;">
            <img src="lc_exemplary-4clr.jpg" alt="[MISSING IMAGE: lc_exemplary-4clr.jpg]" height="272" width="607" >
          </div>
          <div style="margin-top:14.4pt; width:456pt; line-height:12pt;">sunRIZE is currently not being studied in the U.S. because of partial clinical holds (&#8220;<font style="font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;letter-spacing:0.475pt;">PCHs</font>&quot;) imposed by the FDA&#8217;s Office of Cardiology, Hematology, Endocrinology and Nephrology&#8212;Division of Diabetes, Lipid Disorders, and Obesity (&#8220;<font style="font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;letter-spacing:0.475pt;">Division</font>&#8221;). As part of the preclinical program for RZ358, Sprague Dawley rats (&#8220;<font style="font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;letter-spacing:0.475pt;">SD rats</font><font style="letter-spacing:-0.361pt;">&#8221;) </font>demonstrated a microvascular injury in liver sinusoidal endothelial cells (&#8220;<font style="font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;letter-spacing:0.475pt;">LSECs</font>&#8221;) at potentially clinically relevant doses and exposures (&#8220;<font style="font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;letter-spacing:0.475pt;">rat findings</font>&#8221;). Consequently, the Division mandated PCHs that prevent us from dosing participants under the age of 12 and restrict us from dosing participants above the lowest dose studied to date, 3mg/kg.</div>
          <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;">
            <font style="letter-spacing:0.475pt;">sunRIZE Phase 3 Study</font>
          </div>
          <div style="margin-top:2pt; width:456pt; line-height:12pt;">In December 2023, we initiated sunRIZE, a randomized, double-blind, placebo-controlled, parallel arm evaluation of RZ358 in participants with cHI who are not adequately responding to standard-of-care medical therapies. We plan to enroll approximately 56 participants ages three months and above from up to approximately 20 clinical trial sites in more than 15 countries in Europe, the Middle East, Asia and North America, and to complete enrollment by the end of calendar year 2024, to enable announcement of topline results in mid-<font style="letter-spacing:-0.361pt;">2025.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
          <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;">
            <font style="letter-spacing:0.475pt;">RZ358 Ongoing Studies and Development</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
          </div>
          <div style="margin-top:2pt; width:456pt; line-height:12pt;">We do not believe that the rat findings are relevant to humans particularly since no adverse liver findings were observed in monkey toxicology studies at significantly higher RZ358 dose levels (up to 90 mg/kg tested), with drug levels that were more than 8 times higher than those that showed toxicity in SD rats and more than 5 times higher than the top human doses. Moreover, in our clinical studies conducted to date there have been no liver findings, including at the highest human doses that have been administered. While the precise mechanism of liver microvascular injury in SD rats remains unknown, we believe that the SD rat may be hypersensitive to exaggerated pharmacology and severely impaired insulin signaling with RZ358, due to its baseline predisposition to obesity, metabolic syndrome, insulin resistance, and over-dependence on the liver for insulin signaling and glucose handling. Notably, individuals who suffer with cHI are the opposite of insulin resistant as they have excessive insulin activity.</div>
          <div style="margin-top:8pt; width:456pt; line-height:12pt;">As part of our effort to investigate the mechanism of toxicity in SD rats, we have retained advisement from a former senior FDA pharmacology-toxicology official and we have partnered with a research group with LSEC expertise. In the second half of 2023, we conducted additional <font style="font-style:italic;">in-vivo</font> and <font style="font-style:italic;">in-vitro</font> non-clinical studies to enhance our understanding of the mechanism of toxicity in SD rats and its potential relevance to humans, including experiments in SD rat LSECs and another toxicology study in an additional rodent species. We have been unable to reproduce or characterize the toxicity observed in SD rat toxicology studies in our LSEC experiments and we therefore believe that the mechanism of toxicity cannot be characterized <font style="font-style:italic;">in-vitro</font><font style="letter-spacing:-0.361pt;">. </font>Importantly, we conducted a CD-1 mice toxicology study to determine if we could reproduce rat findings in a different rodent species. CD-1 mice were administered significantly higher dose levels of RZ358 (up to 120 </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:-0.361pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11pt;font-size:9pt;">
          <font style="letter-spacing:-0.342pt;">S-4</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:4pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:12.5pt;">
          <font style="letter-spacing:0.625pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;margin-left:12pt;width:456pt;">
          <div style="width:456pt; line-height:11.5pt;">mg/kg tested) with drug levels that were more than 20 times higher than those that caused the SD rat findings and substantially higher than human doses. No adverse liver findings were observed in this study at any dose level.</div>
          <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">To continue along these lines of evaluating and demonstrating the likelihood that liver findings are specific to SD rats and irrelevant to human patients, we then undertook another toxicology study in a different strain of rat. In the first half of 2024, we conducted and recently completed an <font style="font-style:italic;">in-vivo</font> toxicology study in brown Norway rats, using SD rats as a positive control. Early results show that at the highest tested dose of 40 mg/kg, there were no observed liver abnormalities in the brown Norway rat strain. Notably, the 40 mg/kg dose is more than four times the dose that causes liver injury in SD rats. We expect to have final data tabulations and a report for this study completed in the third quarter of 2024 and believe that the Norway rat study further suggests that liver toxicity is specific to the SD rat and not relevant otherwise, based on the absence of findings in other rat strains, other rodent species (&#8220;<font style="font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;letter-spacing:0.475pt;">CD-1 mice</font>&#8221;), primates, or our clinical trials in humans to date. We are conducting additional in-vitro studies and plan to incorporate those studies along with the Norway rat toxicity study into a complete response to the PCHs to be submitted to the Division in the third quarter of 2024. Nonetheless, there can be no assurance that the Division will agree to modify or remove the PCHs.</div>
          <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">Regardless of U.S. trial sites in our current Phase 3 study, we believe data from sunRIZE will be sufficient for a potential submission to FDA for approval for RZ358 for cHI if the study meets its efficacy objectives, with an acceptable safety profile.</div>
          <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">RZ358 has received Orphan Drug Designation in the U.S. and European Union for the treatment of cHI, as well as Pediatric Rare Disease Designation in the U.S., a prerequisite for a request for a Rare Pediatric Disease Priority Review Voucher upon Biologics License Application submission. Based on the RIZE clinical trial outcomes and the substantial unmet medical need, RZ358 was subsequently granted a priority medicines designation by the European Medicines Agency and an Innovation Passport designation by the UK Innovative Licensing and Access Pathway Steering Group for the treatment of cHI in October 2023.</div>
          <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;">
            <font style="letter-spacing:0.475pt;">RZ358 for tumor hyperinsulinism (&#8220;HI&#8221;)</font>
          </div>
          <div style="margin-top:6pt; width:456pt; line-height:11.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;">
            <font style="letter-spacing:0.475pt;">Tumor HI</font>
          </div>
          <div style="margin-top:2pt; width:456pt; line-height:11.5pt;">Tumor HI may be caused by two distinct types of tumors: islet cell tumors (&#8220;<font style="font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;letter-spacing:0.475pt;">ICTs</font>&#8221;) and non-islet cell tumors <font style="letter-spacing:-0.361pt;">(&#8220;</font><font style="font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;letter-spacing:0.475pt;">NICTs</font>&#8221;), both of which lead to hypoglycemia due to excessive activation of the insulin receptor. Insulinomas are the most common type of functional ICT and mediate hypoglycemia through excessive insulin production. NICTs are generally associated with relatively large, solid tumors such as hepatocellular carcinoma, fibrosarcoma and mesothelioma, and can cause hypoglycemia by producing and secreting insulin-like paraneoplastic substances such as IGF-2 or related variants that bind to and activate the insulin receptor. This form of hypoglycemia can occur in more than 15 different tumor types, 60% of which are malignant, including hepatocellular carcinoma.</div>
          <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">Current therapies for insulinomas and NICTs can be grouped into two main categories: (a) tumor directed de-bulking therapies (e.g. surgery, chemotherapy, radiotherapy), which may indirectly and/or eventually lead to decreased levels of circulating insulin and/or insulin-like substances, and therefore control HI and related hypoglycemia; and/or (b) medical therapies that directly treat HI and the associated hypoglycemia. Tumor-directed therapies do not directly treat hypoglycemia caused by insulinomas or NICTs. In many cases, tumor-directed therapies are administered concurrently with medical therapies for hypoglycemia and in other cases successful treatment of hypoglycemia often enables the initiation and/or continuation of tumor-directed therapies, as indicated. During the period from diagnosis to surgical treatment, or if surgery is contraindicated or refused, medical treatments are often necessary to directly manage the HI and hypoglycemia induced by the tumor. Additionally, chronic medical management of refractory hypoglycemia is often necessary for patients who cannot be cured by surgery, such as those with extensive disease of the pancreas, multi-focal insulinomas, inoperable or unresectable benign or malignant insulinomas, metastatic insulinomas, non-pancreatic insulinomas, or NICT hypoglycemia resulting from a variety of other tumors.</div>
          <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">A significant unmet need exists for treatment options with improved efficacy and tolerability as normalization of glucose levels is crucial to ensure patients are fit to receive cancer treatment and to reduce mortality. Unfortunately, some patients are unresponsive to the current standard of care medical therapies for tumor HI and experience debilitating hypoglycemia that is otherwise untreatable. Currently available medical therapies </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:-0.361pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11pt;font-size:9pt;">
          <font style="letter-spacing:-0.342pt;">S-5</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:4pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:12.5pt;">
          <font style="letter-spacing:0.625pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;margin-left:12pt;width:456pt;">
          <div style="width:456pt; line-height:11.5pt;">are directed at reducing or eliminating insulin production and/or secretion from tumors, which may be challenging when the tumor is differentiated or dysregulated, and therefore not responding to usual control mechanisms for suppressing insulin production. In some cases, commonly utilized somatostatin analog therapies may even worsen hypoglycemia due to suppression of glucagon. Therefore, currently available medical therapies directed at suppressing insulin production may have limited effectiveness in tumor HI.</div>
          <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">The total addressable market for the combined indications causing tumor HI is estimated to be approximately 4,500 patients in the U.S. alone, including approximately 1,500 with ICT hypoglycemia and approximately 3,000 with NICT hypoglycemia. We believe this addressable market represents a greater than $1&#160;billion market opportunity.</div>
          <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;">
            <font style="letter-spacing:0.475pt;">Expanded Access Program</font>
          </div>
          <div style="margin-top:2pt; width:456pt; line-height:11.5pt;">RZ358 has been shown to counteract excessive insulin action downstream, at the insulin-receptor on target organs. The unique mechanism of action of RZ358 makes the therapy a potential universal treatment for any form of hyperinsulinism, including tumor HI.</div>
          <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">We maintain an Expanded Access Program (&#8220;<font style="font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;letter-spacing:0.475pt;">EAP</font>&#8221;) for a variety of HI indications for the purpose of making RZ358 available on a compassionate use basis when available therapeutic options have failed, and an individual&#8217;s hypoglycemia is unmanageable. In the fourth quarter of 2022, we received and approved an EAP request from Dr. Mary Elizabeth Patti, Director of the Hypoglycemia Clinic at the Harvard Medical School and Beth Israel Medical Center-affiliated Joslin Diabetes Center, for a patient with intractable hypoglycemia caused by a metastatic insulinoma. Dr. Patti received a single patient investigational new drug (&#8220;<font style="font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;letter-spacing:0.475pt;">IND</font>&#8221;) approval from the Division to treat the patient with RZ358. Dr. Patti reported that the patient safely achieved correction of hypoglycemia with RZ358, enabling the patient to wean off continuous intravenous dextrose and several other medications for hypoglycemia, leave the hospital after a prolonged stay, and resume receiving concurrent treatment for cancer with tumor-directed therapies. The patient remained on RZ358 for more than a year until he eventually passed away due to progression of his underlying malignant/metastatic insulinoma.</div>
          <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">We have received and approved five requests to date for single patient use of RZ358 in patients with tumor HI caused by metastatic insulinomas and other insulin secreting metastatic cancer (cervical). In the U.S., these requests have all been approved by the Division. These patients have been refractory to usual standard of care therapies for chronic management of hypoglycemia and required continuous high volume/concentration intravenous dextrose or nutritional infusion and were hospitalized and in life-threatening or hospice-bound condition because of uncontrollable hypoglycemia. Further treatment with tumor-directed therapies (e.g., embolization, radiotherapy, chemotherapy) was often deferred as a result of the debilitating hypoglycemia.</div>
          <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">Generally, dosing for tumor HI patients has been either 6 mg/kg or 9 mg/kg every 1-2 weeks. In all cases to date, RZ358 has led to substantial improvement in hypoglycemia and has been well tolerated. Within a relatively short period of time after administration of RZ358, continuous intravenous dextrose was discontinued and hospitalized patients were able to be discharged and receive maintenance RZ358 doses on an outpatient basis, with durable benefit. In most cases, other background medical therapies for hypoglycemia were able to be weaned or stopped, and patients were able to resume tumor-directed therapies for treatment of their underlying cancer. Patients with metastatic tumor HI often have underlying hepatic injury (abnormal enzymes) at baseline due to hepatic metastases or previous tumor-directed treatments (e.g., partial liver resection or embolization). The patients with hepatic injury that have been treated under the EAP have not exhibited any indication of hepatic toxicity with the use of RZ358.</div>
          <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;">
            <font style="letter-spacing:0.475pt;">Evaluation of a Clinical and Regulatory Development Path</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
          </div>
          <div style="margin-top:2pt; width:456pt; line-height:11.5pt;">In January 2024, we had a Type B pre-IND meeting with the Division to discuss a potential IND application and a clinical and regulatory development strategy for tumor HI. The Division acknowledged the unmet need as well as the potential therapeutic benefit of RZ358 as demonstrated by the cases under the EAP as well as the efficacy demonstrated in previous clinical experience in cHI. The Division is aligned with us that it would be warranted to study RZ358 in an IND-opening late-stage (registrational) clinical trial, which we are currently evaluating as a development program and second rare disease indication for RZ358. This study could simultaneously include both ICT and NICT patients with tumor HI.</div>
          <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">To further validate the utility of RZ358 in treating hyperinsulinism and hypoglycemia resulting from NICT, we also conducted <font style="font-style:italic;">in-vitro</font> experiments which demonstrated that RZ358 can blunt signaling of IGF-2 at the </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:-0.361pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11pt;font-size:9pt;">
          <font style="letter-spacing:-0.342pt;">S-6</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:4pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:12.5pt;">
          <font style="letter-spacing:0.625pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;margin-left:12pt;width:456pt;">
          <div style="width:456pt; line-height:11.5pt;">insulin receptor. We believe that this is additional proof of mechanism and concept for RZ358 as a potential universal treatment for hyperinsulinism, due to its novel mechanism of action at the insulin receptor.</div>
          <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">In addition to other factors that impact a decision and timing of initiation of a new development program, we are not resourced to support an additional late stage registrational study. While we are optimistic about the positive impact RZ358 is already having on the lives of tumor HI patients, there can be no assurance that we will expand its pipeline to include tumor HI as a new indication for RZ358 nor can there be any assurance that such a program will be successful in a registrational study to support commercial approval for use of RZ358 in tumor HI by FDA or other regulatory authorities worldwide.<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
          <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;">
            <font style="letter-spacing:0.475pt;">RZ402 for DME</font><font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
          </div>
          <div style="margin-top:6pt; width:456pt; line-height:11.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;">
            <font style="letter-spacing:0.475pt;">DME</font>
          </div>
          <div style="margin-top:2pt; width:456pt; line-height:11.5pt;">Diabetic retinopathy (&#8220;<font style="font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;letter-spacing:0.475pt;">DR</font>&#8221;) affects approximately one third of adults with diabetes and is the leading cause of vision loss in the working age population. DME is a severe, systemic, vision-threatening complication of DR characterized by swelling of the retina and thickening of the macula, the part of the eye that is responsible for high-resolution vision. There are an estimated 22&#160;million DME patients worldwide and over 1&#160;million in the U.S. alone, representing a potential addressable market of over $1.5&#160;billion. Anti-vascular growth factor (&#8220;<font style="font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;letter-spacing:0.475pt;">anti-VEGF</font>&#8221;) injections into the eye are the current standard of care for DME, requiring continued administration over long periods of time to preserve vision. Due to their invasive route of administration and occasional serious side effects, there is a tendency to delay treatment until later in the disease course, and long-term compliance with eye injection regimens can be difficult for patients. In addition, only 40-50% of DME patients are responsive to the anti-VEGF treatment, which results in overall undertreatment and suboptimal vision outcomes in DME patients.</div>
          <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">The contact-activation kallikrein-kinin system promotes increased vascular permeability and inflammation via key downstream mediators, including bradykinin, and activation of the intrinsic pathway of coagulation. Pathophysiologic upregulation of this system has been linked to a variety of diseases which are characterized by vascular dysfunction, including DME.</div>
          <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">We believe that an oral PKI therapy is the ideal approach for targeting a systemic vascular disease such as DME. An oral PKI would be a non-invasive approach that allows for earlier disease intervention, directly impacts the site of disease and therapeutic target, and could be used alone or in tandem with anti-VEGF injections, which could potentially lead to better clinical outcomes overall.</div>
          <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;">
            <font style="letter-spacing:0.475pt;">Phase 2 Study</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
          </div>
          <div style="margin-top:2pt; width:456pt; line-height:11.5pt;">In December&#160;2022, we initiated a Phase&#160;2 U.S. multi-center, randomized, double-masked, placebo-controlled, parallel-arm study to evaluate the safety, efficacy, and pharmacokinetics of RZ402 administered as a monotherapy over a 12-week treatment period in participants with DME who are na&#239;ve to, or have received limited anti-VEGF injections. The study population is comprised of DME patients with mild to moderate non-proliferative DR, experiencing compromised vision. Eligible participants were randomized equally, to one of three RZ402 active treatment arms at doses of 50, 200, and 400 mg, or a placebo control arm, to receive study drug once daily for 12-weeks, before completing a four-week follow-up. Topline results were announced on May 21, 2024.<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
          <div style="margin-top:8pt; width:456pt; line-height:12pt;">RZ402 met both primary endpoints of change in macular edema (&#8220;<font style="font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;letter-spacing:0.475pt;">CST</font>&#8221;) and a good safety profile.</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.9pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
            <font style="letter-spacing:-0.361pt;">&#9642;</font>
            <br >
          </div>
          <div style=" margin-top:3.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
            <!--blacklining:none;-->CST improved significantly at all RZ402 dose levels compared to placebo (up to approximately 50&#160;microns; p=0.02)</div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:3.9pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
            <font style="letter-spacing:-0.361pt;">&#9642;</font>
            <br >
          </div>
          <div style=" margin-top:3.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:52pt;">
            <!--blacklining:none;-->Continued downward trajectory in CST over course of study and at end of treatment</div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:3.9pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
            <font style="letter-spacing:-0.361pt;">&#9642;</font>
            <br >
          </div>
          <div style=" margin-top:3.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:52pt;">
            <!--blacklining:none;-->No significant difference between RZ402 dose levels, though response was largest at the 200&#160;mg dose</div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:3.9pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
            <font style="letter-spacing:-0.361pt;">&#9642;</font>
            <br >
          </div>
          <div style=" margin-top:3.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:52pt;">
            <!--blacklining:none;-->Sub-analysis by DME severity (CST &ge;400 microns) indicates an improvement of approximately 75 microns at the 200 mg dose</div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:3.9pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
            <font style="letter-spacing:-0.361pt;">&#9642;</font>
            <br >
          </div>
          <div style=" margin-top:3.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:52pt;">
            <!--blacklining:none;-->CST declined in most patients who received the 200 mg dose of RZ402, including clinically significant improvements from baseline in more than 20% of participants, compared to none in placebo, with high rates of worsening<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        </div>
        <div style="clear:both;font-size:0pt;">&#8203;</div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:-0.361pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11pt;font-size:9pt;">
          <font style="letter-spacing:-0.342pt;">S-7</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:4pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:12.5pt;">
          <font style="letter-spacing:0.625pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;margin-left:12pt;width:456pt;">
          <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:12pt;white-space:nowrap;">
            <font style="letter-spacing:-0.361pt;">&#9642;</font>
            <br >
          </div>
          <div style=" line-height:12pt; text-align:left; margin-left:32pt;">
            <!--blacklining:none;-->RZ402 was safe and well-tolerated</div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:3.01pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
            <font style="letter-spacing:-0.361pt;">&#9642;</font>
            <br >
          </div>
          <div style=" margin-top:3.01pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:52pt;">
            <!--blacklining:none;-->Adverse events (&#8220;<font style="font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;letter-spacing:0.475pt;">AEs</font>&#8221;) were generally mild and rates were comparable to placebo</div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:3pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
            <font style="letter-spacing:-0.361pt;">&#9642;</font>
            <br >
          </div>
          <div style=" margin-top:3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:52pt;">
            <!--blacklining:none;-->Three participants experienced serious AEs which were all judged by the Investigator as unrelated to study drug</div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:3.01pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
            <font style="letter-spacing:-0.361pt;">&#9642;</font>
            <br >
          </div>
          <div style=" margin-top:3.01pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:52pt;">
            <!--blacklining:none;-->No ocular adverse effects that are typically seen with intravitreal injections</div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:3.01pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
            <font style="letter-spacing:-0.361pt;">&#9642;</font>
            <br >
          </div>
          <div style=" margin-top:3.01pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:52pt;">
            <!--blacklining:none;-->Electrocardiograms, vitals, and safety labs were unremarkable</div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
            <font style="letter-spacing:-0.361pt;">&#9642;</font>
            <br >
          </div>
          <div style=" margin-top:3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
            <!--blacklining:none;-->Target concentrations were exceeded at all three dose levels and continue to support once daily oral dosing<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style="position:relative;margin-top:8.61pt; text-align:center; width:456pt;">
            <img src="tb_treatment-4clr.jpg" alt="[MISSING IMAGE: tb_treatment-4clr.jpg]" height="361" width="523" >
          </div>
          <div style="position:relative;margin-top:13.01pt; text-align:center; width:456pt;">
            <img src="lc_primary-4clr.jpg" alt="[MISSING IMAGE: lc_primary-4clr.jpg]" height="348" width="547" >
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:-0.361pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11pt;font-size:9pt;">
          <font style="letter-spacing:-0.342pt;">S-8</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:4pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:12.5pt;">
          <font style="letter-spacing:0.625pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:18pt;margin-left:12pt;width:456pt;">
          <div style="position:relative;margin-top:8pt; text-align:center; width:456pt;">
            <img src="bc_participant-4clr.jpg" alt="[MISSING IMAGE: bc_participant-4clr.jpg]" height="259" width="546" >
          </div>
          <div style="margin-top:18.4pt; width:456pt; line-height:11.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;">
            <font style="letter-spacing:0.475pt;">Secondary and Additional Observations</font>
          </div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.69pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
            <font style="letter-spacing:-0.361pt;">&#9642;</font>
            <br >
          </div>
          <div style=" margin-top:3.69pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
            <!--blacklining:none;-->No significant improvements in Best Corrected Visual Acuity compared to placebo</div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:4.2pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
            <font style="letter-spacing:-0.361pt;">&#9642;</font>
            <br >
          </div>
          <div style=" margin-top:4.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:52pt;">
            <!--blacklining:none;-->In-line with expectations for a study of this duration</div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:4.2pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
            <font style="letter-spacing:-0.361pt;">&#9642;</font>
            <br >
          </div>
          <div style=" margin-top:4.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:52pt;">
            <!--blacklining:none;-->Observed improvements in CST would predict visual improvements in a longer duration study</div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.1pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
            <font style="letter-spacing:-0.361pt;">&#9642;</font>
            <br >
          </div>
          <div style=" margin-top:4.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
            <!--blacklining:none;-->Five RZ402 treated participants at 200 mg (20 percent) experienced a 1-step improvement in Diabetic Retinopathy Severity Score (&#8220;<font style="font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;letter-spacing:0.475pt;">DRSS</font>&#8221;) compared to one participant in placebo<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style="margin-top:6pt; width:456pt; line-height:11.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;">
            <font style="letter-spacing:0.475pt;">Recent Developments</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
          </div>
          <div style="margin-top:6pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;">
            <font style="letter-spacing:0.475pt;">Securities Exchange Agreement</font>
          </div>
          <div style="margin-top:2pt; width:456pt; line-height:12pt;">On March 8, 2024 (the &#8220;<font style="font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;letter-spacing:0.475pt;">Closing Date</font>&#8221;), we entered into a securities exchange agreement (the &#8220;<font style="font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;letter-spacing:0.475pt;">Exchange Agreement</font>&#8221;) with certain of our stockholders (the &#8220;<font style="font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;letter-spacing:0.475pt;">Exchanging Shareholders</font>&#8221;), whereby we purchased 3,000,000 shares of common stock with an aggregate fair value of&#8201; $5,700,000 (the &#8220;<font style="font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;letter-spacing:0.475pt;">Retired Shares</font>&#8221;) from the Exchanging Shareholders. The Retired Shares were immediately cancelled whereby they will remain as authorized shares for future issuance in accordance with Nevada law. Consideration for the acquisition of the Retired Shares consisted of&#8201; (i) a cash payment to the Exchanging Shareholders of&#8201; $3,000, and (ii) the issuance of pre-funded warrants (the &#8220;<font style="font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;letter-spacing:0.475pt;">Exchange PFWs</font>&#8221;) to the Exchanging Shareholders with an estimated fair value of&#8201; $5,697,000. The Exchange PFWs do not expire and are exercisable to purchase an aggregate of 3,000,000 shares of our common stock (subject to adjustment in the event of stock splits, recapitalizations and other similar events) at an exercise price of&#8201; $0.001 per share. The Exchange PFWs are exercisable at any time, subject to the then effective ownership blocker percentage (the &#8220;<font style="font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;letter-spacing:0.475pt;">OBP</font>&#8221;) as elected by the Exchanging Shareholders. The OBP is a percentage designated by the holders whereby the Exchange PFWs cannot be exercised if, after giving effect thereto, the Exchanging Shareholders would beneficially own more than the designated OBP. The terms of the Exchange PFWs initially provide for an OBP of 9.99%. However, upon at least 61 days&#8217; prior notice to us, any holder of Exchange PFWs may elect to increase or decrease the OBP to any other percentage not to exceed 19.99%.</div>
          <div style="margin-top:8pt; width:456pt; line-height:12pt;">Unlike our shares of common stock, the holders of Exchange PFWs do not have voting rights except to the extent required by Nevada law. No later than six months after the Closing Date, we agreed to file a registration statement covering the resale of the shares issuable upon the exercise of the Exchange PFWs.<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
          <div style="margin-top:8pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;">
            <font style="letter-spacing:0.475pt;">Prefunded Warrant Exercises</font>
          </div>
          <div style="margin-top:2pt; width:456pt; line-height:12pt;">On October 4, 2023, an investor from our May 2022 registered direct offering provided notice of cashless exercise of their class B pre-funded warrants. We issued 2,797,704 shares of our common stock on October&#160;6, 2023, and we did not receive any cash proceeds from the exercise.</div>
          <div style="margin-top:8pt; width:456pt; line-height:12pt;">On March 1, 2024, an investor provided notice of cashless exercise for 1,973,684 class A pre-funded warrants, resulting in the issuance of 1,972,486 shares of common stock. On March 7, 2024, certain holders </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:-0.361pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11pt;font-size:9pt;">
          <font style="letter-spacing:-0.342pt;">S-9</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:4pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:12.5pt;">
          <font style="letter-spacing:0.625pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;min-height:660pt;margin-left:12pt;width:456pt;">
          <div style="width:456pt; line-height:12pt;">of 2021 pre-funded warrants provided notice of cashless exercise for 1,538,461 shares resulting in the issuance of 1,529,890 shares of common stock.</div>
          <div style="margin-top:8pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;">
            <font style="letter-spacing:0.475pt;">Milestone Payment</font>
          </div>
          <div style="margin-top:2pt; width:456pt; line-height:12pt;">Pursuant to the XOMA License agreement discussed under the caption Liquidity and Capital Resources in our latest Form&#160;10-Q for the quarter ended March 31, 2024 filed with the SEC on May 15, 2024, subsequent to March 31, 2024, a $5.0 million milestone payment was incurred and paid to XOMA upon the dosing of the first patient in our Phase 3 clinical study for RZ358. Accordingly, we expect to recognize the related license expense for the fiscal quarter ending June 30, 2024.</div>
          <div style="margin-top:8pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;">
            <font style="letter-spacing:0.475pt;">Employees</font><font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
          </div>
          <div style="margin-top:2pt; width:456pt; line-height:12pt;">As of June&#160;10, 2024, we had 59 full time employees, of which 42 employees were engaged in research and development, manufacturing, clinical operations, regulatory and quality activities and 17 employees were engaged in administrative functions. Of the 59 employees, all were located in the United States. We have a number of employees who hold Ph.D. degrees and other advanced degrees. None of our employees are covered by a collective bargaining agreement, and we have experienced no work stoppages nor are we aware of any employment circumstances that are likely to disrupt work at any of our facilities. As part of our measures to attract and retain personnel, we provide a number of benefits to our full-time employees, including health insurance, life insurance, retirement plans, paid holiday and vacation time. In addition, we grant stock options to certain key employees as added incentive to remain in our employment. We believe that we maintain good relations with our employees.<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
          <div style="margin-top:8pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;">
            <font style="letter-spacing:0.475pt;">Corporate Transactions</font><font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
          </div>
          <div style="margin-top:2pt; width:456pt; line-height:12pt;">From time to time the Company may enter into various strategic transactions, joint ventures, licensing transactions and partnerships with certain current and future stockholders and other related parties. Such transactions might result in issuing certain securities and may result in additional dilution. There is no guarantees that we are going to complete these transactions.<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
          <div style="margin-top:8pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;">
            <font style="letter-spacing:0.475pt;">Corporate Information</font><font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
          </div>
          <div style="margin-top:2pt; width:456pt; line-height:12pt;">We were incorporated in Delaware in 2010 and we re-incorporated in Nevada in June&#160;2021. We maintain an executive office located at 275 Shoreline Drive, Suite 500, Redwood City, CA 94065 and our phone number is (650) 206-4507. Our website is located at www.rezolutebio.com. We file annual, quarterly, current reports, proxy statements and other information with the SEC. The SEC maintains a website that contains our public filings and other information regarding the Company, at www.sec.gov. The information contained in, or that can be accessed through, our website is not part of, and is not incorporated into this document. </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:-0.361pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11pt;font-size:9pt;">
          <font style="letter-spacing:-0.342pt;">S-10</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="sTHOF">&#8203;</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:4pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:12.5pt;">
          <font style="letter-spacing:0.625pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;margin-bottom:25.92pt; margin-left:12pt;width:456pt;">
          <div style="text-align:center; width:456pt; line-height:12.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:10pt;">
            <font style="text-transform:uppercase;letter-spacing:0.5pt;">THE OFFERING</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="width:168pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:12pt; line-height:11.5pt;">Common stock offered by us: </div>
          </div>
          <div style="margin-left:180pt; margin-top:-11.5pt; width:276pt; line-height:12pt;">
            <font style="letter-spacing:-0.361pt;">11,250,000</font> shares of common stock (<font style="letter-spacing:-0.361pt;">13,500,000</font> shares of common stock if the underwriters&#8217; option to purchase additional shares of common stock is exercised in full).<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
          <div style="width:168pt;">
            <div style="white-space:nowrap; margin-left:10pt; text-indent:-10pt; margin-top:18pt; line-height:11.5pt;">Pre-Funded Warrants we are <br >offering: </div>
          </div>
          <div style="margin-left:180pt; margin-top:-11.5pt; width:276pt; line-height:12pt;">We are also offering, in lieu of common stock to certain investors that so choose, <font style="letter-spacing:-0.361pt;">3,750,000 </font>Pre-Funded Warrants to purchase common stock. The purchase price of each Pre-Funded Warrant will equal the price per share at which common stock are being sold to the public in this offering, minus $0.001, and the exercise price of each Pre-Funded Warrant will equal $0.001 per share. Each Pre-Funded Warrant will be exercisable from the date of issuance until the date the Pre-Funded Warrant is exercised in full, subject to an ownership limitation. See &#8220;<font style="font-style:italic;">Description of Securities</font><font style="letter-spacing:-0.361pt;">&#8221; </font>on page <font style="letter-spacing:-0.361pt;"><a href="#sDOS">S-19</a></font> for additional information. This prospectus supplement also relates to the offering of the Pre-Funded Warrant Shares.<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
          <div style="width:168pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:18pt; line-height:11.5pt;">Option to purchase additional common shares:</div>
          </div>
          <div style="margin-left:180pt; margin-top:-11.5pt; width:276pt; line-height:12pt;">We intend to grant the underwriters an option to purchase up to <font style="letter-spacing:-0.361pt;">2,250,000</font> additional shares of common stock. This option is exercisable, in whole or in part, for a period of 30&#160;days from the date of this prospectus supplement.<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
          <div style="width:168pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:18pt; line-height:11.5pt;">Common stock to be outstanding following this offering: </div>
          </div>
          <div style="margin-left:180pt; margin-top:-11.5pt; width:276pt; line-height:12pt;">
            <font style="letter-spacing:-0.361pt;">51,382,647 </font>shares of common stock (or<font style="letter-spacing:-0.361pt;"> 53,632,647 </font>shares of common stock if the underwriters&#8217; option is exercised in full).<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
          <div style="width:168pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:18pt; line-height:11.5pt;">Use of Proceeds: </div>
          </div>
          <div style="margin-left:180pt; margin-top:-11.5pt; width:276pt; line-height:12pt;">Net proceeds from the offering will be used for research and development, general corporate expense and working capital needs. See <font style="font-style:italic;">&#8220;Use of Proceeds</font>&#8221; on page <font style="letter-spacing:-0.361pt;"><a href="#sUOP">S-16</a></font> of this prospectus supplement.<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
          <div style="width:168pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:18pt; line-height:11.5pt;">Risk Factors: </div>
          </div>
          <div style="margin-left:180pt; margin-top:-11.5pt; width:276pt; line-height:12pt;">Investing in our securities involves a high degree of risk. Please read the information contained in and incorporated by reference under the heading &#8220;<font style="font-style:italic;">Risk Factors</font>&#8221; beginning on page <font style="letter-spacing:-0.361pt;"><a href="#sRIFA">S-13</a></font> of this prospectus supplement and the other information included in, or incorporated by reference into, this prospectus supplement for a discussion of certain factors you should carefully consider before deciding to invest in our securities.<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
          <div style="width:168pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:18pt; line-height:11.5pt;">Nasdaq trading symbol: </div>
          </div>
          <div style="margin-left:180pt; margin-top:-11.5pt; width:276pt; line-height:12pt;">Our common shares are listed on Nasdaq under the symbol &#8220;RZLT&#8221;. There is no established public trading market for the Pre-Funded Warrants, and we do not expect a market to develop. We do not intend to list the Pre-Funded Warrants on Nasdaq or any other national securities exchange or nationally recognized trading system. Without an active trading market, the liquidity of the Pre-Funded Warrants will be limited.</div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:-0.361pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11pt;font-size:9pt;">
          <font style="letter-spacing:-0.342pt;">S-11</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:4pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:12.5pt;">
          <font style="letter-spacing:0.625pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;min-height:660pt;margin-left:12pt;width:456pt;">
          <div style="width:456pt; line-height:12pt;">Unless otherwise indicated, the number of shares of common stock to be outstanding after this offering is based on 40,132,647 shares of common stock outstanding as of March&#160;31, 2024. The number of shares of common stock outstanding after this offering excludes:<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
            <font style="letter-spacing:-0.361pt;">&#9642;</font>
            <br >
          </div>
          <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
            <!--blacklining:none;-->10,907,472 shares of our common stock issuable upon the exercise of stock options outstanding as of March&#160;31, 2024, at a weighted average exercise price of&#8201; $3.82 per share, of which stock options to purchase 4,374,179 shares of common stock were then exercisable;<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
            <font style="letter-spacing:-0.361pt;">&#9642;</font>
            <br >
          </div>
          <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
            <!--blacklining:none;-->401,928 shares of our common stock reserved for future grants of stock options (or other similar equity instruments) under our equity incentive plans;<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
            <font style="letter-spacing:-0.361pt;">&#9642;</font>
            <br >
          </div>
          <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
            <!--blacklining:none;-->500,000 shares of our common stock reserved for issuance pursuant to our 2022 Employee Stock Purchase Plan;</div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
            <font style="letter-spacing:-0.361pt;">&#9642;</font>
            <br >
          </div>
          <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
            <!--blacklining:none;-->860,562 shares of our common stock reserved for issuance upon the exercise of warrants outstanding as of March 31, 2024, at a weighted average exercise price of&#8201; $20.28 per share; and<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
            <font style="letter-spacing:-0.361pt;">&#9642;</font>
            <br >
          </div>
          <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
            <!--blacklining:none;-->11,270,371 shares of our common stock issuable upon the exercise of outstanding pre-funded warrants, at a weighted average exercise price of&#8201; $<font style="letter-spacing:-0.361pt;">0.001.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style="margin-top:8pt; width:456pt; line-height:12pt;">Except as otherwise indicated, all information in this prospectus supplement assumes (i) no exercise of the underwriters&#8217; option to purchase additional shares of common stock and (ii) no exercise of Pre-Funded Warrants offered in this offering.</div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:-0.361pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11pt;font-size:9pt;">
          <font style="letter-spacing:-0.342pt;">S-12</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="sRIFA">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:12.5pt;">
          <font style="letter-spacing:0.625pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:10pt;">
          <font style="text-transform:uppercase;letter-spacing:0.5pt;">RISK FACTORS</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:18pt; width:456pt; line-height:12pt;font-style:italic;">Investing in our securities involves significant risks. Please see the risk factors below and the additional risk factors set forth under the heading &#8220;Risk Factors&#8221; in Item&#160;1A. of our most recent <a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1509261/000155837023015755/rzlt-20230630x10k.htm">Annual Report on Form 10-K for the fiscal year ended June&#160;30, 2023</a>, which is on file with the SEC and is incorporated by reference in this prospectus. These risks may be revised or supplemented in future filings of our Quarterly Reports on Form&#160;10-Q and Annual Reports on Form 10-K, which is also incorporated by reference in this prospectus. Before making an investment decision, you should carefully consider these risks as well as other information we include or incorporate by reference in this prospectus.<font style="font-style:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;">
          <font style="letter-spacing:0.475pt;">Risks Related to this Offering and Our Common Stock</font>
        </div>
        <div style="margin-top:7pt; width:456pt; line-height:11.5pt;font-style:italic;">Since we have broad discretion in how we use the proceeds from this offering, we may use the proceeds in ways with which you disagree.<font style="font-style:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="margin-top:2pt; width:456pt; line-height:12pt;">Our management will have significant flexibility in applying the net proceeds of this offering, including for any of the purposes described in the section titled &#8220;<font style="font-style:italic;">Use of Proceeds</font>.&#8221; You will be relying on the judgment of our management with regard to the use of these net proceeds, and you will not have the opportunity, as part of your investment decision, to assess whether the proceeds are being used in ways you would agree with or ways which are likely to increase the value of your investment. Because of the number and variability of factors that will determine our use of the net proceeds from the offerings, their ultimate use may vary substantially from their currently intended use. It is possible that the net proceeds will be invested in a way that does not yield a favorable, or any, return for our company or your investment. The failure of our management to use such funds effectively could have a material adverse effect on our business, financial condition, operating results and cash flow.<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;font-style:italic;">If you purchase our securities in this offering, you may incur immediate and substantial dilution in the book value of your shares. You will also experience further dilution if we issue additional equity or equity-linked securities in the future.<font style="font-style:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">The public offering price of the securities offered pursuant to this prospectus supplement may be substantially higher than the net tangible book value per share of our common stock immediately prior to the offering. After giving effect to the sale of<font style="letter-spacing:-0.361pt;"> 11,250,000 </font>shares of our common stock and Pre-Funded Warrants to purchase <font style="letter-spacing:-0.361pt;">3,750,000</font> shares of common stock in this offering at the public offering price of&#8201; $<font style="letter-spacing:-0.361pt;">4.00 </font>per share (or <font style="letter-spacing:-0.361pt;">$3.999 </font>per Pre-Funded Warrant), and after deducting the underwriting discounts and commissions, and estimated offering expenses payable by us, purchasers of our common stock in this offering will incur immediate dilution of&#8201; $<font style="letter-spacing:-0.361pt;">1.70 </font>per share in the net tangible book value of the common stock they acquire.<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">If we issue additional shares of common stock (including pursuant to the exercise of outstanding stock options or warrants), or securities convertible into or exchangeable or exercisable for shares of common stock, our shareholders, including investors who purchase shares of common stock in this offering, will experience additional dilution, and any such issuances may result in downward pressure on the price of our common stock. We also cannot assure you that we will be able to sell shares or other securities in any other offering at a price per share that is equal to or greater than the price per share paid by investors in this offering, and investors purchasing shares or other securities in the future could have rights superior to existing shareholders.<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="margin-top:4pt; width:456pt; line-height:11.5pt;font-style:italic;">Sales of a significant number of shares of our common stock in the public markets, or the perception that such sales could occur, could depress the market price of our common stock.<font style="font-style:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="margin-top:2pt; width:456pt; line-height:12pt;">Sales of a substantial number of shares of our common stock in the public markets could depress the market price of our common stock and impair our ability to raise capital through the sale of additional equity securities. We, our directors, our executive officers and certain of our significant shareholders have agreed not to sell, dispose of or hedge any common stock or securities convertible into or exchangeable for shares of common stock during the period from the date of this prospectus supplement continuing through and including the date 90&#160;days after the date of this prospectus supplement, subject to certain exceptions. The underwriters may, in their discretion, release the restrictions on any such shares at any time without notice. See &#8220;Underwriting.&#8221; We cannot predict the effect that future sales of our common stock would have on the market price of our common stock.<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.361pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11pt;font-size:9pt;">
          <font style="letter-spacing:-0.342pt;">S-13</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:12.5pt;">
          <font style="letter-spacing:0.625pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;font-style:italic;">We will not receive any meaningful amount of additional funds upon the exercise of the Pre-Funded Warrants.<font style="font-style:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="margin-top:2pt; width:456pt; line-height:12.5pt;">Each Pre-Funded Warrant may be exercised by way of a cashless exercise, meaning that the holder may not pay a cash purchase price upon exercise, but instead would receive upon such exercise the net number of shares of our common stock determined according to the formula set forth in the Pre-Funded Warrant. Accordingly, we may not receive any additional funds upon the exercise of the Pre-Funded Warrants. Furthermore, if exercised by means of cash payment of the exercise price, we will not receive any meaningful additional funds upon the exercise of the Pre-Funded Warrants.<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="margin-top:4pt; width:456pt; line-height:11.5pt;font-style:italic;">If the price of our common stock fluctuates significantly, your investment could lose value.<font style="font-style:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="margin-top:2pt; width:456pt; line-height:12.5pt;">Our common stock is traded on Nasdaq, under the symbol &#8220;RZLT,&#8221; and, to date, has traded on a limited basis. We cannot assure you that an active public market will continue for our common stock. If an active public market for our common stock does not continue, the trading price and liquidity of our common stock will be materially and adversely affected. If there is a thin trading market or &#8220;float&#8221; for our stock, the market price for our common stock may fluctuate significantly more than the stock market as a whole. Without a large float, our common stock would be less liquid than the stock of companies with broader public ownership and, as a result, the trading prices of our common stock may be more volatile. In addition, in the absence of an active public trading market, investors may be unable to liquidate their investment in us. Furthermore, the stock market is subject to significant price and volume fluctuations, and the price of our common stock could fluctuate widely in response to several factors, including, but not limited to:<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.5pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->our quarterly or annual operating results;<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.5pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->additions or departures of key or qualified personnel;<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.5pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->failure to adequately protect our intellectual property;<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.49pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4.49pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->costs associated with defending claims, including intellectual property infringement claims and related judgments or settlements;<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.5pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->changes in governmental or other regulations affecting our business; and<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.49pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4.49pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->our compliance with governmental or other regulations affecting our business.<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:8pt; width:456pt; line-height:12.5pt;">The stock market has experienced extreme price and volume fluctuations in recent&#160;years that have significantly affected the quoted prices of the securities of many companies, including companies in our industry. The changes may not be possible to predict and often appear to occur without regard to specific operating performance. The price of our common stock could fluctuate based upon factors that have little or nothing to do with our company and these fluctuations could materially reduce our stock price.<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="margin-top:4pt; width:456pt; line-height:11.5pt;font-style:italic;">Proposed legislation in the U.S. Congress, including changes in U.S. tax law, may adversely impact us and the value of shares of our common stock and Pre-Funded Warrants.<font style="font-style:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="margin-top:2pt; width:456pt; line-height:12.5pt;">Changes to U.S. tax laws (which changes may have retroactive application) could adversely affect the Company or holders of our common stock and Pre-Funded Warrants. In recent&#160;years, many changes to U.S. federal income tax laws have been proposed and made, and additional changes to U.S. federal income tax laws are likely to continue to occur in the future.<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;">We do not currently intend to pay dividends on our common stock, and any return to investors is expected to come, if at all, only from potential increases in the price of our common stock.<font style="font-style:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="margin-top:2pt; width:456pt; line-height:12.5pt;">At the present time, we intend to use available funds to finance our operations. Accordingly, while payment of dividends rests within the discretion of our board of directors, we have no intention of paying any such dividends in the foreseeable future. Any return to investors is expected to come, if at all, only from potential increases in the price of our common stock.<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;">
          <font style="letter-spacing:0.475pt;">Risks Related to Investing in the Pre-Funded Warrants</font><font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:7pt; width:456pt; line-height:11.5pt;font-style:italic;">There is no public market for the Pre-Funded Warrants being offered in this offering.<font style="font-style:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="margin-top:2pt; width:456pt; line-height:12.5pt;">There is no established public trading market for the Pre-Funded Warrants being offered in this offering, and we do not expect a market to develop. In addition, we do not intend to apply to list these warrants on any securities exchange or nationally recognized trading system, including Nasdaq. Without an active market, the liquidity of these warrants will be limited.<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.361pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11pt;font-size:9pt;">
          <font style="letter-spacing:-0.342pt;">S-14</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:12.5pt;">
          <font style="letter-spacing:0.625pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:382.5pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;font-style:italic;">Holders of Pre-Funded Warrants purchased in this offering will have no rights as common stockholders until such holders exercise their warrants and acquire our common stock.<font style="font-style:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="margin-top:2pt; width:456pt; line-height:12pt;">Until holders of the Pre-Funded Warrants acquire shares of our common stock upon exercise of such warrants, the holders will have no rights with respect to the shares of our common stock underlying such warrants. Upon exercise of the Pre-Funded Warrants, the holders will be entitled to exercise the rights of a common stockholder only as to matters for which the record date occurs after the exercise.<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="margin-top:4pt; width:456pt; line-height:11.5pt;font-style:italic;">Significant holders or beneficial holders of our common stock may not be permitted to exercise Pre-Funded Warrants that they hold.</div>
        <div style="margin-top:2pt; width:456pt; line-height:12pt;">A holder of a Pre-Funded Warrant will not be entitled to exercise any portion of any Pre-Funded Warrant which, upon giving effect to such exercise, would cause (i) the aggregate number of shares of our common stock beneficially owned by the holder (together with its affiliates) to exceed 4.99% (or, at the election of the holder, up to 19.99%) of the number of shares of our common stock outstanding immediately after giving effect to the exercise, or (ii) the combined voting power of our securities beneficially owned by the holder (together with its affiliates) to exceed 4.99% (or, at the election of the holder, up to 19.99%) of the combined voting power of all of our securities then outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the Pre-Funded Warrant. As a result, you may not be able to exercise your Pre-Funded Warrants for shares of our common stock at a time when it would be financially beneficial for you to do so. In such circumstance you could seek to sell your Pre-Funded Warrants to realize value, but you may be unable to do so in the absence of an established trading market for the Pre-Funded Warrants. </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.361pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11pt;font-size:9pt;">
          <font style="letter-spacing:-0.342pt;">S-15</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="sUOP">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:12.5pt;">
          <font style="letter-spacing:0.625pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:370pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:10pt;">
          <font style="text-transform:uppercase;letter-spacing:0.5pt;">USE OF PROCEEDS</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:18pt; width:456pt; line-height:12pt;">We estimate that the net proceeds of this offering will be approximately $56.0 million (or approximately <font style="letter-spacing:-0.361pt;">$</font>64.5 million if the underwriters exercise the option to purchase an additional<font style="letter-spacing:-0.361pt;"> 2,250,000 </font>shares of common stock in full), after deducting underwriting discounts and commissions and estimated offering expenses. We will receive nominal proceeds, if any, from the exercise of the Pre-Funded Warrants.<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">We intend to use the net proceeds from this offering to fund the continued research and development, and for working capital and general corporate purposes. We may also use a portion of the net proceeds from this offering for the&#160;investment in, technologies, intellectual property or businesses that complement our business, although we have no present commitments or agreements to this effect.<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">Based on our planned use of the net proceeds of this offering, we estimate such funds, together with our existing cash and cash equivalents, will be sufficient for us to fund our operating expenses and capital expenditures into 2026.<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">The amounts and timing of our actual expenditures will depend on numerous factors, including the progress of our clinical trials and other development efforts and other factors described under &#8220;Risk Factors&#8221; in this prospectus supplement and the documents incorporated by reference herein, as well as the amount of cash used in our operations. As a result, our management will have broad discretion over the uses of the net proceeds in this offering and investors will be relying on the judgment of our management regarding the application of the net proceeds. </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.361pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11pt;font-size:9pt;">
          <font style="letter-spacing:-0.342pt;">S-16</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="sDIF1">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:12.5pt;">
          <font style="letter-spacing:0.625pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;">
          <font style="letter-spacing:0.475pt;">DILUTION</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">If you invest in our securities in this offering, you will experience dilution to the extent of the difference between the public offering price per share of our common stock and the net tangible book value per share of our common stock immediately after this offering.<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">As of March&#160;31, 2024, our net tangible book value was approximately $70.86&#160;million, or $1.77 per share of common stock. Net tangible book value per share is determined by dividing our total tangible assets, less total liabilities, by the number of shares of our common stock outstanding as of March&#160;31, 2024. Dilution with respect to net tangible book value per share represents the difference between the amount per share paid by purchasers of shares of common stock and Pre-Funded Warrants in this offering and the net tangible book value per share of our common stock immediately after this offering.<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">After giving effect to the sale of<font style="letter-spacing:-0.361pt;"> 11,250,000 </font>shares of our common stock at the public offering price of <font style="letter-spacing:-0.361pt;">$4.00 </font>per share of common stock, the sale of<font style="letter-spacing:-0.361pt;"> 3,750,000 </font>Pre-Funded Warrants to purchase <font style="letter-spacing:-0.361pt;">3,750,000</font> shares of our common stock at an offering price of&#8201; $<font style="letter-spacing:-0.361pt;">3.999 </font>per Pre-Funded Warrant (which equals the public offering price per share of the common stock less the $0.001 per share exercise price of the Pre-Funded Warrants) (excluding the Pre-Funded Warrant Shares), and after deducting underwriting discounts and commissions, and estimated offering expenses, our as adjusted net tangible book value as of March&#160;31, 2024 would have been approximately $<font style="letter-spacing:-0.361pt;">126.9 </font>million, or $<font style="letter-spacing:-0.361pt;">2.30 </font>per share. This represents an immediate increase<font style="letter-spacing:-0.361pt;"> </font>in net tangible book value of&#8201; $<font style="letter-spacing:-0.361pt;">0.54 </font>per share to existing shareholders and immediate dilution of&#8201; $<font style="letter-spacing:-0.361pt;">1.70 </font>per share to investors purchasing our common stock and Pre-Funded Warrants in this offering. We determine dilution by subtracting our as adjusted net tangible book value per share after this offering from the amount of cash paid by an investor for a share of common stock in this offering. The following table illustrates this dilution on a per share basis as of March&#160;31, 2024:<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <table style="width:456pt;margin-top:10.5pt;border-collapse: collapse;border-top:0.75pt solid #000000; border-bottom:0.75pt solid #000000; font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
          <tr style="line-height:9.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:11.5pt 0pt 0.5pt 0pt; width:371.07pt;text-align:left;">
              <div style="white-space:nowrap;">Public offering price per share </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:11.5pt 0pt 0.5pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="margin-left:5.8pt;letter-spacing:-0.361pt;">&#8199;&#8199;&#8199;&#8199;&#8199;</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:11.5pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:11.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">4.00</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            <td style="border-bottom:1px solid #FFFFFF;padding:3pt 0pt 2.25pt 0pt; width:371.07pt;text-align:left;">
              <div style="margin-left:9.5pt;">Historical net tangible book value per share as of March&#160;31, 2024 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">1.77</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
            <td style="border-bottom:1px solid #CCEEFF;padding:2.75pt 0pt 2.25pt 0pt; width:371.07pt;text-align:left;">
              <div style="margin-left:9.5pt;">Increase in net tangible book value per share attributable to this offering</div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">0.54</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            <td style="border-bottom:1px solid #FFFFFF;padding:2.75pt 0pt 2.25pt 0pt; width:371.07pt;text-align:left;">
              <div style="white-space:nowrap;">As adjusted net tangible book value per share after this offering</div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">2.30</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 4pt 0pt; width:371.07pt;text-align:left;">
              <div style="white-space:nowrap;">Dilution per share to investors participating in this offering </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 3.25pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 3.25pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">1.70</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="height:7.5pt;line-height:7.5pt;">
            <td style="padding:0pt;font-size:0pt;line-height:0pt;" colspan="15">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:7.1pt; width:456pt; line-height:11.5pt;">If the underwriters exercise their option to purchase an additional <font style="letter-spacing:-0.361pt;">2,250,000</font> shares of common stock in full, at the public offering price of&#8201; $<font style="letter-spacing:-0.361pt;">4.00 </font>per share of common stock, the as adjusted net tangible book value per share after giving effect to this offering would be $<font style="letter-spacing:-0.361pt;">2.36 </font>per share of common stock, representing an immediate increase in net tangible book value to existing stockholders of&#8201; $<font style="letter-spacing:-0.361pt;">0.59 </font>per share of common stock and immediate dilution in net tangible book value of&#8201; $<font style="letter-spacing:-0.361pt;">1.64 </font>per common share to new investors.<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">The number of shares of common stock shown above to be outstanding after this offering is based on 40,132,647 shares of common stock outstanding as of March&#160;31, 2024. The following shares are excluded:<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.61pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:3.61pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->10,907,472 shares of our common stock issuable upon the exercise of stock options outstanding as of March&#160;31, 2024, at a weighted average exercise price of&#8201; $3.82 per share, of which stock options to purchase 4,374,179 shares of common stock were then exercisable;<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.6pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:3.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->401,928 shares of our common stock reserved for future grants of stock options (or other similar equity instruments) under our equity incentive plans;</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.6pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:3.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->500,000 shares of our common stock reserved for issuance pursuant to our 2022 Employee Stock Purchase Plan;<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.6pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:3.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->860,562 shares of our common stock reserved for issuance upon the exercise of warrants outstanding as of March 31, 2024, at a weighted average exercise price of&#8201; $20.28 per share; and<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.61pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:3.61pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->11,270,371 shares of our common stock issuable upon the exercise of outstanding pre-funded warrants, at a weighted average exercise price of&#8201; $<font style="letter-spacing:-0.361pt;">0.001.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">Except as otherwise indicated, all information in this prospectus supplement assumes (i)&#160;no exercise of the underwriters&#8217; option to purchase additional shares of common stock and (ii) no exercise of Pre-Funded Warrants offered in this offering.<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.361pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11pt;font-size:9pt;">
          <font style="letter-spacing:-0.342pt;">S-17</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Helvetica, Arial, sans-serif;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:12.5pt;">
          <font style="letter-spacing:0.625pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:580.5pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">From time to time the Company may enter into various strategic transactions, joint ventures, licensing transactions and partnerships with certain current and future stockholders and other related parties. Such transactions might result in issuing certain securities and may result in additional dilution. There is no guarantees that we are going to complete these transactions.</div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11.5pt;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
          <font style="letter-spacing:-0.361pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11pt;font-family:Arial, Helvetica, sans-serif;">
          <font style="letter-spacing:-0.342pt;">S-18</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="sDOS">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:12.5pt;">
          <font style="letter-spacing:0.625pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:10pt;">
          <font style="text-transform:uppercase;letter-spacing:0.5pt;">DESCRIPTION OF SECURITIES</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:10pt;">
          <font style="letter-spacing:0.5pt;">General</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:18pt; width:456pt; line-height:12pt;">This prospectus supplement describes the general terms of our capital stock. For a more detailed description of our capital stock, you should read the applicable provisions of the Nevada Revised Statutes (the &#8220;<font style="font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;letter-spacing:0.475pt;">NRS</font>&#8221;), our amended and restated articles of incorporation (our &#8220;<font style="font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;letter-spacing:0.475pt;">Articles of Incorporation</font>&#8221;) and our amended and restated bylaws (our &#8220;<font style="font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;letter-spacing:0.475pt;">Bylaws</font><font style="letter-spacing:-0.361pt;">&#8221;).</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="margin-top:12pt; width:456pt; line-height:12.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:10pt;">
          <font style="letter-spacing:0.5pt;">Common Stock</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:18pt; width:456pt; line-height:12pt;">Our Articles of Incorporation provides authority for us to issue up to 100,000,000 shares of common stock, par value $0.001 per share. As of June&#160;7, 2024 there were 40,135,980 shares of our common stock outstanding. Under the NRS, stockholders generally are not personally liable for our debts or obligations solely as a result of their status as stockholders. Our outstanding shares of common stock are, and any shares offered by this prospectus will be, when issued and paid for, fully paid and nonassessable.<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">Holders of our common stock are entitled to one vote per share on all matters submitted to our stockholders for a vote. There are no cumulative voting rights in the election of directors. Our shares of common stock are entitled to receive such dividends as may be declared and paid by our Board of Directors out of funds legally available therefor and to share ratably in the net assets, if any, of Rezolute upon liquidation. Our stockholders have no preemptive rights to purchase any shares of our capital stock. Our Articles of Incorporation provides that the Eighth Judicial District Court of Clark County, Nevada shall be the sole and exclusive forum for (i)&#160;any derivative action or proceeding brought on our behalf, (ii)&#160;any action asserting a claim for breach of a fiduciary duty owed by any of our directors, officers, employees or agents to us or our stockholders, (iii)&#160;any action asserting a claim arising pursuant to any provision of the NRS Chapters 78 or 92A, our Articles of Incorporation or our Bylaws or (iv)&#160;any action asserting a claim governed by the internal affairs doctrine. Notwithstanding this exclusive forum provision, the exclusive forum provision shall not preclude or contract the scope of exclusive federal or concurrent jurisdiction for actions brought under the Exchange Act or the Securities Act, or the respective rules and regulations promulgated thereunder.<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="margin-top:12pt; width:456pt; line-height:12.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:10pt;">
          <font style="letter-spacing:0.5pt;">Pre-Funded Warrants</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:18pt; width:456pt; line-height:12pt;">In this offering, we are offering<font style="letter-spacing:-0.361pt;"> </font>Pre-Funded Warrants to purchase<font style="letter-spacing:-0.361pt;"> 3,750,000 </font>shares of our common stock. The following description is subject in all respects to the provisions contained in the form of Pre-Funded Warrant. You should review a copy of the form of Pre-Funded Warrant, which will be filed as an exhibit to our Current Report on Form 8-K being filed with the SEC in connection with this offering, for a complete description of the terms and conditions of the Pre-Funded Warrants.<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">The Pre-Funded Warrants will be issued as individual warrant agreements with the holders. The Pre-Funded Warrants are exercisable at any time after their original issuance at an exercise price of&#8201; $0.001 per share. The Pre-Funded Warrants will be exercisable, at the option of each holder, in whole or in part by delivering to us a duly executed exercise notice and by payment in full in immediately available funds for the number of shares of common stock purchased upon such exercise. As an alternative to payment in immediately available funds, the holder may, in its sole discretion, elect to exercise the Pre-Funded Warrant through a cashless exercise, in which case the holder would receive upon such exercise the net number of shares of common stock determined according to the formula set forth in the Pre-Funded Warrant. No fractional shares of common stock will be issued in connection with the exercise of a Pre-Funded Warrant. In lieu of issuing fractional shares, we will pay the holder an amount in cash equal to the fair market value of any fractional share, calculated based on the trading price of our common stock.<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">The exercise price per whole share of our common stock purchasable upon the exercise of the Pre-Funded Warrants is $0.001 per share of common stock. The exercise price of the Pre-Funded Warrants is subject to adjustment from time to time in the event of certain stock dividends and distributions, stock splits, stock </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.361pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11pt;font-size:9pt;">
          <font style="letter-spacing:-0.342pt;">S-19</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:12.5pt;">
          <font style="letter-spacing:0.625pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:296.5pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">combinations, reclassifications or similar events affecting our common stock and also upon any distributions for no consideration of assets, including cash, stock or other property, to all of our stockholders.<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">A holder will not have the right to exercise any portion of the Pre-Funded Warrant if the holder (together with its affiliates) would beneficially own in excess of&#8201; (i) 4.99% (or, at the election of the purchaser, up to 19.99%) of the number of shares of our common stock outstanding immediately after giving effect to the exercise or (ii) 4.99% (or, at the election of the purchaser, up to 19.99%) of the combined voting power of all of our securities then outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the Pre-Funded Warrants. However, any holder may increase or decrease such ownership&#160;percentage limit to any other&#160;percentage not in excess of 19.99% upon at least 61&#160;days&#8217; prior notice from the holder to us. We do not plan on applying to list the Pre-Funded Warrants on Nasdaq or any other national securities exchange or any other nationally recognized trading system.<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">Subject to applicable laws, the Pre-Funded Warrants may be offered for sale, sold, transferred or assigned without our consent.<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">In the event of a fundamental transaction, as defined in the Pre-Funded Warrants and generally including, without limitation, any reclassification of our common stock into other securities, cash or property, the sale, transfer or other disposition of all or substantially all of our properties or assets, our consolidation or merger with or into another person, the acquisition by any person or group, whether in a tender offer, exchange offer, stock purchase agreement, or other business combination, of more than 50% of the voting power of our capital stock, the holders of the Pre-Funded Warrants will be entitled to receive upon exercise of the Pre-Funded Warrants the same amount and kind of securities, cash or other property that the holders would have received had they exercised the Pre-Funded Warrants immediately prior to such fundamental transaction.<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">Except as otherwise provided in the Pre-Funded Warrants or by virtue of such holder&#8217;s ownership of shares of our common stock, the holder of a Pre-Funded Warrant does not have the rights or privileges of a holder of our common stock, including any voting rights, until the holder exercises the Pre-Funded Warrant. Direct Transfer, LLC will serve as warrant agent for the Pre-Funded Warrants. </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.361pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11pt;font-size:9pt;">
          <font style="letter-spacing:-0.342pt;">S-20</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="sMUTC">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:12.5pt;">
          <font style="letter-spacing:0.625pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:10pt;">
          <font style="text-transform:uppercase;letter-spacing:0.5pt;">MATERIAL U.S. TAX CONSIDERATIONS FOR NON-U.S. HOLDERS OF COMMON STOCK AND PRE-FUNDED WARRANTS </font>
        </div>
        <div style="margin-top:18pt; width:456pt; line-height:11.5pt;">The following is a discussion of material U.S. federal income tax considerations applicable to a non-U.S. holder (as defined below) arising from and relating to the acquisition, ownership and disposition of Common Stock, the acquisition, ownership and disposition of Pre-Funded Warrants, and the acquisition, ownership and disposition of Pre-Funded Warrant Shares received upon acquisition of the Pre-Funded Warrants, all as acquired pursuant to this offering. This summary is for general information purposes only and does not purport to be a complete analysis or listing of all potential U.S. federal income tax considerations that may apply to a non-U.S. holder arising from or relating to the acquisition, ownership and disposition of Common Stock, Pre-Funded Warrants or Pre-Funded Warrant Shares, all as acquired pursuant to this offering. In addition, this summary does not take into account the individual facts and circumstances of any particular non-U.S. holder that may affect the U.S. federal income tax consequences to such non-U.S. holder, including, without limitation, specific tax consequences to a non-U.S. holder under an applicable income tax treaty. Accordingly, this summary is not intended to be, and should not be construed as, legal or U.S. federal income tax advice with respect to any particular non-U.S. holder. This summary does not address the U.S. federal alternative minimum, U.S. federal net investment income, U.S. federal estate and gift, U.S. state and local, and non-U.S. tax consequences to non-U.S. holders of the acquisition, ownership and disposition of Common Stock, Pre-Funded Warrants or Pre-Funded Warrant Shares. In addition, except as specifically set forth below, this summary does not discuss applicable income tax reporting requirements. Each prospective non-U.S. holder should consult his, her or its own tax advisors regarding the U.S. federal income, U.S. federal alternative minimum, U.S. federal net investment income, U.S. federal estate and gift, U.S. state and local, and non-U.S. tax consequences relating to the acquisition, ownership and disposition of Common Stock, Pre-Funded Warrants or Pre-Funded Warrant Shares.</div>
        <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">No ruling from the Internal Revenue Service (the &#8220;IRS&#8221;) has been requested, or will be obtained, regarding the U.S. federal income tax consequences to a non-U.S. holder of the acquisition, ownership and disposition of Common Stock, Pre-Funded Warrants or Pre-Funded Warrant Shares. This summary is not binding on the IRS, and the IRS is not precluded from taking a position that is different from, or contrary to, the positions taken in this summary. In addition, because the authorities on which this summary is based are subject to various interpretations, the IRS and the U.S. courts could disagree with one or more of the conclusions described in this summary.<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="margin-top:12pt; width:456pt; line-height:12.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:10pt;">
          <font style="letter-spacing:0.5pt;">Scope of this Summary</font>
        </div>
        <div style="margin-top:18pt; width:456pt; line-height:12pt;">This discussion is based on current provisions of the Internal Revenue Code of 1986, as amended (the <font style="letter-spacing:-0.361pt;">&#8220;</font><font style="font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;letter-spacing:0.475pt;">Code</font>&#8221;), existing and proposed U.S. Treasury Regulations promulgated thereunder, current administrative rulings and judicial decisions, all as in effect as of the date of this prospectus supplement and all of which are subject to change or to differing interpretation, possibly with retroactive effect. Any change or differing interpretation could alter the tax consequences to non-U.S. holders described in this prospectus supplement. There can be no assurance that the IRS will not challenge one or more of the tax consequences described in this summary. This summary does not discuss the potential effects, whether adverse or beneficial, of any proposed legislation that, if enacted, could be applied on a retroactive or prospective basis.</div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">For purposes of this discussion, the term &#8220;non-U.S. holder&#8221; means a beneficial owner (other than a partnership or other pass-through entity) of Common Stock, Pre-Funded Warrants or Pre-Funded Warrant Shares that is not, for U.S. federal income tax purposes:</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->an individual who is a citizen or resident of the United States;</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->a corporation, or other entity treated as a corporation for U.S. federal income tax purposes, created or organized in or under the laws of the United States, any state thereof, or the District of Columbia;</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->an estate the income of which is subject to U.S. federal income taxation regardless of its source; or</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->a trust if&#8201; (1) a U.S. court is able to exercise primary supervision over the administration of the trust and one or more U.S. persons have authority to control all substantial decisions of the trust or (2) the trust has a valid election in effect under applicable U.S. Treasury Regulations to be treated as a U.S. person.<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.361pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11pt;font-size:9pt;">
          <font style="letter-spacing:-0.342pt;">S-21</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:12.5pt;">
          <font style="letter-spacing:0.625pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">We assume in this discussion that each non-U.S. holder holds Common Stock, Pre-Funded Warrants or Pre-Funded Warrant Shares, as applicable, as a capital asset (generally, property held for investment) within the meaning of Section 1221 of the Code. This discussion does not address all aspects of U.S. federal income and estate taxation that may be relevant to a particular non-U.S. holder in light of that non-U.S. holder&#8217;s individual circumstances. This discussion also does not consider any specific facts or circumstances that may apply to a non-U.S. holder and does not address the special tax rules applicable to particular non-U.S. holders, such as:<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.2pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->financial institutions;<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.2pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->brokers or dealers in securities;<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.2pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->tax-exempt organizations;<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.2pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->pension plans, including &#8220;qualified foreign pension funds&#8221; as defined in Section&#160;897(l)(2) of the Code and entities all of the interests of which are held by qualified foreign pension funds;<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.1pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->persons deemed to sell Common Stock, Pre-Funded Warrants or Pre-Funded Warrant Shares under the constructive sale provisions of the Code;<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.1pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->owners that hold Common Stock, Pre-Funded Warrants or Pre-Funded Warrant Shares as part of a straddle, hedge, conversion transaction, synthetic security or other integrated investment or who have elected to mark securities to market;<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.1pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->insurance companies;<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.1pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->controlled foreign corporations and passive foreign investment companies and shareholders in each type of entity;<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.1pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->corporations organized outside the U.S., any state thereof or the District of Columbia that are nonetheless treated as U.S. taxpayers for U.S. federal income tax purposes;<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.1pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->non-U.S. governments; and<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.1pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->certain U.S. expatriates and former long-term residents of the U.S.<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">This discussion also does not address the tax treatment of entities or arrangements classified as a partnership or other entities that are pass-through entities for U.S. federal income tax purposes or persons who hold their shares of Common Stock, Pre-Funded Warrants or Pre-Funded Warrant Shares through partnerships or such other pass-through entities. A partner in a partnership or other pass-through entity that will hold shares of Common Stock, Pre-Funded Warrants or Pre-Funded Warrant Shares should consult his, her or its own tax advisor regarding the tax consequences of the ownership and disposition of shares of Common Stock, Pre-Funded Warrants or Pre-Funded Warrant Shares through a partnership or other pass-through entity, as applicable.</div>
        <div style="margin-top:12pt; text-align:justify; width:456pt; line-height:12.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:10pt;">
          <font style="text-transform:uppercase;letter-spacing:0.5pt;">THIS DISCUSSION IS FOR INFORMATIONAL PURPOSES ONLY AND IS NOT, AND IS NOT INTENDED TO BE, LEGAL OR TAX ADVICE. PROSPECTIVE INVESTORS SHOULD CONSULT THEIR OWN TAX ADVISORS REGARDING THE U.S. FEDERAL, STATE, LOCAL, AND NON-U.S. INCOME, ESTATE AND OTHER TAX CONSIDERATIONS OF ACQUIRING, HOLDING AND DISPOSING OF COMMON STOCK, PRE-FUNDED WARRANTS OR PRE-FUNDED WARRANT SHARES.</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; text-align:justify; width:456pt; line-height:12.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:10pt;">
          <font style="letter-spacing:0.5pt;">Treatment of Pre-Funded Warrants</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:18pt; width:456pt; line-height:12pt;">Although it is not entirely free from doubt, a Pre-Funded Warrant should be treated as a share of our common stock for U.S. federal income tax purposes and a holder of Pre-Funded Warrants should generally be taxed in the same manner as a holder of Common Stock as described below. Accordingly, upon exercise, the holding period of a Pre-Funded Warrant Share received upon exercise of a Pre-Funded Warrant should generally include the holding period of such Pre-Funded Warrant. Similarly, the tax basis of the Pre-Funded Warrant should carry over to the Pre-Funded Warrant Share received upon exercise increased by the exercise price of $0.001. However, such characterization is not binding on the IRS, and the IRS may treat the Pre-Funded Warrants as warrants to acquire a share of common stock. Each non-U.S. holder should consult his, her or its own tax advisor regarding the risks associated with the acquisition of a Pre-Funded Warrant pursuant to this offering (including potential alternative characterizations). The balance of this discussion generally assumes that the characterization described above is respected for U.S. federal income tax purposes.<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.361pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11pt;font-size:9pt;">
          <font style="letter-spacing:-0.342pt;">S-22</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:12.5pt;">
          <font style="letter-spacing:0.625pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11pt;font-style:italic;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;">
          <font style="letter-spacing:0.475pt;">U.S. Federal Income Tax Consequences to Non-U.S. Holders of the Acquisition, Ownership and Disposition of Common Stock, Pre-Funded Warrants and Pre-Funded Warrant Shares</font>
        </div>
        <div style="margin-top:6pt; text-align:justify; width:456pt; line-height:12.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:10pt;">
          <font style="letter-spacing:0.5pt;">Distributions</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:18pt; width:456pt; line-height:11.5pt;">We have no intention of paying any cash dividends with respect to the Common Stock, Pre-Funded Warrants or Pre-Funded Warrant Shares in the foreseeable future. If we make distributions in respect of Common Stock, Pre-Funded Warrants or Pre-Funded Warrant Shares, those distributions generally will constitute dividends for U.S. federal income tax purposes to the extent paid from our current or accumulated earnings and profits, as determined under U.S. federal income tax principles. If a distribution exceeds our current and accumulated earnings and profits, the excess will be treated as a tax-free return of the non-U.S. holder&#8217;s investment, up to the holder&#8217;s tax basis in the Common Stock, Pre-Funded Warrants or Pre-Funded Warrant Shares (and will reduce the non-U.S. holder&#8217;s basis in the Common Stock, Pre-Funded Warrants) or Pre-Funded Warrant Shares, but not below zero). Any remaining excess will be treated as capital gain, subject to the tax treatment described below under the heading &#8220;Gain on Sale, Exchange or Other Taxable Disposition of Common Stock, Pre-Funded Warrants, or Pre-Funded Warrant Shares.&#8221; Any dividends paid to a non-U.S. holder with respect to Common Stock, Pre-Funded Warrants or Pre-Funded Warrant Shares generally will be subject to withholding tax at a 30% gross rate, subject to any exemption or lower rate under an applicable treaty if the non-U.S. holder provides us with a properly executed IRS Form W-8BEN or W-8BEN-E, unless the non-U.S. holder provides us with a properly executed IRS Form W-8ECI (or other applicable form) relating to income effectively connected with the conduct of a trade or business within the U.S. If we are unable to determine, at the time of payment of a distribution, whether the distribution will constitute a dividend, we may nonetheless choose to withhold any U.S. federal income tax on the distribution as permitted by Treasury Regulations. If we are a USRPHC (as defined below) and we do not qualify for the Regularly Traded Exception (as defined below), distributions which constitute a return of capital will be subject to withholding tax unless an application for a withholding certificate is filed to reduce or eliminate such withholding.<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">Dividends that are effectively connected with the conduct of a trade or business within the U.S. and includible in the non-U.S. holder&#8217;s gross income are not subject to the withholding tax (assuming proper certification and disclosure), but instead are subject to U.S. federal income tax on a net income basis at applicable graduated individual or corporate rates. Any such effectively connected income received by a non-U.S. corporation may, under certain circumstances, be subject to an additional branch profits tax at a 30% rate, subject to any exemption or lower rate as may be specified by an applicable income tax treaty.</div>
        <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">A non-U.S. holder of Common Stock, Pre-Funded Warrants or Pre-Funded Warrant Shares who wishes to claim the benefit of an applicable treaty rate or exemption is required to satisfy certain certification and other requirements. If a non-U.S. holder is eligible for an exemption from or a reduced rate of U.S. withholding tax pursuant to an income tax treaty, it may obtain a refund of any excess amounts withheld by timely filing an appropriate claim for refund with the IRS.<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="margin-top:12pt; text-align:justify; width:456pt; line-height:12pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:10pt;">
          <font style="letter-spacing:0.5pt;">Gain on Sale, Exchange or Other Taxable Disposition of Common Stock, Pre-Funded Warrants, or Pre-Funded Warrant Shares</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:18pt; width:456pt; line-height:11.5pt;">A non-U.S. holder generally will not be subject to U.S. federal income tax on any gain realized upon such non-U.S. holder&#8217;s sale, exchange or other disposition of Common Stock, Pre-Funded Warrants or Pre-Funded Warrant Shares unless:<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.8pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:3.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->the gain is effectively connected with a U.S. trade or business carried on by the non-U.S. holder (and, where an income tax treaty applies, is attributable to a U.S. permanent establishment of the non-U.S. holder), in which case the non-U.S. holder will be subject to tax on the net gain from the sale at regular graduated U.S. federal income tax rates, and if the non-U.S. holder is a corporation, may be subject to an additional U.S. branch profits tax at a gross rate equal to 30% of its effectively connected earnings and profits for that taxable year, subject to any exemption or lower rate as may be specified by an applicable income tax treaty;<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.8pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:3.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->the non-U.S. holder is an individual who is present in the U.S. for 183&#160;days or more in the taxable year of disposition and certain other conditions are met, in which case the non-U.S. holder will be subject to a 30% tax on the gain from the sale, which may be offset by U.S. source capital losses; or<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.361pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11pt;font-size:9pt;">
          <font style="letter-spacing:-0.342pt;">S-23</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:12.5pt;">
          <font style="letter-spacing:0.625pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->we are or have been a &#8220;United States real property holding corporation&#8221; &#8203;(&#8220;<font style="font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;letter-spacing:0.475pt;">USRPHC</font>&#8221;) for U.S. federal income tax purposes at any time during the shorter of the non-U.S. holder&#8217;s holding period or the 5-year period ending on the date of disposition of Common Stock, Pre-Funded Warrants or Pre-Funded Warrant Shares; provided, with respect to the Common Stock and Pre-Funded Warrant Shares, that as long as our Common Stock is regularly traded on an established securities market as determined under the Treasury Regulations (the &#8220;<font style="font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;letter-spacing:0.475pt;">Regularly Traded Exception</font>&#8221;), a non-U.S. holder would not be subject to taxation on the gain on the sale of Common Stock or Pre-Funded Warrant Shares under this rule unless the non-U.S. holder has owned: (i)&#160;more than 5% of our Common Stock at any time during such 5-year or shorter period; (ii) Pre-Funded Warrants with a fair market value on the date acquired by such holder greater than the fair market value on that date of 5% of our Common Stock; or (iii) our aggregate equity securities with a fair market value on the date acquired in excess of 5% of the fair market value of the our Common Stock on such date (in any case, a &#8220;<font style="font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;letter-spacing:0.475pt;">5% Shareholder</font><font style="letter-spacing:-0.361pt;">&#8221;). </font>Special rules may apply to the Pre-Funded Warrants. In determining whether a non-U.S. holder is a 5% Shareholder, certain attribution rules apply in determining ownership for this purpose. Although there can be no assurance, we believe that we are not currently, and we do not anticipate becoming, a USRPHC for U.S. federal income tax purposes. No assurance can be provided that our Common Stock will be regularly traded on an established securities market for purposes of the rule described above. Accordingly, we can provide no assurances that the Common Stock, Pre-Funded Warrants or Pre-Funded Warrant Shares will meet the Regularly Traded Exception at the time a non-U.S. holder purchases such securities or sells, exchanges or otherwise disposes of such securities. If we are determined to be a USRPHC and the foregoing exception does not apply, then the non-U.S. holder generally will be taxed on its net gain derived from the disposition at the U.S. federal income tax rates applicable to U.S. persons (as defined in the Code). Non-U.S. holders should consult with their own tax advisors regarding the consequences to these rules on their investment.<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:10.12pt; width:456pt; line-height:12.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:10pt;">
          <font style="letter-spacing:0.5pt;">Information Reporting and Backup Withholding</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:18pt; width:456pt; line-height:11.5pt;">We must report annually to the IRS and to each non-U.S. holder the gross amount of the distributions on our Common Stock, Pre-Funded Warrants or Pre-Funded Warrant Shares paid to such holder and the tax withheld, if any, with respect to such distributions. Non-U.S. holders may have to comply with specific certification procedures to establish that the holder is not a U.S. person (as defined in the Code) in order to avoid backup withholding at the applicable rate with respect to dividends on Common Stock, Pre-Funded Warrants or Pre-Funded Warrant Shares. Generally, a non-U.S. holder will comply with such procedures if it provides a properly executed IRS Form W-8BEN or W-8BEN-E (or other applicable Form W-8), or otherwise meets documentary evidence requirements for establishing that it is a non-U.S. holder, or otherwise establishes an exemption. Dividends paid to non-U.S. holders subject to withholding of U.S. federal income tax, as described above under the heading &#8220;Distributions,&#8221; will generally be exempt from U.S. backup withholding.<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">Information reporting and backup withholding generally will apply to the proceeds of a disposition of Common Stock, Pre-Funded Warrants or Pre-Funded Warrant Shares by a non-U.S. holder effected by or through the U.S. office of any broker, U.S. or non-U.S., unless the holder certifies its status as a non-U.S. holder and satisfies certain other requirements, or otherwise establishes an exemption. Generally, information reporting and backup withholding will not apply to a payment of disposition proceeds to a non-U.S. holder where the transaction is effected outside the United States through a non-U.S. office of a non-U.S. broker. Non-U.S. holders should consult their own tax advisors regarding the application of the information reporting and backup withholding rules to them.<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">Copies of information returns may be made available to the tax authorities of the country in which the non-U.S. holder resides or is incorporated under the provisions of a specific treaty or agreement.<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">Backup withholding is not an additional tax. Rather, any amounts withheld under the backup withholding rules from a payment to a non-U.S. holder can be refunded or credited against the non-U.S. holder&#8217;s U.S. federal income tax liability, if any, provided that an appropriate claim is timely filed with the IRS.<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="margin-top:12pt; width:456pt; line-height:12.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:10pt;">
          <font style="letter-spacing:0.5pt;">FATCA</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:18pt; width:456pt; line-height:11.5pt;">Provisions of the Code commonly referred to as the Foreign Account Tax Compliance Act (&#8220;<font style="font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;letter-spacing:0.475pt;">FATCA&#8221;</font>), generally impose a 30% withholding tax on dividends on, and gross proceeds from the sale or other disposition of, </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.361pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11pt;font-size:9pt;">
          <font style="letter-spacing:-0.342pt;">S-24</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:12.5pt;">
          <font style="letter-spacing:0.625pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:310pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">Common Stock, Pre-Funded Warrants or Pre-Funded Warrant Shares if paid to a foreign entity unless (1)&#160;if the foreign entity is a &#8220;foreign financial institution,&#8221; the foreign entity undertakes certain due diligence, reporting, withholding, and certification obligations, (2)&#160;if the foreign entity is not a &#8220;foreign financial institution,&#8221; the foreign entity identifies certain of its U.S. investors, or (3)&#160;the foreign entity is otherwise excepted under FATCA.<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">Withholding under FATCA generally applies to payments of dividends on Common Stock, Pre-Funded Warrants or Pre-Funded Warrant Shares. While withholding under FATCA may apply to payments of gross proceeds from a sale or other disposition of Common Stock, Pre-Funded Warrants or Pre-Funded Warrant Shares, withholding on payments of gross proceeds is not required under proposed U.S. Treasury Regulations. Although such regulations are not final, applicable withholding agents may rely on the proposed regulations until final regulations are issued.<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">If withholding under FATCA is required on any payment related to Common Stock, Pre-Funded Warrants or Pre-Funded Warrant Shares, investors not otherwise subject to withholding (or that otherwise would be entitled to a reduced rate of withholding) on such payment may be required to seek a refund or credit from the IRS. An intergovernmental agreement between the United States and an applicable foreign country may modify the requirements described in this section. Non-U.S. holders should consult their own tax advisors regarding the possible implications of FATCA on their investment in Common Stock, Pre-Funded Warrants or Pre-Funded Warrant Shares and the entities through which they hold Common Stock, Pre-Funded Warrants or Pre-Funded Warrant Shares.<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="margin-top:12pt; text-align:justify; width:456pt; line-height:12.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:10pt;">
          <font style="letter-spacing:0.5pt;">The preceding discussion of material U.S. federal tax considerations is for informational purposes only. It is not legal or tax advice. Prospective investors should consult their own tax advisors regarding the particular U.S. federal, state, local, and non-U.S. tax consequences of purchasing, holding and disposing of Common Stock, Pre-Funded Warrants or Pre-Funded Warrant Shares, including the consequences of any proposed changes in applicable laws.</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.361pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11pt;font-size:9pt;">
          <font style="letter-spacing:-0.342pt;">S-25</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="sUNF1">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:12.5pt;">
          <font style="letter-spacing:0.625pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:10pt;">
          <font style="text-transform:uppercase;letter-spacing:0.5pt;">UNDERWRITING</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:18pt; width:456pt; line-height:11.5pt;">Subject to the terms and conditions set forth in the underwriting agreement, dated June&#160;<font style="letter-spacing:-0.361pt;">13</font>, 2024, between us and Jefferies LLC and Cantor Fitzgerald &amp; Co., as the representatives of the underwriters named below and the book-running manager of this offering, we have agreed to sell to the underwriters, and each of the underwriters has agreed, severally and not jointly, to purchase from us, the respective number of shares of common stock and Pre-Funded Warrants shown opposite its name below:<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <table style="width:456pt;margin-top:2.5pt;border-collapse: collapse;border-top:0.75pt solid #000000; border-bottom:0.75pt solid #000000; font-style:normal;font-weight:bold;font-variant:normal;text-transform:uppercase;color:#000000;font-family:Arial Narrow, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:10.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial Narrow, Helvetica, sans-serif;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:9.833pt 0pt 1.667pt 0pt; width:338.08pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="text-transform:uppercase;letter-spacing:0.4pt;">Underwriters</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:9.833pt 0pt 1.667pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="text-transform:uppercase;letter-spacing:0.4pt;">Number of</font>
                <br >
                <font style="text-transform:uppercase;letter-spacing:0.4pt;">Firm Shares</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:9.833pt 0pt 1.667pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="text-transform:uppercase;letter-spacing:0.4pt;">Number of</font>
                <br >
                <font style="text-transform:uppercase;letter-spacing:0.4pt;">Pre-Funded</font>
                <br >
                <font style="text-transform:uppercase;letter-spacing:0.4pt;">Warrants</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:2.75pt 0pt 1.5pt 0pt; width:338.08pt;text-align:left;">
              <div style="white-space:nowrap;">Jefferies LLC  </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">5,765,625</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">1,921,875</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:3pt 0pt 1.5pt 0pt; width:338.08pt;text-align:left;">
              <div style="white-space:nowrap;">Cantor Fitzgerald &amp; Co. </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">2,953,125</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">984,375</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:3pt 0pt 1.5pt 0pt; width:338.08pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.361pt;">BTIG, LLC</font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">506,250</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">168,750</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:3pt 0pt 1.5pt 0pt; width:338.08pt;text-align:left;">
              <div style="white-space:nowrap;">Craig-Hallum Capital Group LLC </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">506,250</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">168,750</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:3pt 0pt 1.5pt 0pt; width:338.08pt;text-align:left;">
              <div style="white-space:nowrap;">H.C. Wainwright &amp; Co., LLC </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">506,250</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">168,750</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:3pt 0pt 1.5pt 0pt; width:338.08pt;text-align:left;">
              <div style="white-space:nowrap;">JonesTrading Institutional Services LLC </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">506,250</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">168,750</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3pt 0pt 2.25pt 0pt; width:338.08pt;text-align:left;">
              <div style="white-space:nowrap;">Maxim Group LLC </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:42pt; text-align:right; white-space:nowrap;">506,250</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:37.5pt; text-align:right; white-space:nowrap;">168,750</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial Narrow, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:2.75pt 0pt 3pt 0pt; width:338.08pt;text-align:left;">
              <div style="margin-left:9.5pt;font-weight:normal;font-family:Arial, Helvetica, sans-serif;">Total </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.25pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.25pt 0pt;border-bottom:3pt double #000000; min-width:42pt; text-align:right; white-space:nowrap;">11,250,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.25pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.25pt 0pt;border-bottom:3pt double #000000; min-width:37.5pt; text-align:right; white-space:nowrap;">3,750,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="height:7.5pt;line-height:7.5pt;">
            <td style="padding:0pt;font-size:0pt;line-height:0pt;" colspan="14">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:7.1pt; width:456pt; line-height:11.5pt;">The underwriting agreement provides that the obligations of the several underwriters are subject to certain conditions precedent such as the receipt by the underwriters of officers&#8217; certificates and legal opinions and approval of certain legal matters by their counsel. The underwriting agreement provides that the underwriters will purchase all of the shares of common stock and Pre-Funded Warrants if any of them are purchased. If an underwriter defaults, the underwriting agreement provides that the purchase commitments of the non-defaulting underwriters may be increased or the underwriting agreement may be terminated. We have agreed to indemnify the underwriters and certain of their controlling persons against certain liabilities, including liabilities under the Securities Act, and to contribute to payments that the underwriters may be required to make in respect of those liabilities.<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">The underwriters have advised us that, following the completion of this offering, they currently intend to make a market in the common stock as permitted by applicable laws and regulations. However, the underwriters are not obligated to do so, and the underwriters may discontinue any market-making activities at any time without notice in their sole discretion. Accordingly, no assurance can be given as to the liquidity of the trading market for the common stock, that you will be able to sell any of the common stock held by you at a particular time or that the prices that you receive when you sell will be favorable.<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">The underwriters are offering the shares of common stock and Pre-Funded Warrants subject to their acceptance of the shares of common stock and Pre-Funded Warrants from us and subject to prior sale. The underwriters reserve the right to withdraw, cancel or modify offers to the public and to reject orders in whole or in part.<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="margin-top:12pt; width:456pt; line-height:12.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:10pt;">
          <font style="letter-spacing:0.5pt;">Commission and expenses</font><font style="font-weight:normal;text-transform:uppercase;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:18pt; width:456pt; line-height:11.5pt;">The underwriters have advised us that they propose to offer the shares of common stock and Pre-Funded Warrants to the public at the public offering price set forth on the cover page of this prospectus supplement and to certain dealers, which may include the underwriters, at that price less a concession not in excess of <font style="letter-spacing:-0.361pt;">$0.144 </font>per share of common stock and $<font style="letter-spacing:-0.361pt;">0.143964 </font>per Pre-Funded Warrant. After the offering, the public offering price, concession and reallowance to dealers may be reduced by the representatives. No such reduction will change the amount of proceeds to be received by us as set forth on the cover page of this prospectus supplement.<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">The following table shows the public offering price, the underwriting discounts and commissions that we are to pay the underwriters and the proceeds, before expenses, to us in connection with this offering. Such amounts are shown assuming both no exercise and full exercise of the underwriters&#8217; option to purchase additional shares.<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.361pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11pt;font-size:9pt;">
          <font style="letter-spacing:-0.342pt;">S-26</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:12.5pt;">
          <font style="letter-spacing:0.625pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <table style="width:456pt;margin-top:0pt;border-collapse: collapse;border-top:0.75pt solid #000000; border-bottom:0.75pt solid #000000; font-style:normal;font-weight:bold;font-variant:normal;text-transform:uppercase;color:#000000;font-family:Arial Narrow, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:8pt;min-height:21.75pt;height:21.75pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial Narrow, Helvetica, sans-serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:182.08pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:11.5pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="22">
              <div style="white-space:nowrap; text-align:center;">
                <font style="text-transform:uppercase;letter-spacing:0.4pt;">TOTAL </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial Narrow, Helvetica, sans-serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:182.08pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:1.083pt 0pt 1.667pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="text-transform:uppercase;letter-spacing:0.4pt;">PER SHARE </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:1.083pt 0pt 1.667pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="text-transform:uppercase;letter-spacing:0.4pt;">PER</font>
                <br >
                <font style="text-transform:uppercase;letter-spacing:0.4pt;">PRE-FUNDED</font>
                <br >
                <font style="text-transform:uppercase;letter-spacing:0.4pt;">WARRANT </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:1.083pt 0pt 1.667pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="text-transform:uppercase;letter-spacing:0.4pt;">WITHOUT </font>
                <br >
                <font style="text-transform:uppercase;letter-spacing:0.4pt;">OPTION TO </font>
                <br >
                <font style="text-transform:uppercase;letter-spacing:0.4pt;">PURCHASE </font>
                <br >
                <font style="text-transform:uppercase;letter-spacing:0.4pt;">ADDITIONAL </font>
                <br >
                <font style="text-transform:uppercase;letter-spacing:0.4pt;">SHARES </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:1.083pt 0pt 1.667pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="text-transform:uppercase;letter-spacing:0.4pt;">WITH</font>
                <br >
                <font style="text-transform:uppercase;letter-spacing:0.4pt;">OPTION TO </font>
                <br >
                <font style="text-transform:uppercase;letter-spacing:0.4pt;">PURCHASE </font>
                <br >
                <font style="text-transform:uppercase;letter-spacing:0.4pt;">ADDITIONAL </font>
                <br >
                <font style="text-transform:uppercase;letter-spacing:0.4pt;">SHARES</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:2.75pt 0pt 1.5pt 0pt; width:182.08pt;text-align:left;">
              <div style="white-space:nowrap;">Public offering price </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.615pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 1.5pt 0pt; min-width:21.75pt; text-align:right; white-space:nowrap;">4.00 </td>
            <td style="padding:0pt;padding-left:5.615pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">3.999</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 1.5pt 0pt; min-width:57.75pt; text-align:right; white-space:nowrap;">59,996,250.00 </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 1.5pt 0pt; min-width:53.25pt; text-align:right; white-space:nowrap;">68,996,250.00</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:1.333pt 0pt 0.667pt 0pt; width:182.08pt;white-space:normal;text-align:left;">
              <div style="margin-left:9.5pt; text-indent:-9.5pt;">Underwriting discounts and commissions paid by us </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.615pt;width:0pt;">&#8203;</td>
            <td style="padding:1.333pt 0pt 0.667pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:1.333pt 0pt 0.667pt 0pt; min-width:21.75pt; text-align:right; white-space:nowrap;">0.24 </td>
            <td style="padding:0pt;padding-left:5.615pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.333pt 0pt 0.667pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:1.333pt 0pt 0.667pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">0.23994</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.333pt 0pt 0.667pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:1.333pt 0pt 0.667pt 0pt; min-width:57.75pt; text-align:right; white-space:nowrap;">3,599,775.00 </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.333pt 0pt 0.667pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:1.333pt 0pt 0.667pt 0pt; min-width:53.25pt; text-align:right; white-space:nowrap;">4,139,775.00</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="border-bottom:0.75pt solid #000000; ;padding:3pt 0pt 12pt 0pt; width:182.08pt;text-align:left;">
              <div style="white-space:nowrap;">Proceeds to us, before expenses </div>
            </td>
            <td style="padding:0pt;border-bottom:0.75pt solid #000000; ; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:0.75pt solid #000000; ; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.615pt;width:0pt;border-bottom:0.75pt solid #000000; ;">&#8203;</td>
            <td style="padding:3pt 0pt 12pt 0pt;border-bottom:0.75pt solid #000000; ; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 12pt 0pt;border-bottom:0.75pt solid #000000; ; min-width:21.75pt; text-align:right; white-space:nowrap;">3.76 </td>
            <td style="padding:0pt;padding-left:5.615pt;width:0pt;border-bottom:0.75pt solid #000000; ;">&#8203;</td>
            <td style="padding:0pt;border-bottom:0.75pt solid #000000; ; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:0.75pt solid #000000; ; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:0.75pt solid #000000; ;">&#8203;</td>
            <td style="padding:3pt 0pt 12pt 0pt;border-bottom:0.75pt solid #000000; ; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 12pt 0pt;border-bottom:0.75pt solid #000000; ; min-width:30.75pt; text-align:right; white-space:nowrap;">3.759</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:0.75pt solid #000000; ;">&#8203;</td>
            <td style="padding:0pt;border-bottom:0.75pt solid #000000; ; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:0.75pt solid #000000; ; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:0.75pt solid #000000; ;">&#8203;</td>
            <td style="padding:3pt 0pt 12pt 0pt;border-bottom:0.75pt solid #000000; ; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 12pt 0pt;border-bottom:0.75pt solid #000000; ; min-width:57.75pt; text-align:right; white-space:nowrap;">56,396,475.00 </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:0.75pt solid #000000; ;">&#8203;</td>
            <td style="padding:0pt;border-bottom:0.75pt solid #000000; ; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:0.75pt solid #000000; ; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:0.75pt solid #000000; ;">&#8203;</td>
            <td style="padding:3pt 0pt 12pt 0pt;border-bottom:0.75pt solid #000000; ; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 12pt 0pt;border-bottom:0.75pt solid #000000; ; min-width:53.25pt; text-align:right; white-space:nowrap;">64,856,475.00</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:0.75pt solid #000000; ;">&#8203;</td>
            <td style="padding:0pt;border-bottom:0.75pt solid #000000; ; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:7.4pt; width:456pt; line-height:11.5pt;">We are offering to those purchasers whose purchase of shares of common stock in this offering would result in the purchaser, together with its affiliates and certain related parties, beneficially owning more than 4.99% (or, at the election of such purchaser, up to 19.99%) of our outstanding common stock following the consummation of this offering, the opportunity to purchase, in lieu of the shares of our common stock that would result in ownership in excess of 4.99% (or, at the election of such purchaser, up to 19.99%), Pre-Funded Warrants to purchase such excess shares of our common stock. Each Pre-Funded Warrant has an exercise price of&#8201; $0.001. The purchase price for each such Pre-Funded Warrant equals the per share public offering price for the common stock in this offering less the $0.001 per share exercise price of each such Pre-Funded Warrant.<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">We estimate expenses payable by us in connection with this offering other than the underwriting discounts and commissions referred to above, will be approximately $<font style="letter-spacing:-0.361pt;">400,000</font>. We have also agreed to reimburse the underwriters for certain of their expenses.<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="margin-top:12pt; width:456pt; line-height:12.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:10pt;">
          <font style="letter-spacing:0.5pt;">Listing</font><font style="font-weight:normal;text-transform:uppercase;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:18pt; width:456pt; line-height:11.5pt;">Our common stock is listed on the Nasdaq Capital Market under the trading symbol &#8220;RZLT&#8221;. There is no established public trading market for the Pre-Funded Warrants, and we do not expect a market to develop. We do not intend to list the Pre-Funded Warrants on the Nasdaq Capital Market, any other national securities exchange or any other nationally recognized trading system.<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="margin-top:12pt; width:456pt; line-height:12.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:10pt;">
          <font style="letter-spacing:0.5pt;">Option to Purchase Additional Shares</font>
        </div>
        <div style="margin-top:18pt; width:456pt; line-height:12pt;">We have granted to the underwriters an option, exercisable for 30 days from the date of this prospectus supplement, to purchase, from time to time, in whole or in part, up to an additional<font style="letter-spacing:-0.361pt;"> 2,250,000</font> shares of common stock from us at the public offering price set forth on the cover page of this prospectus supplement, less underwriting discounts and commissions. If the underwriters exercise this option, each underwriter will be obligated, subject to specified conditions, to purchase a number of additional shares of common stock proportionate to that underwriter&#8217;s initial purchase commitment as indicated in the table above.<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="margin-top:12pt; width:456pt; line-height:12.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:10pt;">
          <font style="letter-spacing:0.5pt;">No Sales of Similar Securities</font><font style="font-weight:normal;text-transform:uppercase;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:18pt; width:456pt; line-height:12pt;">We, our executive officers, directors and certain of our shareholders have agreed, subject to specified exceptions, not to directly or indirectly:<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->sell or offer to sell any shares of common stock or related securities currently or hereafter owned either of record or beneficially (as defined in Rule 13d-3 under the Exchange Act);<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->enter into any swap;<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->make any demand for, or exercise any right with respect to, the registration under the Securities Act of the offer and sale of any shares of common stock or related securities, or cause to be filed a registration statement, prospectus or prospectus supplement (or an amendment or supplement thereto) with respect to any such registration; or<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.361pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11pt;font-size:9pt;">
          <font style="letter-spacing:-0.342pt;">S-27</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:12.5pt;">
          <font style="letter-spacing:0.625pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->publicly disclose the intention to do any of the foregoing.<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">This restriction terminates after the close of trading of the common stock on and including the 90th day after the date of this prospectus supplement.<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">Jefferies LLC may, in its sole discretion and at any time or from time to time before the termination of the 90-day period, release all or any portion of the securities subject to lock-up agreements. There are no existing agreements between the underwriters and any of our shareholders who will execute a lock-up agreement providing consent to the sale of common stock securities prior to the expiration of the lock-up period.</div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">The foregoing restrictions do not apply to the registration of the offer and sale of the securities sold in this offering, in each case as contemplated by the underwriting agreement. In addition, the foregoing restrictions do not apply to: (i) transfers of shares or related securities by gift to a family member or to a trust whose beneficiaries consist exclusively of one or more of the securityholders and/or a family member, provided that (A) such transfer is not for value, (B) if required during the lock-up period, any public report or filing shall clearly indicate in the footnotes thereto that such transfer is being made pursuant to the circumstances described in this clause (i), and (C) the securityholder does not otherwise voluntarily effect any other public filing or report regarding such transfers during the lock-up period; (ii) transfers by the securityholders by will or intestate succession to a family member or to a trust whose beneficiaries consist exclusively of one or more of the securityholders and/or a family member; (iii) transfers by the securityholders by operation of law pursuant to a court order or settlement agreement related to the distribution of assets in connection with the dissolution of a marriage or civil union; (iv) the entry into any trading plan established pursuant to Rule 10b5-1 of the Exchange Act, provided that (A) such plan does not permit transfers by the securityholders during the lock-up period and (B) to the extent a public announcement of filing under the Exchange Act, if any, is required by or behalf of the securityholders or us regarding the establishment of such plan, such announcement or filing shall include a statement to the effect that no transfers by the securityholders may be made under such plan during the lock-up period; (v) transfers by the securityholders to us upon the exercise of options to cover tax withholding obligations in connection with the exercise or for the primary purpose of paying the exercise price of options to acquire shares of common stock in each case pursuant to a stock option, stock bonus or other stock plan or arrangement existing as of the date of the lock-up agreement and described in this prospectus supplement, provided that any underlying shares of common stock or related securities received as a result of such exercise shall remain subject to the terms of the lock-up agreement; (vi) transfers by the securityholder pursuant to a sale of or an offer to purchase 100% of our common stock in a transaction approved by us, whether pursuant to a merger, tender offer or otherwise, to a third party or group of third parties, provided that in the event that the merger, tender offer or other such transaction is not completed, the shares of common stock and related securities owned by the securityholder shall remain subject to the restrictions contained in the lock-up agreement; (vii) if the securityholder is a non-individual, transfers of shares of common stock or related securities to any affiliate (as such term is defined in Rule 405 of the Securities Act), limited partners, general partners, limited liability company members or stockholders of the securityholder, or, if the securityholder is a corporation, to any wholly owned subsidiary of such corporation, if, in any such case, such transfer is not for value; or (viii) transfer by the securityholder to a charitable trust</div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">Notwithstanding the foregoing, in the case of any transfer described in clauses (i), (ii), (vii) and (viii) above, it shall be a condition to such transfer that (A) any such transferee executes and delivers to the representatives a lock-up agreement stating that such transferee is receiving and holding such shares of common stock or related securities subject to the provisions of the lock-up agreement and agrees not to sell or offer to sell such shares of common stock or related securities, engage in any swap or engage in any other activities restricted under the lock-up agreement; and (B) except in the case of clause (i) above, prior to the expiration of the lock-up period, no public disclosure or filing by any party under the Exchange Act, shall be required or shall be made voluntarily, reporting a reduction in beneficial ownership of shares of common stock or related securities in connection with such transfer.<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="margin-top:12pt; width:456pt; line-height:12.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:10pt;">
          <font style="letter-spacing:0.5pt;">Stabilization</font><font style="font-weight:normal;text-transform:uppercase;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:18pt; width:456pt; line-height:12pt;">The underwriters have advised us that they, pursuant to Regulation&#160;M under the Securities Exchange Act as amended, may engage in short sale transactions, stabilizing transactions, syndicate covering transactions or the </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.361pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11pt;font-size:9pt;">
          <font style="letter-spacing:-0.342pt;">S-28</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:12.5pt;">
          <font style="letter-spacing:0.625pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">imposition of penalty bids in connection with this offering. These activities may have the effect of stabilizing or maintaining the market price of the common stock at a level above that which might otherwise prevail in the open market. Establishing short sales positions may involve either &#8220;covered&#8221; short sales or &#8220;naked&#8221; short sales.<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">&#8220;Covered&#8221; short sales are sales made in an amount not greater than the underwriters&#8217; option to purchase additional shares of our common stock in this offering. The underwriters may close out any covered short position by either exercising their option to purchase additional shares of our common stock or purchasing shares of our common stock in the open market. In determining the source of shares to close out the covered short position, the underwriters will consider, among other things, the price of shares available for purchase in the open market as compared to the price at which they may purchase shares through the option to purchase additional shares.<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">&#8220;Naked&#8221; short sales are sales in excess of the option to purchase additional shares of our common stock. The underwriters must close out any naked short position by purchasing shares in the open market. A naked short position is more likely to be created if the underwriters are concerned that there may be downward pressure on the price of the shares of our common stock in the open market after pricing that could adversely affect investors who purchase in this offering.<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">A stabilizing bid is a bid for the purchase of shares of common stock on behalf of the underwriters for the purpose of fixing or maintaining the price of the common stock. A syndicate covering transaction is the bid for or the purchase of shares of common stock on behalf of the underwriters to reduce a short position incurred by the underwriters in connection with the offering. Similar to other purchase transactions, the underwriter&#8217;s purchases to cover the syndicate short sales may have the effect of raising or maintaining the market price of our common stock or preventing or retarding a decline in the market price of our common stock. As a result, the price of our common stock may be higher than the price that might otherwise exist in the open market. A penalty bid is an arrangement permitting the underwriters to reclaim the selling concession otherwise accruing to a syndicate member in connection with the offering if the common stock originally sold by such syndicate member are purchased in a syndicate covering transaction and therefore have not been effectively placed by such syndicate member.<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">Neither we, nor any of the underwriters make any representation or prediction as to the direction or magnitude of any effect that the transactions described above may have on the price of our common stock. The underwriters are not obligated to engage in these activities and, if commenced, any of the activities may be discontinued at any time.<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">The underwriters may also engage in passive market making transactions in our common stock on the Nasdaq Capital Market in accordance with Rule&#160;103 of Regulation&#160;M during a period before the commencement of offers or sales of shares of our common stock in this offering and extending through the completion of distribution. A passive market maker must display its bid at a price not in excess of the highest independent bid of that security. However, if all independent bids are lowered below the passive market maker&#8217;s bid, that bid must then be lowered when specified purchase limits are exceeded.<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="margin-top:11.82pt; width:456pt; line-height:12.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:10pt;">
          <font style="letter-spacing:0.5pt;">Electronic Distribution</font><font style="font-weight:normal;text-transform:uppercase;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:18pt; width:456pt; line-height:11.5pt;">A prospectus supplement in electronic format may be made available by e-mail or on the web sites or through online services maintained by one or more of the underwriters or their affiliates. In those cases, prospective investors may view offering terms online and may be allowed to place orders online. The underwriters may agree with us to allocate a specific number of shares of common stock for sale to online brokerage account holders. Any such allocation for online distributions will be made by the underwriters on the same basis as other allocations. Other than the prospectus supplement in electronic format, the information on the underwriters&#8217; web sites and any information contained in any other web site maintained by any of the underwriters is not part of this prospectus supplement, has not been approved and/or endorsed by us or the underwriters and should not be relied upon by investors.<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="margin-top:11.72pt; width:456pt; line-height:12.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:10pt;">
          <font style="letter-spacing:0.5pt;">Other Activities and Relationships</font><font style="font-weight:normal;text-transform:uppercase;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:18pt; width:456pt; line-height:11.5pt;">The underwriters and certain of their affiliates are full service financial institutions engaged in various activities, which may include securities trading, commercial and investment banking, financial advisory, </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.361pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11pt;font-size:9pt;">
          <font style="letter-spacing:-0.342pt;">S-29</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:12.5pt;">
          <font style="letter-spacing:0.625pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">investment management, investment research, principal investment, hedging, financing and brokerage activities. The underwriters and certain of their affiliates have, from time to time, performed, and may in the future perform, various commercial and investment banking and financial advisory services for us and our affiliates, for which they received or will receive customary fees and expenses. For example, we are a party to an Open Market Sale Agreement<font style=" position:relative; bottom:4pt;font-size:7pt;letter-spacing:-0.266pt;">SM</font>, dated November 14, 2023, with Jefferies LLC, pursuant to which we may offer and sell an aggregate of up to $50,000,000 of our shares of our common stock from time to time through Jefferies LLC, acting as sales agent, under an &#8220;at the market offering&#8221; program.<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">In the ordinary course of their various business activities, the underwriters and certain of their affiliates may make or hold a broad array of investments and actively trade debt and equity securities (or related derivative securities) and financial instruments (including bank loans) for their own account and for the accounts of their customers, and such investment and securities activities may involve securities and/or instruments issued by us and our affiliates. If the underwriters or their respective affiliates have a lending relationship with us, they routinely hedge their credit exposure to us consistent with their customary risk management policies. The underwriters and their respective affiliates may hedge such exposure by entering into transactions which consist of either the purchase of credit default swaps or the creation of short positions in our securities or the securities of our affiliates, including potentially the common stock offered hereby. Any such short positions could adversely affect future trading prices of the common stock offered hereby. The underwriters and certain of their respective affiliates may also communicate independent investment recommendations, market color or trading ideas and/or publish or express independent research views in respect of such securities or instruments and may at any time hold, or recommend to clients that they acquire, long and/or short positions in such securities and instruments.<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="margin-top:12pt; width:456pt; line-height:12.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:10pt;">
          <font style="letter-spacing:0.5pt;">Disclaimers about non-U.S. jurisdictions</font><font style="font-weight:normal;text-transform:uppercase;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;">
          <font style="letter-spacing:0.475pt;">European Economic Area</font><font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:2pt; width:456pt; line-height:12pt;">In relation to each Member State of the European Economic Area (each a Relevant State), no shares or Pre-Funded Warrants have been offered or will be offered pursuant to the offering to the public in that Relevant State prior to the publication of a prospectus in relation to the shares or Pre-Funded Warrants which has been approved by the competent authority in that Relevant State or, where appropriate, approved in another Relevant State and notified to the competent authority in that Relevant State, all in accordance with the Prospectus Regulation, except that the shares or Pre-Funded Warrants may be offered to the public in that Relevant State at any time:</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(a)<br ></div>
        <div style=" margin-top:8.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <!--blacklining:none;-->to any legal entity which is a qualified investor as defined under Article 2 of the Prospectus Regulation;<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(b)<br ></div>
        <div style=" margin-top:8.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <!--blacklining:none;-->to fewer than 150 natural or legal persons (other than qualified investors as defined under Article 2 of the Prospectus Regulation), subject to obtaining the prior consent of representatives for any such offer; or<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(c)<br ></div>
        <div style=" margin-top:8.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <!--blacklining:none;-->in any other circumstances falling within Article 1(4) of the Prospectus Regulation, provided that no such offer of the shares or Pre-Funded Warrants shall require us or any of the underwriters to publish a prospectus pursuant to Article 3 of the Prospectus Regulation or supplement a prospectus pursuant to Article 23 of the Prospectus Regulation.<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">For the purposes of this provision, the expression an &#8220;offer to the public&#8221; in relation to the shares or Pre-Funded Warrants in any Relevant State means the communication in any form and by any means of sufficient information on the terms of the offer and any shares or Pre-Funded Warrants to be offered so as to enable an investor to decide to purchase or subscribe for any shares or Pre-Funded Warrants, and the expression &#8220;Prospectus Regulation&#8221; means Regulation (EU) 2017/1129.<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;">
          <font style="letter-spacing:0.475pt;">United Kingdom</font>
        </div>
        <div style="margin-top:2pt; width:456pt; line-height:12pt;">No shares or Pre-Funded Warrants have been offered or will be offered pursuant to the offering to the public in the United Kingdom prior to the publication of a prospectus in relation to the shares or Pre-Funded Warrants which has been approved by the Financial Conduct Authority, except that the shares or Pre-Funded Warrants may be offered to the public in the United Kingdom at any time:<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.361pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11pt;font-size:9pt;">
          <font style="letter-spacing:-0.342pt;">S-30</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:12.5pt;">
          <font style="letter-spacing:0.625pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">(a)<br ></div>
        <div style=" line-height:12pt; text-align:left; margin-left:40pt;">
          <!--blacklining:none;-->to any legal entity which is a qualified investor as defined under Article 2 of the UK Prospectus Regulation;</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(b)<br ></div>
        <div style=" margin-top:8.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <!--blacklining:none;-->to fewer than 150 natural or legal persons (other than qualified investors as defined under Article 2 of the UK Prospectus Regulation), subject to obtaining the prior consent of the representatives for any such offer; or</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(c)<br ></div>
        <div style=" margin-top:8.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <!--blacklining:none;-->in any other circumstances falling within Section 86 of the Financial Services and Markets Act 2000, or FSMA.</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">provided that no such offer of the shares or Pre-Funded Warrants shall require us or any underwriter to publish a prospectus pursuant to Section 85 of the FSMA or supplement a prospectus pursuant to Article 23 of the UK Prospectus Regulation. For the purposes of this provision, the expression an &#8220;offer to the public&#8221; in relation to the shares or Pre-Funded Warrants in the United Kingdom means the communication in any form and by any means of sufficient information on the terms of the offer and any shares or Pre-Funded Warrants to be offered so as to enable an investor to decide to purchase or subscribe for any shares or Pre-Funded Warrants and the expression &#8220;UK Prospectus Regulation&#8221; means Regulation (EU) 2017/1129 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018.<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;">
          <font style="letter-spacing:0.475pt;">Canada</font><font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style=" float:left; line-height:11.5pt; margin-top:11pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-style:italic;">(A)<br ></div>
        <div style=" margin-top:11pt; margin-bottom:0pt; line-height:11.5pt; text-align:left; margin-left:20pt;font-style:italic;">
          <!--blacklining:none;-->Resale Restrictions<font style="font-style:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:2pt; width:456pt; line-height:12pt;">The distribution of shares of common stock or Pre-Funded Warrants in Canada is being made only in the provinces of Ontario, Quebec, Alberta, British Columbia, Manitoba, New Brunswick and Nova Scotia on a private placement basis exempt from the requirement that we prepare and file a prospectus with the securities regulatory authorities in each province where trades of these securities are made. Any resale of the shares of our common stock or Pre-Funded Warrants in Canada must be made under applicable securities laws which may vary depending on the relevant jurisdiction, and which may require resales to be made under available statutory exemptions or under a discretionary exemption granted by the applicable Canadian securities regulatory authority. Purchasers are advised to seek legal advice prior to any resale of the shares of common stock or Pre-Funded Warrants.<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style=" float:left; line-height:11.5pt; margin-top:4.6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-style:italic;">(B)<br ></div>
        <div style=" margin-top:4.6pt; margin-bottom:0pt; line-height:11.5pt; text-align:left; margin-left:20pt;font-style:italic;">
          <!--blacklining:none;-->Representations of Canadian Purchasers<font style="font-style:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:2pt; width:456pt; line-height:12pt;">By purchasing our shares of common stock or Pre-Funded Warrants in Canada and accepting delivery of a purchase confirmation, a purchaser is representing to us and the dealer from whom the purchase confirmation is received that:<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.1pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->the purchaser is entitled under applicable provincial securities laws to purchase the shares of our common stock or Pre-Funded Warrants without the benefit of a prospectus qualified under those securities laws as it is an &#8220;accredited investor&#8221; as defined under National Instrument 45-106&#8212;Prospectus Exemptions or Section&#160;73.3(1) of the Securities Act (Ontario), as applicable,<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.1pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->the purchaser is a &#8220;permitted client&#8221; as defined in National Instrument 31-103&#8212;Registration Requirements, Exemptions and Ongoing Registrant Obligations,<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.1pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->where required by law, the purchaser is purchasing as principal and not as agent, and<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.19pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->the purchaser has reviewed the text above under Resale Restrictions.<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:11.5pt; margin-top:4.7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-style:italic;">(C)<br ></div>
        <div style=" margin-top:4.7pt; margin-bottom:0pt; line-height:11.5pt; text-align:left; margin-left:20pt;font-style:italic;">
          <!--blacklining:none;-->Conflicts of Interest<font style="font-style:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:2pt; width:456pt; line-height:12pt;">Canadian purchasers are hereby notified that certain of the underwriters are relying on the exemption set out in section&#160;3A.3 or 3A.4, if applicable, of National Instrument 33-105&#8201;-&#8201;Underwriting Conflicts from having to provide certain conflict of interest disclosure in this document.<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style=" float:left; line-height:11.5pt; margin-top:4.6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-style:italic;">(D)<br ></div>
        <div style=" margin-top:4.6pt; margin-bottom:0pt; line-height:11.5pt; text-align:left; margin-left:20pt;font-style:italic;">
          <!--blacklining:none;-->Statutory Rights of Action<font style="font-style:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:2pt; width:456pt; line-height:12pt;">Securities legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if the prospectus (including any amendment thereto) such as this document contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of the purchaser&#8217;s province or territory. The purchaser of these securities in Canada should refer to any applicable provisions of the securities legislation of the purchaser&#8217;s province or territory for particulars of these rights or consult with a legal advisor.<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.361pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11pt;font-size:9pt;">
          <font style="letter-spacing:-0.342pt;">S-31</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:12.5pt;">
          <font style="letter-spacing:0.625pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; line-height:11.5pt; text-align:left; width:20pt;white-space:nowrap;font-style:italic;">(E)<br ></div>
        <div style=" line-height:11.5pt; text-align:left; margin-left:20pt;font-style:italic;">
          <!--blacklining:none;-->Enforcement of Legal Rights<font style="font-style:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:2pt; width:456pt; line-height:12pt;">All of our directors and officers as well as the experts named herein may be located outside of Canada and, as a result, it may not be possible for Canadian purchasers to effect service of process within Canada upon us or those persons. All or a substantial portion of our assets and the assets of those persons may be located outside of Canada and, as a result, it may not be possible to satisfy a judgment against us or those persons in Canada or to enforce a judgment obtained in Canadian courts against us or those persons outside of Canada.<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style=" float:left; line-height:11.5pt; margin-top:4.5pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-style:italic;">(F)<br ></div>
        <div style=" margin-top:4.5pt; margin-bottom:0pt; line-height:11.5pt; text-align:left; margin-left:20pt;font-style:italic;">
          <!--blacklining:none;-->Taxation and Eligibility for Investment<font style="font-style:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:2pt; width:456pt; line-height:12pt;">Canadian purchasers of shares of common stock or Pre-Funded Warrants should consult their own legal and tax advisors with respect to the tax consequences of an investment in the shares of our common stock or Pre-Funded Warrants in their particular circumstances and about the eligibility of the shares of our common stock or Pre-Funded Warrants for investment by the purchaser under relevant Canadian legislation.<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;">
          <font style="letter-spacing:0.475pt;">Australia</font><font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:2pt; width:456pt; line-height:12pt;">This prospectus is not a disclosure document for the purposes of Australia&#8217;s Corporations Act 2001 (Cth) of Australia, or Corporations Act, has not been lodged with the Australian Securities &amp; Investments Commission and is only directed to the categories of exempt persons set out below. Accordingly, if you receive this prospectus in Australia:<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">You confirm and warrant that you are either:<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->a &#8220;sophisticated investor&#8221; under section 708(8)(a) or (b) of the Corporations Act;<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->a &#8220;sophisticated investor&#8221; under section 708(8)(c) or (d) of the Corporations Act and that you have provided an accountant&#8217;s certificate to us which complies with the requirements of section 708(8)(c)(i) or (ii) of the Corporations Act and related regulations before the offer has been made;<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->a person associated with us under Section 708(12) of the Corporations Act; or<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->a &#8220;professional investor&#8221; within the meaning of section 708(11)(a) or (b) of the Corporations Act.<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">To the extent that you are unable to confirm or warrant that you are an exempt sophisticated investor, associated person or professional investor under the Corporations Act any offer made to you under this prospectus supplement is void and incapable of acceptance.<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">You warrant and agree that you will not offer any of the securities issued to you pursuant to this prospectus supplement for resale in Australia within 12 months of those securities being issued unless any such resale offer is exempt from the requirement to issue a disclosure document under section 708 of the Corporations Act.<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;">
          <font style="letter-spacing:0.475pt;">Hong Kong</font><font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:2pt; width:456pt; line-height:12pt;">No securities have been offered or sold, and no securities may be offered or sold, in Hong Kong, by means of any document, other than to persons whose ordinary business is to buy or sell shares or debentures, whether as principal or agent; or to &#8220;professional investors&#8221; as defined in the Securities and Futures Ordinance (Cap.&#160;571) of Hong Kong, or SFO, and any rules made under that Ordinance; or in other circumstances which do not result in the document being a &#8220;prospectus&#8221; as defined in the Companies Ordinance (Cap. 32) of Hong Kong, or CO, or which do not constitute an offer or invitation to the public for the purpose of the CO or the SFO. No document, invitation or advertisement relating to the securities has been issued or may be issued or may be in the possession of any person for the purpose of issue (in each case whether in Hong Kong or elsewhere), which is directed at, or the contents of which are likely to be accessed or read by, the public of Hong Kong (except if permitted under the securities laws of Hong Kong) other than with respect to securities which are or are intended to be disposed of only to persons outside Hong Kong or only to &#8220;professional investors&#8221; as defined in the SFO and any rules made under that Ordinance.<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">This prospectus supplement has not been registered with the Registrar of Companies in Hong Kong. Accordingly, this prospectus supplement may not be issued, circulated or distributed in Hong Kong, and the securities may not be offered for subscription to members of the public in Hong Kong. Each person acquiring the securities will be required, and is deemed by the acquisition of the securities, to confirm that he is aware of the restriction on offers of the securities described in this prospectus supplement and the relevant offering documents and that he is not acquiring, and has not been offered any securities in circumstances that contravene any such restrictions.<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.361pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11pt;font-size:9pt;">
          <font style="letter-spacing:-0.342pt;">S-32</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:12.5pt;">
          <font style="letter-spacing:0.625pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;">
          <font style="letter-spacing:0.475pt;">Israel</font><font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:2pt; width:456pt; line-height:11.5pt;">This document does not constitute a prospectus under the Israeli Securities Law, 5728-1968, or the Securities Law, and has not been filed with or approved by the Israel Securities Authority. In Israel, this prospectus supplement is being distributed only to, and is directed only at, and any offer of shares or Pre-Funded Warrants is directed only at, (i)&#160;a limited number of persons in accordance with the Israeli Securities Law and (ii)&#160;investors listed in the first addendum, or the Addendum, to the Israeli Securities Law, consisting primarily of joint investment in trust funds, provident funds, insurance companies, banks, portfolio managers, investment advisors, members of the Tel Aviv Stock Exchange, underwriters, venture capital funds, entities with equity in excess of NIS 50&#160;million and &#8220;qualified individuals,&#8221; each as defined in the Addendum (as it may be amended from time to time), collectively referred to as qualified investors (in each case, purchasing for their own account or, where permitted under the Addendum, for the accounts of their clients who are investors listed in the Addendum). Qualified investors are required to submit written confirmation that they fall within the scope of the Addendum, are aware of the meaning of same and agree to it.<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;">
          <font style="letter-spacing:0.475pt;">Japan</font><font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:2pt; width:456pt; line-height:11.5pt;">The offering has not been and will not be registered under the Financial Instruments and Exchange Law of Japan (Law No. 25 of 1948 of Japan, as amended), or FIEL, and the underwriters will not offer or sell any securities, directly or indirectly, in Japan or to, or for the benefit of, any resident of Japan (which term as used herein means any person resident in Japan, including any corporation or other entity organized under the laws of Japan), or to others for re-offering or resale, directly or indirectly, in Japan or to, or for the benefit of, any resident of Japan, except pursuant to an exemption from the registration requirements of, and otherwise in compliance with, the FIEL and any other applicable laws, regulations and ministerial guidelines of Japan.<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;">
          <font style="letter-spacing:0.475pt;">Singapore</font><font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:2pt; width:456pt; line-height:11.5pt;">This prospectus supplement has not been and will not be lodged or registered as a prospectus with the Monetary Authority of Singapore. Accordingly, this prospectus supplement and any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of the common stock or Pre-Funded Warrants may not be circulated or distributed, nor may the common stock or Pre-Funded Warrants be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore other than (i)&#160;to an institutional investor under Section&#160;274 of the Securities and Futures Act, Chapter 289 of Singapore, or the SFA, (ii)&#160;to a relevant person pursuant to Section&#160;275(1), or any person pursuant to Section&#160;275(1A), and in accordance with the conditions specified in Section&#160;275, of the SFA, or (iii)&#160;otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA.<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">Where the shares of our common stock or Pre-Funded Warrants are subscribed or purchased under Section&#160;275 of the SFA by a relevant person which is:<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.9pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:3.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->a corporation (which is not an accredited investor (as defined in Section&#160;4A of the SFA)) the sole business of which is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; or<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.9pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:3.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary of the trust is an individual who is an accredited investor,<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">securities (as defined in Section&#160;239(1) of the SFA) of that corporation or the beneficiaries&#8217; rights and interest (howsoever described) in that trust shall not be transferred within six&#160;months after that corporation or that trust has acquired the shares of our common stock or Pre-Funded Warrants pursuant to an offer made under Section&#160;275 of the SFA except:<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.9pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:3.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->to an institutional investor or to a relevant person defined in Section&#160;275(2) of the SFA, or to any person arising from an offer referred to in Section&#160;275(1A) or Section&#160;276(4)(i)(B) of the SFA;<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.9pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:3.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->where no consideration is or will be given for the transfer;<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.91pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:3.91pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->where the transfer is by operation of law;<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.9pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:3.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->as specified in Section&#160;276(7) of the SFA; or<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.9pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:3.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->as specified in Regulation&#160;32 of the Securities and Futures (Offers of Investments) (Shares and Debentures) Regulations&#160;2005 of Singapore.<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.361pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11pt;font-size:9pt;">
          <font style="letter-spacing:-0.342pt;">S-33</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="sLEMA">&#8203;</a><a name="sEXF1">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:12.5pt;">
          <font style="letter-spacing:0.625pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:258pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;">
          <font style="letter-spacing:0.475pt;">Switzerland</font><font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:2pt; width:456pt; line-height:12pt;">The securities may not be publicly offered, directly or indirectly, in Switzerland within the meaning of the Swiss Financial Services Act and will not be listed or admitted to trading on the SIX Swiss Exchange, or SIX, or on any other stock exchange or regulated trading facility in Switzerland. This prospectus supplement has been prepared without regard to the disclosure standards for issuance prospectuses under art. 652a or art. 1156 of the Swiss Code of Obligations or the disclosure standards for listing prospectuses under art. 27 ff. of the SIX Listing Rules or the listing rules of any other stock exchange or regulated trading facility in Switzerland. Neither this prospectus supplement nor any other offering or marketing material relating to the securities or the offering may be publicly distributed or otherwise made publicly available in Switzerland.<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">Neither this prospectus supplement nor any other offering or marketing material relating to the offering, us or the securities have been or will be filed with or approved by any Swiss regulatory authority. In particular, this prospectus supplement will not be filed with, and the offer of securities will not be supervised by, the Swiss Financial Market Supervisory Authority, or FINMA, and the offer of securities has not been and will not be authorized under the Swiss Federal Act on Collective Investment Schemes, or CISA. The investor protection afforded to acquirers of interests in collective investment schemes under the CISA does not extend to acquirers of securities.<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:10pt;">
          <font style="text-transform:uppercase;letter-spacing:0.5pt;">LEGAL MATTERS</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:18pt; width:456pt; line-height:12pt;">Certain United States legal matters in connection with this offering will be passed upon on our behalf by Dorsey &amp; Whitney LLP, Denver, Colorado. Certain legal matters in connection with the offering will be passed upon for the underwriters by Paul Hastings LLP, New York, New York.<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:10pt;">
          <font style="text-transform:uppercase;letter-spacing:0.5pt;">EXPERTS</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:18pt; width:456pt; line-height:12pt;">Plante &amp; Moran, PLLC has audited our consolidated financial statements included in our Annual Report on Form 10-K for the&#160;years ended June&#160;30, 2023 and June&#160;30, 2022, which is incorporated by reference in this prospectus and elsewhere in the registration statement. Our financial statements are incorporated by reference in reliance on Plante &amp; Moran, PLLC&#8217;s report, given their authority as experts in accounting and auditing. </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.361pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11pt;font-size:9pt;">
          <font style="letter-spacing:-0.342pt;">S-34</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="sWYCF">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:12.5pt;">
          <font style="letter-spacing:0.625pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:10pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:10pt;">
          <font style="text-transform:uppercase;letter-spacing:0.5pt;">WHERE YOU CAN FIND ADDITIONAL INFORMATION</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:18pt; width:456pt; line-height:12pt;">We file annual, quarterly and current reports, proxy statements and other information with the SEC. The SEC maintains an Internet website at http://www.sec.gov that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC. Our reports on Forms 10-K, 10-Q and 8-K, and amendments to those reports, are also available for download, free of charge, as soon as reasonably practicable after these reports are filed with, or furnished to, the SEC, at our website at www.rezolutebio.com. Information contained on or accessible through our website is not a part of this prospectus supplement, and the inclusion of our website address in this prospectus supplement is an inactive textual reference only.<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">The SEC allows us to &#8220;incorporate by reference&#8221; into this prospectus supplement the information in other documents that we file with it. This means that we can disclose important information to you by referring you to those documents. The information incorporated by reference is considered to be a part of this prospectus supplement, and information in documents that we file later with the SEC will automatically update and supersede information contained in documents filed earlier with the SEC or contained in this prospectus supplement. We incorporate by reference in this prospectus supplement (i)&#160;the documents listed below, (ii)&#160;all documents that we file with the SEC under Section&#160;13(a), 13(c), 14 or 15(d) of the Exchange Act after the date of the initial filing of the registration statement of which this prospectus supplement is included and prior to the effectiveness of such registration statement, and (iii)&#160;any future filings that we may make with the SEC under Sections&#160;13(a), 13(c), 14, or 15(d) of the Exchange Act prior to the termination of the offerings under this prospectus supplement; provided, however, that we are not incorporating, in each case, any documents or information deemed to have been furnished and not filed, including any information that we disclose under Items&#160;2.02 or 7.01 of any Current Report on Form 8-K, in accordance with SEC rules:<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1509261/000155837023015755/rzlt-20230630x10k.htm">the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended June&#160;30, 2023, filed on September&#160;14, 2023;</a><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->the Company&#8217;s Quarterly Reports on Form 10-Q for the quarter ended September&#160;30, 2023, filed on <a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1509261/000155837023018839/rzlt-20230930x10q.htm">November&#160;13, 2023</a>, December&#160;31, 2023 filed on <a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1509261/000155837024001069/rzlt-20231231x10q.htm">February&#160;13, 2024</a>, and for the quarter ended March&#160;31, 2024 filed on <a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1509261/000155837024008294/rzlt-20240331x10q.htm">May&#160;15, 2024</a><font style="letter-spacing:-0.361pt;">;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->the Company&#8217;s Current Report on Form 8-K filed with the SEC on <a style="-sec-extract:exhibit" href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1509261/000110465923120789/tm2331358d1_8k.htm">November 22, 2023</a><font style="letter-spacing:-0.361pt;">, </font><a style="-sec-extract:exhibit" href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1509261/000110465924007811/tm244315d1_8k.htm">January 29, </a><font style="letter-spacing:-0.361pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1509261/000110465924007811/tm244315d1_8k.htm">2024, </a></font><a style="-sec-extract:exhibit" href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1509261/000110465924026582/tm245849d2_8k.htm">February 22, 2024</a><font style="letter-spacing:-0.361pt;">, </font><a style="-sec-extract:exhibit" href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1509261/000110465924034564/tm248506d2_8k.htm">March 14, 2024</a> and <a style="-sec-extract:exhibit" href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1509261/000110465924063029/tm2414592d2_8k.htm">May 17, 2024</a>; and<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->the description of the Company&#8217;s common stock, par value $0.001 per share, as contained in <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1509261/000155837023015755/rzlt-20230630xex4.htm">Exhibit&#160;4.1</a> to the Form 10-K for the fiscal year ended June&#160;30, 2023 filed on September&#160;14, 2023, including any amendment or report filed under the Exchange Act for the purpose of updating such description.<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">You may request a copy of these filings, other than an exhibit to these filings unless we have specifically included or incorporated that exhibit by reference into the filing, at no cost, by writing or telephoning us at the following address:<font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="margin-top:8pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;">
          <font style="letter-spacing:0.475pt;">Rezolute, Inc.</font>
          <br >
          <font style="letter-spacing:0.475pt;">275 Shoreline Drive, Suite 500</font>
          <br >
          <font style="letter-spacing:0.475pt;">Redwood City, CA 94065</font>
          <br >
          <font style="letter-spacing:0.475pt;">(650) 206-4507</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">Any statement contained in a document incorporated or deemed to be incorporated by reference into this prospectus will be deemed to be modified or superseded for purposes of this prospectus to the extent that a statement contained in this prospectus, any prospectus supplement, or any other subsequently filed document that is deemed to be incorporated by reference into this prospectus modifies or supersedes the statement. Any statement so modified or superseded will not be deemed, except as so modified or superseded, to constitute a part of this prospectus.</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.361pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11pt;font-size:9pt;">
          <font style="letter-spacing:-0.342pt;">S-35</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:27.85pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">PROSPECTUS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:9.7pt; text-align:center; width:456pt;">
          <img src="lg_rezolute-4clr.jpg" alt="[MISSING IMAGE: lg_rezolute-4clr.jpg]" height="40" width="216" >
        </div>
        <div style="margin-top:16.41pt; text-align:center; width:456pt; line-height:15.5pt;font-weight:bold;font-size:14pt;">
          <font style="letter-spacing:-0.28pt;">$200,000,000</font>
          <br >
          <font style="letter-spacing:-0.28pt;">Debt Securities</font>
          <br >
          <font style="letter-spacing:-0.28pt;">Common Stock</font>
          <br >
          <font style="letter-spacing:-0.28pt;">Preferred Stock</font>
          <br >
          <font style="letter-spacing:-0.28pt;">Warrants</font>
          <br >
          <font style="letter-spacing:-0.28pt;">Subscription Rights</font>
          <br >
          <font style="letter-spacing:-0.28pt;">Purchase Contracts</font>
          <br >
          <font style="letter-spacing:-0.28pt;">Depositary Shares</font>
          <br >
          <font style="letter-spacing:-0.28pt;">Units</font><font style="font-weight:normal;letter-spacing:0.28pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">We may offer for sale from time to time, either separately or together in one or more offerings, our debt securities, common stock with a par value of $0.001 per share (&#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">Common Stock</font><font style="letter-spacing:0.2pt;">&#8221;), preferred stock, warrants, subscription rights, purchase contracts, depositary shares and&#160;units (collectively, the &#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">securities</font><font style="letter-spacing:0.2pt;">&#8221;). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">The specific terms of any securities to be offered will be contained in one or more supplements to this prospectus. Any prospectus supplement may also add, update or change information contained in this prospectus. You should read this prospectus, any applicable prospectus supplement and the documents incorporated by reference herein and therein carefully before you invest in any securities. </font><font style="font-weight:bold;letter-spacing:-0.2pt;">This prospectus may not be used to sell securities unless accompanied by a prospectus supplement describing the method and terms of the offering.</font><font style="letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">We may offer and sell the securities from time to time in amounts, at prices and on other terms to be determined at the time of offering. We may offer and sell the securities to or through one or more underwriters, dealers or agents, or directly to purchasers, on a continuous or delayed basis. If any underwriters, dealers or agents are involved in the sale of any of the securities, their names, and any applicable purchase price, fee, commission or discount arrangement between or among us and them will be set forth, or will be calculable from the information set forth, in any applicable prospectus supplement. See the sections entitled &#8220;About this Prospectus&#8221; and &#8220;Plan of Distribution&#8221; for more information. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">Pursuant to General Instruction I.B.6 of Form S-3, in no event will we sell our Common Stock in a public primary offering with a value exceeding more than one-third of our public float in any 12-month period so long as our public float remains below $75.0&#160;million. As of September&#160;13, 2023, the aggregate market value of our outstanding common stock held by non-affiliates, or public float, was approximately $52,953,108, based on 33,514,625 shares of our outstanding Common Stock that were held by non-affiliates on such date and a price of $1.58 per share, which was the price at which our common stock was last sold on the Nasdaq Capital Market on September&#160;13, 2023 (a date within 60&#160;days of the date hereof), calculated in accordance with General Instruction I.B.6 of Form S-3. During the 12 calendar&#160;months prior to and including the date of this prospectus, we have not offered and sold any of our securities pursuant to General Instruction I.B.6 of Form S-3. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">Each prospectus supplement to this prospectus will indicate if the securities offered thereby will be listed on any securities exchange. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Investing in the securities involves risks. You should carefully review the risks and uncertainties described under the heading &#8220;Risk Factors&#8221; beginning on page <a href="#tRIFA">7</a> of this prospectus, any applicable prospectus supplement or any related free writing prospectus, and in any documents incorporated by reference herein or therein before investing in our securities.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">THE SECURITIES HAVE NOT BEEN APPROVED OR DISAPPROVED BY THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR ANY STATE SECURITIES COMMISSION NOR HAS THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR ANY STATE SECURITIES COMMISSION PASSED UPON THE ACCURACY OR ADEQUACY OF THIS PROSPECTUS. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:center; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The date of this prospectus is November 29, 2023</font>
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="TOC2">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:357.5pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">TABLE OF CONTENTS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:233.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:427.33pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;text-align:center;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Page </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tATP"><font style="letter-spacing:0.2pt;">ABOUT THIS PROSPECTUS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tATP">1</a></font> <a href="#tATP"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tSNRF"><font style="letter-spacing:0.2pt;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tSNRF">2</a></font> <a href="#tSNRF"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tTHCO"><font style="letter-spacing:0.2pt;">THE COMPANY </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tTHCO">3</a></font> <a href="#tTHCO"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tRIFA"><font style="letter-spacing:0.2pt;">RISK FACTORS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tRIFA">7</a></font> <a href="#tRIFA"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tUOP"><font style="letter-spacing:0.2pt;">USE OF PROCEEDS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tUOP">10</a></font> <a href="#tUOP"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tDODS"><font style="letter-spacing:0.2pt;">DESCRIPTION OF DEBT SECURITIES </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tDODS">11</a></font> <a href="#tDODS"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tDOCS"><font style="letter-spacing:0.2pt;">DESCRIPTION OF CAPITAL STOCK </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tDOCS">18</a></font> <a href="#tDOCS"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tDOW"><font style="letter-spacing:0.2pt;">DESCRIPTION OF WARRANTS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tDOW">20</a></font> <a href="#tDOW"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tDOPC"><font style="letter-spacing:0.2pt;">DESCRIPTION OF PURCHASE CONTRACTS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tDOPC">26</a></font> <a href="#tDOPC"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tDODS1"><font style="letter-spacing:0.2pt;">DESCRIPTION OF DEPOSITARY SHARES </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tDODS1">27</a></font> <a href="#tDODS1"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tPOD"><font style="letter-spacing:0.2pt;">PLAN OF DISTRIBUTION </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tPOD">31</a></font> <a href="#tPOD"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tWYCF"><font style="letter-spacing:0.2pt;">WHERE YOU CAN FIND MORE INFORMATION </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tWYCF">35</a></font> <a href="#tWYCF"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tIBR"><font style="letter-spacing:0.2pt;">INCORPORATION BY REFERENCE </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tIBR">35</a></font> <a href="#tIBR"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tLEMA"><font style="letter-spacing:0.2pt;">LEGAL MATTERS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tLEMA">37</a></font> <a href="#tLEMA"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tEXP"><font style="letter-spacing:0.2pt;">EXPERTS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tEXP">37</a></font>
            </td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">i</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tATP">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">ABOUT THIS PROSPECTUS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:7.12pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">This prospectus is part of a registration statement on Form S-3 that Rezolute, Inc., a Nevada corporation, which is also referred to as &#8220;the Company,&#8221; &#8220;Rezolute,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;ourselves&#8221; and &#8220;our,&#8221; has filed with the United States Securities and Exchange Commission (the &#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">SEC</font><font style="letter-spacing:0.2pt;">&#8221;) using a &#8220;shelf&#8221; registration procedure. Under this procedure, we may offer and sell at any time and from time to time, in one or more offerings, any combination of the securities described in this prospectus. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">To understand the terms of the securities offered by this prospectus, any applicable prospectus supplement, any free writing prospectus that we authorize and any pricing supplement, you should carefully read this prospectus, any applicable prospectus supplement, any free writing prospectus that we authorize and any pricing supplement, and all documents incorporated by reference herein or therein. You should rely only on the information contained or incorporated by reference in this prospectus, any applicable prospectus supplement, any free writing prospectus that we authorize and any pricing supplement. We have not authorized any person, including any salesman or broker, to provide information other than that provided in this prospectus, any applicable prospectus supplement, any free writing prospectus that we authorize or any pricing supplement. We do not take responsibility for, and can provide no assurance as to the reliability of, any information that others may give you. We are not making an offer of the securities in any jurisdiction where the offer is not permitted. You should assume that the information in this prospectus, any applicable prospectus supplement, any free writing prospectus that we authorize and any pricing supplement is accurate only as of the date on its cover page and that any information we have incorporated by reference is accurate only as of the date of such document incorporated by reference was filed with the SEC. You should also read the documents referred to under the heading &#8220;Where You Can Find More Information&#8221; for information regarding us and our financial statements. Certain capitalized terms used in this prospectus are defined elsewhere in this prospectus. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">This prospectus provides you with a general description of the securities we may offer. Each time we offer securities, we will prepare and distribute a prospectus supplement that will describe the specific amounts, prices and terms of that offering. That prospectus supplement may include a discussion of any risk factors or other special considerations applicable to those securities. The prospectus supplement may also contain information about any material U.S. federal income tax considerations relating to the securities covered by the prospectus supplement. The prospectus supplement may also add, update or change information contained or incorporated by reference in this prospectus. If there is any inconsistency between the information in this prospectus and any prospectus supplement, you should rely on the information in the prospectus supplement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The registration statement containing this prospectus, including the exhibits to the registration statement, provides additional information about us and the securities offered under this prospectus. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The exhibits to the registration statement contain the full text of certain contracts and other important documents we have summarized in this prospectus. You should review the full text of these documents because these summaries may not contain all the information that you may find important in deciding whether to purchase the securities we offer. The registration statement, including the exhibits, can be read at the SEC&#8217;s website or at the SEC&#8217;s offices mentioned under the heading &#8220;Where You Can Find More Information.&#8221; </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We may sell securities to underwriters who will sell the securities to the public on terms fixed at the time of sale. In addition, the securities may be sold by us directly or through dealers or agents designated from time to time, which agents may be affiliates of ours. If we, directly or through agents, solicit offers to purchase the securities, we reserve the sole right to accept and, together with our agents, to reject, in whole or in part, any offer. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">A prospectus supplement will also contain, with respect to the securities being offered thereby, the names of any underwriters, dealers or agents, together with the terms of the offering, the compensation of any underwriters, dealers or agents and the net proceeds to us. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Any underwriters, dealers or agents participating in any offering may be deemed &#8220;underwriters&#8221; within the meaning of the United States Securities Act of 1933, as amended, which we refer to in this prospectus as the &#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">Securities Act</font><font style="letter-spacing:0.2pt;">&#8221;. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This prospectus may not be used to sell any securities unless accompanied by a prospectus supplement. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">1</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tSNRF">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:320pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This prospectus, and the documents incorporated by reference herein, contain certain &#8220;forward-looking statements&#8221; within the meaning of Section&#160;27A of the Securities Act, Section&#160;21E of the Exchange Act, and the Private Securities Litigation Reform Act of 1995, and are based on management&#8217;s current expectations. These forward-looking statements can be identified by the use of forward-looking terminology, including, but not limited to, &#8220;believes,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;seek,&#8221; &#8220;see,&#8221; &#8220;confidence,&#8221; &#8220;trends,&#8221; &#8220;intend,&#8221; &#8220;estimate,&#8221; &#8220;on track,&#8221; &#8220;are positioned to,&#8221; &#8220;on course,&#8221; &#8220;opportunity,&#8221; &#8220;continue,&#8221; &#8220;project,&#8221; &#8220;guidance,&#8221; &#8220;target,&#8221; &#8220;forecast,&#8221; &#8220;anticipated,&#8221; &#8220;plan,&#8221; &#8220;potential&#8221; and the negative of these terms or comparable terms. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Various factors could adversely affect our operations, business or financial results in the future and cause our actual results to differ materially from those contained in the forward-looking statements, including those factors discussed under &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; or otherwise discussed in our Annual Report on Form 10-K for the fiscal year ended June&#160;30, 2023 and in our other filings made from time to time with the SEC after the date of this prospectus. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">For additional information about factors that could cause actual results to differ materially from those described in the forward-looking statements, please see the documents that we have filed with the SEC, including our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form&#160;8-K and other documents and reports filed from time to time with the SEC. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">All subsequent forward-looking statements attributable to us or any person acting on our behalf are expressly qualified in their entirety by the cautionary statements contained or referred to in this section. We are not under any obligation to, and expressly disclaim any obligation to, update or alter any forward-looking statements whether as a result of such changes, new information, subsequent events or otherwise. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">2</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tTHCO">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">THE COMPANY</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We are a clinical stage biopharmaceutical company specializing in the development of innovative drug therapies to improve the lives of patients with metabolic and orphan diseases. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Summary of Clinical Assets</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">RZ358</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our lead clinical asset, RZ358, is a potential treatment for congenital hyperinsulinism (&#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">HI</font><font style="letter-spacing:0.2pt;">&#8221;), an ultra-rare pediatric genetic disorder characterized by excessive production of insulin by the pancreas. If untreated, the elevated insulin levels in patients suffering with congenital HI can induce extreme hypoglycemia (low blood sugar) events, increasing the risk of neurological and developmental complications, including persistent feeding problems, learning disabilities, recurrent seizures, brain damage or even death. There are no FDA approved therapies for all forms of congenital HI and the current standard of care treatments are suboptimal. The current treatments used by physicians include glucagon, diazoxide, somatostatin analogues and pancreatectomy. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">RZ358 is an intravenously administered human monoclonal antibody that binds to a unique site (allosteric) on the insulin receptor in insulin target tissues, such as in the liver, fat, and muscle. The antibody down modulates insulin&#8217;s binding, signaling, and action to maintain glucose levels in a normal range thereby counteracting the effects of elevated insulin in the body. RZ358 shows dose dependent pharmacokinetics with a half- life greater than two weeks which has the potential for twice or even once monthly dosing. Therefore, we believe that RZ358 is ideally suited as a potential therapy for conditions characterized by excessive insulin levels, and it is being developed to treat hyperinsulinism and low blood sugar. As RZ358 acts downstream from the beta cells, it has the potential to be universally effective at treating congenital HI caused by any of the underlying genetic defects. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In the fourth quarter of 2023, we plan to initiate a pivotal Phase&#160;3 clinical study of RZ358 for the treatment of hypoglycemia in participants with congenital HI (the &#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">sunRIZE study</font><font style="letter-spacing:0.2pt;">&#8221;) outside of the U.S. The sunRIZE study is a randomized, double-blind, placebo-controlled, parallel arm evaluation of RZ358 in participants with congenital HI who are not adequately responding to standard of care medical therapies. Topline results from the study are anticipated to be available in the first half of 2025. The Phase&#160;3 study follows the Company&#8217;s multinational Phase&#160;2b study (&#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">RIZE</font><font style="letter-spacing:0.2pt;">&#8221;) conducted in participants 2&#160;years of age and older who were failing medical therapies. The RIZE study demonstrated that RZ358 was generally safe and well-tolerated, as well as highly effective in improving hypoglycemia. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We have concluded our pre-Phase&#160;3 regulatory and scientific advice meetings with regulatory authorities outside of the U.S. and have reached agreement on the design of the Phase&#160;3 study that will include participants&#160;3&#160;months of age and older. In the U.S., we had similar interactions with the U.S. Food and Drug Administration (&#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">FDA</font><font style="letter-spacing:0.2pt;">&#8221;) culminating in a meeting held with the agency on May&#160;24, 2023 (as confirmed by meeting minutes received from the FDA on June&#160;22, 2023), and the FDA has maintained an existing age restriction of 12&#160;years of age and older on RZ358 clinical studies, and imposed dose level restrictions based on historical rat toxicology findings. We believe that the FDA restrictions make it infeasible to include the U.S. in the Phase&#160;3 study at this time, since the pediatric population with congenital HI has the greatest therapeutic need. We are pursuing some additional nonclinical studies that may potentially address the FDA&#8217;s concerns, in parallel with the initiation and advancement of the Phase&#160;3 study outside of the U.S. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The sunRIZE study will evaluate the safety and efficacy of RZ358 in participants with congenital HI who are unable to achieve control of low blood sugars (&lt;70 mg/dL) with available medical therapies (&#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">hypoglycemia</font><font style="letter-spacing:0.2pt;">&#8221;). The study will determine the ability of RZ358 to correct hypoglycemia as assessed by (i)&#160;hypoglycemia events using self-monitored blood glucose (&#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">SMBG</font><font style="letter-spacing:0.2pt;">&#8221;) and (ii)&#160;time in hypoglycemia using continuous glucose monitoring (&#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">CGM</font><font style="letter-spacing:0.2pt;">&#8221;) over 24 weeks of treatment. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The study will also measure the levels of RZ358 and its effects on other important blood and clinical markers of hypoglycemia, as well as quality of life measures. The primary and key secondary efficacy endpoints are the following: </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Primary efficacy endpoint: </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">3</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Change in average weekly occurrence of hypoglycemia events as measured by SMBG after 24 weeks </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Key secondary efficacy endpoint: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Change in average daily&#160;percent time in hypoglycemia as measured by CGM after 24 weeks </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Approximately 56 participants between 3&#160;months and 45&#160;years of age are intended to be enrolled. Participants between 1 and 45&#160;years of age (approximately 48 participants) will be enrolled in a randomized, double-blind, placebo-controlled fashion to receive RZ358 or placebo at dose levels of 5 or 10 mg/kg while on standard of care. Infant participants between 3&#160;months and 1 year of age (approximately 8 participants) will be enrolled in open label fashion to receive RZ358 at a starting dose level of 5 mg/kg, which may be increased to 10 mg/kg at the discretion of the investigator. Participants will receive RZ358 as an intravenous infusion every 2 weeks over an initial 4-week loading period (3 doses), followed by monthly doses over an additional 16-week maintenance period (4 doses), for a total of 7 doses over the total 24-week treatment period. Following the study period, participants may proceed into an open-label extension program where investigators shall be permitted to: (i)&#160;adjust the dose between 5 and 10 mg/kg; (ii)&#160;adjust the dosing frequency between 2 and 4 weeks; and (iii)&#160;wean or stop other background hypoglycemia therapies. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In summary, the study will be comprised of the following treatment groups: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Participants &ge;1 year old: 5 mg/kg (n = 16) </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Participants &ge;1 year old: 10 mg/kg (n = 16) </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Participants &ge;1 year old: placebo (n = 16) </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Infant Participants: starting at 5 mg/kg (n = 8) </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">RZ402</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our second clinical asset, RZ402, is an oral plasma kallikrein inhibitor (&#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">PKI</font><font style="letter-spacing:0.2pt;">&#8221;) being developed as a potential therapy for the chronic treatment of diabetic macular edema (&#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">DME</font><font style="letter-spacing:0.2pt;">&#8221;). DME is a vascular complication of diabetes and a leading cause of blindness in the U.S. and elsewhere. Chronic exposure to high blood sugar levels can lead to inflammation, cell damage, and the breakdown of blood vessel walls. Specifically, in DME, retinal blood vessels at the back of the eye become porous and permeable leading to the unwanted infiltration of fluid into the macula. This fluid leakage creates distorted vision, and if left untreated, blindness. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Currently available treatments for DME include anti-vascular growth factor (&#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">anti-VEGF</font><font style="letter-spacing:0.2pt;">&#8221;) injections into the eye or laser surgery. RZ402 is designed to be a once daily oral therapy for the treatment of DME and unlike the anti-VEGF therapies, RZ402 targets the Kallikrein-Kinin System to address inflammation and vascular leakage. We believe that systemic exposure through oral delivery is critical to target the retinal microvasculature at the back of the eye. Further, as an oral therapy, RZ402 has the potential to substantially change the therapeutic paradigm for patients suffering with DME by providing a convenient, self-administered treatment option to encourage earlier initiation of therapy, adherence to prescribed treatment guidelines, and improved overall outcomes. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In December&#160;2022, we initiated a Phase&#160;2 multi-center, randomized, double-masked, placebo-controlled, parallel-arm study to evaluate the safety, efficacy, and pharmacokinetics of RZ402 administered as a monotherapy over a twelve week treatment period in participants with DME who are na&#239;ve to, or have received limited anti-VEGF injections. The study population is comprised of DME patients with mild to moderate non-proliferative diabetic retinopathy. Eligible participants are being randomized equally, to one of three RZ402 active treatment arms at doses of 50, 200, and 400 mg, or a placebo control arm, to receive study drug once daily for twelve weeks, before completing a four-week follow-up. The study is expected to enroll up to approximately 100 patients overall, across approximately 25 investigational sites in the United States. The principal endpoints of the trial include (i)&#160;changes in central subfield thickness of the macula, as measured by Spectral Domain Ocular Coherence Tomography, (ii)&#160;changes in visual acuity as measured by the early treatment diabetic retinopathy scale, (iii)&#160;the repeat dose pharmacokinetics of RZ402 in patients with DME, and (iv)&#160;the safety and tolerability of RZ402. We expect to complete enrollment in 2023 and to provide an update on the study prior to year end.</font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">4</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">RZ358 Regulatory Status</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As discussed in our disclosures filed with the SEC, toxicology studies in rats and monkeys were conducted as part of the early RZ358 development program and in these studies, rats demonstrated a microvascular liver injury at potentially clinically relevant doses and exposures (&#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">rat findings</font><font style="letter-spacing:0.2pt;">&#8221;). However, there were no adverse liver findings in monkeys at dose levels that were more than 10 times higher than doses that were toxic in rats, and more than four times higher than human doses evaluated in clinical studies. Based on the absence of liver toxicity in monkeys and the lack of adverse liver findings in closely monitored human trials, the Company believes that the toxicity is unique to rats and unlikely relevant to humans. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As is customary in pediatric drug development, there is a progression of the inclusion of younger participants as a program advances through different stages and continues to demonstrate a good safety profile and a prospect of benefit for children based on previous stages. After the completion of Phase&#160;1 adult healthy volunteer studies for RZ358, Phase&#160;2a single-dose proof of concept studies (&#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">Phase&#160;2a</font><font style="letter-spacing:0.2pt;">&#8221;) were conducted in participants with congenital HI who were twelve&#160;years of age and older in countries governed by the regulatory authorities in the European Union and elsewhere in Europe. In the US, the FDA restricted enrollment in Phase&#160;2a to participants eighteen&#160;years of age and older and, based on the rat findings, imposed a human drug exposure limit equating to repeat doses of approximately 3 mg/kg per week (&#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">exposure cap</font><font style="letter-spacing:0.2pt;">&#8221;). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Subsequently, in the RIZE study European Authorities and other regulatory bodies continued the expected downward age progression, lowering the age for study participants down from twelve&#160;years of age to two&#160;years of age and older. At the start of the RIZE study the clinical program in the US remained under the eighteen&#160;years of age and older restriction as well as the exposure cap. However, in the first half of 2020, while the RIZE study was underway, we reached agreement with the FDA to proceed with the RIZE study in the US at all dose levels (no exposure cap) and in younger participants (ages twelve and older). Following these developments, the study protocol was harmonized globally, other than a regional difference in the minimum permitted age (twelve&#160;years and older in the US versus two&#160;years and older in all other geographies). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">After the completion of the RIZE study, in the second half of 2022 and the first half of 2023, the Company conducted scientific advice meetings with the regulatory authorities in Europe which resulted in alignment with our proposed Phase&#160;3 program including overall study design, dosing regimen, endpoints, sample size and patient population. Notably, with all available nonclinical (including the rat findings) and clinical information under review, European Authorities aligned with a further downward age progression whereby participants 3&#160;months of age and older will be permitted to be enrolled in the Phase&#160;3 study. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Prior to engaging the FDA on Phase&#160;3 planning in the US, we began interacting with the agency in the second half of 2022 to further liberalize the age restriction to achieve alignment with the parameters established by the European Authorities in the RIZE study. Over the course of these post-RIZE regulatory interactions with the FDA, the agency revisited prior concerns regarding the rat findings and, despite the absence of new clinical or nonclinical data (other than the RIZE data), the agency decided to maintain the age restriction of twelve&#160;years and above and re-imposed the previous exposure cap which had been removed during the RIZE study (collectively, &#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">New Restrictions</font><font style="letter-spacing:0.2pt;">&#8221;). In the second half of 2022 and the first half of 2023, we interacted with the FDA to resolve the New Restrictions, particularly in the context of the advancement of the clinical program in the rest of the world. Nonetheless, the FDA affirmed the New Restrictions at a meeting held with us on May&#160;24, 2023. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We have concluded pre-Phase&#160;3 regulatory and scientific advice meetings with regulatory authorities outside of the U.S. and have reached agreement on the design of the Phase&#160;3 study that will include participants three&#160;months of age and older. We believe that the New Restrictions make it infeasible to include the U.S. in the Phase&#160;3 study at this time, particularly given that the pediatric population with congenital HI has the greatest therapeutic need. We are evaluating potential nonclinical studies to address the FDA&#8217;s concerns in parallel with the initiation and advancement of the Phase&#160;3 study outside of the U.S. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Specifically, in the fourth quarter of 2023, we plan to initiate the Phase&#160;3 sunRIZE clinical study of RZ358 which will be a randomized, double-blind, placebo-controlled, parallel arm evaluation of RZ358 in participants with congenital HI who are not adequately responding to standard of care medical therapies. Topline results from the study are anticipated to be available in the first half of 2025. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">5</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:56pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Competition</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We face competition from pharmaceutical and biotechnology companies, academic institutions, governmental agencies, and private research organizations in recruiting and retaining highly qualified scientific personnel and consultants and in the development and acquisition of technologies. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">There are other companies developing therapies for HI that are potential competitors to RZ358, including, Eiger Biopharmaceuticals, Hanmi Pharmaceuticals, and Zealand Pharma. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">There are also companies developing therapies for DME that are potential competitors to our PKI including Curacle, KalVista, Ocuphire Pharma, Oxurion and Verseon. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Government Regulation</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Regulation by governmental authorities in the U.S. and other countries is a significant factor in the development, manufacture and marketing of pharmaceutical products. All of our potential products will require regulatory approval by governmental agencies prior to commercialization. In particular, pharmaceutical therapies are subject to rigorous preclinical testing and clinical trials and other pre-market approval requirements by the FDA and regulatory authorities in foreign countries. Various federal, state and foreign statutes and regulations also govern or influence the manufacturing, safety, labeling, storage, record keeping and marketing of such products. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In addition, we are subject to various federal, state, and local laws, regulations and recommendations relating to safe working conditions; laboratory and manufacturing practices; the experimental use of animals; and the use and disposal of hazardous or potentially hazardous substances, including radioactive compounds and infectious disease agents, used in connection with our research, development and manufacturing. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Employees</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As of June&#160;30, 2023, we had 51 full time employees, of which 38 employees were engaged in research and development, manufacturing, clinical operations, regulatory and quality activities and 13 employees were engaged in administrative functions. Of the 51 employees, all were located in the United States. We have a number of employees who hold Ph.D. degrees and other advanced degrees. None of our employees are covered by a collective bargaining agreement, and we have experienced no work stoppages nor are we aware of any employment circumstances that are likely to disrupt work at any of our facilities. As part of our measures to attract and retain personnel, we provide a number of benefits to our full-time employees, including health insurance, life insurance, retirement plans, paid holiday and vacation time. In addition, we grant stock options to certain key employees as added incentive to remain in our employment. We believe that we maintain good relations with our employees. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Corporate Information</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We were incorporated in Delaware in 2010 and we re-incorporated in Nevada in June&#160;2021. We maintain an executive office located at 275 Shoreline Drive, Suite 500, Redwood City, CA 94065 and our phone number is (650) 206-4507. Our website is located at www.rezolutebio.com. We file annual, quarterly, current reports, proxy statements and other information with the SEC. The SEC maintains a website that contains our public filings and other information regarding the Company, at www.sec.gov. The information contained in, or that can be accessed through, our website is not part of, and is not incorporated into this document. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">6</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tRIFA">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">RISK FACTORS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Investing in shares of our Common Stock involves significant risks. Please see the risk factor below and the additional risk factors set forth under the heading &#8220;Risk Factors&#8221; in Item&#160;1A. of our most recent Annual Report on Form 10-K for the fiscal year ended June&#160;30, 2023 as filed with the SEC and are incorporated by reference in this prospectus. These risks may be revised or supplemented in future filings of our Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K, which are also incorporated by reference in this prospectus. Before making an investment decision, you should carefully consider these risks as well as other information we include or incorporate by reference in this prospectus. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Risks Related to Our Product Development and Commercialization</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Any delays in the commencement or completion, or termination or suspension, of our future clinical trials, if any, could result in increased costs to us, delay or limit our ability to generate revenue and adversely affect our commercial prospects.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Before obtaining approval from the government authorities or professional bodies with authority to grant regulatory approval for our drug candidates in a particular country, such as the European Medicines Agency (&#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">EMA</font><font style="letter-spacing:0.2pt;">&#8221;), the FDA and analogous authorities in other jurisdictions outside of the United States (&#8220;regulatory authorities&#8221;), we must conduct extensive clinical studies to demonstrate safety and efficacy. Clinical testing is expensive, time consuming and uncertain as to outcome. Any delays in the commencement or completion of our ongoing, planned or future clinical trials could significantly increase our costs, slow down our development and approval process and jeopardize our ability to commence product sales and generate revenues. We do not know whether our planned trials will begin on time or at all, or be completed on schedule, if at all. The commencement and completion of clinical trials can be delayed for a number of reasons, including delays related to: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">regulatory authorities disagreeing as to the design or implementation of our clinical trials or with our recommended dose for any of our pipeline programs; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">obtaining regulatory authority authorization to commence a trial or reaching a consensus with such regulatory authorities on trial design; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.31pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.31pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">identifying and activating investigators and clinical trial sites to conduct trials; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">obtaining approval from one or more independent institutional review board (&#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">IRB</font><font style="letter-spacing:0.2pt;">&#8221;) or Ethics Committee (&#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">EC</font><font style="letter-spacing:0.2pt;">&#8221;) at each clinical trial site before each trial may be initiated; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">IRBs/ECs refusing to approve, suspending or terminating the trial at an investigational site, precluding enrollment of additional subjects, or withdrawing their approval of the trial; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">changes to clinical trial protocol; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">clinical sites deviating from trial protocol or dropping out of a trial; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.21pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.21pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">failing to manufacture or obtain sufficient quantities of drug candidate, or, if applicable, combination therapies for use in clinical trials; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">patients failing to enroll or remain in our trial at the rate we expect, or failing to return for post-treatment follow-up; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">patients choosing an alternative treatment, or participating in competing clinical trials; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.21pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.21pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">lack of adequate funding to continue the clinical trial; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">patients experiencing severe or unexpected drug-related adverse effects; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">occurrence of serious adverse events in trials of the same class of agents conducted by other companies; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">selecting or being required to use clinical end points that require prolonged periods of clinical observation or analysis of the resulting data; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.21pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.21pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">a facility manufacturing our drug candidates, or any of their components, including without limitation, our own facilities being ordered by regulatory authorities to temporarily or permanently </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">7</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:30pt; width:426pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">shut down due to violations of current good manufacture practices, regulations or other applicable requirements, or infections or cross-contaminations in the manufacturing process; </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">lack of stability of our clinical trial material or any quality issues that arise with the clinical trial material; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any changes to our manufacturing process that may be necessary or desired; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.19pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our, or our third-party contractors, not performing data collection or analysis in a timely or accurate manner or improperly disclosing data prematurely or otherwise in violation of a clinical trial protocol; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any third-party contractors becoming debarred or suspended or otherwise penalized by regulatory authorities or other government or regulatory bodies for violations of regulatory requirements, in which case we may need to find a substitute contractor, and we may not be able to use some or all of the data produced by such contractors in support of our marketing applications; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">a clinical trial being suspended or terminated by us, by the IRBs/ECs of the institutions in which such trials are being conducted, by a Data Safety Monitoring Board for such trial or by regulatory authorities, due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using the product under investigation, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">changes in regulatory requirements and policies and our need to amend clinical trial protocols to comply with these changes and potentially resubmit our clinical trial protocols to IRBs/ECs for reexamination. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Delays in initiating a new phase of clinical trials resulting from action by the FDA or any other regulatory authority would delay the approval obtainment and commercialization of our product candidates and our ability to generate revenue, which would have an adverse effect on our business. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">The clinical hold in the U.S. on RZ358 may impact our development plans, staffing needs and may impact our ability to access the capital markets.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our most advanced product candidate, RZ358, is currently under clinical hold in the U.S. It may take considerable time and expense to respond to the New Restrictions that have been placed on RZ358 by the FDA, and no assurance can be given that the FDA will remove the New Restrictions or that we will receive FDA approval for RZ358, in which case our business and prospects will likely suffer material adverse consequences. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In May&#160;2023, based on historical rat toxicology found during an early RZ358 development program, the FDA affirmed its decision to impose the New Restrictions after we completed our multinational Phase&#160;2b RIZE study conducted in participants two&#160;years of age and older, which consisted of the age restriction of twelve&#160;years and above for U.S. patients, and to re-impose impose a human drug exposure cap equating to repeat doses of approximately 3 mg/kg per week, a limit which was previously removed during the RIZE study. The New Restrictions delay our progression to include younger participants and consequentially delay the sunRIZE study in the U.S. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A clinical hold for RZ358 and sunRIZE continues to be in place in the U.S., and we do not know whether or when the clinical hold for the development of RZ358 will be lifted. However, we currently expect to commence the sunRIZE study outside of the U.S. as we have concluded our pre-sunRIZE regulatory and scientific advice meetings with regulatory authorities outside of the U.S. and have reached agreements on the design of the sunRIZE study that will include participants 3&#160;months of age and older. Positive or promising results from clinical trials of RZ358 conducted in jurisdictions outside of the U.S. may not be predictive of similar results, or may not be replicated, in clinical trials within the U.S. Accordingly, even if we continue to observe the lack of adverse liver findings in the sunRIZE study outside of the U.S., it is not </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">8</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:12pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">guaranteed that the FDA will accept such findings and lift the New Restrictions which could impact our development plans or ability to file for approval or market RZ358 in the U.S. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">It may take a considerable period of time, the length of which is not certain at this time, and expense for us to fully address the FDA&#8217;s concerns, if at all. Even if we are able to fully respond to the FDA&#8217;s questions, the FDA may subsequently make additional requests that we would need to fulfill prior to the lifting of the New Restrictions. It is possible that we will be unable to fully address the FDA&#8217;s concerns and as a result the New Restrictions may never be lifted, and we may never be able to begin the sunRIZE study or complete our clinical trials of RZ358 in the U.S. Many of the factors that cause, or lead to, a delay in the commencement or completion of the sunRIZE study may also ultimately lead to the denial of regulatory approval from the FDA for RZ358. If we don&#8217;t receive regulatory approval from the FDA for RZ358 our ability to raise capital and the terms of such raise could be impacted and our staffing levels may need to be adjusted. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We are exposed to additional risks as we conduct the sunRIZE study outside of the U.S. and may not be successful in meeting the study&#8217;s primary endpoint.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We are initiating and advancing the sunRIZE study outside of the U.S. The sunRIZE study may not produce positive results and meet its primary endpoint outside of the U.S. We may need to commence and complete additional clinical trials that satisfy the specified primary endpoint criteria in order to obtain necessary regulatory approvals from the EMA for RZ358. It is possible that we may not observe the lack of adverse liver findings in the sunRIZE study outside of the U.S., which could potentially impact the FDA&#8217;s decision regarding the New Restrictions. Conducting clinical trials outside the U.S. also exposes us to additional risks, including risks associated with: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">additional foreign regulatory requirements; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">foreign exchange fluctuations; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">compliance with foreign manufacturing, customs, shipment and storage requirements; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">potential political or economic instability in the jurisdictions where we initiate clinical trials; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">cultural differences in medical practice and clinical research; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">diminished protection of intellectual property in some countries. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">After the completion of our clinical studies, we cannot predict whether or when we will obtain regulatory approval to commercialize our product candidates and we cannot, therefore, predict the timing of any future revenue from these product candidates. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Even if we achieve positive clinical results and file for regulatory approval, we cannot commercialize any of our product candidates until the appropriate regulatory authorities have reviewed and approved the applications for such product candidates. We cannot assure that the regulatory authorities will complete their review processes in a timely manner or that we will obtain regulatory approval for any product candidate we develop. Satisfaction of regulatory requirements typically takes many&#160;years, is dependent upon the type, complexity and novelty of the product and requires the expenditure of substantial resources. In addition, we may experience delays or rejections based upon additional government regulation from future legislation or administrative action or changes in regulatory authority policy during the period of product development, clinical studies and regulatory review. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Even if a regulatory authority outside of the U.S. approves a product candidate, the approval may impose significant restrictions on the indicated uses, conditions for use, labeling, advertising, promotion, marketing and/or production of such product and may impose requirements for post-approval studies, including additional research and development and clinical trials. The regulatory authorities outside of the U.S. may also impose various civil or criminal sanctions for failure to comply with regulatory requirements, including substantial monetary penalties and withdrawal of product approval.</font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">9</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tUOP">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:476pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">USE OF PROCEEDS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We will retain broad discretion over the use of the net proceeds from the sale of the securities offered hereby. Except as described in any applicable prospectus supplement or in any free writing prospectuses that we may authorize to be provided to you in connection with a specific offering, we currently intend to use the net proceeds from the sale of the securities offered hereby for working capital, capital expenditures and general corporate purposes. We may also use a portion of the net proceeds to invest in or acquire businesses or technologies that we believe are complementary to our own, although we have no current plans, commitments or agreements with respect to any acquisitions as of the date of this prospectus. We will set forth in the applicable prospectus supplement or free writing prospectus our intended use for the net proceeds received from the sale of any securities sold pursuant to the prospectus supplement or free writing prospectus. Pending these uses, we intend to invest the net proceeds in investment-grade, interest-bearing securities. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">10</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tDODS">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">DESCRIPTION OF DEBT SECURITIES</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">This section describes the general terms and provisions of the debt securities that we may offer using this prospectus and the related indenture. This section is only a summary and does not purport to be complete. You must look to a future prospectus supplement that will describe the relevant form of debt security and the related indenture for a full understanding of all terms of any series of debt securities. The form of debt security and the related indenture have been or will be filed or incorporated by reference as exhibits to the registration statement of which this prospectus is a part. See &#8220;Where You Can Find More Information&#8221; for information on how to obtain copies. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We may issue debt securities from time to time, in one or more series, as either senior or subordinated debt or as senior or subordinated convertible debt. While the terms we have summarized below will apply generally to any debt securities that we may offer under this prospectus, we will describe the particular terms of any debt securities that we may offer in more detail in the applicable prospectus supplement. The terms of any debt securities offered under a prospectus supplement may differ from the terms described below. Unless otherwise mentioned or unless the context requires otherwise, whenever we refer to the indenture, we also are referring to any supplemental indentures that specify the terms of a particular series of debt securities. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We will issue the debt securities under the indenture that we will enter into with the trustee named in the indenture. The indenture will be qualified under the United States Trust Indenture Act of 1939, as amended (the &#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">Trust Indenture Act</font><font style="letter-spacing:0.2pt;">&#8221;). We have filed the form of indenture as an exhibit to the registration statement of which this prospectus is a part, and supplemental indentures and forms of debt securities containing the terms of the debt securities being offered will be filed as exhibits to the registration statement of which this prospectus is a part or will be incorporated by reference from reports that we file with the SEC. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The following summary of material provisions of the debt securities and the indenture is subject to, and qualified in its entirety by reference to, all of the provisions of the indenture applicable to a particular series of debt securities. We urge you to read the applicable prospectus supplements and any related free writing prospectuses related to the debt securities that we may offer under this prospectus, as well as the complete indenture that contains the terms of the debt securities. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">General</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The indenture will not limit the amount of debt securities that we may issue. It will provide that we may issue debt securities up to the principal amount that we may authorize and may be in any currency or currency unit that we may designate. Except for the limitations on consolidation, merger and sale of all or substantially all of our assets that may be contained in the indenture, the terms of the indenture will not contain any covenants or other provisions designed to give holders of any debt securities protection against changes in our operations, financial condition or transactions involving us. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We may issue the debt securities issued under the indenture as &#8220;discount securities,&#8221; which means they may be sold at a discount below their stated principal amount. These debt securities, as well as other debt securities that are not issued at a discount, may be issued with &#8220;original issue discount,&#8221; or OID, for U.S. federal income tax purposes because of interest payment and other characteristics or terms of the debt securities. Material U.S. federal income tax considerations applicable to debt securities issued with OID will be described in more detail in the applicable prospectus supplement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We will describe in the applicable prospectus supplement the terms of the series of debt securities being offered, including: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the title of the series of debt securities; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any limit upon the aggregate principal amount that may be issued; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the maturity date or dates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the form of the debt securities of the series; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the applicability of any guarantees; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">11</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">whether or not the debt securities will be secured or unsecured, and the terms of any secured debt; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">whether the debt securities rank as senior debt, senior subordinated debt, subordinated debt or any combination thereof, and the terms of any subordination; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.71pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.71pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">if the price (expressed as a&#160;percentage of the aggregate principal amount thereof) at which such debt securities will be issued is a price other than the principal amount thereof, the portion of the principal amount thereof payable upon declaration of acceleration of the maturity thereof, or if applicable, the portion of the principal amount of such debt securities that is convertible into another security or the method by which any such portion shall be determined; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the interest rate or rates, which may be fixed or variable, or the method for determining the rate and the date interest will begin to accrue, the dates interest will be payable and the regular record dates for interest payment dates or the method for determining such dates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our right, if any, to defer payment of interest and the maximum length of any such deferral period; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">if applicable, the date or dates after which, or the period or periods during which, and the price or prices at which, we may, at our option, redeem the series of debt securities pursuant to any optional or provisional redemption provisions and the terms of those redemption provisions; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.71pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.71pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the date or dates, if any, on which, and the price or prices at which we are obligated, pursuant to any mandatory sinking fund or analogous fund provisions or otherwise, to redeem, or at the holder&#8217;s option to purchase, the series of debt securities and the currency or currency unit in which the debt securities are payable; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the denominations in which we will issue the series of debt securities, if other than denominations of $1,000 and any integral multiple thereof; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.71pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.71pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any and all terms, if applicable, relating to any auction or remarketing of the debt securities of that series and any security for our obligations with respect to such debt securities and any other terms which may be advisable in connection with the marketing of debt securities of that series; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">whether the debt securities of the series shall be issued in whole or in part in the form of a global security or securities; the terms and conditions, if any, upon which such global security or securities may be exchanged in whole or in part for other individual securities; and the depositary for such global security or securities; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">if applicable, the provisions relating to conversion or exchange of any debt securities of the series and the terms and conditions upon which such debt securities will be so convertible or exchangeable, including the conversion or exchange price, as applicable, or how it will be calculated and may be adjusted, any mandatory or optional (at our option or the holders&#8217; option) conversion or exchange features, the applicable conversion or exchange period and the manner of settlement for any conversion or exchange; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">if other than the full principal amount thereof, the portion of the principal amount of debt securities of the series which shall be payable upon declaration of acceleration of the maturity thereof; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">additions to or changes in the covenants applicable to the particular debt securities being issued, including, among others, the consolidation, merger or sale covenant; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">additions to or changes in the events of default with respect to the securities and any change in the right of the trustee or the holders to declare the principal, premium, if any, and interest, if any, with respect to such securities to be due and payable; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">additions to or changes in or deletions of the provisions relating to covenant defeasance and legal defeasance; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">additions to or changes in the provisions relating to satisfaction and discharge of the indenture; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">additions to or changes in the provisions relating to the modification of the indenture both with and without the consent of holders of debt securities issued under the indenture; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the currency of payment of debt securities if other than U.S. dollars and the manner of determining the equivalent amount in U.S. dollars; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">12</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">whether interest will be payable in cash or additional debt securities at our or the holders&#8217; option and the terms and conditions upon which the election may be made; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the terms and conditions, if any, upon which we will pay amounts in addition to the stated interest, premium, if any, and principal amounts of the debt securities of the series to any holder that is not a &#8220;United States person&#8221; for federal tax purposes; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any restrictions on transfer, sale or assignment of the debt securities of the series; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any other specific terms, preferences, rights or limitations of, or restrictions on, the debt securities, any other additions or changes in the provisions of the indenture, and any terms that may be required by us or advisable under applicable laws or regulations. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Conversion or Exchange Rights</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We will set forth in the applicable prospectus supplement the terms on which a series of debt securities may be convertible into or exchangeable for our Common Stock or our other securities. We will include provisions as to settlement upon conversion or exchange and whether conversion or exchange is mandatory, at the option of the holder or at our option. We may include provisions pursuant to which the number of shares of our Common Stock or our other securities that the holders of the series of debt securities receive would be subject to adjustment. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Consolidation, Merger or Sale</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Unless we provide otherwise in the prospectus supplement applicable to a particular series of debt securities, the indenture will not contain any covenant that restricts our ability to merge or consolidate, or sell, convey, transfer or otherwise dispose of our assets as an entirety or substantially as an entirety. However, any successor to or acquirer of such assets (other than a subsidiary of ours) must assume all of our obligations under the indenture or the debt securities, as appropriate. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Events of Default under the Indenture</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Unless we provide otherwise in the prospectus supplement applicable to a particular series of debt securities, the following are events of default under the indenture with respect to any series of debt securities that we may issue: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">if we fail to pay any installment of interest on any series of debt securities, as and when the same shall become due and payable, and such default continues for a period of ninety days; provided, however, that a valid extension of an interest payment period by us in accordance with the terms of any indenture supplemental thereto shall not constitute a default in the payment of interest for this purpose; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">if we fail to pay the principal of, or premium, if any, on any series of debt securities as and when the same shall become due and payable whether at maturity, upon redemption, by declaration or otherwise, or in any payment required by any sinking or analogous fund established with respect to such series; provided, however, that a valid extension of the maturity of such debt securities in accordance with the terms of any indenture supplemental thereto shall not constitute a default in the payment of principal or premium, if any; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">if we fail to observe or perform any other covenant or agreement contained in the debt securities or the indenture, other than a covenant specifically relating to another series of debt securities, and our failure continues for 90&#160;days after we receive written notice of such failure, requiring the same to be remedied and stating that such is a notice of default thereunder, from the trustee or holders of at least&#160;25% in aggregate principal amount of the outstanding debt securities of the applicable series; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">if specified events of bankruptcy, insolvency or reorganization occur. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If an event of default with respect to debt securities of any series occurs and is continuing, other than an event of default specified in the last bullet point above, the trustee or the holders of at least 25% in </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">13</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">aggregate principal amount of the outstanding debt securities of that series, by notice to us in writing, and to the trustee if notice is given by such holders, may declare the unpaid principal of, premium, if any, and accrued interest, if any, of such series of debt securities due and payable immediately. If an event of default specified in the last bullet point above occurs with respect to us, the principal amount of and accrued interest, if any, of each issue of debt securities then outstanding shall be due and payable without any notice or other action on the part of the trustee or any holder. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The holders of a majority in principal amount of the outstanding debt securities of an affected series may waive any default or event of default with respect to the series and its consequences, except defaults or events of default regarding payment of principal, premium, if any, or interest, unless we have cured the default or event of default in accordance with the indenture. Any waiver shall cure the default or event of default. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Subject to the terms of the indenture, if an event of default under an indenture shall occur and be continuing, the trustee will be under no obligation to exercise any of its rights or powers under such indenture at the request or direction of any of the holders of the applicable series of debt securities, unless such holders have offered the trustee reasonable indemnity. The holders of a majority in principal amount of the outstanding debt securities of any series will have the right to direct the time, method and place of conducting any proceeding for any remedy available to the trustee, or exercising any trust or power conferred on the trustee, with respect to the debt securities of that series, provided that: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the direction so given by the holder is not in conflict with any law or the applicable indenture; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">subject to its duties under the Trust Indenture Act, the trustee need not take any action that might involve it in personal liability or might be unduly prejudicial to the holders not involved in the proceeding. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A holder of the debt securities of any series will have the right to institute a proceeding under the indenture or to appoint a receiver or trustee, or to seek other remedies only if: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the holder has given written notice to the trustee of a continuing event of default with respect to that series; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the holders of at least 25% in aggregate principal amount of the outstanding debt securities of that series have made written request; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">such holders have offered to the trustee indemnity satisfactory to it against the costs, expenses and liabilities to be incurred by the trustee in compliance with the request; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the trustee does not institute the proceeding, and does not receive from the holders of a majority in aggregate principal amount of the outstanding debt securities of that series other conflicting directions within 90&#160;days after the notice, request and offer. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">These limitations do not apply to a suit instituted by a holder of debt securities if we default in the payment of the principal, premium, if any, or interest on, the debt securities. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We will periodically file statements with the trustee regarding our compliance with specified covenants in the indenture. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Modification of Indenture; Waiver</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Unless we provide otherwise in the prospectus supplement applicable to a particular series of debt securities, we and the trustee may change an indenture without the consent of any holders with respect to specific matters: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">to cure any ambiguity, defect or inconsistency in the indenture or in the debt securities of any series; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">to comply with the provisions described above under &#8220;Description of Debt Securities &#8212; Consolidation, Merger or Sale; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">to provide for uncertificated debt securities in addition to or in place of certificated debt securities; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">14</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">to add to our covenants, restrictions, conditions or provisions such new covenants, restrictions, conditions or provisions for the benefit of the holders of all or any series of debt securities, to make the occurrence, or the occurrence and the continuance, of a default in any such additional covenants, restrictions, conditions or provisions an event of default or to surrender any right or power conferred upon us in the indenture; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.21pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.21pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">to add to, delete from or revise the conditions, limitations, and restrictions on the authorized amount, terms, or purposes of issue, authentication and delivery of debt securities, as set forth in the indenture; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.21pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.21pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">to make any change that does not adversely affect the interests of any holder of debt securities of any series in any material respect; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">to provide for the issuance of and establish the form and terms and conditions of the debt securities of any series as provided above under &#8220;Description of Debt Securities&#8201;&#8212;&#8201;General&#8221; to establish the form of any certifications required to be furnished pursuant to the terms of the indenture or any series of debt securities, or to add to the rights of the holders of any series of debt securities; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">to evidence and provide for the acceptance of appointment under any indenture by a successor trustee; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.21pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.21pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">to comply with any requirements of the SEC in connection with the qualification of any indenture under the Trust Indenture Act. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition, under the indenture, the rights of holders of a series of debt securities may be changed by us and the trustee with the written consent of the holders of at least a majority in aggregate principal amount of the outstanding debt securities of each series that is affected. However, unless we provide otherwise in the prospectus supplement applicable to a particular series of debt securities, we and the trustee may make the following changes only with the consent of each holder of any outstanding debt securities affected: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">extending the fixed maturity of any debt securities of any series; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">reducing the principal amount, reducing the rate of or extending the time of payment of interest, or reducing any premium payable upon the redemption of any series of any debt securities; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.21pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.21pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">reducing the&#160;percentage of debt securities, the holders of which are required to consent to any amendment, supplement, modification or waiver. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Discharge</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The indenture will provide that we can elect to be discharged from our obligations with respect to one or more series of debt securities, except for specified obligations, including obligations to: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">provide for payment; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.21pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.21pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">register the transfer or exchange of debt securities of the series; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">replace stolen, lost or mutilated debt securities of the series; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">pay principal of and premium and interest on any debt securities of the series; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.21pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.21pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">maintain paying agencies; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">hold monies for payment in trust; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.11pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.11pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">recover excess money held by the trustee; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">compensate and indemnify the trustee; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.11pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.11pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">appoint any successor trustee. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In order to exercise our rights to be discharged, we must deposit with the trustee money or government obligations sufficient to pay all the principal of, any premium, and interest on, the debt securities of the series on the dates payments are due. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We will issue the debt securities of each series only in fully registered form without coupons and, unless we provide otherwise in the applicable prospectus supplement, in denominations of&#8201;$1,000 and any integral </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">15</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">multiple thereof. The indenture will provide that we may issue debt securities of a series in temporary or permanent global form and as book-entry securities that will be deposited with, or on behalf of, The Depository Trust Company, or DTC, or another depositary named by us and identified in the applicable prospectus supplement with respect to that series. To the extent the debt securities of a series are issued in global form and as book-entry, a description of terms relating to any book-entry securities will be set forth in the applicable prospectus supplement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">At the option of the holder, subject to the terms of the indenture and the limitations applicable to global securities described in the applicable prospectus supplement, the holder of the debt securities of any series will be able to exchange the debt securities for other debt securities of the same series, in any authorized denomination and of like tenor and aggregate principal amount. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Subject to the terms of the indenture and the limitations applicable to global securities set forth in the applicable prospectus supplement, holders of the debt securities may present the debt securities for exchange or for registration of transfer, duly endorsed or with the form of transfer endorsed thereon duly executed if so required by us or the security registrar, at the office of the security registrar or at the office of any transfer agent designated by us for this purpose. Unless otherwise provided in the debt securities that the holder presents for transfer or exchange, we will impose no service charge for any registration of transfer or exchange, but we may require payment of any taxes or other governmental charges. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We will name in the applicable prospectus supplement the security registrar, and any transfer agent in addition to the security registrar, that we initially designate for any debt securities. We may at any time designate additional transfer agents or rescind the designation of any transfer agent or approve a change in the office through which any transfer agent acts, except that we will be required to maintain a transfer agent in each place of payment for the debt securities of each series. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If we elect to redeem the debt securities of any series, we will not be required to: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">issue, register the transfer of, or exchange any debt securities of that series during a period beginning at the opening of business fifteen days before the day of mailing of a notice of redemption of any debt securities that may be selected for redemption and ending at the close of business on the day of the mailing; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.91pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.91pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">register the transfer of or exchange of any debt securities so selected for redemption, in whole or in part, except the unredeemed portion of any debt securities we are redeeming in part. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Information Concerning the Trustee</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The trustee, other than during the occurrence and continuance of an event of default under an indenture, will undertake to perform only those duties as are specifically set forth in the applicable indenture. Upon an event of default under an indenture, the trustee must use the same degree of care as a prudent person would exercise or use in the conduct of his or her own affairs. Subject to this provision, the trustee is under no obligation to exercise any of the powers given it by the indenture at the request of any holder of debt securities unless it is offered reasonable security and indemnity against the costs, expenses and liabilities that it might incur. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Payment and Paying Agents</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Unless we otherwise indicate in the applicable prospectus supplement, we will make payment of the interest on any debt securities on any interest payment date to the person in whose name the debt securities, or one or more predecessor securities, are registered at the close of business on the regular record date for the interest. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We will pay principal of and any premium and interest on the debt securities of a particular series at the office of the paying agents designated by us, except that unless we otherwise indicate in the applicable prospectus supplement, we will make interest payments by check that we will mail to the holder or by wire transfer to certain holders. Unless we otherwise indicate in the applicable prospectus supplement, we will designate the corporate trust office of the trustee as our sole paying agent for payments with respect to debt securities of each series. We will name in the applicable prospectus supplement any other paying agents </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">16</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:480pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">that we initially designate for the debt securities of a particular series. We will maintain a paying agent in each place of payment for the debt securities of a particular series. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">All money we pay to a paying agent or the trustee for the payment of the principal of or any premium or interest on any debt securities that remains unclaimed at the end of two&#160;years after such principal, premium or interest has become due and payable will be repaid to us, and the holder of the debt security thereafter may look only to us for payment thereof. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Governing Law</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The indenture and the debt securities, and any claim, controversy or dispute arising under or related to the indenture or the debt securities, will be governed by and construed in accordance with the laws of the State of New York, except to the extent that the Trust Indenture Act is applicable. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">17</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tDOCS">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">DESCRIPTION OF CAPITAL STOCK</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">General</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">This prospectus describes the general terms of our capital stock. For a more detailed description of our capital stock, you should read the applicable provisions of the Nevada Revised Statutes (the &#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">NRS</font><font style="letter-spacing:0.2pt;">&#8221;), our amended and restated articles of incorporation (our &#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">Articles of Incorporation</font><font style="letter-spacing:0.2pt;">&#8221;) and our amended and restated bylaws (our &#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">Bylaws</font><font style="letter-spacing:0.2pt;">&#8221;). </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Common Stock</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our Articles of Incorporation provides authority for us to issue up to 100,000,000 shares of Common Stock, par value $0.001 per share. As of November 22, 2023, there were 39,625,271 shares of our Common Stock outstanding. Under the NRS, stockholders generally are not personally liable for our debts or obligations solely as a result of their status as stockholders. Our outstanding shares of Common Stock are, and any shares offered by this prospectus will be, when issued and paid for, fully paid and nonassessable. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Holders of our Common Stock are entitled to one vote per share on all matters submitted to our stockholders for a vote. There are no cumulative voting rights in the election of directors. Our shares of Common Stock are entitled to receive such dividends as may be declared and paid by our Board of Directors out of funds legally available therefor and to share ratably in the net assets, if any, of Rezolute upon liquidation. Our stockholders have no preemptive rights to purchase any shares of our capital stock. Our Articles of Incorporation provides that the Eighth Judicial District Court of Clark County, Nevada shall be the sole and exclusive forum for (i)&#160;any derivative action or proceeding brought on our behalf, (ii)&#160;any action asserting a claim for breach of a fiduciary duty owed by any of our directors, officers, employees or agents to us or our stockholders, (iii)&#160;any action asserting a claim arising pursuant to any provision of the NRS Chapters 78 or 92A, our Articles of Incorporation or our Bylaws or (iv)&#160;any action asserting a claim governed by the internal affairs doctrine. Notwithstanding this exclusive forum provision, the exclusive forum provision shall not preclude or contract the scope of exclusive federal or concurrent jurisdiction for actions brought under the Exchange Act or the Securities Act, or the respective rules and regulations promulgated thereunder. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Preferred Stock</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our Articles of Incorporation provides authority for us to issue up to 400,000 shares of preferred stock, par value $0.001 per share. Our Board of Directors is authorized, without further stockholder action, to establish various series of preferred stock from time to time and to determine the rights, preferences and privileges of any unissued series including, among other matters, any dividend rights, dividend rates, conversion rights, voting rights, terms of redemption, liquidation preferences, sinking fund terms, the number of shares constituting any such series, and the description thereof and to issue any such shares. As of November 22, 2023, there are no issued and outstanding shares of preferred stock and our Board of Directors has not designated any series of preferred stock for future issuance. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The rights of the holders of our Common Stock will be subject to, and may be adversely affected by, the rights of holders of any preferred stock that may be issued in the future. Such rights may include voting and conversion rights which could adversely affect the holders of the Common Stock. Satisfaction of any dividend or liquidation preferences of outstanding preferred stock would reduce the amount of funds available, if any, for the payment of dividends or liquidation amounts on Common Stock. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A prospectus supplement, relating to any offered class or series of preferred stock, will specify the following terms of such class or series, as applicable: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the designation of such class or series of our $0.001 par value preferred stock; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the number of shares of such class or series of preferred stock offered, the liquidation preference per share and the offering price of such class or series of preferred stock; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the dividend rate(s), period(s), and/or payment date(s) or method(s) of calculation thereof applicable to such class or series of preferred stock; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">18</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:284pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">whether dividends on such class or series of preferred stock are cumulative or not and, if cumulative, the date from which dividends on such class or series of preferred stock shall accumulate; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the provision for a sinking fund, if any, for such class or series of preferred stock; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the provision for redemption, if applicable, of such class or series of preferred stock; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any listing of such class or series of preferred stock on any securities exchange; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the preemptive rights, if any, of such class or series of preferred stock; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the terms and conditions, if applicable, upon which shares such class or series of preferred stock will be convertible into shares of our Common Stock or shares of any other class or series of our stock or other securities, including the conversion price (or manner of calculation thereof); </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">a discussion of any additional material federal income tax consequences applicable to an investment in such class or series of preferred stock; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the relative ranking and preferences of such class or series of preferred stock as to dividend rights and rights upon liquidation, dissolution or winding up of the affairs of our Company; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any limitations on issuance of any class or series of stock ranking senior to or on parity with such class or series of preferred stock as to dividend rights and rights upon liquidation, dissolution or winding up of the affairs of our Company; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any voting rights of such class or series of preferred stock; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any other specific terms, preferences, rights, limitations or restrictions of such class or series of preferred stock. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Transfer Agent and Registrar</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The transfer agent of our Common Stock is Issuer Direct Corporation. Their address is One Glenwood Avenue, Suite 1001, Raleigh, NC 27306.</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">19</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tDOW">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">DESCRIPTION OF WARRANTS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We may issue warrants to purchase any combination of debt securities, common stock, preferred stock, depositary shares or purchase contracts or other securities of our company or any other entity. We may issue warrants independently or together with other securities. Warrants sold with other securities may be attached to or separate from the other securities. We will issue warrants under one or more warrant agreements between us and a warrant agent that we will name in a prospectus supplement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The prospectus supplement relating to any warrants we are offering will include specific terms relating to the offering. We will file the form of any warrant agreement with the SEC, and you should read the warrant agreement for provisions that may be important to you. The prospectus supplement will include some or all of the following terms: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the title of the warrants; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the aggregate number of warrants offered; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the designation, number and terms of the debt securities, common stock, preferred stock, depositary shares or purchase contracts or other securities purchasable upon exercise of the warrants, and procedures by which those numbers may be adjusted; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the exercise price of the warrants; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the dates or periods during which the warrants are exercisable; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the designation and terms of any securities with which the warrants are issued; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">if the warrants are issued as a unit with another security, the date, if any, on and after which the warrants and the other security will be separately transferable; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">if the exercise price is not payable in U.S. dollars, the foreign currency, currency unit or composite currency in which the exercise price is denominated; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any minimum or maximum amount of warrants that may be exercised at any one time; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any terms, procedures and limitations relating to the transferability, exchange or exercise of the warrants. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Class&#160;A Pre-Funded Warrants</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In May&#160;2022, we issued and sold Class&#160;A Pre-Funded Warrants (the &#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">Class&#160;A Pre-Funded Warrants</font><font style="letter-spacing:0.2pt;">&#8221;) to purchase an aggregate of 1,973,684 shares of our common stock at an offering price of $3.799 per Class&#160;A Pre-Funded Warrant in an underwritten public offering pursuant to a shelf registration on Form S-3. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Each Class&#160;A Pre-Funded Warrant entitles the holder to purchase one share of our common stock at an exercise price of $0.001 per share. The Class&#160;A Pre-Funded Warrants do not expire and may be exercised at any time after their original issuance. Under the Class&#160;A Pre-Funded Warrants, we may not effect the exercise of any Class&#160;A Pre-Funded Warrant, and a holder will not be entitled to exercise any portion of any Class&#160;A Pre-Funded Warrant, which, upon giving effect to such exercise, would cause (i)&#160;the aggregate number of shares of our common stock beneficially owned by the holder (together with its affiliates) to exceed 4.99% of the number of shares of our common stock outstanding immediately after giving effect to the exercise, or (ii)&#160;the combined voting power of our securities beneficially owned by the holder of the Class&#160;A Pre-Funded Warrant (together with its affiliates) to exceed 4.99% of the combined voting power of all of our securities then outstanding immediately after giving effect to the exercise, as such&#160;percentage ownership is determined in accordance with the terms of the Class&#160;A Pre-Funded Warrants. However, any holder may increase or decrease such&#160;percentage to any other&#160;percentage upon at least 61&#160;days&#8217; prior notice from the holder to us; provided, that a holder of a Class&#160;A Pre-Funded Warrants may not increase such&#160;percentage to a&#160;percentage in excess of 19.99%.The exercise price of the Class&#160;A Pre-Funded Warrants and the number of shares of our common stock issuable upon exercise of the Class&#160;A Pre-Funded Warrants is subject to appropriate adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting our common stock and also upon any distributions of assets, including cash, stock or other property to our stockholders. The Class&#160;A Pre-Funded Warrants </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">20</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">also contain provisions that provide certain rights to holders in the event of a fundamental transaction, including a merger or consolidation with or into another entity, such as the right to receive the same amount and kind of consideration paid to the holders of our common stock in the fundamental transaction. The Class&#160;A Pre-Funded Warrants do not entitle the holders to any voting rights or any of the other rights or privileges to which holders of common stock are entitled. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As of November&#160;13, 2023, we have 1,973,684 shares underlying the Class&#160;A Pre-Funded Warrants outstanding, of which there have been no exercises. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Class&#160;B Pre-Funded Warrants</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In May&#160;2022, we issued and sold Class&#160;B Pre-Funded Warrants (the &#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">Class&#160;B Pre-Funded Warrants</font><font style="letter-spacing:0.2pt;">&#8221;) to purchase an aggregate of 10,947,371 shares of our common stock at an offering price of $3.799 per Class&#160;B Pre-Funded Warrant in an underwritten public offering pursuant to a shelf registration on Form S-3. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Each Class&#160;B Pre-Funded Warrant entitles the holder to purchase one share of our common stock at an exercise price of $0.001 per share. The Class&#160;B Pre-Funded Warrants do not expire and may be exercised at any time after their original issuance. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Under the Class&#160;B Pre-Funded Warrants, we may not effect the exercise of any Class&#160;B Pre-Funded Warrant, and a holder will not be entitled to exercise any portion of any Class&#160;B Pre-Funded Warrant, which, upon giving effect to such exercise, would cause (i)&#160;the aggregate number of shares of our common stock beneficially owned by the holder (together with its affiliates) to exceed 4.99%, 9.99% or 19.99%, as applicable to the holder, of the number of shares of our common stock outstanding immediately after giving effect to the exercise, or (ii)&#160;the combined voting power of our securities beneficially owned by the holder of the Class&#160;B Pre-Funded Warrant (together with its affiliates) to exceed 4.99%, 9.99% or 19.99%, as applicable to the holder, of the combined voting power of all of our securities then outstanding immediately after giving effect to the exercise, as such&#160;percentage ownership is determined in accordance with the terms of the Class&#160;B Pre-Funded Warrants. However, any holder may increase or decrease such&#160;percentage to any other&#160;percentage upon at least 61&#160;days&#8217; prior notice from the holder to us; provided, that a holder of a Class&#160;B Pre-Funded Warrants may not increase such&#160;percentage to a&#160;percentage in excess of 19.99%.The exercise price of the Class&#160;B Pre-Funded Warrants and the number of shares of our common stock issuable upon exercise of the Class&#160;B Pre-Funded Warrants is subject to appropriate adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting our common stock and also upon any distributions of assets, including cash, stock or other property to our stockholders. The Class&#160;B Pre-Funded Warrants also contain provisions that provide certain rights to holders in the event of a fundamental transaction, including a merger or consolidation with or into another entity, such as the right to receive the same amount and kind of consideration paid to the holders of our common stock in the fundamental transaction. The Class&#160;B Pre-Funded Warrants do not entitle the holders to any voting rights or any of the other rights or privileges to which holders of common stock are entitled. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As of November&#160;13, 2023, we have 8,147,371 shares underlying the Class&#160;B Pre-Funded Warrants outstanding. There was a cashless exercise of 2,8000,000 Class&#160;B Pre-Funded Warrants on October&#160;4, 2023 which resulted in an issuance of 2,797,704 shares of Common Stock. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">October&#160;2021 Pre-Funded Warrants</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In October&#160;2021, we issued and sold pre-funded warrants (the &#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">2021 Pre-Funded Warrants</font><font style="letter-spacing:0.2pt;">&#8221;) to purchase an aggregate of 1,661,461 shares of our common stock at an offering price of $6.49 per 2021 Pre-Funded Warrant in an underwritten public offering pursuant to a shelf registration on Form S-3. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Each 2021 Pre-Funded Warrant entitles the holder to purchase one share of our common stock at an exercise price of $0.01 per share. The 2021 Pre-Funded Warrants do not expire and may be exercised at any time after their original issuance. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Under the 2021 Pre-Funded Warrants, we may not effect the exercise of any 2021 Pre-Funded Warrant, and a holder will not be entitled to exercise any portion of any 2021 Pre-Funded Warrant, which, upon giving effect to such exercise, would cause (i)&#160;the aggregate number of shares of our common stock beneficially </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">21</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">owned by the holder (together with its affiliates) to exceed 4.99% or 19.99%, as applicable to the holder, of the number of shares of our common stock outstanding immediately after giving effect to the exercise, or (ii)&#160;the combined voting power of our securities beneficially owned by the holder of the 2021 Pre-Funded Warrant (together with its affiliates) to exceed 4.99% or 19.99%, as applicable to the holder, of the combined voting power of all of our securities then outstanding immediately after giving effect to the exercise, as such&#160;percentage ownership is determined in accordance with the terms of the 2021 Pre-Funded Warrants. However, any holder may increase or decrease such&#160;percentage to any other&#160;percentage upon at least 61&#160;days&#8217; prior notice from the holder to us; provided, that a holder of a 2021 Pre-Funded Warrants may not increase such&#160;percentage to a&#160;percentage in excess of 19.99%.The exercise price of the 2021 Pre-Funded Warrants and the number of shares of our common stock issuable upon exercise of the 2021 Pre-Funded Warrants is subject to appropriate adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting our common stock and also upon any distributions of assets, including cash, stock or other property to our stockholders. The 2021 Pre-Funded Warrants also contain provisions that provide certain rights to holders in the event of a fundamental transaction, including a merger or consolidation with or into another entity, such as the right to receive the same amount and kind of consideration paid to the holders of our common stock in the fundamental transaction. The 2021 Pre-Funded Warrants do not entitle the holders to any voting rights or any of the other rights or privileges to which holders of common stock are entitled. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As of November&#160;13, 2023, we have 1,661,461 shares underlying the 2021 Pre-Funded Warrants outstanding, of which there have been no exercises. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Participating Warrants</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In October&#160;2020, we issued and sold 820,001 warrants (the &#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">Participating Warrants</font><font style="letter-spacing:0.2pt;">&#8221;), and each Participating Warrant entitles the holder to purchase 0.33 shares of our common stock at an exercise price of $19.50 per share of our common stock. Each Participating Warrant is exercisable on or after October&#160;9, 2020 and will expire on or prior to 5:00&#160;p.m. (New York City time) on October&#160;9, 2027. The Participating Warrants were subsequently registered for resale by certain selling stockholders pursuant to a registration statement on Form S-3. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Under the Participating Warrants, we may not effect the exercise of any Participating Warrant, and a holder will not be entitled to exercise any portion of any Participating Warrant, which, upon giving effect to such exercise, would cause the aggregate number of shares of our common stock beneficially owned by the holder (together with its affiliates) to exceed 4.99% or 19.99%, as applicable to the holder, of the number of shares of our common stock outstanding immediately after giving effect to the exercise. However, any holder may increase or decrease such&#160;percentage to any other&#160;percentage; provided, that a holder of Participating Warrant may not increase such&#160;percentage to a&#160;percentage in excess of 9.99% of the number of shares of the common stock outstanding immediately after giving effect to the issuance of shares of common stock upon exercise of the Participating Warrant held by the holder. Any increase in such&#160;percentage will not be effective until the 61st day after such notice is delivered to the company. The exercise price of the Participating Warrants and the number of shares of our common stock issuable upon exercise of the Participating Warrant is subject to appropriate adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting our common stock and also upon any distributions of assets, including cash, stock or other property to our stockholders. The Participating Warrants also contain provisions that provide certain rights to holders in the event of a fundamental transaction, including a merger or consolidation with or into another entity, such as (i)&#160;the right to receive the same amount and kind of consideration paid to the holders of our common stock in the fundamental transaction and (ii)&#160;the right to require the company to repurchase the unexercised portion of certain warrants at the warrant&#8217;s respective fair value using the Black Scholes option pricing formula. The Participating Warrants do not entitle the holders to any voting rights or any of the other rights or privileges to which holders of common stock are entitled. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As of November&#160;13, 2023, we have 820,001 shares underlying the Participating Warrants outstanding, of which there have been no exercises. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">22</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Helvetica, Arial, sans-serif;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:584pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">Other Warrants</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">We have issued warrants in conjunction with debt and equity financings and for services from 2015 to 2019. Such warrants have various expiration dates and exercise prices. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">23</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">DESCRIPTION OF SUBSCRIPTION RIGHTS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We may elect to offer subscription rights from time to time. The following description summarizes the general terms and provisions of the subscription rights that we may offer pursuant to this prospectus. The specific terms relating to any subscription rights that we offer will be described in a prospectus supplement, which you should read. Because the terms of the specific subscription rights offered may differ from the general information that we have provided below, you should rely on information in the applicable prospectus supplement that contradicts any information below. The summary below is not complete and is subject to, and qualified in its entirety by reference to, the provisions of the applicable prospectus supplement. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">General</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We may issue subscription rights to purchase shares of our common stock, preferred stock, debt securities or other securities. These subscription rights may be issued independently or together with any other security offered hereby and may or may not be transferable by the stockholder purchasing or receiving the subscription rights in such offering. In connection with any offering of subscription rights, we may enter into a standby arrangement with one or more underwriters or other purchasers pursuant to which the underwriters or other purchasers may be required to purchase any securities remaining unsubscribed for after such offering. In connection with a subscription rights offering to our stockholders, we will distribute certificates evidencing the subscription rights and a prospectus supplement to our stockholders on the record date that we set for receiving subscription rights in such subscription rights offering. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The applicable prospectus supplement will describe the specific terms of any offering of subscription rights for which this prospectus is being delivered, including the following: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the prices, if any, for the subscription rights; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the exercise price payable for each share of common stock, preferred stock, debt securities or other securities upon the exercise of the subscription rights; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the number of subscription rights issued to each stockholder; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the number and terms of the shares of common stock, preferred stock, debt securities or other securities which may be purchased per each subscription right; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the extent to which the subscription rights are transferable; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any other terms of the subscription rights, including the terms, procedures and limitation relating to the exchange and exercise of the subscription rights; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the date on which the rights to exercise the subscription rights shall commence, and the date on which the subscription rights shall expire; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the extent to which the subscription rights may include an over-subscription privilege with respect to unsubscribed securities; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">if applicable, the material terms of any standby underwriting or purchase arrangement entered into by us in connection with the offering of subscription rights. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Exercise of Subscription Rights</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Each subscription right will entitle the holder of the subscription right to purchase for cash such amount of shares of common stock, preferred stock, debt securities, units, depositary shares, purchase contracts, or other securities, at such exercise price as shall in each case be set forth in, or be determinable as set forth in, the prospectus supplement relating to the subscription rights offered thereby. Subscription rights may be exercised at any time up to the close of business on the expiration date for such subscription rights set forth in the prospectus supplement. After the close of business on the expiration date, all unexercised subscription rights will become void. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Subscription rights may be exercised as set forth in the prospectus supplement relating to the subscription rights offered thereby. Upon receipt of payment and the subscription rights certificate properly completed and duly executed at the corporate trust office of the subscription rights agent or any other office indicated in </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">24</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Helvetica, Arial, sans-serif;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:568pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">the prospectus supplement, we will forward, as soon as practicable, the shares of common stock, preferred stock, debt securities or other securities purchasable upon such exercise. We may determine to offer any unsubscribed offered securities directly to persons other than stockholders, to or through agents, underwriters or dealers or through a combination of such methods, including pursuant to standby underwriting arrangements, as set forth in the applicable prospectus supplement. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">25</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tDOPC">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:14pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">DESCRIPTION OF PURCHASE CONTRACTS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following description summarizes the general features of the purchase contracts that we may offer under this prospectus. Although the features we have summarized below will generally apply to any future purchase contracts we may offer under this prospectus, we will describe the particular terms of any purchase contracts that we may offer in more detail in the applicable prospectus supplement. The specific terms of any purchase contracts may differ from the description provided below as a result of negotiations with third parties in connection with the issuance of those purchase contracts, as well as for other reasons. Because the terms of any purchase contracts we offer under a prospectus supplement may differ from the terms we describe below, you should rely solely on information in the applicable prospectus supplement if that summary is different from the summary in this prospectus. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We will incorporate by reference into the registration statement of which this prospectus is a part the form of any purchase contract that we may offer under this prospectus before the sale of the related purchase contract. We urge you to read any applicable prospectus supplement related to specific purchase contracts being offered, as well as the complete instruments that contain the terms of the securities that are subject to those purchase contracts. Certain of those instruments, or forms of those instruments, have been filed as exhibits to the registration statement of which this prospectus is a part, and supplements to those instruments or forms may be incorporated by reference into the registration statement of which this prospectus is a part from reports we file with the SEC. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We may offer purchase contracts, including contracts obligating holders to purchase from us, and for us to sell to holders, a specific or variable number of our securities at a future date or dates. Alternatively, the purchase contracts may obligate us to purchase from holders, and obligate holders to sell to us, a specific or varying number of our securities. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If we offer any purchase contracts, certain terms of that series of purchase contracts will be described in the applicable prospectus supplement, including, without limitation, the following: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the price of the securities or other property subject to the purchase contracts (which may be determined by reference to a specific formula described in the purchase contracts); </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">whether the purchase contracts are issued separately, or as a part of&#160;units each consisting of a purchase contract and one or more of our other securities, including U.S. Treasury securities, securing the holder&#8217;s obligations under the purchase contract; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any requirement for us to make periodic payments to holders or vice versa, and whether the payments are unsecured or pre-funded; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any provisions relating to any security provided for the purchase contracts; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">whether the purchase contracts obligate the holder or us to purchase or sell, or both purchase and sell, the securities subject to purchase under the purchase contract, and the nature and amount of each of those securities, or the method of determining those amounts; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">whether the purchase contracts are to be prepaid or not; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">whether the purchase contracts are to be settled by delivery, or by reference or linkage to the value, performance or level of the securities subject to purchase under the purchase contract; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any acceleration, cancellation, termination or other provisions relating to the settlement of the purchase contracts; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">a discussion of certain U.S. federal income tax considerations applicable to the purchase contracts; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">whether the purchase contracts will be issued in fully registered or global form; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any other terms of the purchase contracts and any securities subject to such purchase contracts. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">26</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tDODS1">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">DESCRIPTION OF DEPOSITARY SHARES</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:11.61pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">General</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We may offer depositary shares representing a fractional interest in a share of a particular series of preferred stock. Unless otherwise provided in the prospectus supplement, each owner of a depositary share will be entitled, in proportion to the applicable fractional interest in a share of preferred stock represented by the depositary share, to all the rights and preferences of the preferred stock represented by the depositary share. Those rights include dividend, voting, redemption, conversion and liquidation rights. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The shares of preferred stock underlying the depositary shares will be deposited with a bank or trust company selected by us to act as depositary under a deposit agreement between us, the depositary and the holders of the depositary receipts. The depositary will be the transfer agent, registrar and dividend disbursing agent for the depositary shares. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The depositary shares will be evidenced by depositary receipts issued pursuant to the deposit agreement. Holders of depositary receipts agree to be bound by the deposit agreement, which requires holders to take certain actions such as filing proof of residence and paying certain charges. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The summary of terms of the depositary shares contained in this prospectus is not complete. You should refer to the form of the deposit agreement, our certificate of incorporation and the certificate of designation for the applicable series of preferred stock that are, or will be, filed with the SEC. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Dividends and Other Distributions</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The depositary will distribute all cash dividends or other cash distributions, if any, received in respect of the preferred stock underlying the depositary shares to the record holders of depositary shares in proportion to the numbers of depositary shares owned by those holders on the relevant record date. The relevant record date for depositary shares will be the same date as the record date for the underlying preferred stock. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If there is a distribution other than in cash, the depositary will distribute property (including securities) received by it to the record holders of depositary shares, unless the depositary determines that it is not feasible to make the distribution. If this occurs, the depositary may, with our approval, adopt another method for the distribution, including selling the property and distributing the net proceeds from the sale to the holders. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Liquidation Preference</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If a series of preferred stock underlying the depositary shares has a liquidation preference, in the event of the voluntary or involuntary liquidation, dissolution or winding up of us, holders of depositary shares will be entitled to receive the fraction of the liquidation preference accorded each share of the applicable series of preferred stock, as set forth in the applicable prospectus supplement. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Withdrawal of Stock</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Unless the related depositary shares have been previously called for redemption, upon surrender of the depositary receipts at the office of the depositary, the holder of the depositary shares will be entitled to delivery, at the office of the depositary to or upon his or her order, of the number of whole shares of the preferred stock and any money or other property represented by the depositary shares. If the depositary receipts delivered by the holder evidence a number of depositary shares in excess of the number of depositary shares representing the number of whole shares of preferred stock to be withdrawn, the depositary will deliver to the holder at the same time a new depositary receipt evidencing the excess number of depositary shares. In no event will the depositary deliver fractional shares of preferred stock upon surrender of depositary receipts. Holders of preferred stock thus withdrawn may not thereafter deposit those shares under the deposit agreement or receive depositary receipts evidencing depositary shares therefor. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Redemption of Depositary Shares</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Whenever we redeem shares of preferred stock held by the depositary, the depositary will redeem as of the same redemption date the number of depositary shares representing shares of the preferred stock so </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">27</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">redeemed, so long as we have paid in full to the depositary the redemption price of the preferred stock to be redeemed plus an amount equal to any accumulated and unpaid dividends on the preferred stock to the date fixed for redemption. The redemption price per depositary share will be equal to the redemption price and any other amounts per share payable on the preferred stock multiplied by the fraction of a share of preferred stock represented by one depositary share. If less than all the depositary shares are to be redeemed, the depositary shares to be redeemed will be selected by lot or pro&#160;rata or by any other equitable method as may be determined by the depositary. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">After the date fixed for redemption, depositary shares called for redemption will no longer be deemed to be outstanding and all rights of the holders of depositary shares will cease, except the right to receive the monies payable upon redemption and any money or other property to which the holders of the depositary shares were entitled upon redemption upon surrender to the depositary of the depositary receipts evidencing the depositary shares. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Voting the Preferred Stock</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Upon receipt of notice of any meeting at which the holders of the preferred stock are entitled to vote, the depositary will mail the information contained in the notice of meeting to the record holders of the depositary receipts relating to that preferred stock. The record date for the depositary receipts relating to the preferred stock will be the same date as the record date for the preferred stock. Each record holder of the depositary shares on the record date will be entitled to instruct the depositary as to the exercise of the voting rights pertaining to the number of shares of preferred stock represented by that holder&#8217;s depositary shares. The depositary will endeavor, insofar as practicable, to vote the number of shares of preferred stock represented by the depositary shares in accordance with those instructions, and we will agree to take all action that may be deemed necessary by the depositary in order to enable the depositary to do so. The depositary will not vote any shares of preferred stock except to the extent that it receives specific instructions from the holders of depositary shares representing that number of shares of preferred stock. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Charges of the Depositary</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We will pay all transfer and other taxes and governmental charges arising solely from the existence of the depositary arrangements. We will pay charges of the depositary in connection with the initial deposit of the preferred stock and any redemption of the preferred stock. Holders of depositary receipts will pay transfer, income and other taxes and governmental charges and such other charges (including those in connection with the receipt and distribution of dividends, the sale or exercise of rights, the withdrawal of the preferred stock and the transferring, splitting or grouping of depositary receipts) as are expressly provided in the deposit agreement to be for their accounts. If these charges have not been paid by the holders of depositary receipts, the depositary may refuse to transfer depositary shares, withhold dividends and distributions and sell the depositary shares evidenced by the depositary receipt. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Amendment and Termination of the Deposit Agreement</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The form of depositary receipt evidencing the depositary shares and any provision of the deposit agreement may be amended by agreement between us and the depositary. However, any amendment that materially and adversely alters the rights of the holders of depositary shares, other than fee changes, will not be effective unless the amendment has been approved by the holders of a majority of the outstanding depositary shares. The deposit agreement may be terminated by the depositary or us only if: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">all outstanding depositary shares have been redeemed; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">there has been a final distribution of the preferred stock in connection with our dissolution and such distribution has been made to all the holders of depositary shares. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Resignation and Removal of Depositary</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The depositary may resign at any time by delivering to us notice of its election to do so, and we may remove the depositary at any time. Any resignation or removal of the depositary will take effect upon our appointment of a successor depositary and its acceptance of such appointment. The successor depositary must be appointed within 60&#160;days after delivery of the notice of resignation or removal and must be a bank or </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">28</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:372pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">trust company having its principal office in the United States and having the requisite combined capital and surplus as set forth in the applicable agreement. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Notices</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The depositary will forward to holders of depositary receipts all notices, reports and other communications, including proxy solicitation materials received from us, that are delivered to the depositary and that we are required to furnish to the holders of the preferred stock. In addition, the depositary will make available for inspection by holders of depositary receipts at the principal office of the depositary, and at such other places as it may from time to time deem advisable, any reports and communications we deliver to the depositary as the holder of preferred stock. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Limitation of Liability</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Neither we nor the depositary will be liable if either is prevented or delayed by law or any circumstance beyond its control in performing its obligations. Our obligations and those of the depositary will be limited to performance in good faith of our and its duties thereunder. We and the depositary will not be obligated to prosecute or defend any legal proceeding in respect of any depositary shares or preferred stock unless satisfactory indemnity is furnished. We and the depositary may rely upon written advice of counsel or accountants, on information provided by persons presenting preferred stock for deposit, holders of depositary receipts or other persons believed to be competent to give such information and on documents believed to be genuine and to have been signed or presented by the proper party or parties. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">29</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:250pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">DESCRIPTION OF UNITS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We may issue&#160;units comprised of one or more of the securities described in this prospectus in any combination. Each unit will be issued so that the holder of the unit is also the holder of each security included in the unit. Thus, the holder of a unit will have the rights and obligations of a holder of each included security. The unit agreement, if any, under which a unit is issued may provide that the securities comprising the unit may not be held or transferred separately, at any time or at any time before a specified date. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The particular terms and provisions of&#160;units offered by any prospectus supplement, and the extent to which the general terms and provisions described below may apply thereto, will be described in the prospectus supplement filed in respect of such&#160;units. This description will include, where applicable: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the designation and aggregate number of&#160;units offered; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the price at which the&#160;units will be offered; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the currency or currencies in which the&#160;units are denominated; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the terms of the&#160;units and of the securities comprising the&#160;units, including whether and under what circumstances those securities may be held or transferred separately; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the number of securities that may be purchased upon exercise of each unit and the price at which the currency or currencies in which that amount of securities may be purchased upon exercise of each unit; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any provisions for the issuance, payment, settlement, transfer, adjustment or exchange of the&#160;units or of the securities comprising the&#160;units; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any other material terms of the&#160;units. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We reserve the right to set forth in a prospectus supplement specific terms of the&#160;units that are not within the options and parameters set forth in this prospectus. In addition, to the extent that any particular terms of the&#160;units described in a prospectus supplement differ from any of the terms described in this prospectus, the description of such terms set forth in this prospectus shall be deemed to have been superseded by the description of the differing terms set forth in such prospectus supplement with respect to such&#160;units. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">30</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tPOD">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">PLAN OF DISTRIBUTION</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We may sell the securities from time to time pursuant to underwritten public offerings, direct sales to the public, negotiated transactions, block trades or a combination of these methods. We may sell the securities to or through underwriters or dealers, through agents, directly to one or more purchasers, or through any combination of these methods. The distribution of the securities may be effected from time to time in one or more transactions at a fixed price or prices, which may be changed, at market prices prevailing at the time of sale, at prices related to the prevailing market prices or at negotiated prices. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We may also sell equity securities covered by this registration statement in an &#8220;at the market&#8221; offering as defined in Rule&#160;415(a)(4) under the Securities Act. Such offering may be made into an existing trading market for such securities in transactions at other than a fixed price on or through the facilities of the Nasdaq Capital Market or any other securities exchange or quotation or trading service on which such securities may be listed, quoted or traded at the time of sale. Such at the market offerings, if any, may be conducted by underwriters acting as principal or agent. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We may issue securities to other companies or their security holders to acquire those companies or equity interests in those companies, or to acquire assets of those companies, through mergers or consolidations with us or any of our subsidiaries, or through the exchange of our securities for securities of the other companies, or through the exchange of assets of other companies for our securities, or through similar transactions. We may also issue securities to third parties to acquire patents or other intellectual property or licenses or similar rights to use patents or other intellectual property. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">A prospectus supplement or supplements (and any related free writing prospectus that we may authorize to be provided to you) will describe the terms of the offering of the securities, including, to the extent applicable: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the name or names of any underwriters or dealers, if any; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the purchase price of the securities and the proceeds we will receive from the sale; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any over-allotment options under which underwriters may purchase additional securities from us; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any agency fees or underwriting discounts and other items constituting agents&#8217; or underwriters&#8217; compensation; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any public offering price; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any discounts or concessions allowed or reallowed or paid to dealers; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any securities exchange or market on which the securities may be listed. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Only underwriters named in the prospectus supplement are underwriters of the securities offered by the prospectus supplement. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">By Underwriters</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If underwriters are used in the sale, they will acquire the securities for their own account and may resell the securities from time to time in one or more transactions at a fixed public offering price or at varying prices determined at the time of sale. The obligations of the underwriters to purchase the securities will be&#160;subject to the conditions set forth in the applicable underwriting agreement. We may offer the securities to the public through underwriting syndicates represented by managing underwriters or by underwriters without a syndicate. Subject to certain conditions, the underwriters will be obligated to purchase all of the securities offered by the prospectus supplement. Any public offering price and any discounts or concessions allowed or reallowed may change from time to time. We may use underwriters with whom we have a material relationship. We will describe in the prospectus supplement, naming the underwriter, the nature of any such relationship. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">By Dealers</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If a dealer is utilized in the sale of any securities offered by this prospectus, we will sell those securities to the dealer, as principal. The dealer may then resell the securities to the public at varying prices to be </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">31</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">determined by the dealer at the time of resale. We will set forth the names of the dealers and the terms of the transaction in the applicable prospectus supplement. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">By Agents</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We may sell securities directly or through agents we designate from time to time. We will name any agent involved in the offering and sale of securities and we will describe any commissions we will pay the agent in the prospectus supplement. Unless the prospectus supplement states otherwise, our agent will act on a best-efforts basis for the period of its appointment. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">By Direct Sales</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We may also directly sell securities offered by this prospectus. In this case, no underwriters or agents would be involved. We will describe the terms of those sales in the applicable prospectus supplement. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Electronic Auctions</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We also may make sales through the Internet or through other electronic means. Since we may from time to time elect to offer securities directly to the public, with or without the involvement of agents, underwriters or dealers, utilizing the Internet or other forms of electronic bidding or ordering systems for the pricing and allocation of the securities, you will want to pay particular attention to the description of that system we will provide in an applicable prospectus supplement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The electronic system may allow bidders to directly participate, through electronic access to an auction site, by submitting conditional offers to buy that are subject to acceptance by us, and which may directly affect the price or other terms and conditions at which the securities are sold. These bidding or ordering systems may present to each bidder, on a so-called &#8220;real-time&#8221; basis, relevant information to assist in making a bid, such as the clearing spread at which the offering would be sold, based on the bids submitted, and whether a bidder&#8217;s individual bids would be accepted, prorated or rejected. Of course, many pricing methods can and may also be used. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Upon completion of the electronic auction process, securities will be allocated based on prices bid, terms of bid or other factors. The final offering price at which securities would be sold and the allocation of securities among bidders would be based in whole or in part on the results of the Internet or other electronic bidding process or auction. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">General Information</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Underwriters, dealers and agents that participate in the distribution of the securities offered by this prospectus may be deemed underwriters under the Securities Act, and any discounts or commissions they receive from us and any profit on their resale of the securities may be treated as underwriting discounts and commissions under the Securities Act. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We may authorize agents, dealers or underwriters to solicit offers by certain types of institutional investors to purchase securities from us at the public offering price set forth in the prospectus supplement pursuant to delayed delivery contracts providing for payment and delivery on a specified date in the future. We will describe the conditions to these contracts and the commissions we must pay for solicitation of these contracts in the prospectus supplement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We may provide agents and underwriters with indemnification against civil liabilities related to this offering, including liabilities under the Securities Act, or contribution with respect to payments that the agents or underwriters may make with respect to these liabilities. Agents and underwriters may engage in transactions with, or perform services for, us in the ordinary course of business. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Some or all of the securities we offer, other than shares of Common Stock, will be new issues of securities with no established trading market. Any underwriters may make a market in these securities, but will not be obligated to do so and may discontinue any market making at any time without notice. We cannot guarantee the liquidity of the trading markets for any securities. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">32</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We may engage in at-the-market offerings into an existing trading market in accordance with Rule&#160;415(a)(4) under the Securities Act. We may enter into derivative transactions with third parties, or sell securities not covered by this prospectus to third parties in privately negotiated transactions. If the applicable prospectus supplement indicates, in connection with those derivatives, the third parties may sell securities covered by this prospectus and the applicable prospectus supplement, including in short sale transactions. If so, the third parties may use securities pledged by us or borrowed from us or others to settle those sales or to close out any related open borrowings of shares, and may use securities received from us in settlement of those derivatives to close out any related open borrowings of shares. The third parties in such sale transactions will be identified in the applicable prospectus supplement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">One or more firms, referred to as &#8220;remarketing firms,&#8221; may also offer or sell the securities, if the prospectus supplement so indicates, in connection with a remarketing arrangement upon their purchase. Remarketing firms will act as principals for their own accounts or as agents for us. These remarketing firms will offer or sell the securities in accordance with the terms of the securities. The prospectus supplement will identify any remarketing firm and the terms of its agreement, if any, with us and will describe the remarketing firm&#8217;s compensation. Remarketing firms may be deemed to be underwriters in connection with the securities they remarket. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Any underwriter may engage in overallotment, stabilizing transactions, short covering transactions and penalty bids in accordance with Regulation&#160;M under the Exchange Act. Overallotment involves sales in excess of the offering size, which create a short position. This short sales position may involve either &#8220;covered&#8221; short sales or &#8220;naked&#8221; short sales. Covered short sales are short sales made in an amount not greater than the underwriters&#8217; over-allotment option to purchase additional securities in this offering described above. The underwriters may close out any covered short position either by exercising their over-allotment option or by purchasing securities in the open market. To determine how they will close the covered short position, the underwriters will consider, among other things, the price of securities available for purchase in the open market, as compared to the price at which they may purchase securities through the over-allotment option. Naked short sales are short sales in excess of the over-allotment option. The underwriters must close out any naked short position by purchasing securities in the open market. A naked short position is more likely to be created if the underwriters are concerned that, in the open market after pricing, there may be downward pressure on the price of the securities that could adversely affect investors who purchase securities in this offering. Stabilizing transactions permit bids to purchase the underlying security for the purpose of fixing the price of the security so long as the stabilizing bids do not exceed a specified maximum. Penalty bids permit the underwriters to reclaim a selling concession from a dealer when the securities originally sold by the dealer are purchased in a covering transaction to cover short positions. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Any underwriters who are qualified market makers on the Nasdaq Capital Market may engage in passive market making transactions in our Common Stock, preferred stock, warrants, units and debt securities, as applicable, on the Nasdaq Capital Market in accordance with Rule&#160;103 of Regulation&#160;M, during the business day prior to the pricing of the offering, before the commencement of offers or sales of the securities. Passive market makers must comply with applicable volume and price limitations and must be identified as passive market makers. In general, a passive market maker must display its bid at a price not in excess of the highest independent bid for such security; if all independent bids are lowered below the passive market maker&#8217;s bid, however, the passive market maker&#8217;s bid must then be lowered when certain purchase limits are exceeded. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Similar to other purchase transactions, an underwriter&#8217;s purchase to cover the syndicate short sales or to stabilize the market price of our securities may have the effect of raising or maintaining the market price of our securities or preventing or mitigating a decline in the market price of our securities. As a result, the price of our securities may be higher than the price that might otherwise exist in the open market. The imposition of a penalty bid might also have an effect on the price of the securities if it discourages resales of the securities. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Neither we nor the underwriters make any representation or prediction as to the effect that the transactions described above may have on the price of the securities. If such transactions are commenced, they may be discontinued without notice at any time. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">33</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Helvetica, Arial, sans-serif;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:592pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">The underwriters, dealers and agents may engage in transactions with us, or perform services for us, in the ordinary course of business for which they receive compensation. We will describe the terms of such arrangements in the applicable prospectus supplement. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">34</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tWYCF">&#8203;</a><a name="tIBR">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">WHERE YOU CAN FIND MORE INFORMATION</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We file annual, quarterly and current reports, proxy statements and other information with the SEC. You may obtain such SEC filings from the SEC&#8217;s website at http://www.sec.gov/edgar/searchedgar/companysearch.html. Copies of our periodic and current reports and proxy statements, may also be obtained, free of charge, on our website at www.rezolutebio.com. This reference to our Internet address is for informational purposes only and the information contained on or accessible through such Internet address is not and shall not be deemed to be incorporated by reference into this prospectus. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As permitted by SEC rules, this prospectus does not contain all of the information we have included in the registration statement and the accompanying exhibits and schedules we file with the SEC. You may refer to the registration statement, exhibits and schedules for more information about us and the securities. The registration statement, exhibits and schedules are available through the SEC&#8217;s website or at its public reference room. </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">INCORPORATION BY REFERENCE</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In this prospectus, we &#8220;incorporate by reference&#8221; certain information that we file with the SEC, which means that we can disclose important information to you by referring you to that information. The information we incorporate by reference is an important part of this prospectus, and later information that we file with the SEC will automatically update and supersede this information. The following documents or information have been filed by us with the SEC and are incorporated by reference into this prospectus (other than, in each case, documents or information that are or are deemed to have been furnished rather than filed in accordance with SEC rules, including disclosure furnished under Items&#160;2.02 or 7.01 of Form 8-K): </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.31pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.31pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;"><a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1509261/000155837023015755/rzlt-20230630x10k.htm">Annual Report on Form 10-K for the fiscal year ended June&#160;30, 2023 filed with the SEC on September&#160;14, 2023;</a> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;letter-spacing:0.2pt;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;letter-spacing:0.2pt;">
          <!--blacklining:none;-->
          <a style="-sec-extract:exhibit" href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1509261/000155837023018839/rzlt-20230930x10q.htm">Quarterly Report on Form 10-Q for the fiscal quarter ended September&#160;30, 2023 filed with the SEC on November&#160;13, 2023;</a>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.31pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.31pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;"><a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1509261/000110465923120789/tm2331358d1_8k.htm">Current Report on Form 8-K filed with the SEC on November 22, 2023; and</a> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;letter-spacing:0.2pt;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;letter-spacing:0.2pt;">
          <!--blacklining:none;-->
          <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1509261/000110465921082937/tm2120011d10_8a12ba.htm">The description of our Common Stock, par value $0.001 per share, as contained in Item&#160;1 of Amendment No. 1 to the Registration Statement on Form 8-A/A filed on June&#160;21, 2021, under the Exchange Act, including any amendment or report filed under the Exchange Act for the purpose of updating such description.</a><font style="letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">All documents and reports that we file with the SEC (other than, in each case, documents or information that are or are deemed to have been furnished rather than filed in accordance with SEC rules) under Sections&#160;13(a), 13(c), 14 or 15(d) of the United States Securities Exchange Act of 1934, as amended, which we refer to in this prospectus as the &#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">Exchange Act</font><font style="letter-spacing:0.2pt;">&#8221;, from the date of this prospectus until the completion of the offering under this prospectus shall be deemed to be incorporated by reference into this prospectus. Unless specifically stated to the contrary, none of the information we disclose under Items&#160;2.02 or 7.01 of any Current Report on Form 8-K that we may from time to time furnish to the SEC will be incorporated by reference into, or otherwise included in, this prospectus. The information contained on or accessible through any websites, including our website, is not and shall not be deemed to be incorporated by reference into this prospectus. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">You may request a copy of these filings, other than an exhibit to these filings unless we have specifically included or incorporated that exhibit by reference into the filing, at no cost, by writing or telephoning us at the following address: </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11.5pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Rezolute, Inc.</font>
          <br >
          <font style="letter-spacing:-0.2pt;">275 Shoreline Drive, Suite 500</font>
          <br >
          <font style="letter-spacing:-0.2pt;">Redwood City, CA 94065</font>
          <br >
          <font style="letter-spacing:-0.2pt;">(650) 206-4507</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Any statement contained in a document incorporated or deemed to be incorporated by reference into this prospectus will be deemed to be modified or superseded for purposes of this prospectus to the extent </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">35</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Helvetica, Arial, sans-serif;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:580pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">that a statement contained in this prospectus, any prospectus supplement, or any other subsequently filed document that is deemed to be incorporated by reference into this prospectus modifies or supersedes the statement. Any statement so modified or superseded will not be deemed, except as so modified or superseded, to constitute a part of this prospectus. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">36</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tLEMA">&#8203;</a><a name="tEXP">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:468pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">LEGAL MATTERS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Certain legal matters in connection with the offered securities will be passed upon for us by Dorsey &amp; Whitney LLP, Denver, Colorado. Any underwriters or agents will be represented by their own legal counsel, who will be identified in the applicable prospectus supplement. </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">EXPERTS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Plante &amp; Moran, PLLC has audited our consolidated financial statements included in our Annual Report on Form 10-K for the&#160;years ended June&#160;30, 2023 and 2022, which are incorporated by reference in this prospectus and elsewhere in the registration statement. Our financial statements are incorporated by reference in reliance on Plante &amp; Moran, PLLC&#8217;s report, given their authority as experts in accounting and auditing. </font> <br ><font style="letter-spacing:0.2pt;"> </font></div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">37</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style=" width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial Narrow, Helvetica, sans-serif;font-size:12pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:27.85pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7.42pt; width:456pt;">
          <div style="margin-left: 0pt; width: 456pt; margin-top: 0pt; font-size: 2pt; line-height: 0pt; border-bottom: 2pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:3.5pt; width:456pt;">
          <div style="margin-left: 0pt; width: 456pt; margin-top: 3.5pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="position:relative;margin-top:39.5pt; text-align:center; width:456pt;">
          <img src="lg_rezolute-4clr.jpg" alt="[MISSING IMAGE: lg_rezolute-4clr.jpg]" height="40" width="216" >
        </div>
        <div style="margin-top:82.5pt; text-align:center; width:456pt; line-height:18.5pt;font-size:16pt;">
          <font style="text-transform:uppercase;letter-spacing:0.8pt;">11,250,000 S</font><font style="letter-spacing:0.8pt;">hares of Common Stock</font><font style="font-weight:normal;text-transform:uppercase;font-family:Times New Roman, Times, serif ;letter-spacing:0.32pt;"> </font>
        </div>
        <div style="margin-top:24pt; text-align:center; width:456pt; line-height:18.5pt;font-size:16pt;">
          <font style="letter-spacing:0.8pt;">and</font><font style="font-weight:normal;text-transform:uppercase;font-family:Times New Roman, Times, serif ;letter-spacing:0.32pt;"> </font>
        </div>
        <div style="margin-top:24pt; text-align:center; width:456pt; line-height:18.5pt;font-size:16pt;">
          <font style="text-transform:uppercase;letter-spacing:0.8pt;">3,750,000 P</font><font style="letter-spacing:0.8pt;">re-Funded Warrants to Purchase</font>
          <br >
          <font style="letter-spacing:0.8pt;">Shares of Common Stock</font><font style="font-weight:normal;text-transform:uppercase;font-family:Times New Roman, Times, serif ;letter-spacing:0.32pt;"> </font>
        </div>
        <div style="margin-top:36.667pt; text-align:center; width:456pt;">
          <div style="margin-left: 31.579%; margin-right: 31.579%; margin-top: 36.6666666666667pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:14.5pt;">
          <font style="text-transform:uppercase;letter-spacing:0.6pt;">PROSPECTUS SUPPLEMENT</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;font-size:10pt;">&#8203;<font style="letter-spacing:0.2pt;"> </font></font>
        </div>
        <div style="margin-top:16.333pt; text-align:center; width:456pt;">
          <div style="margin-left: 31.579%; margin-right: 31.579%; margin-top: 16.3333333333333pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:77pt; text-align:center; width:456pt; line-height:12pt;font-style:italic;font-weight:normal;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">Lead Bookrunning Managers<font style="font-style:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="margin-top:17pt; width:456pt; line-height:18.5pt;font-size:16pt;">
          <font style="text-transform:uppercase;letter-spacing:0.8pt;">&#8199;</font><font style="margin-left:113.48pt;"><font style="text-transform:uppercase;letter-spacing:0.8pt;">J</font><font style="letter-spacing:0.8pt;">efferies</font>
          </font><font style="margin-left:113.48pt;"><font style="text-transform:uppercase;letter-spacing:0.8pt;">C</font><font style="letter-spacing:0.8pt;">antor</font>
          </font><font style="float:right;"><font style="text-transform:uppercase;letter-spacing:0.8pt;">&#8199;</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.32pt;"> </font>
          </font>
        </div>
        <div style="margin-top:24pt; text-align:center; width:456pt; line-height:12pt;font-style:italic;font-weight:normal;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">Co-Managers<font style="font-style:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="margin-top:29pt; width:456pt; line-height:14.5pt;">
          <font style="text-transform:uppercase;letter-spacing:0.6pt;">BTIG</font><font style="margin-left:36.34pt;"><font style="text-transform:uppercase;letter-spacing:0.6pt;">C</font><font style="letter-spacing:0.6pt;">raig-</font><font style="text-transform:uppercase;letter-spacing:0.6pt;">H</font><font style="letter-spacing:0.6pt;">allum</font>
          </font><font style="margin-left:36.34pt;"><font style="text-transform:uppercase;letter-spacing:0.6pt;">H.C. W</font><font style="letter-spacing:0.6pt;">ainwright &amp; </font><font style="text-transform:uppercase;letter-spacing:0.6pt;">C</font><font style="letter-spacing:0.6pt;">o.</font>
          </font><font style="margin-left:36.34pt;"><font style="text-transform:uppercase;letter-spacing:0.6pt;">J</font><font style="letter-spacing:0.6pt;">ones</font>
          </font><font style="float:right;"><font style="text-transform:uppercase;letter-spacing:0.6pt;">M</font><font style="letter-spacing:0.6pt;">axim</font><font style="text-transform:uppercase;letter-spacing:0.6pt;"> G</font><font style="letter-spacing:0.6pt;">roup</font><font style="text-transform:uppercase;letter-spacing:0.6pt;"> LLC</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.24pt;"> </font>
          </font>
        </div>
        <div style="margin-top:96pt; text-align:center; width:456pt; line-height:13.5pt;font-weight:normal;font-family:Arial, Helvetica, sans-serif;font-size:11pt;">The date of this prospectus supplement is June <font style="letter-spacing:-0.418pt;">13, 2024</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.22pt;"> </font></div>
        <div style="margin-top:11.483pt; width:456pt;">
          <div style="margin-left: 0pt; width: 456pt; margin-top: 11.4833333333335pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:3.5pt; width:456pt;">
          <div style="margin-left: 0pt; width: 456pt; margin-top: 3.5pt; font-size: 2pt; line-height: 0pt; border-bottom: 2pt solid #000000; ">&#8203;</div>
        </div>
      </div>
      <hr >
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>lg_rezolute-4clr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 lg_rezolute-4clr.jpg
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M_\0 O@ !  $% 0$!              @!!08'"00" P$!  ,! 0$
M      ,$!0(!!A   0,# @,#!0@'$!(#     0(#!  %!A$'(1((,4$342+3
M%!5A<3(CI!96&(&10E*S=96AT9*R,X,D-)2T)355-A=7L?%B@L+20V-SDU1T
MU*5&=B='-R@X$0 " 0,# 04'! (#         0(1 P0A41(Q03)2$Q3P87&!
MH2(SD;'1(\$T0F(%_]H # ,!  (1 Q$ /P"?U * 4 H!0"@% * 4 H!0"@%
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IAPVH]JDQ74/LNQVDA*5I<;)2OFTU*AVFOG9MMOD;$4DE0R&N3H4!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>lc_exemplary-4clr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 lc_exemplary-4clr.jpg
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M_\0 XP !  $% 0$!              $"! 4&!P,("0$! 0$! 0$! 0
M      $" P0%!@<0  $# P(#! ,("@H.!0H""P$" P0 $042!B$Q!T$B$Q11
M,@AA<=&3TY05%H&10E+2(R14)1>QX3-#4S1$-556H<%B<I*R<X.S="8V-QAC
MA$5UE?""XF1VEB=7. FBPK1&\:/#985'Q-0H$0 " 0("! H&!P@" @,!
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M5?U?[FNN[;CK<!AS2=#JB. L>=<S95<4!%Q0"XH";B@(!!%[\* 7'+MH!J%
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M * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
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MXN0W&TKN%!IR2\M'/TI((KO:_69FXGNN8W1'5G(]'/9 V7N?#Q42<S*::QD
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M,U&*6@U#=?L:['S&Y).Z=I9W*[(R4U:G9+6'<2(_B.'4M3:#8HU*[Q3JTWY
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M^L/LO[%ZQ91K<F0?E8/=+:$-.93'%-WFVA^+\9"A92T?<+!"@.'$5+5]P5.
MZRMJ1=]&?9RVIT4E9'+X:=.R^X\LRB+,R>0<"OQ#:M80AM/  J%S<FL7;SEP
M&HP2-2W9[&^Q\UN:3NO:6=RVR,E.6MV6WAW4A@N.'4LMI-BC43<I!T^@"ND<
MS*E&JG)V4W6IN_2'H%M_I#-RF9@9C*9W<&8;;8G9'+/^+=II6I*4( &GCSXF
ML7+FOR'2$=54K4]-@] MH].M^[DZAX27/>S&YO%$N/*=0N.T'W@^OPTI0D^L
M!;4H\*D[KE%1XA&"B%] =H.=94];U29WUI2@($/Q4>2N&/+!6G1J]7^ZYU5=
M>KJC45:D[^Z";1ZA[^VWU$S<J<UF=M>$F)'C.H1'=##Q?0'4E"B>\>-B*6[L
MH)I<(E&I3U.Z!;1ZL[EV]NC<4J<Q/VZ4JBHA.H;:<"'0\$N!2%'UAV$5(7'!
M-(DX*352GK1[/^T>MK$%S./2,9G,7J&.S$$I#R&UFZFUI5<+1?O <"#Q!JV[
MC@\"RCK(T%/L3].I>/:1N#.9S,[C3(;?>W%)DI,MQEH63& 4E24M?=6 OJXW
MK?>7Q&7:3/I9M&A(3V   >X!:O-4ZG,.LO0O:W7"!BH&ZI4V(WB'7GHKF/=0
MVH^80$.)7K2L$$ 6X<*Z0FX:#$X:VDN=^=%]L]0^G,+ICEGY<7 XT0TQ'XCB
M4R0,>CPVKJ4E0/=Y\*D+CBZHTU54+@](]NGI,.C@>E?5CR'T69'B)\YX(.K5
MKTVU7_N:N\;EK&5"BH.FO2+;O2_8KO3_  ;\J3AWUR7'WYCB5R%*F)TN=Y*4
M@<!PX4E.KJRQC14,;TBZ';5Z)8_-PML2YTMO-.IDR59!Q#JDEI"DI2C0A%A9
M564W+29C!1T'Q7[._1C:O6S)[_QF<DR8.0Q,EM_$Y> YH?C*===#B;<E)6!W
M@>->^_<<:4//:CK5J?8'1?V;=D]$WI>4P[LC+;DFM^ [EYY3K0QJU%MI";!(
M4;%1XDVYUX+MUR1Z(6U%E_'Z![2B=8G.MK<N>=T.)6CRBG4&$"ZP8ZB$:-7J
M'AWN=-Z]75-.*K4W?>&S<#OS;D_:FZ(:9N$R*/#D,J)"A8W2M"AQ2M) 4DBL
M1DTZHK550^:O^0G8'G2/K3F_H/Q/$^B]37*_+Q--B?[K1>O7WUI:,>,Y.U54
MJ?2FSMF;?V%MZ#M;:L%$#"P$:6&$<5%1XJ6M1XJ6H\5*->24FW5G6*25$<BW
M][(G3+J'O27O?+R,E%G9!QIZ?#AOMMQG7&0 564VHC6!W^/.NT+\H*B,2MIG
M;Y.'Q\O%.X21%:=Q#S!AN0EI"FE1BCPRV4G[DIX5PJSI1'S5)]B+:,3(R).S
M=X[@VMC92M3V,AOI6WIO<(2HZ5:1?NZKGW:]2S/&JGG=E5P;1UKIYT5VSTUV
M7DMDX>3.FPLTN0[E9L]X/2G7);09<.JP [HX"U<)W*NIU4:(\NCG0_;'1#&Y
M/&;4ES9C.5?;DR5Y!Q#BDJ:24)"="$6%CQI<N.Y2O 6,=4M^G70+:'3+>6X]
M\8&3/D9;<H<3*:EO(6RVAU[QU!L)0D^L.TGA5G<<TJ\!%%)M\9,3H#L^%U@>
MZU,R9YW.^E:5PRZ@P=;K/@*4$:-7J_W7.KO):FKP#52=2QZO>S=L;K%,BYK*
MN2L/NF$V&6<WC%AMY3:#J2EU*@0O2>*3P4/34A=E&.KP$G!2-=V5[)F!VONG
M%;PS>\=P;HRF#>3*Q;4^2!';>1P!4@:M0 [+UTN7]9:"1MT>DVS?GL_;0ZB=
M0,!U&S<N>SFMO%@QH\9U"(S@C/>.@.)4A1XJYV4.%<H76DT5VUK:Q>]9.B.V
M.M^*QV(W5*FQ&,7)5*CN8]Q#2RIQ'AJ2K6E8((]RI;NN-:&IP4E1F4WATIVQ
MOCIY^K7.(>7@6V(\>,\VL)E,F&E*674.$$:TZ>=N/&D9-2J'%-4-%Z*^S)M_
MHKFYV?QV>R&8F3(QA-MRRA##+*EAPV0C@5$@<>%;N77(D8)'<QR%<C9- * 4
M H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"
M@% * 4 H!0"@% * 4 H!0"@% * 4! 2 ;BK4E":A14H!5 H!4H!5!!%Q:@,)
MF]F[4W,]#D[CPL'+2<>K7!=FQVWU,J)!N@K!T\1V5I2:T&7%/29L)L./$^FL
MFB: 5* 5018&@   L* P^X=I;8W:RS&W1B(>8C1U^*PS/8;D(0Y:VI(<! -J
MU&3CH(TGI,E'BL1&FX\5M+,9E(;98;2$-H0D62E*18  < !67B4]Z 5* 504
MJ1JMQM:@,%!V3M'%YJ5N3&X.!$W#.*C,RK,9I$MTN<5%3H3J)4?6X\>VM.;:
MH2BK4RTV!"R4-['Y".W*@R4%J1&?0'&G&U"RDJ2JX(([#65@ZH-5+3 [<P&U
MH Q6V\9%Q.,2HN"'"91'9"U>LK2@ 7-N)K4I.3JPDEH,I62B@*5("K5 8+/;
M'V?NHH5N; X[,+;3H;<G1&9"TIO>R5.)) OZ#72,Y1T,CBF>V#VGMG;#"HNW
M,/"Q$=RWB-P8[4<+MRU>&D7M?MK,FY:0DEH,P!:H4Q&X-J[;W9%1!W/BHF8@
MMK#K<:<RB0VEP"VH)6"+V/.JFUH(TGI+^) B8^.S#@LMQH4= ;8C,H#;3;:1
M8)2E-@ .P 4J$DE0N:A10$:4^BK4E  !R%0I-2@%4$6%   * F@% * 4 H!4
MH!2@*2F]4&%P>SMJ[8<EO;<PL'$O3U!R:Y!C-QU/*%[%9; U<^VM2DWI,J*6
M@SE9-$6!H": 6H!87OVT H!0$%()N>= 30"I0"J!0"I0"J!:@% * 4 H!0"@
M% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
M H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"
M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
M4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0
M"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
M 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!
M0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
M* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H
M!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
M * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
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MP'JR_A]V]106,J^S2;HW)92JRWDW5P2-0-R.8'IMVUNN-#P:C-#SO6?9V W
MYM6?'RB\TD@(9CX]]X/)X76T4BRT)OWE)Y5QEF(1EJMXGU[/@^8NVM[%+4TU
MUH^ZM39]N;JQ^?AO3FFI$%EJ0]$"9[?EUK4P=)<0DDW;4?55VUVC),\%[+RM
M2U7II7#'29OS<<DI#B2I)LI(-RDVO8@<N'IK1YZ%'FH[S>IEU#B3>RDJ"DFW
M/B.%"TII,3MG<V/W%B&LRPT_ 9?*TIBY% CR4^&X6KJ05&P4I/=X\1:HG4ZW
MK$[4G&2Q7KX*^XHW3O' [0AQI^;?6TQ-F,8Z*EI"G7')4I6EM"4IX\:S*:CB
MS67RT[[:@JT57Z#T@[KPD_/Y7;<:0597"ICJR#920A!EI4II(4>"E$()L*:Z
MJUPK3ZRRRUR-N-UKX9N23X]6E>:IE#D8*2H&0@:/6[PL#RK9YJ/B/0RXR2E*
MG$I6N^A"C92K<[ \3]BCP+JNE2DRXREF.'4A[AW"0%=[EP/&JT1)O&AKVU=Y
MX7=427DL8IQ,.'+D8];KX"/$<B*T+6@!1NV3P2JN4)QGH/7F,I<L-*:HVE)>
MAZ#8D3(JU)0AU!6H:D)N+J3Z0.T>[70\E'2O !-B$%27D*2#I*DJ! 5>UKCM
MOV4(U0H7(CN^&&WD*\2^BR@=0' D6/&W;1NA=5F'VWNF!N3&_2;3$G'Q_,/1
M4-Y)ORKREQU%*E)25&Z#:Z3VBI6K.]VQ*VZ/BKAC@RXS^[MM;6Q;F:W#DF<=
MB6E(0N6^K2WK<-DA)%]1/]S693455F;%F=Z6K!.3,3G.IVQ\#A<AN&;FHZ\5
MC'4193L=7CGS+J$N(:0$7UK*5!5D]G.H[L5'6K@>NUX=F+MQ6XP>M+%+1@O2
M8O)]:.G^'^C1/R#H.3C1YZ0W'==\"),(2R[)*$D-)638:JXO-6TDZX,]-KP7
M-7=;5C]EM/XHK%::5>/J+D=6MB?2>5Q;N4\%S"LNR9LEYIQ$;PXZDI>#;A39
MQ3:E)24IXZC87-=5=BZXZ#SKPW,.$9*.$Z4T<.CT>LVS%9-C*P(N180ZTQ+:
M2^RV^VIIT(6+IU(5Q22.PUU1\Z2U71F@[XZK_5_=\'8&UL!)W;OJ;%5D%XN*
M^U$9B04$I\:3(>[K84H:4)M=1]\5T4/AUGH,-E&Q>LV!W4WG6<]'7M'/[6F-
M8[<.)RSS0\N]*-HZD/I(0XAWDA0YU'!JCXR*53=\7N7;NX_,#;V7AY-4-PM2
MO)/MR"TOT+#:C;E66FC2=3E>^.M.\-D[NQ>TSTZ>R"MQ3'8.V)J,M$:1,6P@
M+4I2%))9%C^^&NB@FJU,.33I0Z%@MZX/)F'"FS8,'=+Q6S)V^)S$F4Q*80%O
ML?BU=]30-UD#A7-IG2ID,3O+:.?<EM8/.P,D[ N9J(DIEY3(',K"%'2/=/"C
M31$TS$S>INP8^#S>XF=PP9N-V^RI_**@R69"VDH%P+(6>\L]U /K*X5=5C61
M:[5ZL; W7MO&[L@YR+&Q>425,IGO-1GT+0WXCC3J5+LEQ">\I-^ HXM"J,Q'
MZ@;%EJQZ(VY<6\O*DHQB43&%&0I)L0T OO&_"PIJL51<R]W[4Q^78P$[-P8V
M<E &/C7I+3<E>KU;-J4%<>SAQ[*E&*H\)F^=EPI"H$[<.-BS?'\D8STMEIT2
M2 H-:5+!UV(X5=5BJ-?Q_5_8DWJ+D>E[61"=V8UIIQUMPH2PZMW]Y:5JNMU
M]=&FXIJNE0I*M#?T$$<*R4JH!0"@% * I4+\/32H/E&%[3F_TXP;VS. PKVQ
ME;H=VFO'P7I SH6V\6DOH0LJ;<'(E">/O<Z]*M+AXCDYFV=0NIO6C8V\<#MJ
M/!VKEU[KRI@[>QC"LA])^02JZY4C40V@-(XN*!M?E6(0BTVS3E1GMO'K3OC9
MF_,1A96'PT_!9C-HP+.(Q\Y4G<J&WO4G+91="6K=Y2"-21S-9C!-$<FN JQ?
M57J5NCJ;NC9VVQM2'B]K95K&.,Y=^6G*RVE-)><<80RK22 ;"Z;7JN*23*I-
MMF!W[[2.Y]L;FW3"P^$QCF*V=-@P).'R$EYG<&85/4E <Q;*!I4E.KM"KV)K
M2MX(CF=7ZI]28O3#92MU2(2YDM]Z- QF-4XE@NSIITM-N.*[K:1Q*U'@ #7.
M,-9T1IRHB.EFY]U;FB9"3NF7MJ:IAU#<9[:<MR8P@J2?$:D%PDAQ! Y<%<Z2
M5"JI1D^O?2+#9:1A,INF/%R428K&S&G&WPF/*1:Z7E^'H;''@M:@D]AJJW)Z
M$9<TM)=XGK1TNS</.3\?N:*N'MM =S3KOB1Q':5?2X?&0@J0JUDK1<*/ $U-
M1C715LSK#T\ZAY*5AMH9<S\I#9$F5'5%EQE-M*4$I4HR&FQQU @7N1QHX-:2
MJ29PK<_6GJ&U!W]OG;.09&U\?NC%;1VO'<8;?:46WD-Y%\'@I1<*]""38<;5
MUA!-T9AR:J^ [E+ZQ=,\:SG7I.X&4Q]N3&\7E7$H><")[U],9O0A7C.\#J0U
MJ4GMM7'4E4VI(R&QNIFR>I#$Z1LO)_2;.-=3'FK\"1'\-Y8*@@^.VW<V'&W+
MMI*+CI*I)Z#;:R44 H!0"@% * 4 H!0"@% * 4 H!0"@% :]OC=N(V'M7);P
MSQ6,1B&O'D^"G6X05!"0D$@$E2@.)M0&EKZX[5C/X6+D84Z(_F4,OJ(2S):A
M1YCWEXSTEV.ZX@(==[B2A2K'UK4!U2]AQ[.=  0>5 30"@+#+9O$X&"[D\S,
M:@P&;!R0^K0D%1L +\R3R XF@+$[SVF)&,BG-0_,9E'B8MOQD7D(]*./$$\!
MZ3PYT!7"W?MC)-LNX_+19*)$E4!@M.)7KE-@J4T+?= "Y]R@+M>;Q+>7;P"Y
MC0S;K!F-X_6/'5&2K07 CGI"N%Z OM0L#Z>5 -0O;^U0$:T\!?GRX&@&M/\
MY T!.H>[]HT!&M) (X@\K"@(+K:2 I025&R0K@2?0+\^5 5 @\J F@% * 4
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MQ.,PZ-KO9M,3;D:)B7%Y!+,7%9>0\IV<^I)6"X^==DD<+"W$5G<77&CTT_\
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M*2YBU7!<9.H:5 K2;I/ CGRH1*CKPD1_HB&RB-$\M'CM)TM,M%#:$I]"4IL
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MMZ4+N#]J@*H:<+CX[4. (L6(P+,QV/#:;0/0E"+ ?8%&Z@N/.P_SAK_#3\-
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MW#\D9YC[A/P4!5Y#'_FK7Q:?@H"E,''][\D9Y_P:?@H 8..M_%&N8YMI^"E
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MG()66" #;N%:C0I=P\)"ASUY)M*E3G&&XCLAQ:EK4TR247OVW4;GMH0R= *
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M4 JM<V!/&U 7NVL:]AMNX?#R%I<D8^%&B.N(OI4MAI+:BF_&Q*>% 96@% *
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M'B-O2<4_Y;!/.R<9)3-E)FM.2?W?\I#GB%+H%EI*K$5-=C53+G"]#NG&WU8
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ME(_*Y?QZJ GZ(;N/RJ5\>J@'T.W^=R_CU4 &&;M_&Y?QZJ @X=JX_*Y?QZJ
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M4=-)N)8P4O:N,>P\:6O(QX2XS9:;F.JU+=2+<%*/K'M[::[7"*(KE=+>G,[
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M<4/:-WX3VE[J1^8DS^KW]&[?^=2ODJ:V8XH>T;OPGM+W4A\Q'GNKU_YMV_\
M.I7R5-;,<4/:-WX3VE[J1^8>>ZO'_LW;_P ZE?)4ULQQ0]HW?A/:7NI'YB?/
M]7OZ-V_\ZE?)4ULQQ0]I=WX3VE[J1^8@3NKI)(QNW[]OY5*^2IKYCBA[2;OP
MGM+W4C\P,_J];^;MO_.I7R5-;,<4/:-WX3VE[J1^8GS_ %>_HW ?.I7R5-;,
M<4/:-WX3VE[J0^8@3^KUS^C=O_.I7R5-;,<4/:-WX3VE[J1^8*G]7B"#C=OV
M_P!:E?)4ULQQ0]HW?A/:7NI'YB?/]7OZ-P'SJ5\E36S'%#VC=^$]I>ZD?F(\
M_P!7N/Z-V_\ .I7R576S'%#VC=^$]I>ZD?F!G]7K$?1NWS_UJ5\E4ULSQ0]H
MW?A/:7NI'YB?/]7OZ-V_\ZE?)4ULQQ0]HW?A/:7NI#YB//\ 5Z_\V[?^=2OD
MJ:V8XH>T;OPGM+W4C\P,_J];^;=O_.I7R5-;,<4/:-WX3VE[J1^8GSW5ZUOH
MW;_SJ5\E36S'%#VC=^$]I>ZD?F(\]U=N?T;M_P"=2ODJ:^8XH>T;OPGM+W4C
M\P\]U>M_-NW_ )U*^2IKYGBA[1N_">TO=2/S$^?ZO?T;M_YU*^2IK9CBA[2[
MOPGM+W4C\Q'GNKUS^C=O_.I7R577S'%#VDW?A/:7NI'Y@9W5ZQ'T;M_YU*^2
MIK9GBA[1N_">TO=2/S$^?ZO_ -&[?^=2ODJFMF.*'M&[\)[2]U(?,09W5[C^
MC, >'(2I5S_^ZJJ68KHA[2.WX3MWNI'YB/-=6U:+XS H3J'B7E20H)OQL WS
MMRKNM[7&ASG#PW5K"5VO+&/2:](PO4-W);ME8^),AKR+#T'$K5DFW6'+JUB6
MH$_BEV_%LMA(T)]8\;UWH?#;Y:FY].,9N/$[5@0MTN%W+-%T*4MSQ7/!*R6@
ML@J&I*38@*-O30R;A0"@% * 4 H# [T3G%;5RPVU.9QN>$5TP,A)9\RTPXE-
M_$4U<:M(!L/30'RQB^J6_P!V#L)U[<,D3W<1B9<5E8!^F9LS+*AS$O)";N:6
M1JT)]3G0'0.J.]Y>7WCL;;;VT\WCF(.]\<EK.S&$(QKX:\4 MN!9)"[]SA0'
MT(* *Y&JB,^5O:%_W\C<_P";6N7]^JOA9W[9_1?]?_ZLOW_H1R@Z>/!0]'N5
MXV?H!J2+^L;VX6Y6]% 1>YX"R;<!;M[: #AI''A?G>U"4.L>SSQWY*_[N<_T
MB:]^2_4/SG^PK_Q5^]]!]3I]'OU]D_ ,KH04 H!0"@% * 4 H!0"@% * A0N
M"* Y-O\ Z+0^I>_\'N#=DY4C:6 @268. 94]&<5D92@%23(9<0L60D)"4FND
M9ZJP,2C5FC3_ &5VV\=O;;FU\XG';4W3.Q&5@8]Y#LE<&9C%I+Y\1QQ2G ^D
M?=&X-JWO7I,;LV+?/023O3/[_P M]8EXMK>V%@8=KRS9\Q%7CGDO:RH*3J0Y
MITK1PNDD5%<HER%<*U--;]E3*N8O>\61GL9#E[RPD3">%B<:(4&(N&^ASQ4M
M)7WM80-1/$J-ZUOM'(-32;+EN@^[6\CN%_96\F\-!WICH>,W9'D04R3>'$$,
MR(9*AH6MJX*57 )O6=YQ\ <'P/2<4ZC=/,MM7?3D#$[?R4W"X#;N*Q6R0O"H
MW%#R4B%J66E*U(3'NX;N!05>Y5Z!7>$TUCI.4HM'V1L9_/R=I861NN$SC=RN
MPV597'Q3J88D:!J;1Z .5NSE7BEIP/2M!L-"B@% +7YT!Y^"GM)Y6MV6H5.A
MC6A;<,@_^J-_XZJ&:8U,DI TJ/N'A0I*4C2#<\A0M1I[W,\O[=2A*A2>!XFE
M 0IE*P 21[QM5(U4D) 5]BE"U*B.!% +"@*;?C/L?VZ E0[I]Z@"0+"@&D<.
M)^Q4H";6![?=-4$( T#WJ 6[P]ZE - ]WWJE $I Y5: A0NI/O'^U2@J386J
M4%2 G@.)J:H! U)^SQJT%2JU4%*!W10!2 2.RWHH &P!:Y/OT!"6TE(M<>]0
M/$%I.H<_MU"U)\)//C>A"4I ' FU* I+:0H<SQY$U2:"H( OQ/'T]GO4*$BZ
M1QH"%)%T\3S_ +5"U*@+4!1H2I OQMQXU'@0^</:U  Z:CL^L;7_ .2ON>%_
MW/W&<YZ#Z2*0:^(=" !Q]^E %#E[XH";4!"!ZWOF@"NSWQ0%5J @"E 0H7%*
M FU 0$@$T!#@%A[XH"N@(L+D^F@(4.% 54!0D=]?V/V* E0[OHY4!-J I2.\
MO['[% '!W#]C]F@*K4! ]97V*@"QW#5#)'*@(MQ)O0!8[IXT!5:@*0!J/O4H
M"2 : F@*0.\H^]0$D7%J4  X4H!;C0%*D]T\3]N@ ;2!84!58</<Y4!- * 4
M H!0"@*5H#B=)MI/ @B]P>R@+).&Q:515IA1PN#J\BH,MW8U\%>$;=R_;IM0
M'-^M5P_TV3<V.]<2;>\'J ZL.WWZ *]4U41GRO[1  W[&]S'-?Z1=?"SOVS^
MB> .F4E^\_<CE MQ_9KQL_0L?9M_9H9Q%A?@;J]'*H,2+#AQ''LJEJSJ_L\_
M[^2K#3^CG/\ 2)KWY+]0_._[#_U%^]]!]3I];[=?9/Y^RNA"+\Z $@<Z :AZ
M: :AZ: :D^F@*=5U"RA8]EJHI4KJ 4 H!0"@% * 6% 184 L* :1Z*E +#E2
M@(";<N5$"0D#D+5030"@% * @J M<\Z Q;?^\,CT>5;_ ,=5 9)9LD\R+$<*
M )/=3Z+#]B@)!NJXY6X?;H H\#[E 2""* @JLKD>7[% %*L"3V<>%  H'_R]
M- 1<:S_>T!4>1]Z@*4K&E)XV-K?9H"HD<Z @D<?M4!"3W1[P[*$)OQ'O7O0I
M)58@'MO:@(2H$"W(T!"B M/O'^U0%5Z I2K@!QX &] 22-:?LT *@#;[7NT!
M"5#0+<>WA0 K%TCCQOV4!5?E[M 4H5W0>0'.@*KBXH!J]_T<: 7%N% 4D\1Z
M;GA[U 5?9H" H!/#E0A"E"Z??_M4*5 WH"E)!3P_:YU): CYO]K8C_X:WX#Z
MQM<__,K[GA?]S]QG.>@^D=7N&OB'0!7.WI/OT"(4?5]\&@*KT!2DCC[YO5("
M0;6Y7%0I5J';]OLH" H7(XWO0 D$7JD)!J%(!XF@(</#AQX@_P!F@*M0_P#+
MW* 7[/10$$W'#WZ$)U>_Z*%*4GOK^Q^Q0!Q0";GE^W0%6KWZ IO8J/IM^Q0!
M9&F@*KCTT!2#91]TC]B@"SP(](Y]E 5"@("@21V^]0!9 2: F_90%.H:B?<%
M_L\J G6/=_\ V4!.H V]R_*@*=0"E=MK7'OT 6H $^@'^Q0$A7"]C0#4+_:H
M"20010$CE0"@% * 4 H!0"@% 1?G[E <IZU_QGIK_P"VF)_8=H#JP[??H KD
M:$/E?VB.._8_I^CFO](NOAYW[9_0O G3)M\K]QR@<N5>2A^AWB>..CB''LM3
M5&NN7F OVCC[E*#77+S \P:4-:R.K>SS_OY*/9]'._Z1->W)87/4?G?]A:>4
M5-KZ#ZF00;*OP/\ ;K[9_/:UQ*S4!Q#J)ULS&R]WS-O0L5%E,1VV7 ^\MQ*R
MIY 4;A/"PKY][-RA)QH?J?#? XYJTIN35:FKGVE=Q'G@X/QCM<N_2XCZ4O\
M6()XS?,/^9/</]!0?C'J=_EQ&?\ UFWMOF'_ #);C/\ V#!^,=^&IW^7$/\
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MH$_W2N^: \_U8]9?+-M_K8D>,F,VRIWR37>=0Z5J=(["I/<M0%?ZL^L?>_\
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MQW%(\FUWD,H*7$?YQ1U&@*/U8=9?+):_6P_XH86T7O)-7+BG_$#EO2E'XNU
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MH"E/3'K)X7A'JN^73'#/B>3;_=0_XGB^_H_%V^S0%3O3/K&I2E(ZJOH25R5
M>3:L$OI"6D_YH@D>F@ Z:=8[I_\ BJ^2%1B1Y)H7# (='^=YD]E >9Z8]9A'
M+7ZV'_%\'PO%\DU?Q/&\0+_P/Q?]F@/=WIKU@4^XZCJD^AM3S[J&Q$;LEMUO
M2VW[S9[U^V@*$=,NL:7&5.=5GU(1Y3Q$>2:&ORY_'?'=OHH#LZ5"W'A[@[*
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MJ(7WO";UH=3VJL:$-USTS=D?);?1A8+;^(D2 G<+ZB/$98*.&A%P?6]97&U
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M7-"E(475)U+'?#H0@-_>$J[* ],[G>J\?(-##8!I['!,5M\7027TE+LI225
M^&I!4RV;>L-7*@,M'F]0']F2)[D*/'WCXRU18"TW9\#Q@4(597K>'P*K\^-
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M4"%>*RI)(!%N\+B@-SZ7[VD]1=EX[=TG%+PJYZWP(#CJ7B$L/+9U:D@ @Z*
MW2U 30"@% * 4 H!0"@% * 4 H!0"@% 4A"021S- -"?10$Z4^B@&D4 "0*
M:1_Y&@&E/HH!I% -(H"-";WH!H3Z* :$^B@&A/'ASYT!.D>CG0#2GE0"PH!I
M'_D: :$^B@&D4 TCT4 TBUJ @(2.SG0$Z1P]SE0$:$WO:@)TIO>U -*>5N%
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M * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
MH!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@
M% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
M H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"
M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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M#4/35 N!SH!J'/LJ 7!Y&J!J% 30"@% +VX]E 4^(B]K\: FX/&@)H!0"@%
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MXV"K*[LD,S,S%RF3QCDR.T(R'D0);C"%EI)(2HI2+@4!U ) Y"U 30"@% *
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M.T5"DA"?10%*$I.KAVF@*BA/HH!H3Z* IT))/"C)0^?/;# _59 X#^?(9O\
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M_1DCA[K?X5 3])2B?YMD#[*/PJ @9*4/^S)'VV_PJ ?24HJ'Z,D</=;_  J
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M?I.5_1DC[:/PJH(&1E D_1LCC[K?X5 #DI1!OC)'VV_PJ D9.5_1DC[;?X5
M1])2@HGZ-D<?=1^%0 Y*4>'T9(^VC\*H] -.=D/%R5^1.\4S;@E'(VY\:^%<
M^T_1+W'%OZ2UQCCQR4W(>#)?\>5&9:0X6[,H9BE)0@@WLH]XTBJ<\/Y"O2>,
M!V0T9#)AO6"XSC9)1Q0ZK58<>0-<HK'UQ,(NG'W_  ?XF]^YRAS1VN#W:R_L
MKT2*R^:ER$9-MP07CIE7M='9']^O4V]XGR_\2K28S*[KB--OR\HGRZUM0BZB
MZ5%/B/Z$*T))4 H\ ;5RS$G/6IPQB6IET9S(P424(A.*LJ4[^,4DG4VH6'/E
MQKV.^U)\6/L&M0V)O)RBE"_HV024 FQ1;B+_ 'U?2BZJIU*SDY1'\V2/MM_A
M5:@L\AG),6(XXWCW1(;1K0APHM8$ D][W:Y7;JB1NA=#)2B ?HV1Q'86[<?_
M #JZ1K0IKV7R,QV0^T[$D".E<92471W>)N>?;7R<S-O#@JO><Y&H(8S66QS,
MN:J5!D.1'&VHV->2F,FTO4A06JZE*58))/ 7KRO@]#_F.? 9R)DG)A6ZB$X7
M6W9B)+:%MK\)X-@+0H@\"D^FMPQEURHS&"F2$R'[0'E$QHP[NC[T^[7KR:<F
MT]E?2;AI9;YN:[(=<4W">-XJ0+%L\GA[M<LRTWAQ+^8DS"3Y&7D3&\?CFO*M
MK;R*I,A24N/M%20EM;22H)N%7OJKC'2OXC+9Z8B=*<AL%Z+(6^A;+4A:_#"U
M.M,E"E$ \U>MPJ69:NJ^6/N9-)F\#D9+#L=*XKWAB$V G4@(U%P\>*K<:]&2
MD_AKLKWLW%EQD]Q./M+BLP'P'$2&UJ44I4E3(!-N/&N]_,84CI=?8&S&B4^7
MFR83W\8BDDE%[^"?=YUXM,D^.47^4SB48S*OX]7FACW7"AD)T:D $+?(]/9>
MEFYJSKP4J6+-JD9B1'9=D'&2%!I!41= N +_ 'U?;<TDWP(ZMT1(RTAYM*QC
M9!N JP*#;4 ?OO=I&:D%B<Z>Z@;CC=4<AMJ4TAC:D>*5-R%1G%+:=\!+B%J*
M>*DJ<44 @Z3ZHXULT;#TSW)EMQ8W(/9<I?5%GNQH.0:8,=N5%"$J2X$JM8W*
MDJ%N[:QXT(;T#>@)H!0$$7%J ^=_::>SFW8>)RF(W+D,0K-SXN):6O+-X7#0
MEH2Z[XKSRF'E!3H&BP'&W,4!T3HBJ>YTTP2LIDV<O-"74N3XLY.586 ZL (D
MH;:"PD=W@@6Y4!T6@% <;W3_ /4GT_\ ^X<U_C-4!V2@*5^J?>H5:3Y+Z\?\
M1)'^J1O\6OAYY_U#^B> *N37[S.:UXS[M*<*_;[OTBAEI<:Z?_SH%0-IK2OV
MT<_ *I<>-?7L_MQG1.AMOUEXS_(2O]%7KR?ZJ/B^-?\ 3>-<?V7JT'UTWZHK
M[S/YNM!54** 4 H!0"@% * 4 H!0"@-'C=/<=$ZHS^J*);YRL_%-X-R"=/ET
MLMNI>#@[2JZ;<>%:UL*$IC4YUN+V8=M9_*9V6C<64@8C<&79W)D,0R&%-*RS
M"PKQ2XM!<*#:P;U6!XUI770SJ8F0R7L[[<R;FY7',O.95N;<<+=L@I"/Q4K'
MFZ&F[CBA1/&_&KO'AR%<:E\WT/9QNY,KF-J;LRVWL7G,A],YC"PDQEM+G$@K
M6RZZTI;(<MWTI/'C4WE5B35H8?=/LT[<W,YNJ.WN7,8K;N[Y(R>4P$1QORAR
MB2E7F!J256.@*4U?256/8!17&'!'1=W]/=M[[V4[L+<K*Y6$>999UH7X<AM<
M;3X;S2P#I<0I(4#:N<)N,L#HT:EA>B$:/N'"[AW?NK+;RE;8)5MR-E%-(CQ'
M=(0'U):2GQ7@D?NBS6W(QJEA/]GC"S(F_P#%-;AR4;;O4-Y<[(8<!I;4;(//
M-O.R&5%.JZBT$Z2;6JJZZI\1'"J?*9C+=#]J9[.L9?,2)$IAO:Z]FOX\Z0V]
M"=()=4JUPZ+<".1XU%-K$KB6^!Z+/8?"S]N3-YY?*[>DXE_ PH$AN*@1HCZ"
MV%*6TTE;KC:39"EGA5<ZNI%&AO.Q]K1-C[3PVT83[DJ/A(C4%B0^ '5H:%@5
M:>%_>KFY59M*B--ZP;TWQM%IM6#BPDX69&?;<RLLNA4>4E"BE-T* !7P#5QW
ME\* Z!MLR'-OX=<PNKE*@QB^M\:72X6DE16.Q5_6'IH#)&.R3J4A)44E!.D7
MT$W*>7(^B@+&2E*<OC0D )"'P . %DIH#)#E0  6H0=M"DV% 4HXIO0!7K)^
MS0$V% +"@*5&RD>Z>/VJ KL!0%"1P'V?V:$"N"D_9_8H4J'*@(2!8^^: 'A:
MWIH"J@*4@<??-"$GLH":%( %4%*@.[[XJ JL* IL./N$T8/-EYJ0VEUE8<;*
MN"D\KCA64Z@]K"M BX -^ O0$'L]^J0KM4*>=TH2M2C9*;DD]@ XT!Y-R6'P
MDLN)6% +&DW)0>VWHK"FF*%S6P4(YJ]\T!40+4!-K4!0.:J/0#Y\]L( =+(%
MOZ<A_P"C>K[/@7_8_@?T'.[H.A>89AXU,M\E,>/$ENO* *B$ICH)-AQ)]ROQ
M4_U'Z9^XP]![07426(\EBZF7G6'6U$$'0J-<$@\N=8AP_M]T(\V0##TVX&/&
M_P!/4C]CU1(M![+3=,GCS$[_ !DT5,<=OZ"XF0^E9C3R64KLRR\TV$@<T%G5
MI/V:]"OSBZ+0=:ERC<EVRX]'L AE=D*N2IY6FWO"O1#.<:%:FQ "OH&BE(&I
M7OT!*P-)H"H4!3]T1V6H0*%DFU9>@IH$Z2S":R,R0L-L,-9!UU:N24)3Q)]R
MOB7/M/T2]QQ?#Z&4XA*$,L>&H.(4N(X'!R7XD4KO]F](_3#^0M:T]7N,9+E+
MQ4I&2FO)3A7HT%A20TI3C4CQE!*U%-R4*]6UN';7-:>K])C09'Q&W8X<:<0Z
MV6I=EMJ"TDAT7L4DCA6)?97HD4])F2CP,K#;?;>6J5-6VR([1>-T1-1U:?5%
MNTUZFOC7[?=+P^LQ^'\.9CU95V-I?R$>*"V^T&WDQO&*4-+!XCAQY]M<7P_N
MH)8$1G%0?-8:7,$F4AN>]$4H)0XN*5@ )2#<^%;2HFDU36_B,LZ+!<;=2D(4
M%%M"$.)!OI5I!L?=K[=J2:_;B/1P'I,E,1$(4\2 ZL-)L">\KE5G<4-(-2R<
MM4T*D% 1:*^W8&X[KJ0./NU\;,7'/%;,O>CC-XF19FAM.3:?=(<=46XR3?F&
M;V'HKVV[C474Z5-;DS6_)2D-.H<FM1X16P%A3J2Y<(*D\Q?L/;7SG+6BWRKW
MG*3^@R6$@-O)@PG2="(BTJ*38W0]\(KI9CKR2?$_YC48U,9(P<%Z>J3&*X,Q
MN1DW4R(A\.[KS02IQQ/JN&P^Z%(_J>N9$BYPDU]HICE]2IT;R,6:M5M;G=-G
M% =C@X@U;4FFJ<4?>1.C,9EO+9!E>W5O^$Y)C+>D!I90^W$1*%W$%/*Z@ *Y
MUKS?\B<!<8U,TKD.9&/X4CQ9K"+*"_%99; 0X+<M?K%)XBK#2OXBG@<;,9>>
MFXV8ZA]Z3'??A.V<8<+<8@MH! \,KMZP[:S'1'U>X:2[QDHS\;"D+85&=5'C
M)=B.$+6TZE\ZFU%/#4.%6'V8T_#[R%M,E3WYTAW#NLR6\>O)(F0B4Z9$A2!I
M:#U_Q:F_NN%N/&K)-)/][Z33TOUDM[DQQDQH[Q<:G&9 C28OA*68S[K!*4N+
M TA/H7>U6/VH^E?R@\\L].CXESZ.4TB>4L(1XZ2M)2F45. )!!)T VKA6B?[
MIFM%^W&9PRER8NMMU2V7A-*03?4BP*;^]7IG.4HR_B]QINJYS,X( N9"_I8O
M\4*]>7JU+U>Y'6!FFDW;38\.=OLU]$IC]QOOPL%D9L51$MB.ZMA0M<+"21;N
MJ[?[DT!K'2C-;DSF!F2MRE2WFYSK4)Y24I+D9*4:572A 4-15QTBA3?*$(-P
M.'/TT!P"'[23TGK#)Z8'!-A+>53AH[:9!.6(2%^+/7%T63%3I"@K5Q0=7N4!
MY>U;(@Q,'M"<J8Y&SL;-!S#Z8T.4PM?@K2]X_P!($,)0ELJ5WKJ40 D7Y ;]
MT1S#.<Z:X>>Q+\[94EIR1Y.-CDJ<9?6A6EF'=@)N.ZILV4./.] 7_4SJ5!Z7
M[?&X\KC9^2QR5Z92\<TASR[0MJ==4XM"0D7"0+W4H@#C0&,PG6S:F?WNYL>$
MB4F1>0Q$RCK7APY,V RW(F14$G4'&&W4%>M(',=E 8#<$J/+]H_I^Y%>;D(&
M"S84MI:5@&[7/23:@.U4!"CP- CY*Z[_ /$.1?\ -(W^*:^%GOU#^B^ )]S7
M[S.:UXS] M;C?J7NY?H% ];C?5]W_(4,UEQOJ\__ -?6/<H:^+CEU>#YCH?0
M[_B7C/\ (2O]%7LR?ZJ/B>.5[HZNN*X*?MR\I]=M^J*^\S^:+055"B@% * 4
M H!0"@% * 4 H"E7(F@.+]4.M^>Z99=F&_T]R&6PLZ3&QV-S<>9&;9DSI8.A
ME+:[J2;@BZN%=+=O6J9E.A.'ZUS'-_1=G[OP;6T&7-O_ $_.7DYK/B1'_-F,
MEA;@(:(4+*!"K\:SNZ*J&O5T.L3\YA</ 3D<QDHL#'$I F2WFV&"5BZ0''%)
M2;CEQK)HB5G\!!2ER;DXD9"F3*2IY]IL%@6NZ"I0NCO#O<N-6@(^L6WCDV\(
M,K#.9>;\=G'>8:\TMDB^M+6K64V^Z M4H"#N7;B93,)67A";(=7&CQS):#KC
M[7KMH1JN5IOWD@7%6@-?V]O*=EMV;LP&0PQQF,VRN.(^8<E,N-S$OM%Q:_#2
M=301;CKIJDJ;##W%M[(XYS,8_*PY>(:U^-D(\AIV,CPN*]3J%% T]MSPJ4*>
M^.RV*R\1N?B)K$^ [<M2HCJ'V5VX'2MLE)^P: NSRH#CW7*'CG/H)^0XM&1<
M<DL1@%*0VI)9N2I0<0 IL]]N]QJYT!OVRL9D<1MV# R&3=S+J$:DSY/[L6E]
MY"5&Y*BD&VHF@-DH#&R_YWQO][(_Q4T!DA0$#E0B':*%)H"E'JB@!]9/V: J
MH"!RH"E?KH]\_L4!70%*>S[- 0NVI-_=_8I0%0(Y5 0CB#[YK3 5S3[]0%5
M4)//WS0%*'FW@%-+"T7MJ2;BXX&LII@]+BJ"$F]_?-4!?-/OT!50'G?@?<O6
M)8193$[>L,2P?^D< _PU5QL+"IF.*,LEQMPK"%A10=*[&]CZ#76J=31BLR3?
M'\;?EK?VN-<,RZ*/I,F641<<>VO44+6D)))  %R3P'V:S-X UW*9-14Y&8*D
M%I]+3W(A86@FWO5X,Q=I5+C1ALQ422Y&7&6T="U,16E&WW*G3<5XHSU>:/\
M,83-@@9MI3;GFU!+J%/* 2DV\)I5B:^E:S":QXV=:EX<A%2&E*7PD+2AK2+G
M4H7%_1>N^]C5+C+4DY!@2U1%$I6E =*S8(L3:U_?J[Q5H2I> W%ZZE('K*HP
M?/GMA_\ "V!?^G(?^C>K[/@/_8_@?T'.[H-RC1<T^8:YKT9..93,<$=A*_$=
M2EE!9*UJ/ I/%0M8U^*G^H_3/W&&4KQ*VGOI!J5*<$><S-9@(<T,"T<^(@)
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M%EE\I'9@/OQY;0>;;4I!UI-E=AM>N-UM1J1NAAF-U1(DU#$V8U>?*3'CI<<
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M85N9UWQVPAM:&1WAS4PI1KRO&Y_%_P #E%_$7C$9A_%-/-2V@ZZVRCPEK2D
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M?=.WIJ6_HH;G90WEX;S.IM]MTH).A9"5MH4;I3V]M =DO0$T!QO=/_U)]/\
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M,MGRX/XL"Y?20FQMQ/&ER=;:7")-41@IV,D0T,3\6AMZ2F$(SF.>T-1WO#E
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MGK'BOM-<IRLM4<H\X\ISS_LW.I+H/.-N38,<.VW+BW"Z4W*IL8D*0C2"GO\
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M5]8\.5D %1EQR>'+[OLK.\MUK6(\ISO8W.I+H*COS8BTZ7-S8E2".-YC!O\
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M4R&PCZ+0ZM0<U@6+EE#N<ZJN*K?('!TIRFM,8)K;77[>R52FY73OIVJ9U$3
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MM 4K]4T*M)\E]>/^(DC_ %2-_BFOB9[]0_H?@$DLFJ[3.:UXF?<>K)5HN?\
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M;Y2ONH_F+TE0ZL],.W>>%_\ $(WX= 3^M?IA:_URPMN5_I"-S_PZ W"@% *
MMI\"%DXCD'(Q69L)X .Q9+:765@$$:D+!!L1?B* \).'Q<UZ')F8^/(DX]17
MCWGF6W'(ZR+$M*4"4&P'%-J \!MK;IR_U@^AH(SW+Z4\LSYSEI_=M.OEPYTJ
M*%S-Q>.R?@_24)B9Y9Q,B.)#2'0V\CU7$:P=*AV*'&@/![;V"D(G-2,3#>;R
MA2<FER.TI,HH]4O@I_&%-N&N]*@\<CM+:^8<CO9?!8_(/1$AN(Y+B,OJ90GB
M$ME:24@>@54V#UF;;V_DI+,[)8>%,FQT%F/)DQFGG6VE7!0A:TDI203< U*L
M'DO:.U7)<2>Y@<<N=CD(:Q\I41@O1VV_42TLHN@)^Y"2+5:D,T.7&H4F@% *
M TW>QWBSY%_;#;C\1'F!E(<<L(D.A3=F/#<?N$Z7.)L.5"FKYE76!*L;]&I4
M^TEAHY-;8CLJ4-*@[H0X2 ]XF@IXZ=&KMH0NLZ]UF3E$'!QHZL;X49ET%; )
MD,A+S[J0X+Z'3JC@7[O!= 73RNIHVFPIYH_6U^>HJ$4QRU&B+<*D:]7!Q+:+
M)*4]Y9H"QG?K;^LP3 0/H%3H"E_B4M@*4CPE:5$KT!'B>..>O3IH4IF2NM2,
MY+<@P&%X9YYUV"TIU@%#"$%EMIR_$%1*7[W/(I-"&9S">I;>SL0G"I8<W?JA
MC-..*: \,*3YDM!7XO4H7 ] Y<;4!C9(ZKJW@E,9 &U2^ 5DL"WXU)!TDZO"
M$?4%#UO%M;A0%G*D]<3D9:X>/C_1SQDNP&5O1KM)4GP6&UDB]T'3(]WBDT*;
M#GAOY&TL0,.$N;D2(WTTI/AI6LA'XWP]7<%W.?\ <\J$,1DE]6CN% @,@8<N
M(\4@LAM(4$>'I"KJTC\;X_;?3IX4*4Y&1UH;SLJ1CH$=["*D*<AQ5/1TJ$9I
M)9#2B0""Z2']5R4VT=M"&2SB>I36T\-]%Z7]U!;/TPM/@I2=*3JTA5D:2JU[
M=E 6,L]63NA*8[:1M\NH!6DLZ 2I!"B#=?AAKQ X!Q\2VGA0I;RI?6_Z7DN0
M\?&5B'79#L-AQV,%-,!)99:63Q*M13(O?L*#0AGLJSU&&T\-]%/-'=:#&^FR
MI+(0\-!#X23W4758C3[PH#7<HOK&<;B3C6CYV[@G F.E?@B0?W0FZ2Z8]O#*
M>'B<Z ]LRKK/HQ_T&RR-,1#,Y3BH^M4N022_I6+$1TA.I(("BI5N5 7JU]5#
M@W9KS*&<N,JAX8^*8[A.'2@:XZ%K.GQ"0;+/&]J QLY75_Z$Q:\:TKZ25J5.
M:<\N%MMET$H6HFRUI9NEM:;7<YBU >TZ'UDDMM/8V4S#=:Q;!"'?!<4O(&0X
M'$K2>X?Q&BYY!5]- 7;TCJ?]!9EZ7#6G,NS&DX>- 7'(9C*2 2I2[A24J!6J
M_>([HH"TSBNKXR[ PS8=Q>A/F7/R=K4OPD>"4H62I/XWQ#(%SW+::%/:?'ZO
MQ\M(R>-6Q*QR<B\&L.M32?&QR4#POQB_W,E5^7'TT(9*:CJ<GIVA./,9?40I
M'C..>$EK5XI*B@6+=]'!-^% 8K.+ZLJW E6'8MA+ME20J. -3:- [W>[KWB>
M/Z4:=- 5SHW5^/D).2QCT>3#3DG0WB%EI(>QX3^*/B+ \,@\]/>5VT!E9K?4
M%O83*8ZVU[V2A'G7$ALZ@%GQ/!%PC64^K?A]F@-?SB^L!>B*Q;!#'EV%3$-J
M8N#X)UI25<W?'TE1]7PM5N- 7N6B]74S7<EBGXRF6I,7P\7^+TR(J6T&0D*<
MX-ZEZPE?K<: O7?UDIV"\I8;5OHK6H!KPM*6EO7"4_<DI;[ONVO0&%S*^L)E
MQ#CV/Q)89,WPC'"0LLV5IU']T\QQ5;N^%>W&@+W(Q>K:)\S(8QZ.N*S/;$3&
M*+>F1 0TA2DZE_N>I86G5Z_&A3(N-]2U["!;<9:Z@>*%JNEE;!;\U?1ST >
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M;[$8$6*S&!U!E"6PKD3H %_[%>=NKJ4]J@% * 4 H!0"@% * 4 H!0"@% *
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M&9S"P<@_/,DL-?2BWX7F$E=UA<8Z4*()U6ORH#Z.H!0"@% * 4 H!0"@% *
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M"TI*A6YVG&AF,TS)]!^N&7ZQ/;I9RF 3@', [$\JVEXO*>C9!I3S*U@I&DE
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M] /!;N3;B?[5 /!:^]% 5!M (-N(XWH"J@% * 4 H!0"@% * 4 H!0"@% *
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M*JKKP-:NDL^H73O=V5W;DI6\,?FY.'W#@,-#Q<_';>;W+)94U$2B0RDNN(5
M?2[J7XB;%2C<GA55Q)8&7%MXFRY?I&]E]S]1UY[;4S.,L]/8,+;N3R<13CLC
M*Q\>47;MJ2984$A6@E05R-9<\%Z2ZF.)&W-G9/%[YZ-;NW;LF?EHYVC%Q&6D
M#&^=DQLXTI*6')P4-3:F6P+/.<4 4E)--+C"CHKQ&Y^U#@YF8S73"?\ 1.;R
MF"Q64FO9QS;;3[L^.PXPE*5(5'[Z25< 01>N=J6JFN,U-5:-$WYB=QX5K:O4
M_H_MG<LJ:_B,IL?*0,O&D_37A2M1A2927-3A0R\LK#BON4I%[5N+6AAUX#"=
M0^E>Y]M8O#].L;L]<_$0MGK@P\W#PB=Q2I>9D+6_(86\ZH)@I\12UAY*=9YW
M/ 5J,U6O*9<72AG$[!WYFDXB$]AIYF2>C<G;ZWY;;B4#++<5HB/.K'==(MP4
M;U-95KRC5;5.0C:D'>>4W1TKEQ=AYJ+]3]EY;!2U9J*YCV',JG'^&(X<O=+;
MBTA"7K@*OW>525*MUX1&JHN0USIMM'? W]M[-2=I3L,TUM[.X_.,Q]O_ $'!
MC2W(;A;C>*A2US 5VT//$J6JUN)K<I1IZQ%.I=]+NGV;9E]%H&,V%E=M;TVQ
M,=RF]]S38BHK+N.>2L*:5*)_'%T:4AD\4<>'.LR:=<20BU3C,>YT\Z@-[*V-
M+EX'))V_A=Q;EE9S$_1"<Q(;,YW\BE*Q<@I$ENP4$DCN7U#G6M:-611:IZSZ
M+Z&;).(Z39';K3^50SEY&1<CISF/&(?C)G(L4M0TK7X3(42I"+CF> KA.595
M.R6!J'0W-;FZ;[,Q'13<NQMP?6#%/R,>WE\?$\7$/1),A:Q+\[<(2$I<)*3Q
M[M:FJO6J8BVE1HYNO;_4CI]TPR'2>-C=Z0MY8.?DY6S\[LM*U8O+)G.*=CJE
MO-@Z4IOWVUV*?36VU*294J*AL>[NF6\=\;IR$;,XZ:<A)Z70(_TRMLEL;GA3
M&Y(:\;U2^7$<1>]C>D;B6CC]AEQJ_4:_%V?U.W&ULCJ/NS;D]&]=R]0,?E-P
M14QW$JQV)Q<4Q&/$01J:;!2M1*N'$5I35&EQ$U:T;XSKOM#)6QO;HGGGA^AX
M6[VXDMT\$(>G("6%&_"UT*XUSM:)+D.D^ T[JEN#);WZKQ,-O/:.Z3TJV1/1
M*B1,9AI$].=RS)LAYQQ-DIBLDG2..OW+\$,(X4JP\6=-WSTSW=OC;N],5FMV
M'+[=W!CI(PNVG,8Q$5"ED!Z(3*0HN++;B4@A0XURBZ%:JCY?5M[K?(@N=61M
M?+?6W/0'.G$W!*CO>89QZ<<U%&06DBX;5(2X[J(L#VUZE*&@XTD\3,[YZ-9K
M ;LF8'(XW*2=DN[>Q6!VSD,1MYK=!93&8#<IML+6DPG5/ZW?%38J)U$T5W#U
MFG%UQ/?J+TRW2G=Q.XXV<RVTY^U,9@\+E&MO-;FG,EEG2^TXRMS\BDE1*_%0
MJ^H^MPK&O&G+4KB>?4'I;O\ E;@6[B,1E<[@,+L[;OTGCIK+C+FXXV,?;7)Q
MCSK1)\R4I\1325$DIT\:VKD=6C,J,D])MDS RQUIP^Z]D;*R<PYU[#.Y7&[D
MP 1"QD&/'2E+V/R94##5'3I0J.E-BH6Y<*Y*B3JRM-NIO_0=)F=5NN>;BHTX
MI[<,6 VM/%#DJ!%T/D=EP5 &LW&G&*.D75L[]7$V* 4 H!0"@% * 4 H!0"@
M% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
M H!0"@% 01>I0$! '+MYU00&T@W]RU 3H% - [* : 18T T)N3VGG0$%L<^W
ME>HP3I%,0 @#]BJ"/#3]CMH"= [: @MCLX4!9Q<+BX$F5+@0V(LJ>L/3WF6T
MMK?= L%NJ2 5J X752H+S2DT!.@#E0$Z1S[: C0!RH""V#[GIHP6B<1CFY[V
M4:BLMY.2A+4B8AM(?<;;]5*U@:E!-^[<\* O BUO<H!I!YT T#['HH!H%  @
M W[: LG<-C'\A'RKT-AS)Q$+;B35M(4^RAS@M+;A&I(5VZ3QH"\+8XVYGMJ,
M%KCL3C</'\IBHC,&)J6YX$9M++>MQ14M6E  U*)N3VU6R4+VA10"@% * 4 H
M!0"@% * I4G4.=O[% 4^%P OP% "WJ&DGA0 -GM4?<%S:@)T&WK$D< : CPR
M!8*Y<J@)"".WW^RJ!X?*QY4! :/&ZC8\Z@'A&]PHT0 :(XZCJ(L3[GV:H(\(
M\@JWO<* !JPYDW-^/IH 6B01J)OPL22+4!/AJ^_-O@H""T3?4JZ>'=/+A0$A
MLBQ)N?30#023=7/L]R@)\/A:_ ]E 0&R/NC_ &J >&; 7X"@(\(WOJ-SSH##
M;HV;MO>N(5@=TP$9/$J=9D&.X5HL]'6'&UI6VI*DJ2H7!2:)T#Q,T&R!;6>
ML.-0#PN)/II0#PC>^HWY7[;50$ME(L#P]- 2&R.1]\U 06C;@HC^QQJ@:% \
M%G[/&@,/M7:&W-E8YS%;8@-XZ ](>FO--E:RN3)5K==6IQ2E*4H\R35;J1*A
MG*A10"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>tb_treatment-4clr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tb_treatment-4clr.jpg
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M_\0 U0 !  (" P$!              $' @8#!0@$"0$! 0 # 0
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M^8U1(@=J18'*?00.))G.H8IM6GPO!CMY>",X[H:,\EZIZY+/2$]\<3>F 0"
M0" 0" 0" 0" 0" 0" 0" 0" 0" 0" 0" 0" 0" 0" 0" 0" 0" 0" 0" 0"
M0" 0" 0" 0" 0" 0" 0" 0" 0'E?CSD&*J++[.(?G*T=GB?5^C1S_2^+A6L[
M&M:P4P?7C1**\<G<ORN7E11;"MS(*B7PE%/"  #=MV1?(UJ.3HG#$3CJ\X6
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M4SF=4*DKL$42E'8#5DET]<0$.03"(QCCY.&9^++4]W)$?!T6:TE,1<6B%UM
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M0);1,8P[8XN34]\RZ<Q';3Q;PJ-4&'$ZE3VI.;:M!K2#=.8CI32(H4I9CMV
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MP@,F(S -T<O-C&:G$M^)U,?,W\.%O !" !;$8R -W..?*QK^_OXL^R/@\<9
MP5<#+B#"B6[83X<>K51CT<C9NLI3S4\P$Y\>> 1D7WVJ9MD=V.6/MW,]7+KC
MGO\ P>Q\@X,MJO8=JF);/9-Z$Q$O/T4I=8HHODU.>*8PB)C2.:93#MD QP8Y
M9C?=+IUB)BGC+'V0L^<-)ZO:0V<NX;.W J"R?M'*S<CL  @K-EFVPY3@4NX1
M 9!'H;QQ\M3;FQW8F8IOO#EA?(%[Y2/G#*3)>GMV[Q2J()/DC-G#ZI* /-G(
MCL$B"$YEF$M@ $PG+5S<N<Y[,LN/$S/=+NN-RG92N2NVU;MNT:IU6R$V9GSA
M.FME'")JKSQR?3A3 9B1/2) -NU#*,?%G,1,SZL^:)GT53CR]N)/%=#ZOV3C
MU5FS.<5G;A6A.%73I41V'74':80#87D (W[SQ[FYEIS/)F*B'ISAJR;G6^J]
M76.5[=/2J0T:)+4]X>GJT^;DRFDR8<X/AS+X7>E''S8QF([9=''.ICYGI&.5
MM:]>MNHW9:M<MAP4IDJS3W+'Z9[T#+I&*4P_[DP@,99UVS$I,7%/RN882S \
MJ;:T3V=6DN==IHK"HS5*V((&!,RQE!#2  01\*>Z/9GEQ5VX(XM73]-KZL-K
M<&*ZSCM@23=:C&IE.((AL.@CI;[1[AB$CR,;K7<[M1<4_,ZW\)Y>K=:I5HNK
M/K+5)1\DFZ%RU52:-@,<I5EC*& "@ %#::>Z/7GEQ$7;ACBFZGT?I]>-F)7!
MCFLV+3U"M4W](6I#-8\Q*EJ0%)(32 ?! 9:I!NCQ\ZK5NZ8N*> \17=ECABN
M*X*$_P >/JJZK',(+-BI+!J68\X5)1NNDFH51,P*&'9OV;8]+DSGEB)MRX[L
M3,5T?36K,SO=.<;0R!>]H/$GM>?TZI"DQ;'.WI[%!;FR(KF+/FSIIDU& XZI
M#,VV$;Q&)S$LNS4ZN7JCB'OO-&/'UNW%C6A=8[7(#@ERTTC<S@\_ YHPBE]-
M(  )I&+LG[Z.+AQC5QJ:ENW,QUAY6RS>^4N*-]0:%1,:.Z:XIBB@%7%)4YA4
M7 "CSKA5-,J:)93$!CMX\YXKF9<_)W;F(I[PQ39BF/<=VW9BS@KMQ1F1&[AR
M2>@ZXS.H))R'3K,(%GR1YN]=VIEU9BHIN<8,GDGC<QA7[OHML7/:U%<5BI4A
M==E4$6*9EW'1')0.0W-EF(D(<HS'DU1V^+R1F9B9<_-CNCHT;@VQ;>C?)=3O
MR\Z'4*:C3Z<=LP=5- Z!UGCDQ2&T:P 3:4@, ^S&SR>3/;42QX<3$W+:.-W%
MUSW,I:EXVI1G=878E6IM218(F7621$0604$A)CI VL)RWB$8>+R1%Q++FQ,]
M8=3P6XOO&F7G<5_WG1GM,$K0&-/4JB1T%UW#A0#K*$ X (@4I-)A[\9>3R1,
M1F)8\.)B;E<'%1ARHY>L1N2W"E/=5O+G?4QLH8"%<IJDTKMP$=@&. %$HCRA
M+EC1P<O9KKZ-W)CNAY\QOQ'YAPY;+7'MRXVJ-4]%:D*:HJBY:N"):A$$CR24
M*<"B,BB$MD=.^'&YN):<:U$5,>CT!@C*67\H5^M/+ZLTUJ6:W:I^AN=16255
M=BIX7AK2$_@3GI* !'-R\>,QTFY;L:F>LO/'%%CR_P"X.(<M3H-KU2ITQRG2
MBH/FC515N84='.?3"@)0TR&<XZ>#>8X^LM.\3.XE>W&G;MQ7-BMDSMNDNZPZ
M0K#9PL@P1,X5(B5)4HG$A $=("8 G'/XVHC?7X-G+$S'1W?"/;]<MS"5)IEQ
M4YS2:ETIVMT-XF9%<$U%)E,)#2$)ANG&/D3$[Z,N.*S$2O4 D$IS[L<[8PT
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M-Y1$!GW8"1+,=H^U 9 $@D$ @($H#W0]@90$:0V;1V=^ D2@/= >Z&R @"@
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M8-4]T]L!PV=GS#U_UY6V+/O!C5J\F!A!FD*B9E 3]\*)E"$*J ;_ *6)MFV
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M.8:7;EO6#;+&W".D;DJMXH<]7*JN9$R7.-@ 2B49DDEO#5IY1E :I7U3&_\
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MQ,00\$1W1!]K')G#32QKAJ<\9-1N90ZUQ"E37A>GJ*@8IS./TOX>H#FG/NC
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M;WXF(5O(1-RSBC5F;S@NIU:)<3*DT)O6$E0<I.249R&A8#:@.0G1M!3 .T!
ML!M!<I\-Z5RGO<E19%N]=OT%6NA3W@/3M@E)(5 ;ST^"&SO1"G0UJL<'MQW
M-SUYA1*C<1S%65J#BCN3J*J%E(ZOZ7DH8)!M. P*=Y=&1^&F]J8G1;O<TZMT
MI 0,W:/:8Z6(B(   *4V\R#()>!+9%*?/9E]\+N/$W"5CGIM!*\T]+,QICM)
M171/2!S@AJ, 3V (Q"F5WY#X7[[*U3OA:FU\C(3&9EJ-+=N 2%20'$FMN,M4
M@G%*<%HWKPJV,[<5"R I5 >NDP0<N*=2G38ZB0& P$,)&X3"8 ,H@Y*'?O"Y
M:U:?W%;AJ92:_4P,#^I,J2Z176!0^LX&.1M]$;:/=& ^2[[MX3+_ '"+V]BT
MFN/D"\VB[>4MT9P4@#,"<X#<#B4/R(C**4D;KX2S4BEVYS-'"AT=QTZE4XM)
M<E0;NYS%9,I6X "@B.TV\8@[9_E'AOJUPL+KJ3]D\NBD%,2F59:G.SNFQ33F
M"2@MYE 9CN[L!UU5O;A4K=S-;SJY:6\NQD9)1K6EJ2Z,[(=N,TC<YT:8B00#
M2([H%/A:UC@]8W&%X-&%$1N7G3.2U$E'<@H5P81,*I2]'TE/,9ZP"<]L!O\
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MEJ]<[&C5BM. *5=^\H[I98X$#2748S81&0!* ^JD7=PGT&D5.WJ*A2&-!K0
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MD C 5C:YC!F[()0'8-+H B'((@#L)P7V6?!$",@$8#X6]8I3E^[I3=^W6J;
MJ9GS)-4AUVX+AJ3%5,!$Q-8;2Z@"?) ?:!BCM TX#* @1 -_+ -10Y=V^ C6
M6<I[1W0'QOJM3*8HT2J+YNS.^6*U9%<JD1%=P>8E22 XAK.(!L*7:,!]H& =
MP[8"8"K<O"8*UC =P]<&H3[PLGD%6B&Z")$90'POJO3*<LT;OGR#5Q4%>88(
MK*$34<+  F$B13" G-()R+/9 ?: A /;@ [-HC(( !@&4AG/:'L0$:RRG/9
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M>2^'ZQS.1?UAC55:_57 2UBE168 =<X#N*HH80GW8#T80=19]W= 2;849]R
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M2J8CV_V\$O ZK5/;_?K6*+/+N@B8! (! (! (! (! (! (! (! (! (! (!
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M=:VL1DWBIE'U@+>&>SJM4PT_WZUBHM -T$3 (! (! (! (! (! (! (! (!
M(! (! (! (! (! (! (! (! (! (! (! (! (! (! (! ("K<3A*Y\HS&<[H
M,/ZP:P65I00@$ @$ @$ @$ @$ @$ @*NX=_Y(+>#\O4?Q*DY@LK1@A (! (!
M (! (! 0;WHP%7VN66<<AC.>JET ?8V.@_&@OLM&"$ @$ @$ @$ @$ @*KR^
M7Z]XO-/=>#8-/=FR=_.@L+3+N"")@$ @$ @$ @$ @$!T5ZE UFW$4PR :8]
M?8%N> KWA;_J^8\^U"7YH\%6_!" 0" 0" 0" 0" 0" 0" # >>J5_)?7/_4$
MG^E;6(R;M4_Y?[>[O5>I_5K6*BS@W>[!$P" 0" 0" 0" 0" 0" 0" 0" 0"
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MS20#VP =L%.QW/X&$WK!O]0[PZM4F7N3E!#L<S^("'K!OY#O^YJD@/M#/9
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MG\TM7$&^#E"5M4DOS!@(##N?]_K!O_O:I/SX*GL>X@"S-ZP;[;OG;-)$/<G
M:/0,89J5R?>=/;YQ?-ZLV8T95Y4PM^F'Z6FJ5SS912$=).:TC(2[3:AG ;SV
M0<0/^T&]^]BD?/@AV/\ $#_M!O?O8I'SX".QWB _V@WVW?\ <S2?GP4['>(
M T^L&_E_!FDS]V<! X<X@#?_ +!OOO:I(?CP1'8SG[_:$J'WMTKQH*$PUGXF
MTG$)4!G^2MRE'#_YC#$&1L/9_-[[B#?>U;5)+\P8HGL?X@?]H-[][%(^?!$#
MAWB F(^L&^F.S_)FD_/@,.QC/O\ M!U'[W*7XT%:1D/%^:F%4L,M3S>]J2CJ
MXT6K!4;?IB/1')VCDQ5P NQ00 IB:3[/"& WKL<X@!$#>L&_GR?<U20#W)P$
M]C_$"'_[!O?O9I _CP0'#W$ .P>(-][5LTD/QX@#B#B!#?Q"/?O9I'SX" P[
MG^8F#B$?3Y?N:I(A[DX*#A[B .&GU@WTN];-) ?= 8H!A_B *$@X@WTN_;-(
M$?=$8(=CN?Q-J]8-]J_@U29>Y.4%3V0<0(?_ +!O?O8I'SX(Q-AS/QQU&XA'
M_P#O;:I10_$& D<.<0 R_I!OMFZ5M4D/QX#J[EQ#GEO;M87=9\?.FQ&+HRS4
M;<I1 5(5$XF)J 1$NH-DPVA!6G8'QCF>M8;LNHV_FQ[0**ZIB1V=&3H%-=%:
MIS-]+*LI(YP ?HC;8"Q.QO/_ (/](.H>#N^YJE?B[=OMP$&PUGXPZC<0=0GW
MK;I90]P!@ 8<S\4!*'$&_D.^=M4H1]T1@B28>S^0NDO$&^E^6MFDF'W1& D<
M/<0 B!AX@WTPW2MFD@'N ,!B.&L_B(CZP=0F/_ENE 'N3@IV-Y^_VA'_ -[=
M*\:")'#F?C !?6#?R#=*VJ4 ^Z P4-AO/YMIN(-^ ]ZVJ47\0!@B.QO/N[UA
M'_WMTKY\%9%P]Q %"0<0CZ7?MFD#\T8"#8=S\?WW$(__ -[;5)+\P8(@N&<_
M$W<0=1]NVZ6;YHP5EV.\0$I>L&^D._[F:3/W9P0['>( 1"?$&^V;ON9I(?C[
M8*U>F4:X!X>:S;P7&J6Z"WB5F:[>C)BL+SK0V#I?1I\WJF.K1.406I4I]OUO
M &[JM4Y>STUK%&F#FW)=TUBY#8BQ^A<UIVC45J-4WS^J$ISJHOV@%%PBQ3,0
MP%YO5L.J,C\DA@B[:94TETV?3=+&IO&Q'(TM90@N4M10$Y1* [>;$=)C!LG
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M]P,R; 1JC!0R#@LOH0,8NL"\@&" ^/+XCZ9QAW.N+6?P)Y$5: @)B"!1D([
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MK:9RIZ%R/:>IH?-SFG],F0Y5@'Z$-D$;O>I^;LVX3AM$E,>F#VFYX"O>%O\
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M93>OTJJ8[=V@S28O;B+4Z-B9*YBJJITVWVB8O']8=(D$ICU"J&/SFDNDI4Q
M)Z=P6/>5Y.,A<*V1:A>#5LPK5-:U:CUI)B8QV8OZ6J)"J-Q4$3:#& AB@;:
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M*80][W-L!YFR3=%]+8\R1CN\*X%UL\8W1;:R]T@0J2SJE/' F.@Z!/P15;F
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M$Y7)'0FYPJP&,(Z@-WMVR X;2P'CNT*37J.W9N:PC="/1*^YKCQ:HNG370)
M0,HJ81*0H&&0%EOG =$SX6L9,+="VF2U<0:)/$W[%V2KN@>,U4$^:(5NKJ\!
M,">#HW;NX$%;UCK%]IXNI3FE6LW6F^7,\J=1>KG>/WCDVSG'"ZHB8Y@#8'(
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MC$0*(B%WM1]H&+R?S(+"T0$9;I#!%"5CA!Q)7:PM7ZDK7E*JHLNX37"M.P%
M[H1%7F?"\ #3D(!R;(+;N+KX9L;7D\HE1K)ZP6I6_2TJ'3WK6J.6Z_0D0$
MYR& 3&,!AUF':;E@6V/&^'[6Q6G4D[8<5-<M5,D9R%4?K5#2* & O-\\(Z??
M#.6_VH(UO,UEW(]K^/<E6>Q&H7'9%8'I5/(<J9W-%JJ?1GI2F,( )R%$IR@/
M<& [;(6"[+R55V]>K2E5IU9:HBT*_HM2<4Y51OJ$P$4!(P%, ".P1"<%=E;>
M&\=VI9KVPJ30D1MBJ%5"L-7(F<*/SKETJ*.55!$ZAS!]$)IAR2@C6K'X:L8X
M_KS.Y*.U?OJE2TSHT0M7J"]00II% TF!HFL82ICI\'5O (#=E,?T-Q?3?(CP
M%W-Q,F!J73064U-FB*IM2QT$MQ%5=A3J;Q*$MT!K=R8%Q[=5V'N^KM79GCH[
M9:K4Y%VJE3*BM3QFU4>M2FT*F2V:1'N;9P'Q+6I<EQ<0;:[:LP,A9]DT-1I;
MKDQRB#FK5DP=*5(4!F!4T2%2'5R[H"PKQ"=HU\!#9Z-> /\ S!X$*\X6P,7A
M\QY,/^Z$A]H3&$(*MV?>@@.T)2@/DJ--;52FO*2]*8[-\@JU<$*82B*2Q!(8
M $! 0&0[P@*]>8(L9WCNCXP3](LK;H!RJTE5D_7;/D3D$X@/2$S 8?[8;8;9
M[D!]^.,.V/BXCT]L,UC5.J"4:I6JBNH^J3H"3T%5<+"8PE+/P2A(.]. QS3C
MPV4,87-9*!@1?U%KJIBYI ";]L8%VYA'D#G"% P_D9P'1.\:-<R6)::V4:>_
MHMW4]LFJX&FOU63ML]$G-. *JW. &(H)=0 ,^3E@.]QUAJQL7)5 ;69KFJE6
M$/2M;J#A1[4W0% 0(51PJ(F$I0'P2A( ]F KU+@VP\W*JFS5N%FBNJHX41;U
MMXDF*RHS.?24\ICRC!;60ZQ3;+]:S3U 7CMO8A@5H3-PY.H@+E-($DG#@#;5
ME4@":9CCL,(CO@CX[_PI9>2:@VJ]P%?-JH@V/3EG=*>*L57=.5-J49N12$.<
M0,.T2C[0A :Y?U@5FXKVQ7:U&I@,\96>Y&OU14@E! %J8ES--:)DGJF!C"8>
M33 72$Y!,("8")CW(#SU2DOXKJXEH&7:"0NB6V76MK$9.XO^RK8OG-EMTJZJ
M?Z1IZ-MU-=%$55D!*KTQJ74!D#IFW"(2$901W/JWX8E_DSM_5]0\YBE@\.&%
MPWVS^OZAYS M'JXX5#][/NOJAYQ!+/5QPM\FOU_4/.8+9ZMV% "?5@.[/IS^
M?N](@6!PXX7':%M?K^H><P+3ZM^%_DS^OZAYS L]6_"WR:_7]0\Y@6#PX86
M)]6?U_4/.8%H]7'"V\+:#VW]0\Y@6>KAA40EU8++]7/_ #B!: X;\* ,@M@L
M_P!7U#SB(6R]6_"W+:Y?AK_SB*6>KAA:<NK6WN=/J'G,"P.'#"P_O9 0Y)OG
MX_-<0+/5OPOR6S+O ^J !^(X@6!PWX7^37Z_J'G,0L]6_"WR:_7]0\YBEI'A
MPPN/[V?U]4 _9,"V/JXX5Y;:_7]0\YB%GJXX5  'JT&W=-_4/.8I:?5PPL/[
MV0'O].J$_=Z1 M/JX87W=6?U]4/.8"/5NPO\F?U_4/.8A9ZM^%ODU^OZAYS
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M18.U$E.FOSZ3%0.(#(S@0&(-'X><'8LN?"-C5RMV^#FJ/*4DHY7!X]2UGU&
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MG.L))&$QH)+W/1AJGH]L%<% :R"*85 6>L&O2=/TSF><\+1/WNK;+?!780"
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M"+>#4 'O"R=S^9!86D&Z")@$ @.HNBYZ#9E ?7/<[TM.H--("SUXH4YRIDU
M68E3*8P[1#< P'E+!&;<5N<YY4*WN1%12^:S2@M,@(N0Z<*;,4C:!%( +(_@
M_3-.V WGB#7<Y"NZR>'NF',"5PN2U^]S$G).WJ6<#\T<=WZ85*!0#NE[\!Z%
M1022*0$2@FD0H%33* %*4A0D   ;@ .2 YH! (#HKUT]3KAU^\]&/=7L='/
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MU162 0,!%:#53EU!N&1F@A.*)[;\8D4%4JE2!09 8P4*J@80#< B#0(A30+
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MUPTVF59YM:LGCM%!=0!G*1#F =LMG=@CO 63'E_^!@,%%BE*)Q-(A0$3#W
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MJVP&NUZ][=MNKV_0:N\%*L72Y494)F1,ZBBZJ"?.JCX #I(F7:8QI $!L!%
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M9<O<@)$0 )CN@(!0@[A@ J$ 9"8-NZ CG4_R7>@)YPG=@(YU/\E .<).4]L
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MI#/P[Z%:OQD^\U@(](9_G/T%:LNYZ2?>:P [_/@RG0;5]NI/O-8@QZ=GL?\
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MFR'!0\S[9REN@+& VDLS!L[L!G (! (! (! (! (! (! (! (! (! (! (!
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M5*?6Z8SK-)<D=TNHH)NV3E,9D406*!R'+WA 0& [" 0" 0%4Y@,8*_BU,!\
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MU.:F4YDM;-T/.)20"1PE*?<$>[$%@=CIQ#^4*\_C8GF\4L['#_A#O/XV)YO
ML['#_A#O/XV)YO L['#_ (0[S^-B>;P+.QP_X0[S^-B>;P+0.'3%WY#O/XV)
MYO L##QA_G#O/XV)YO$&78Z>7\H5Y_&Q/-XI8&'3@,^T*\Q]FK$\W@6CL</^
M$*\_C8GF\"SL</\ A#O/XV)YO MU=S8D4:6U6G'7V[UQ28.S@DM52&2-) ^P
MP @$P&(-'X=\9FK>$+$J@7I=-.Z12DC="85(J+5/:8))D%$T@V;IQ19HX=./
M\X-Y_&Q/-X%G8X;ER#>8_NN7\9"!9V.'G_*%>?L>EB>;P+.QT_X0;R^-B>0@
M6=CI_P (-Y?&Q/-X%@X<./\ .%>?QL3S>!:#8=.&T<AWF'[K$\W@6Q[(!'^<
M2\_C8GF\"V78Z<0_E"O/XV)YO L['#_A"O/XV)YO M(8=.'\X5YC[-6)YO L
M##IP_G"O/XV)YO M'8X?\(5Y_&Q/-X%G8X?\(5Y_&Q/-X%I##QRB ]H5Y#WA
MJQ/-X%JUI=),.$*U0?2+X#A?!&?I8%_KE/K2V+SPKZ?[;RZ]._DB*L.IB(\0
M5NE[EK509?WZUBHTE;+.:J_D"][3QQ9]!J-+LIVW8KN:K4%FCA8[E'GBB %(
M8H!O""-YQ/E<+\4K5"N"C*VOD2V%$V]R6TNH"XI\\74DX05*  JW5#:0X!^,
M(AM+O(MA,:\G:KVYJ6WN500 E)5>H$=B892+S8G VH9A(H[1@.2Y+]LNS2)G
MNVOTZA@K(4BU!TDV.<!'3,I3F 1"?* 0'!<M_6W;UEO[Y4?MG%"9LUGK=RFY
M2!!US29CE316U:#&4$NDDAVC 4Y?/$ +_A]-E#'#YJUN10E)74IPJH5!=@6H
MNDDC)KIEF &$IC &HH0)7/1+YL^L5)Q;]+K].?7"P*4:A2VKI%9R@,@U:TR'
M$P2'?LV<L!G7<@6/;#UI3KDN*FTBH/A &;5^[1;JJSF "4JA@&0B$I[H#8$U
M2*;2;2B$P,&X0'E >Y 9P" 0" 0" 0" 0" 0" 0" 0" 0" 0" 0" 0" 0" 0
M" 0" 0" 0" 0" 0" 0" JK$8B-T94GN"Z3R^ -H+*U8(0" 0" Q.80D !OV0
M% O<KY6NZXKM98;M>DU&@V4Y-3'M1KCE5(]4J:! .LU9%1#23FP-IYQ0TA&
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MWV$I_P $0\2 !:EK!_W)3_@B/B0 ;3M8=]$I_P $0\2 CJE:OV#I_P $0\2
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M=%%45A)S (2^G:M?O8#;G=HUBU+TX8K<?$5>N;=8U%A4WA"&52(LC2T4AU*
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M!!594>_ L_ -Z8%J-MUMQE)!*OLO0[5@NHD=!T994'A7($%+F"IGU^^U#+8
MS 8)3[;ZM1U34<%9 K[VY*-8]/LQM0*W5[3,LA4Z8Z5:(F2.L"::B@(J#]+/
M(FP0V\D!:6 :1C5:Z;FNZRZY==U5GHK>DU&O789<Z9FX&%0B+<[A%$QM(A,=
M@R]N"N?B?,XI:&,KS.T<NJ#:-Y4^JU]1FB=RJW8E35(*W-I@)S% 3  Z0Y8(
MZ;(-W-4;_P 6<1;9A4*AB]!A5:94UT6*YWE/](!H1=':B7GBD,8HD.8"S .3
M: "*<MJ58N8N(BDY/M)D]1L&S: [I"]>?-56):B_?*3!N@FN4AS$2 =9CZ9
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MBH$R"$!YIOJH]C_$.GEBX&3Q7'MV6\2@5*JLFRKT&539K\ZD"R:!3J%(H0)
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M[Q U.;E#ZH@H7B-N,9 ?".0"@'<IS<=W]\!! .(NX=0F'"600'D^MS?;^N(
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MOYQ 9>L9<6K^1/(.GN^C6\_<Z3 0/$=<L]F$+_EW?1S</V1!4>L=<WX$+_\
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M" 0" 0" 0" 0$&W# 5A;&S-^01#?Z*H'S'<15H14(! (! (! (! (! 5;E\
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M+NNAMQYT@<Z&@HD$I=,QV@(\L0;QU*XKY_RIV]+^#O\ =HHCJ5Q9?A3MX/\
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M\R!"<[X/-R/JV^%J#N1!NYK*XL-FG*=O=^=NR_1ABB>I/%=.?:I;WL=70\O
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M*BJ?0*PG*,A(7:(^Q >AU7S9J*:;A9-(RQM"(*'*03F[A0,(3'V(#E%03^"
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M"8@<0'P1#EG <C9R@[2*NV4*L@<)IJIF Y#!W0,41 8#F@$ @$ @$ @$ @$
M@$ @$ @$ @$!56(A$;GRIWKJ/]0MHBRM6*A (! (! (! (! (! (! 5;PZ_R
M/6[R^%4=O[HN8+*TH(0" 0" 0" 0" 0$#M 8"KK6'^/+(FW_ +KH$^]X+J"K
M2@A (! (! (! (! ("JLP2].XNVC/K>VD7D$.A.Y^Y$6%J%W143 (! (! (!
M (! (#H[TEU/N 1&0!3'LQ[GZ7/ 5YPM?U?,>?:A+\T>"K?@A (! (! (! (
M! (! (! (#SU2OY+ZY_Z@D_TK:Q&3=:F4.W^WAWFZK50 '^_6L5'DO(^5;#K
MW$[=CB^4:G4;1M2BN+2I"-*8>D)/7J8I.U32, !I%14"B([=(0'68LO0E2X,
MLN8^754%Y:!7 -4W(<VOZ/>JE43$4Q\(LC@I,.2<H"U^%JW.(L+-Q[5S7G1A
MQ(#,BG5[H(>D>A^%)+G>8 =6KZ+G8#0N(&SGU!R]<N0,U6I5[RQ$_2:EH5=H
M;U1N>WB *91,")!  ,!@D(GD [Y[90'M:R:A1JI:E!J%NN5'M!<4YN>FNUS"
M==5L"( 0RIC;1.(>_$?HH(_/3$>#;3R-AC)EZ7)7'Z50MQ[55Z(S1=\TS8.&
MB0N <"B ^$=49$U&Y V;8#O[CJEX*\/&%>(=%T[5N&Q'H-*LY$ZAC.J:#HR1
M!.&TI@ $P2,8VT=0S& M_%M73S-Q47;DVDO3N;'L>DMZ+0E$U/TNLZ?IB90T
M@V#(!5GW/!@-ZX@L%FS,A0GEN7#U9R+:BIG]O5$HC+:<@B!P(/.%*4Y2B"A
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M:.\1D$$49PBX:>TF[LDY+K=KN[7:UQZYIMN46IIG0<I4Y58RRII' I@ W@$
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MWX?1&?5QV'[LU8?FNX"/4WX??DX[^.:L'S'4!HN/^%W"5:KU_M*A;SA5&DW
M+-@4E7JJ0IM^AH*:!$CH!-X1S#,XB;DG$5OOJ=</DY]6G0?NU6//(J <'/#X
M 2ZM._CJL>>0 .#KA\E+JTZ'V:U6//(!ZG7#Y,!"VG02[E:K'GD #@ZX? G]
MS3H9_DJS5QE[KN Q'@[X>RA(;:=[?VZK'S.F2@(]3_AY#8-LNMG[=5CSV DO
M!WP]ZA'JVZ-/D-6:N:7NNX"0X.>'P $.K;O;^W58#YCP(!ZG'#Y\FW?QU5Q_
M9D!(\'7#WJ >K+G9R>F:O(?UW 0/!QP^",^K3H.\%9J_G< ]3GA\TZ>K;OV?
M358\\E "<'/#X0P&ZMNS2&<AK58EL[LG@0&B89X6\)7/C>B5NLV^X<5)P9Z5
M=8E7JJ)3 B^72(.A)T4H>"4 V!!6]AP<\/@ /W-N]O[=5C9^O((>IQP^2 .K
M;O9R^FJQYY 3ZG/#YJU=6W?L>FJQYY. Q'@XX?1&?5QV'>],U8?FNQ& &X/>
M'M,NVVG7L^FJQYY* Q]4+AZ"0=6G>W=]>JSYY 9AP=</@CKZMN]O)Z:K'GDX
M"0X.>'P $.K;O;^W58\\@,?4XX?)2ZN._9]-5CSR4!/J<\/DP$+;=A+D"M5C
MSR >IUP^EU&"VW8SY/3=8\\@-%H/"YA!WE2\[><V\X/2J;3Z,NR1"K54IDU'
M(..=$3@Z YM6@NPQA .2"M['@ZX?!E]S3H)<GIJL"'XKP8(GU.^'SY,N0]BL
MU@/F/(!ZG7#W\F7/QS5_/(!ZG?#Y\FG7QU6)>YTR4! \'7#X,ON:=!+N5FL!
M/]>0& \(?#S(96TZV?MW6?/8 7@_X>E9@6VW8#*<_358\\@'J;\/OR==_'-6
M\[@'J;\/OR==_'-6\[@,B\''#X6?W-NQGW:U6/QGD!/J<\/DI=6G?L^FJQYY
M :%D;A=PC0JK8*5-M]PFE5+E0IS\AZM55!4;*-'!Q* G=&$OA)E'400'OP5O
MH<'?#X/[VG7MUFKC\UY!$^IUP^?)EU['IFL2]SID!'J=</GR:=?'58\\@)]3
MOA\^3+D?9K-8'YKR >IWP^?)ET'L5JL!\QY 8&X/>'H@!.VG6WD],UCYG3(
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M%4C<#CJY=NV!3[S9JP8=^G537'3#U5),4$GYD%!<D1,.HR95!2U 01VB4!E
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MW4=.E2(-40FJNJ8J:90#E,8P@ !!&39ZW=HIN6JA%VRH:DETC%43.7NE,41
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M_P"Z$OS1X*MZ"$ VP" 0$&'2 CR! <(NDRB0IQ IU $4R"( 8P%WB ;QE/;
M09T4A#*'\!,@"8YS"!2E -LQ$=@! <Q#@<H&*,P$)@(;0V]R R@(V]V F 0"
M @9[)0'GJE!_%=7"\G:"0)2Y.M;6(R;I4B?T@[>,/):M3 /9Z<U@BDZ2PL_.
M-2R%E[-JZCC&MCU=[0[=MY15PG36C>EE(#A\LDV-J555$W* RW2'P95&]8!-
MPY'KMPN<"5@RIUFR)ZQ06RK[H"<CCH7(@]* %4,/@")!E+D@.&ZLRYLQ^U+>
ME[670V5A$=I-JA2VE5.YN!HV<+@@FZ&28-U F8IA3)X6W?L$8#N;WR[??:@?
M$>,*717-R,J22O/75RO%FB+A%502%;LTVY#'.?9,R@CH+RP&G\0ET9;IQL/*
M4-FVI3NIW/3$*FQ"I*D ]2.53](+'1+I4:'EX9]NX-D!WEX9JRG:5T6ACMK9
M+"KW[=M+>N@;M'J@,6CQLMI*=58Y $6Q4_#4&0&GX(0'<75EV_K:0LJRT+89
MU3-EX)+G&CHNS)T=DFR";ATJY$ICBB4!#20 U&VA.8;0X*!EFZQNFKXES#;[
M!A="E&<UFDNJ,X5<4FK4],#)K$)SQ2JI*%VS*;>$QV;)B&E6[F-EC7AJL*][
M-LE)O3ZM54*6E:;1RJJ)"OG2Y3@W57$QC*F,29=8RF;N0&[VWES)3/)=$Q_E
M:U6%")>3=X[M1Y2GIGHIGIY.=6:/-9"E%8$Q VM/P.0)\@:/9MSYL=<2V1**
M=I3G%-:HT/I=/7J;H6K)@J4^E=HGH$O/*$\)4ND/"#? =NYX@LBUYM7KQQS;
M=$?X[MIPZ;B%6J9FE9K):<8Q7*K!,I!32*728"<_M/+8') =C5>(.M7-4K*M
MS#[&EN:Q>M$-<S1_<[E5FR3:)GYH6P$;E,HJYUS*)2>]D(C,-P:[Q-W5ENF8
MAM^JI,F]O5AQ5::G< ,JDL55NN9V0J:2"J)2\XBK_P 9,0D4=PP&Q7%4G7:3
MAM/)-G4M2]GSRMITZH,'CE1.F%;MR* =*8)@H*H2U@H4=,MD!PJ9IS!<MZ7U
M8F-;*IKUW93\J"M:JSU1!BJ@=N"I$0(F43BY4-, V@0H;30&VV?EVNY$Q CD
M.R;9Z=="PJ-1M9P[(V*G4&ZXMUTSNCE N@@E$^K3X1>_ =5:65\AM<FT[&.5
M*+1VSVOLW-0H%6MMVLY;:F(:EFS@C@I3E4*49ZR^"/('<#X^&8I1=9<$ E_&
M!6C;.[,D!?D @$ @$ @$ @$ @$ @$ @$ @$ @$ @$ @$ @$ @$ @$ @*LQ+M
MN7*4]_6D_N=!:RB+*TXJ$ @$ @.-4XDEIE,1E(8#Q]Q2U>I9.I5^6K3'!TK#
MQG1U:G<KUN;_ *9<JB<V; # (> W(85UI3\+24P0'I?%XB;&MF'.(BH:B4T1
M$PB(B(M$QGM@-N@$ @$ @$!5W#L&G#]NE[AJB'N5%S!96C!" 0" Z.[Z14*_
M;[VC4NL.+??/2<TE6&12'=-P$0U&2YP!*!A+,H&$-DY[X"@.&*W6=JY(SC;;
M!=TY94^MTTB:[]P=VY4,=H8YU%%3[3&.81$PP'IN 0" 0$#N& J^UPEG'(0]
MVET#YCJ"K1@A (! (#Q%Q'4SAQMQE=E%6;NG6;:VZ36I]275>$<-ZJ[$#ME0
M?K"1N@@G,)@!P*!=@A!'KJQ&]8:6=;K:XGI*C7TJ6S3JC](VM-PZ(@4%%2FV
MZ@,:8@;E@R;'!" 0" JK,!1]/8N-R!=[8/;%DZ@L+4+N@B8! ("# !@$!W#
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MGA>%J*._3 ?-?-C9;)B+$SRHM5+QR'CZN4FOW$P;K$%T]39\X50B2JDBJ*$
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M!Z\YIW=DI-/\)&,_SF*(Z\9IV_Q2DGR?=*RE^<P$]>,U;@Q,G/OW*RE^<",
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MF5.<=(=S; 6A9V'CVG9M]VD-:%X-Z/ZQ4 >]'!,6OID@DT:-0Z^;G.<PU=Z
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MQ_? :D4HQ0_W("C(/:@([/,H<V*7:U4-(C,1]$4K7[1N9G 9=G^4?!_C9?\
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M <#!LTRVS@K E59*.BLDW*)G9D@< W*J0510,,@4 @"(Z1'<:4H@^T!G%1,
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MQ2@&@?IX#KU=[= :58^;[TKV5.RR[,>FMNI%I1JVY=)55O4R-V^OFT^>*@0
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MLY9F1!-ZS9)"HX:JU) P+%37 HZI<@RV!M@+*PG=-/O;%=I7/2*7Z#ICZG)
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MI=2H%33%%ZU.\1#478(&*8J@"4Q1 #%,49@,%5_8^)<-V%<#>Z6ESKUZNT]
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MR*( AO#T>V\2!;/L?Q3\B:)\7MO$@'8]BCY$T3XO;>)  P]BD-UDT3XO;>)
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M.T;(H<^_3FWB02T]C^*/D10_BYMY. =C^*/D30_BYMY. =C^*/D10_BYMY.
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M=C^*?D30_BYMXD5#L>Q1\B:'\7-O$@'8]BCY$4/XN;>3@'8_BGY$T3XO;>)
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MPOHC0*;S9>B]'ZTM2\US<M.B0RTQ&2PJC_6!M\>0;5J8?KYK%1: ;0@C!83
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M(@'+(R(")9>Z >ER; EW-D!E (! 0;<,!6%KR'..00Y?15 G[CN"K0@A (!
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M(:ZS3))ZW7ENKYFBZ[RK!4RB9LJV(1,Q52KE$"E\*6S;(-L!T;DAR<%.)$S
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M+I->F5I3Z(]2?&%PY$P\H@H<2S[@! 61 (! (! (! (! (! (! (! (! (!
M(! (! 59B0!"YLI3Y;I/]0M8+*TX(0" 0" @VZ \I<4^7L:-W%I6>O<;=&XZ
M!>E"J=:8B18QVK) 3J*+'$J8AI*4Y1&0C >C[2O&V[[HC6Y[2J*=5H+T3@U>
MH@8"'%(PD/(#E*(2,40VA =_ (! (! ("K^'@)8AMX!W@>H_^).8+*T((0"
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M+3=%,J2&.[S22+[U-.B@4H3[A05  @.%QDZDNUR.G>,+M<.TP $W"M 344*
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M,7R\"DAF<3 (&QY>Q?9HP?C+C IPKY9:ND1;N<=7DNW-[Y%6B%4(,NZ4RHA
M0AE=FT2*W:8XO)L@41$J2-#*F0!'?X)50"!3Z.V?3( QY>HA]I@_'7@4CMI'
M\'=[?$P>7@4!FDPCMQY>Q0[]&++\_&!3(<SR_F]O4?W&_NT0I YH$!EV>7L/
M?]#!Y>*4=M$PGV>WJ'>]#?W:!2.V@PB =GE[?$Q0#\_@4KBEU@P8-K5P>C7X
MG&]R//0X(!Z3 >M+8W,"AJ_MNR6C5OY8@LFI ';_ &]W>J]3^K6L!9P#,(J)
M@$ @.,QS;0 LS=P("$E!4 1'9* Y8! (! </.G$XD*6<H#D*,P'V=L!E (!
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MN6S*G<];H;:JW=;O56N+"?I%$%ZC4A1* R*(KH !#"8-L@#9!&RP" 0" 0"
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MQ:3_ )N9=SZ^?-@']+/_ %<_X\@A_2S_ -7,^[]?(!/BR_U<S]FN0"?%GO\
MXN?9^OD EQ:]W'/N5SY\%0/K:<@XX#N[*X/XX01(>MF&[LYEW/KY )\6G=QS
M_CSY\%!];00E/',_W<@A_2S#\'/^/(!/BTY!QS_CR ?TM>[CGW*Y\^ C^EIR
MCCCW*Y\^ G^EF/X.=/*'U\@']+,/P<][_#D%1/BTW";'$NY*N?/@B?Z68[NS
MF7[N0"?%G_JY]VN0#^EF/X.?\>0 0XLQ_!S/N_7P8*2XM.3LY /8K@_.@B/Z
M6GY+''N5SY\ _I:"&_'(CW95SYDX"?Z6G=QSW_\ #D! !Q9@.SLYEW/KY\V
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M"(EQ;=W''N5SY\ EQ;<AL<?V-<^?!3^EM^2QQ[E<^?!$@'%KRCCD?:K@?CC
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MT;NHM\V[2KMMIV#RWZRB#EBY HD,8@S 2F*:0E,4P"4Q1W" A ;#* 2@$ E
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MNBMK4=0H&(1SM-J,D,R@<1&8>Q 7I (! (! (! (! (! (! (! (! (! (!
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M,>?:A+\T>"K?@A (! (! ?*[I[!\HV4>M47)VBH+M3+)E4%)8H" *)B8!TF
M!]\&V H+@P'^)?:.^O5O:/ZM/ >AX! (! (! 0/=@//5*#^*ZMA_K!)_I6UB
M,F[U&9L_4#2 CHM6IF-()R 7S0)CW-L5%G!!&)P$TI<FV<!0KKAI<)U2OM[9
MO^LVWCV['2S^XK.IZ;<2*.'9=+CHSLX"JW*K]&4@=[=N*[%7AVIRF(+5Q!Z=
M<E86L^:5%"K BGSRQF3D[DI#)ST@ B?3,!Y(#=\N$I:F+[Q3K3%:I4L](>E<
ML&J9EG"Q11, $3(4!$3",I;-F^"-*X6,>O\ '6&*#3ZZFJ6YZL!JS71<:A<
MY>^$4BHF\+4FD":9@'<(# ;7E7%E,RE2V+5R^=4:MT5V2J6[<%/,!7=/?I (
M%4*!O!.49R.0VPP=S?!7S638-_T"MJ5F\LCO;O2Z.#9M3#,&M+:)GF F6,1M
M/6<9;)C(((JG$V.T7/$KE7);>FNV-"8KA3*2#XBB9%JLZ3(-3=-BG"6@PD*7
M67WVJ L.\L+OZU>R62+(NU[9%Z&9EIE5<MD$:@SJ#),PF3*NU<2**B8CX"@#
M, V0&UV+:EPVO1S,;ENAW>-757.X5J[Y))L( >0 DFBB&@A"RV $!N$ @(G
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M^/OC=P+/5/LKEN^^!_SC=P+0'";9 #J"[KW W="XW<X%LB<*-F$$#)WC?)!
M=0"6Y'8#/NP6SU4K-F(=<;YV[1^Z1WMG M'JG62'[[KW#_.-W!+/50LL!U!>
M%\ /*(7&[G MEZJ=G& L[ROD=(:2SN1WL#N!WH+;#U3;'#;UNO<!'EZQNH)8
M/"=9 [!NV]Q#N#<;J4%M <)ECANNV]PGW+B=02P>$RQQWW;>XAW[B=0+2'"=
M9(!(+NO@ [G6-W*!9ZIED?*V]_OB=0+ X3;)#==U[A_G&[@6D>$^RA"0W??
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MB<H#$&TQ0@$ @$ @$ @$ @$ @$ @$ @$ @$ @$ @$ @$ @$ @$ @$ @$ @$
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M9/=W1"Z2C,H# 3 (! =%>O\ D;<7VL>_4YX+"O>%O^KYCS[4)?FCP%OP0@$
M@$ @-2R%7+NH=(0&Q[<ZR7$]<%:MT%7!6C-L!RF$7+I09CS2<@U%(&HVX(#3
M.&S(=T90QDA=5X@T"OA4'[!QZ/3,DV$&:YD@T%.)AW!O$8"X(! (! (! 0,!
MY[I7\E]<_P#4$G^E;6(R]VYU(#AQ!6^/T(VK4P]OIS48J+1#=!&)IZB]R>V
M\#XT:Y(JE$R901NRQZ,H^K]90O:EW<U.>J'%502@HX4,J0#HZ#?23:= <G+!
M6]UNW@P;1<)Y56KJ=;9V@0+2N^XFH&53<V]4Q,")PTZ]2+933HV]R"/@)1;F
M=\+F7<IMD52WCDX[VOG!+4#A.B%4!%NB'T6DK0JAP#\B<8#XV5IWG?EJX\9J
M9)QXQM2ENZ94;8-1VIFM304;Z#@BV RPZ53!,BB8%F(^^#D@KU9DO6?&MZZ
MD<:'4P+[/0U>[WX#QZ_JF'S\#"-)H"]+&O+LF((4]H*?I4]S=)3+JYH!YX5]
M>KPI3YN<O @D+1JF0[L2OY.P:$C:MO7O0K:ICF[;QO TEW2:Z9!.@TYH2'43
M(8#"H<RF@#<@;Q*K2RU"FX*<PE*X:N4$ZI<)45Z> D8G**J)@,V*;:5(1-,A
M>X,$AN5-H]%K>?,((UADW?I,\< ]:)N"%5*FX3 @$5*4P"&HH".D>3>&V WK
M%;=G3>)#-]-IQ$VS(Z=MOE6B( 1/I3AFH9142A]$<=IAY8"_X! (! (! (!
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MGKRGJK:"#,I1,*DS%#D TX#;T<GXJ0T)IWQ;I$DP B:9*HQ*4I"A("@ *R
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M,5';!EG%HC+KO0/C1IY6 D<L8M#;UWH >S56?E8""Y9Q:?WM[V_,/VU9^5@
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M1>-?M.N4Q)0'";5_4&*Z152@( 8"F5W@ CM@.DMEIPN6350KMHNK)H=8!,R
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MD4 L.R VA;5)G^H&WB00&P[('?;5)'^\&WB0 +#LB7^35)^ -O$@(ZAV1/\
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M9I/P!MXD%=/=EE68UM2O+I6[2TE$Z:\,51-BW*8H@@?: @39 AH7#1:5JU+
MN/WE0H5.=O%*0EK<+LT%%#"!C $S&((C 6MU#LC?U9I,_P!0-O$@'4.R.6VJ
M3\ ;>) 1U"LF>RVJ3\ ;>)!+2%AV0&WJU29]T&#;Q(!U#LC;]S-)E^H&WB0#
MJ'9$I=6:3+N= ;2_,0&"MC6073]S-)$1V?\ 0&P_H<%26Q;) 0G;-* W>8-O
M$@EN0;'LL?WN4N7ZA;^) .HUE\EMTKX"W\2 @;%LH0\*VZ4/]XM_$@J L.R
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MNRW5RMG+ZT7:SM!Z1VFR*!U47 (_VEP4GTP4YC(-F^ NDLQ*$]\!, @$ @$
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MY,25V?T7Z=I4O:_3.V #D[(8^\Q)7/\ ?/J47YCD8@!DW(W+B6M?#Z6/Z/%
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#!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>lc_primary-4clr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 lc_primary-4clr.jpg
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M_\0 Y  !  $% 0$!              8! @4'" 0#"0$!  (# 0$
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M);2G6T14/49<^0C/&.-.%E3BZ71O532M#H?+@8JM@3K9ZJ&1Z3HJG&A]QTY
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MK:]ML;G2>R.0;M7W#[B>[=E;M>96Z:]%C%H)AN8TAI*FWJ(4I!D:U&G4WX>
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MI)1T3J\-3/NKS&IDJ;J".AU(S]!@!NH2:4J425*]ZDS(C/V", -U)5(Z\/0
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M^\YI86Y#5GN+K!1$S$I0\:69Z6M1I29D6HTU+B-F&DURQ$L,LZTU>+RQG_\
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MT&W+NC)*2XM"B(C(DZM*2/27O4D-4WM,:3.QGHXIW@;CR?/#:X<IE$AB1<+
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M9Z>W=7K?&<NC14:G+9;5(21?BN&6HO:,3K(]P@
M                        !\94.+.8<BS6&Y,5TM+K#R2<;6GN4E1&1E[(
M"R#;K?;(Z(EMBLPXB*FB/';2RTDSYT2@B(JA.T>D    !12245#Y /'/LUIN
MK:6;K!CSV4'5#<II#Z2/T$LC$Q.@^D*W6^VQRB6Z*S#BD=28CMI:;(S_ 'J"
M(A$SJ/N222=2 7
M
M
M
M
M
M
M
M
M                          &=.)@+269E4DG3V@%-=3--#U%V &NAD2BI
M4!>
M
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MQEUYU9%6B4I49F=",!.:U 5
M
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M9[MC@.V?FNV-@X'88UCBSES7IC<;69.N(2I*35K4H^!<@2[@!
M
M
M                   H9$?,!:2*%0CH7< H3*4G4C/5W]H"IMD9U,Z@+B(B
MX$5 ')F^_P"UUL'\6?[B@'6@
M
M
M#DO??]KO8/XL_P!Q0#K0
M
M                                                        !R7O
MO^UUL'\6?[B@'6@
M
M                                                   #DO??]KK8
M/XL_W% .M
M
M                                              ')>^_[76P?Q9_N
M* =:
M
M                                         .2]]OVNM@_BS_<4 ZT
M
M
M                             %#,BXF=" 4UHJ1:BJ?( ZB/QB 5UI,Z
M$95 5 <E[[_M=;!_%G^XH!UH                              /)<;G;
MK1%5-NDIJ'#29)4^^M+;9&K@1&I1D7$87O6D:VG2&O)DKCCBM,1'C>&%EV+7
M*4W!M]YARIKI&;4=E]M;BB253,DD=3H-=.8QWG2MHF6FG-X;VX:WK,ST:PS(
MWK0
M                                                          "Q
MPJD1=M0''>=>;O<*T7[)Y>#[;'>=LL)EE"R"_P M3K#IK2O0M;9<"2FI'H/2
MOA0SI4$I[NAYFH>*;>85E.#V-W),DW%-E&*V-9J176E*EF]HJ9F@UI;TI]\9
M\Z$9@A]-A_,%D&?Y;?=L]S<6^IVY=A:3+.WH4:F)$19).J"6:C)1:TJ\*E)4
MDZD8#H-"]?89 .3M]CKYNM@_BS_<4 ZT
M  'CN4:VRHQM79IEZ%4C4B225-5(^!F2^%1JR\&GMZ:>,]U[WV=.+Q::H)MM
M;\>0J\OQXD-$]J]7!,5;:&B=2UJ*A(,BJ2:=W <[E/=<5M.'BXITW;O$Y?=_
M*16+VBFFE[[=-VUL<=9U
M
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M7K+*V#,S*M2)9$9E3M&[E><IS%9FD3L\,3'I:>9Y2_+S$6TV^"8GT,F+RD
M          \MPMT&Z1E0[C'1*BK,C4RZDE(,R/A4C&G-@IEKPWB+1XV[#GR8
M;<5)FL^&$#VUL-E97>Y[4!E$R+>[A'C/I01+;92I)$A)]A$1\ASN4Y3#%IM%
M(B:VF(\2CR/.Y[8\M)O,UMEO,QKOG7>V,.NL
M
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MC              0O;G_ $?(_P"G[C_#2*/*[K?Q2Y?=^[)_R7]*:"\Z@
M
M                                                           .
M2]]_VNM@_BS_ '% .M              !&=POZEWG_(?^<D<3OS[CEZOG=GN
M7[[CZ_F2&-_HS/Q$^X0Z^/L1U.5D[4];ZC8U@            "%;<_Z/D?\
MO!<?X:12Y7=;^*7+[OW9/^2_I34774                            4,
MZ%4!@;MFN,6.8<"[7%$66E*5FVM+A^%?(ZI29<?9',YCO3EL%^#)>*V\KJ<O
MW5S7,4X\=)M7R>M[[3>[9?8GKUI?*3$UJ;ZI$I):T<RHLB/@+/+\UCYBO'CG
MBC716YGE,O+WX,D<-M_Z:,@+2H                            M<<0TV
MIUQ1);01J6I1T(DD53,S&-K16-9W,JQ,SI&]AT9=C#AH)%YA*-P]*")]LZF?
M B+B*$=Y<K/^Y7ZT+\]V\U&_';ZLLT1U'1<X
M                                 <E[[_M=;!_%G^XH!UH
M     (9N7=K;"Q.ZQ9<QIF4\P1M1U+23JR-9%5**ZCX]Q#A]^3'V+)'3,?.Z
MG<^6E.=QQ:T5V],Q'1XTBM-RM]QAMN6Z6S+0A*$K4PXEPDGI(Z*TF=#]!CK8
M;1-(TGHARYR5O:>&8G;.Z=61&X          !2I %>5 $(VU>9?B9&MAQ+B#
MR"XT4@]1>_3VD*/*;K?Q2Y/=MHM7),3_ +E_2G O.L
M          'Q 1+<1*?JY725?7(53,B,_P#26QY[OV(^S?ST_JAWNY)G[3_+
M?^F4K)"2Y$1=O#@/01$1N<+65PE                            "BDI6
MDT+(E)45%)/B1D?88B8B8TE,3I.L(7 M5K+/;JT4&.3;=OAJ0GI(HE74=XD5
M.!CS6'E\7XADCAKI%*=$>&7HLW,9?L&.>*VLWOTSX(34>F><
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M>LQ]Z8]8KFB<-O!?9$]5NS;R3JFA+2I)*2>I*B(TJ+B1D?;46M785J7(2*@
M                        "*;B_P!6_P#XR%_.6QP._?NW\]/ZH=WN3[S_
M "W_ *92L=]P@                             $2(K!_M!O']'0_SCHX
M.'_R67_CIZ9=S-_X_'_'?T0E0[[A@
M        *&=  CJ J              .2]]_VNM@_BS_ '% .M
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MN3[S_+?^F4L'?<(                             !$B*P?[0;Q_1T/\
M..C@X?\ R67_ (Z>F7<S?^/Q_P =_1"5#ON&
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M'+;?I4_JAW^XJS;F=D:^S?\ IE+B,CXEQ(^)&0[^K@JB4
M             *& @ULO=I>W+O$)J6VJ2<*.RE!'S=94XI:"/D:DDHJD/+\O
MS.*>\\D1:-9I6/+&NL/39^5RU[MQVFLZ<=I\DZ:3Y4Y(>H>:5!  ^+LN*PHD
M/OMM*,JDE:TI,R+MH9C&;1&^6,VB'T;<;=03C2R6VKBE:3(R,O09"8F)W)B=
M5PE(   "E: /$W>;.\ZEAJX1G'EJ-"&T/-J6I2>9$1'4S+N&R<=HVZ2/<1D8
MU@      /B]+BQC24AYMDU^\)Q24ZJ<Z5/B,9M$;Y;*X[6[,3*YE]B0@G8[B
M76CY+;42DG3TE4@BT3MA%J6K.EHTE]!DP             %CAF2:ESJ5/9J
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M/%6ML]JS$;HB)T\6LN'SG>O*Y,MK5Y>LZ],S,3/CTC8RWU7O?VKG_P#1QO\
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MY&1BT["HD             %#H15 4Y__ *"#4(Z<* :KA(
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M9C&]-Q19       B^XO]3+I\5K\\@5>9^'/D]+L]R_?*>7^F4G[1:<94
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M$1Z2IP3V#DYL\Y;<4Q$;.B-%Z(TV)"*[(
M!\I#1OQW62<4T;B%()ULZ+1J*FI)]Y<R&-HUC1$QK&C5UNLEW<SJY8XYE=Y7
M!ML&%-:,WV]:W'W74K)9]/BDR;+@.97%:<DUX[;-N]YS%BR3S=\4Y;\-:4MO
MC?,WUZ/W8;5+D.J](J  (UG'^IF?TZ#_ #E I\WV(ZZ^E4YKL>6OI247%L
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MO5M+U^O+&'Y+#-YQQJZPY+?%]]"U&1NH559&FA:C+N($.OD?"]D!>
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MX,E4             :TV9_T/,_\ >V[_ ,-L=3O#?3^"K5BZ>N6RQRVT
M           !0R.OH 1B^8%CEZE?2BF%V^^EP;O%N6<687&O%:*:B]"R,A5R
M<M2^W=/AASL_=^'+;CTX;_2KLMYXWQXIV,2I>X^+4U(:S.T(YK1H@W9"2+\4
MZ,N^T:#,:_[V/]^/E5IGG.7Z(SU\E;_^VW^EEL?S[&<AD*MT22J+>6N#UHGH
M.)-0?^2<H:O914ANQYZ7\4^"5GEN\<&>W!6=+Q^S;V;>:=OEC8DY'4Z4%AT5
M0     !I_P RO]G#7],VK^=(':[G^/\ RV]"CSWPO+'I;@'%7@
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MAU5PE(  -/\ F5_LX:_IFU?SI [7<_Q_Y;>A1Y[X7ECTMP#BKP
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M6WC>07 S'$7CKMU(J\3X$)%.NBE2]KT@*]9%:=O< J3J#.E:'Z0!3J4TXUJ
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M77TPJ<UV/+7TPD@N+8      (39/[3LK_0;9[CPO9/N].NS&-Z;"BR
M!%]Q?ZF73XK7YYL5N9^'/Z=+L]R_?*>7^F4G[19<94              :0\P
M&$Y=>HV);A;?Q$W/-]NKFJ[P;*\LFT3X;Z.E+C),^!.*01=,Z]AD7$R 1(O.
MEMXRE4*XXIET/*$*)E['CM)KD)DTH;:3)9$?B\->!GW EFMBL9S6]9SF6^V>
M68\9N&8MQ+;8L9=J<N):8!42Y*/A1UTR2HTTX4[*D0(= G2G$!@LDS'%,.CM
MS<JO4.RQ7U=-AV<^B.2U%S).LRK3T ,%;]XMJ+M/C6FU9E:)ESG.ICQ(C,QI
MQUUUS@E"$DHS,S/D0"<-E0C 7@      9$? ^) +2;279R <E;[QV/O;;#,=
M)!LNHN*76S21I42R42B45*'7TB(B(W,M9;8Q=;FU67(VZGJ/ZE7]UV1@\Y:B
M),60HS<>M2S/LXFN/WIJGB8[6>/M6/WT=NO;\?@MZU6D>[GAZ.CU>I/+WA.*
MY(6J]V>-)>2=42=&A]!]Z74467M&.!DP4MOAJYGDL',?$I%IC=.FV.J=["(P
M2_V0C/$LIEM-I*B+?>"*Y1>^A+4:74E_?F*_N+U[%O)*G'(Y<7P<MNJ_MQYY
MTM_J7ED6;V?PY'BY7&.D_P#3K Z3Q:2^$<9XT.%Z"2:A'OLM.W77^'U,OM/,
MX_B8^*/#2=?],Z3YN)[K3N!AUY>*&S<$1KAQU0)R51)*3+@9:'B36G+PU&RG
M-8[[IV^/8WX>\<&2>&+:6^C;V9\TL?N8_$BQ,<?E/-L,(OT!Q;JU$220G6I2
MJGW$51HYZ8B*:_3JU=XVBM:3,Z1QU68I$?RB]O;AW1HT1]"X>*1%E3I0%&6N
M2I)\G9!E[3="[1MPZY)]Y.[]GUM/*4MGRSS-X\-<<>"G3;KO/^G3QI]TT?BD
M+KMG31RH H:4<J<>X!J6>@MT]PBLY%KP/!)*'[J=*M7&_)*K<>A\%-Q2/6Y_
MC*$?(=BO_P ;!Q?MY(V?NU\/\WH:.W;3HKZ?U,_E>SV!YQ=?IO([>N1<>DF/
MU4O.-$:$&9I\*3(JE4>;R\ICR6XK1M>M[N_,O/<AB]U@OI777=$[61P_;G$\
M$C3(>.0C8CSUI<E(=<4]J-"=)>_,Z%0QGBY>F*)BL;U3O/OGFN\+5MGMK--V
MD:;^I];OMY@U\/5=<>@ON&9*ZW12V[5/(]:-*OW1C?E<5]]88<MWQSN#X>6\
M1X-=8\T[&!_5!:(2C<QR]WNPJU&I+42>MUA)*YI)J03J=/<-'V&L=BUJ]4NI
M_P#T>6\:9\6+-_%2(GSUTG5B<BVUS&\P4VRY7:T99;4D:2CY%;*.IKR6B1%6
MA:5_ODD0WXK<Y@G7%DV^.-/1O:K<UW3GU]YR]\<_].^OR7B?2A<7'=^=O=*L
M0C%<K2@R)5@FS_I**2$UX1W'^B^RGCP3K6.A'>-LD_\ R<,?QXYTGKFL[U.W
M=O)6^!S4U\66D^;BIKM\:50=^[5;TMQMR\?N>$3E53U9L=;]O<4FA'HD-)/M
M_&27LBU'*>\K-\,^\B.C=>/Y9^9R[X;4OP6FNW=,6B:S_-Z]&P+)G.%9 WU;
M/?H$U)4*K<A&KQ<BH9D8Y,9\<SIKM\$[)\TK>;NSFL41-\=HB>G39YXV)&2$
M&7(C(^(WN::&S["$!TT=PD5Z:.X!3IH*G"@#6FRY%ZKFQ=GUOO'\)L=/O#?C
M_@JUTW-F=-'<.8V'312E.'< &V@^:2 -">=./, -"3YD ITT<J *DA)<B .F
MC\4@#IH[@%#;;,J:2 5T)X<.7( Z:#YE4^\ T([B 5)*2XD0"G31Q\//F =-
M'=Z0%.DW^* KTT=P!TT=WH .FCN "0DN)$ &A)G4R 4-M!<230_0 Y6\U&,W
MFX.1YUNL33-GCNQ&G[F@VFW)4J2\2$DLB,E&2:DDC47,S&?=V*9YS6*[."^W
M^5X_O3D\V;F(FN.."*SK;9$VM:)B(ZH],MEX-@N9/XY%3D607RQWB,:F'(S<
MB.^RIM%.FM&IMS25.RHXW+<O>*[;6CQ-_(\CS5L%?>Y<F.\;)TFDQ/@G;64H
M;Q#,8A'ZGF\EP_\ WZ%&D=O::20-_N,L3[.3SQJZE>5YBL:1FF?XJUGT1 =F
MW.8/4QDEME]Z95N-HCJ5.;3HF<?,1NM$]<'NN<C=DK/73U6-&[+'B_[ORC_$
M24MDS]LS40B?M,;N&?.F/ML;_=S]:/6?2>YZ%?E<:MKJ2YJ:N"DF?L$MK_QA
MQ\QIV8\Z(R\Y$[<==/XY_P#:N/*,O:\,C!Y*U]JH\R*M-?1J4DPC/EZ<<^>&
M4\UGC?AF>JU?GF!.=2VO].P^^,'_ (J.W)+EWMN&(^US':I:/)J?;K1VL5X\
MD3Z)6+W.L#!TGVZ[P#*M3D6]XJ?^02A$\]2.U%HZX1/>6..U6\?R67-[IX"H
MR)=R4SQX&_&DM%Q]*VR$_;\.O:^24QWGR\_M:=<3'IA[&=P\ D*HUD$!2S+W
MIO)(R+NH9E0;?M>+Z4,J]Y<K:=(R5UZX9=F^8\\6MBYPUDKM3(;57_E#=&:D
M_M1YUN,V.=UH\[WM.1I!:F5H=+\9"B5^Z0SB8G<VQ,2^G316M./>,DFA'=RY
M '31W>G\ "FAON+B J3:"Y$(#0@^PA(&E%.)< %.F@^P!7IH[@#0CN .FCN
M#0FG(!!K41%NUD1%R^A[;^>D"G3X]NIQ,/\ Y#+_ ,>/^K(G8N.V  "-YQ_J
M9G].@_SEL4^;[$==?2J<UV/+7TPD@N+8      (19/[3LK_0;9[CPO9/N].N
MWS,8WIN*+(      $7W%_J;=/BM?GD"MS/PY_3I=GN7[Y3R_TRD_:++C*@
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ME)EN*HV:7NBG0=?A5X :NFT%2I +@   # 4(P"IUY *@.2]]OVNM@_BS_<4
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M;UI]\G4@S*I=HY-,E;QK68F&W/RV7!;ARUFEM^EHTGY7O&U6
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M(      $7W%_J9=/BM?GD"MS/PY_3I=GN7[Y3R_TRD_:++C*@
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M*7,O-R7Q<F7*2>N0^HSX^)7O2[$D1=@PYKF)S9.+=&Z(\$=$)I7AA*A49@
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MV&Y[R1&<0\TKL.BD&9&.;:DUG28TELU>E*R4,4KA
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MFPHL@      1?<7^IET^*U^>;%7F?AS^G2[/<OWRGE_IE)^T6G&5
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MU>:F,%(P5W[[]?1'57TJ]/:GBGR?IXVV"21<AR%A4
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MZ5-+QYZZIDRZV^VEYEQ+K2R)2'$&2DJ(^TC+F+L3J\_:LUG28TE]!+$
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M=N7"?;DQ'2U-2&%I<;6FM*I4DS(R'-M6:SI.R6YZ!B
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MTX\=F*PS&BM(9BL(2TRRVDD(0V@M*4I27 B(BH1$.5,S,ZSO;H?88@
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M3MJ/.=ZUM3-P3V:Q$5ZOTWKO+S%J<4=._K;;+D..L@
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M^*U^>;%;F?AS^G2[/<OWRGE_IE)^T67&5                H7< 4(
M          ')>^_[7>P?Q9_N* =:     !\@&A=SO+/9MP<E7E5ONSECN$W0
M5U;2RE]IXT%IZJ2-2=+FDB+M(QZ#D^^+X,?!->*(W*>;E:WMQ:Z-KX+AMFP'
M&8>+V)LT0H9'J<7Q<>=7Q6ZL^U2C_N#D<SS%\^2;VWRLTI%*Z0D8K,P
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M+WW_ &NM@_BS_<4 ZT
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M<7^IET^*U^>;%;F?AS^G2[/<OWRGE_IE)^T67&5
M            <E[[_M=;!_%G^XH!UH
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M9_N* =:
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MZBBR5      $7W%_J9=/BM?GD"MS/PY_3I=GN7[Y3R_TRD_:++C*@
M                  #YNE4B+O/@ Y-W%\Y%RQ/+,@M>+;>7#)<1PV0F+EF1
M)6XPVRLU$E73(FEITD9*22EJ(CI7WO$$IMN-YH,2PS;;&<]L$&3D<[-TI3B5
MD;)33TAPZ:R=HE1HZ9J)*B(C,U<"[P'UV'\Q:]U;U>L*RO&9&%[A6)LI$NR2
ME*63D91D6M!K2VJJ=2=233R,C(P0WSJKR(P')N^W'S=;!G^]G^XH$NM 0
M
M                  !E4  8B[8MC=]2I-ZM,.?JXF<AAMQ5>7OE$9C1?!CO
MVJQ*_P OWAS/+_"R6IU6F$55M#C\-9O8U<;KCCY4T)MT][H5+M-AXW&SX<*:
M14^P4KV)M3JEVX_,G,7C3/3'FC]^E=?K5TGY5JK/NW9U&JV9%;L@C)(R3&N\
M0XKQD7$ORT95#/LJ: ]WS--UHMUQIZ$QS/=.;XF&^&?#CMQ1]6WK53G>76I)
M'E.$36FR*KDJRNMW1LB^(G0YS_>!]IR4[>.?Y=J)[IY3-]WYFLSX,D3CGS[:
M_*]EMW9P.XK)A5U*W2SX'&NC3MO<)5::?Y0E!&9'W&-E>>PS.G%I/CV*^?\
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M;LP[6NT-FVEMDD+ZA.5;;J9G2G $N_@0
M
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M4X'PK4!N<    !%]Q?ZF73XK7YYL5N9^'/Z=+L]R_?*>7^F4G[19<94
M                   !:I.HN= %BD*(J)50@&C<_P#*/LGN/EB\UR.S/HO4
ME27+CZC)7%8F.)X:WD)^$9>^4C2:NWB"4MR_8_;/-\(A;=7VP-?56UI05GC1
M34PY!-M)H2IAQ)ZDG0S(ZUU=M00^6T>PVV^RL27&P6VK9D7#3Z_<I;AR);R4
M<4H-9THA)G4DI(BJ V>1$7(!R7OL7_Y=;!_%G^XH!UH
M
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M4O0-^.;3'M1I+G<Q3'6^F.TVKX=-/D>X;%8
M      !R7OOQ\W6P?Q9_N* =:
M
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M?7]KG8+XL_W% .M0
M
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M\IYGKM%<FY!G5*EN,*-3%-*4TI4^0=1H^$7<8"\
M       !R7OM^USL'\6?[B@'6@
M
M            \-TM4"\PI-KNT5N;;)C9LRHKZ26TXVKF2DF \]KQRR6:3-EV
MJ U$DW%32I[S946^IALFFS<,^)FE!:2$#*$A)'6G$2!H29ZN1^@!3I(I0BIQ
MJ $TDN'9W '321<.!T.A@/%9[-;+#!:M=GB-PK<P2^C&9+2A)N+-Q9D7>I2C
M49]I@/:I9DK25*GR(!YYL*!=(BX5QCLSH3I$3L:0VAYI95J54J(R,!%,<VQP
MO%,JO&98_:VH5XO;4:-+0RVTVPVU$2:4DRA"$Z-5:N4/Q'Q,!Z\"P2Q;=8VU
MBN-D^=L8?DR27+<ZSZW9CZWW%*69%7Q+.GH :OW'V:N>X>]&/Y3*DS+=B5LQ
MZ9;GKI9YYV^XM3WI2'$H2:/&:%MZDJ^#Q!*78MLE@^&2L4F6-J8TK#HUPA61
MIV0;C:6;NYU7R=(RJL]7O3,^ (>BW[/XC:K/8++&3,*!C-V7D-LUOZG/7G%N
MN'U#T^)%7E>'V &P4&7?Q5Q+M_= ?0                            !R
M7OM^UUL'\6?[B@'6@
M
M             #5&^DZ8Y:\;PN"\J/\ 7:^P['<9#:C0ZBV+U/2^FHN2EMHZ
M9>A1@(-?-U-X8U^SV!@>/8\]B.V*XYS%7!Z4U+FP2AIDN1HQ-F:4/-H)5''/
M ?A*G,P'GR_S(7RTW%M-AAXNJT2[?"N4,KYD"+;<";G1TR"2]'T*T&6JG S
M?"\XY:M^]R(%CS[J.X]"PB-?(=KM<]TH"+K<I"VU3&GF31U5-)0265GX2YT
M2C;S-\E^[!]=YDE<[)K/8;LZW.DD2E2'K24AMEUS\8S)I)K/M.H#6^(X9"V_
MO^S&08S<[@F_;GP)C6;3G9;LA=R?F6TIR9:D.FI!.1WE&ILTH*B.!U 9;$]N
M\3Q?>C'[=M+)GS;[8BF.;M9/(F/RF)C,EM6F+-4M2FERUR-+J6VR2;9),S]
M;(VAF/VC,=QMLEN]:VXK<8L^QZE+6MF#?6#E^KFI9G5+3FO1QY'3L ;@+D J
M                           #DO??]KK8/XL_W% .M
M
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M:"-Q=#^$1=@#9I<@                            ')>^W[76P?Q9_N*
M=:
M                                                           *
M&E*N)E4^\ T)(ZT 5  %*%W %"I2G  ,B,J'R "2DN14IR 5
M          %JE$DN(#7.5;^[.X/?)&-9;E\"T7Z*EM4F!)4LG4$\@G$5TH,O
M$E1*+T& S1[H8 6&M[AKR"$WA#J.HU>W7.G&4DE&BB361&9U(R))%4!]\-W$
MPG<.VN7?"+Y%OMO:7TGG8;A+-M?&B5H.BDF=.&HN/8 DQ&1E4@')F^_[76P?
MQ9_N* =:
M
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M899K)=;5=84-5P=.YM(:+II6A%*$HU$9ZR,N #>Y<@
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M A+K\2@
M    1&^;=X;D.663-;U:DR\GQLUE9+BI;B51R=]]1*5$E7]\1@):7: J
M         CF;87C.X-@D8IE]O3=+!-T')AJ4MLE&THEH/4VI*B,E%7@8#+VR
M#$M=OB6N T3$""RW%BL)K1#+*20A/'CP21$ ]@            "Q:#49&E6D
MR]L!#\(VVPK;5B=!PBT-VB+=)1S9Z4+<<)Z0HJ&HS<4JG#L($IF"
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MLYM=F"B7"[$MPU.LEH(DF@U&@O>)XDDCX E+TN5YD9&??P!#Z
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M5@7F%=V'W'RI&=VR99UWQFZZ")^(95TZSIK21FG2:'#/WR5%SXAUZ7(@
M                                                   8Z]6\[I:I
M]M)?2]>C/12<I4DF\VI&HR]%0'YDPMR5[>[$9QY7+YCES3NA<+JXQ;XB&=:'
M6Y3K*M9:>)T)KPZ2,E:B,C ?H5LOB\W"=K,.Q&Y?ZSM%HBQYJ>6E\FR-:>9^
M]49D GH           +5T))UY .)O-%YGK;"RY6R-KO\O&;.T1)SC*[>PJ3<
M&TJ3J.!"15&E:DF6M[5PK0N1U);C\L6:;09'@SM@V5A2H.-XRZW&DIG,DT^]
M(D(-9O+42E=1:]-5J/V"H5" ;W+D0(5           !SKYK-M-VMTX6+6+ 4
M6V5C$.=])9+:KI(7&:G+C+;5&9<T$9J:/\IK3PXT/F1 -![)2-WD^<O,BEVV
MQLWY46.UF,9AUWU.-:T%"3_(#X&;B4DT1$KT@/T&             1#<_&Y>
M7;=Y;BT ],Z]VB= BF=*=9^.M"*U,B*IF _+'U7;A&U1;5)P.\->9QF\E&2^
MA*C>-1/<*<>"-'Y/I$CWWC)5 'ZOX9&NT'$\?@WY:G;Y&ML-FZNK7U5*F-QT
M)>,U\=1ZR.I]H#/            L=IHX\JE7V*@/SWSZX[=1=_MS/O719SUM
M7!)G;93B)+D1$#QJ,HA1R-).'5!I6?A)>O5Q,$N@?)FO.7-CK=]=CF>&8^C'
M/I*OK7T*A+91R5JXZ2,EDBOP:4\- 0Z*           !8ZE*T&E9$I)\R452
M_  X^8,O_P#H?*_W8(B^:H,$H;==PHWEC\R.ZV09]:)[MBSN(F3C<^(TE;4A
MQ)$OIZC,B(M2E-J/FG34RX@-N^1[#[]C.T4B[9#$7 E95=9-ZC0GDFAQ$5U*
M&VS,CX^/2:DU(O"9 ATR           #DCS]FE.U&.I(J?\ >2)0DE_BW3/@
M0"7^9KS#-[#X1;3M3296:Y"T;-D0\1G&CDTA).27B(C-1(UEI1\)7H(P&N?*
MAN/LG)RN18K!<[SD^\66-N3,CS"\1":5*5&1U5M-F:U&TRDD^!!=Q5/@DB)=
MFER!"H
MM4DE\#Y=P#RKM<%R6B>Y'95-:3I:E*:0;Z$TI0EF6HN8#TH;)!U(S.O> O
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M0DC(GF&&VW"(^9$I*2/B R)%0J
M
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M ,;BV5X]F5BBY+C%Q:NEBFDLXD]BO3<)M1H5341'P4DR 9DC(^0"H
M
M
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M)3H2M9%XE$FIZ2,^15 >@
M
M                                    'GE)2M!H74D+2I*C3P41**G
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MD*9)7O2+P^(R =GX[>SO]EMEX3#D6\KA';D*@S4&U*CJ6DC-IU!\E)/@8#,
M
M
M               H9$?,J@!$1%0N !I( -)'SX@*T *$7(@&*R"TE?;//LJI
M+T)$]AR-ZY$7TI+)NIH3C2J'I6D^)'W@(3M+LSCVT%ON4>T2YUXO-]DE-ON0
MWA[UBX3'DEI1U%D22TH(STE3M/O ;+( H0"FE/.@!I3W%QY@!D1\# -)%RX>
MP 4(!0TE6M./> K0NX!4
M
M
M
M
M
M
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MR3,BY@*:T\ZE3V0#4GO+\( 2DGVD $9'6G8 J
M
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MQLCLB83#+,(IQ*<-F"ZDC,VO\&YJXJH2BIQ =9-E345.%3(!>
M
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M "\
M
M            H M-"3.H ;9&5#J9=P E))K2O'O 7          "E %0%*%S
MIQ 5   !2A=P :2,J *&@C*AF?X0%4I))4+@ J
M
M                                           MUH+M -:>\!76FE:@
M*U                ,R(JGR 4U$ :D]X 1D?(P%0   4UIK2O'N 5
M
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MZV>_6J_P6[I8Y\:Z6Q[^*EPG4/LJISHM!F52[2 90
M
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MI;'L@)L_6EP=)=,TDG23W3X&JAEPH Z/3[TJ\P%0
M
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MHZ-1UZ/0\%-5?>]H#.
7                           /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>bc_participant-4clr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 bc_participant-4clr.jpg
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M_\0 U  !   ' 0$               $" P0%!@<("0$! 0 # 0$!
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MQV!;3X0-$^8DZCV@VTKGW]NM;<&_;OJAVQUYIA"G'EAMM *EK4;)2E(N22=
M *T-C!3.=<*Q^'/()O(L:S@PLM?:2Y;/RQ<'5 <W;2K_ %(-ZN)3,*T/E_%<
MAA%<EA9N#(X\A)4O*-R&E14@6ON="MHZ^)IB3*3CO->(\N9=?XMG(.9:8(#Y
M@2&Y'ED]-X0HE-[>-6:S',B8E6SW*>-\6A#(<DRT3$022$OSGVXZ5$:D)+A%
MR/8*D1,DSACH/<GMYDF67X'+,/(;D$!@HGQB5E1L !OO<^RDQ)ELJB%)-NOL
MJ</$>-/5YW.[E<1[C<5XSPCD;^"B9."@K0QM"%R7Y2F0MQ1238"U=O;;=)K,
MRY>XW)B8B):SSW+^KSL%$B<NY+R^)R#!NR$QGD"TJ.'57*&G4.MMK2%A) 4C
M[XK/;\G<C$<V5[6I&7H',9+N'WH[(8'DG:/*M<3Y3F3&F.NR%*"4--[T2&$K
M2A9MO%TFVH%<T1%+S%N,-FJ;UB8><.Z@]5'9S -\AYAW5C%J2^B+"@PWEKER
M'""5%M*V$C:@"ZR3II73M1MWGDT7\RL<WI3TN9;G^?[2P,]W#EOS\IDI4B1C
MI$H /JQQ(#158#J0HIOX&N3>K75B&_:F=/%PKU+^H/GB>;9'B/:?*.X_#\,C
M>?RK)0TI),EQ:6RE3B@=J6RI*+#JLD5U;&S%HS+3N[LQ;$.Y^GKGF6SW8F%S
M;G615-EQ43GLAD7 E*U1XBUJ)(%A<)37+O;<1;2Z*7S7+SUQ;.^HCU29SD.;
MX;S(\)XGB'4M0H;*W&D7<NIELED%2UE(W.+5H+V%=5XV]N(B8S+FV[6W)F8Y
M-\]+/>GG>9YAGNSG=&2J?R##><J'D'B#)\R(YY<AAQ2=' /KH7UMH?"M>_MT
MQ%JMFUN3,XGFMN:<.]8W<+DV?E8CD+?$.+0Y;S.!@-RODW)$9LG8H&.E:CO%
MOB=5XTV[;58XP6K>9]# >ECOEW*F]S'>U'<#(/YA#R);;3TZRY<29 25K270
M+K00DCXO'6MG<;=(KF&O9W)F<2]OZ "]<#L>8_5-ZALQVTD8_@G &TN<\S#:
M75S%(2^8C#J_+;2VV;A3SJOJ[M$IUL;BW3L[-;1-I:-W<M'"&F,=F?65'Q2>
M5,=SRKDH;^9'''Y#CB-WUO)4I2"R5>%OJ>^L_,V^6&NM-SG,O4_ <ER29PK"
MY+G,5.-Y2[";=S<8[4(9D)!\R]B4I&F[K:N28C/!TUF<<5NCNSVN7D?LE',<
M,<D3M^7$^/N*NEOKVO66F>AF&UN28[3:I#SB6V&T%Q;JR$H2@"Y45'0 #6]8
M9\%86;SSA&.Q S\[D>-8P:E%M.17+8^74XGJE+F_:I0\0-:RBLR9A<,<MXM*
MPBN2Q\U!=XZA)6O+(DM&(E(L#=W=M%K^)J:9,PI\=YEQ+ET=R5Q?-0LS'9.U
MY<!]N1L)Z;@@DB_A>F)@SE?+S>'1DF\,YD(R,P\@N,XY3S8E+0D$E26B=Q
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MR^0DN>5DWB\X&E+6HEVR%(+B%I*2A:%*"1^#6^8M:L>6QI68M.7O?LOA.WV
MX%BX/:Z:<APE9>D8V07S(MYRRI:-R@%#:=-JA=/C7F;F9GBZZ8QP97NGBN/9
MSM_R+$\LR:L-QF5!<1E<HAP,J8CZ%2@L]#I:WCTJ4F8M&%GD\"\MF^C9'#LI
MQ[@_&LS,Y$RPI&.Y,IAY7^,I^HMU:W /+/X5VAIX5Z5:[FJ+3R<UZQIX.L>G
M[B&.[P>EK(\1YS(E2<1A\K)<@?+OEMUH0FTOMH2LA7P!:U63;H:T;LZ=S,&S
M[5,2YEZ5>QW!^[\WD4GF'SI>XS+AN8T0GPPG5:UD. H5NU;3[*W=SNS$1##8
MI&<OH\!K<UY?-VL)R?DV#X?@Y_).12T0<)C6E/RY+AT '0 =5*4?A2D:D]*L
M5S/ F<0\)<)P&;]6'?R7W&R,-R+V\P\EE3OF @%F&08T-)T"G7"-[UOJC[@K
MT;7C:IICCEQUB=RV99OUT+6>X_;Y"A^+$8*2#]6YF)"OITM5[7&BQW&(F)=[
M]5/DCT]\F+EOA9AEH]?B#[5O[%<O;3'FM^[.*/(/*E21Z-^').X,KY)*.OU=
M YM^Y>]J[-OANS+EM.G;A[+X0AH^F.#O(#'YHO!>FEODU[JX;?J?>[(XU<8_
M[O@'[ YQ:^SYS'@>R_DNZ?>M71WG.&CMYX/5'<-(5P/E-^GV/D01],5RN*GO
M0Z9Y/!_I1[$\4[R\?RTCG,F9*P6"?$?&8-AY3+")$QO<[(5:]UV MI]-Z]/N
M-SRYX0X]JFN,RQ?8GM/#YOW.Y1VBSF8G)X#AI$B=.Q$9Q3+>0>@N_+LES:;
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M[E%5Z;5:;<ZIGBRO-[QC#HG?'@8[9>CZ'PA3R9$G&/0OG)"-$+E/O*>>*/\
M4A:R$^ZM6U;5N99;E=.WAL?;K%<4SOHRQ&)YQE%83B<G%O?:N4;<#2V6F\@M
M?PJ(.JBD)M8DWL!6-YGS9QS9[?&D/-?/<EZ0WN#Y+"]N>+Y<\I8; QG(G&'B
MVI]"TW\]:W2D(6F][MC[E=5:[D6S9IW(C3P=S[/]Q.0\:]&F5Y6)*Y&7X\F?
M"P[SI+BF@74M,7*C=0;+MTW\!:N:](\W'5G2\^7EI'IH]-O N\'!,ESWN*Y,
MRV7RF0DQFW4R%(6WY.W>Z5FY6XM:B;JT \*W;N].W;3#7M;>J-4MS]1/VCV"
M].>#[9<3RTEX9"4O%#*N'RY0@$N2'$;DGX;W2V2G\&]:=J(O?,LMV\4B(ZO/
M4EWTS+[5?8,/B_(/TF?*!Q/(U15EM62L%*3N#NWR"JX39%[>-ZZXK?7CAAC,
M5FN(>ANVG)>0<F]&'*%<B=??E8J)DL7%D2@L.+BL!):W*78JVA6T*]@M7):(
M\W$<FVN8IQ<^]+7IQX5W=X1-Y5SQZ7,C-2WL;B<9'>4RW&4EM"W)'B"XHK&W
M32VMZW[^_-+8AIV=N+UG/5E_2'*R/ >]_..T?S2W\&R9B/*5HCYC&O[ \E/0
M*4@D*(ZUAW$1:L67MYQ,PUOM3P^-ZK.]/+N0=SI#\O#8D+7%QK;A;2&_/+4=
MA/78VE()5MU4KJ:SO;RJ1CQ6L:[3QY).>\3C^E[U%<2>[=R9$?!YGY5]W'K<
M)"H[\CY9^,LZ;T&VY&X7'W+U*6\RDY\&N_\ +O&/%]#['S/"W]JO.>@JT"@\
M8^H+MMW!Y#ZF.%<FX_QV=/P$5&-^9RT=O='8+$M2U^8N]D[1K7;M7B-NT9XN
M:])F\3'@]EJU!OT%<+I>0/5_VWYKE>7\.[E<;P*^4XC!(2SDL*TA3QNS(^8N
MXVFY4TX/A41TMK7=V]XB)B9PYM[;FTQ,.?=[1WF[\X'"Y/"=IYN XQA)(;CP
M@V%9*0_(0 IQ+24HM';"+7V]3][+9FM9GVF.[%[3$8=>]6_!^8\M[/\ %</Q
M?!S,UE8,R(N7"A-^:\VE$52%**0>@4;&M6Q:(OF6S=K-JXAW+M7C9V'[:\1Q
MF3C+BY.#B8;$F,Z-KC3J&4A25#P(.A%<NYQM..K;3A$9>2.\W'>YO;/U+?IF
MXUQ23RC$OI:=B".VMULK7%^5=9=+0)0H'XD$BNZEZ3MXF<.>U;1?,1EO_?V%
MW*[M>FO"ROS0EL<UG3HLW(<:B(4[)C)0IU/U%64?AVJ-_;6G:F*WY\&S<B;5
MPR&9[+\@Y]Z4>/\ ;U^,<=S3%Q(LV'!F'RK3HBED,NG\'>A2DZ]"=:RUQ&[,
M^"329ICQ<F[?=U_4MVWX?'[58_M;+R&:QB7(^(G26) #3;BE+'F! V+2@J^%
M>\ IM>MUZ[5ISJAC2;Q&,-O]6O!^Z//.W/;IN)@)6<Y7%\U?(6,8T'4LRGHK
M862E&@3O"@+:5AVUZUM.99;M)M7"7UB17H'IVX/!G-*9D19&+9DL*T6A;<)2
M5I/O!!%7M??E-^/9:&.X?J2@]H8':M'!WLK"SN)9C83E4!IR0I6(E-)*&MK0
M*/-2TKRSNL0.HOK66G;B^9LUYW)IC#K';?T]<GP/IIY1P&440^=<N:=E.LE0
MV,+VH\B*M:=+E*-JR-!O/LK3N;L>9GP;MNF*8ER_M)/[N<-X3D^S&,[/OJYE
ME%R65\BFH\B(RU,3Y:G)+I1\26P3Y92O:1;2MNYIM,3%X8TF8CDZCZ+N!<RX
M'QOFF.Y?@Y>&DR,@T(B9C9;^82TRI!6W[4WZ&M?<WBTQA-BDUB<L/Z-NWW.N
M%\GYY*Y?QZ=A(LWRA#>FM>4AXA]Q1\N_4 $5EW%ZVK&)79I-9G/B8[MYSQOU
MJR>:N<>FIX>?.6,X6[0BE4'RQ9R^IW?#:K-Z^5C/%(I.O+&^J?AG<#$]XN)=
MXN*\??Y%C\2U&+L>,VMX-RH3REA#H:^,(<"M%CQIL7KHFMIP;M)FT3#TEV?Y
MES'G?#6.1\VXVOB>9?D/(3B'=^_Y9%@APA8!&ZYKDM$1.(XNB&2[G\$QW<S@
M^8X/E%%J-EF"VB4D!2F'T$+:= /7:L V\:QI>:VREZQ:,/$'#9'J9],4[(<<
MB<1<Y#QV2^70A++LO'N/6"0_'=CD+0I20-R56]XO7?>=O<G,VPY:ZZSPC@[S
MVDRGJ5YME>3\OYW$3QC#N8=Z#Q+CI;#"4Y11"VY);=W+L.FYTVUT%JT;M:5Q
M%9RZJS/BT-CU">J/BD-OCO*>U;F7Y4T"PWEVF'TM2%I^'S"F."VL?[V4@UE.
MUM?%#5-[Q')L'I,[)\UX;E<_W,[@QCCLYGTK:B8@[0\A$A[SWG7DIT02H (1
MX#K67<[L3$5CBFU2><J'K;[?\XYPQP97#L!-SWR+T\34P&_-4UYR60@K .@.
MTZUCVUHK$YE=^LVY/47%H[\/C6&ARD%J5&@16GVE=4.(92E23;Q!%JY9YMT<
MF65X?345XRX[VUY\QZT9W-9'')K/$529KR,XIJT-3;D(H20YTN5: 5W3:OE8
MSQ<_ESKU)O5QVDYS*YOQGNQVPPTO*9Z/Y:)[6-:+DA$F L.1GR!U!3=L^P"L
M>WO&B8LNY29G,,EZE^U//NY>(X1W6XIB'#S+"Q6%Y7CBP!*1<ID@-H5HM3;N
MY*D7N1TIL;E:YK/B;D3.)QR18]2'=;(0$XS&=AL@[R]* E\N-J1"#O11L60H
M)O[5Z5CY5?"\,HM..3JO='G/=KA7'.+\@XEPI')7W=@YA@XQ6I^,E;"%'Y<H
M))"%[TWVJ%JTTI$VG-L0SF9P\Q.\.YGWY[S\=Y5QSMM)[:X/%O1W\OE9#88\
MQ<9WS2Y\*&TJ=(^!(2FY_"-=<7K6DQG+EOMS:\2J^KP9M?J(X<.,K2WR,PH7
MV0M>W:)GS2_*W;_AL5=;U>WB)I.>3'?F8M&.:W[IY?U'>H+[)[9Y'MZ_@EX^
M4EW)/I0ZF(Y) \I+[CS@V(:0"I0"2;W^BLMKR]O,ZN+/<BUXC@[/WP].F0Y+
MV-XUPOB*DRN1<)9;,%I:@VF8/*#<E*5*L$J4?C1?V6\:YMK=Q>9GQ;;[>:XZ
M.4,]XO4PYP0=I&^V,W[<&/\ L4Y@Q7TNB*&_)W%LCRPOR_AW[K?A5MT[6K.J
M&$VW,8P[3V$[)YGM5V<Y!B,LD.\SY''DR)D9E0<2RHQU-QXX4-%*%S<CQ-:M
MS<U7SX-FW33#7/1'P3FG!L-S)GF.!F8)R;-AJAHGM%E3J6FW0M20>H!(UK/N
M[Q:8PPV*37.6+[7=O.=8KU=\RY?DN.S8G$Y3N37%S+S>V*Z)"@4%"[_%NK+<
MO6=J(B>*5I,7F5_W%[N=R(,SDG">>=DG.7X8R9#/&I\1I3L23&62&5N!2'++
ML1N+:DJ^@UKI6L8G5B6<S,YC"AZ8NQ/*,/VXYW Y[$<PJ.<MF-&Q3NKT=D-.
M-AUQ%S8@N?"DG=9.M9;^[$VB8\&&SMS$3EHG:_)]W_3"<OPKDG;.7R[CLB69
M,+(8Q'F)+Q2$%;;WEK"D+2E!V*L4FL[Z=SC-HB3;K-9QAZ0[.\^[B\]D9R3R
M;MZK@N$8;:&$5,N),IU05NWC:GX4Z6(37->E:\IRW1,S/)PCN-W-[H\QXQD^
MW_/>Q,C(<O>#T7%Y2,TX[%;-RE$A@[%K"A]8;' "?=I6VE8CC%XAA.;1B8=F
M]*7;3E':_M:UB.6H#&9R4Y[)K@!068J'D(0EM1'PA9"-R@.E[=;UK[F\6MP7
M:KICBS_J.X)G>X_:+/\ %N-65FGDM2(K"E;$OF,X'"T2=/B TOI>U8;5]-HR
MRW(S5Y?X5E>[Q[3R.QF [0/P^1K8DQ<CR.>U\M'##V]:UN[VP5/E)V-_&;Z6
MKKMIUQ;5#5BVC#L?I$X-RCC'9S+<=Y9BI> R4W(S?)8GM^6_Y+K#;:7"CV:&
MWMK3OVB;9A=FDUKB7".STGOCZ?N8YWBD/MO*S;V>F,-J?V/!A#;+JD^>T\V"
MA390LJ-SH16_>G;O$>UQ:MJ+UM/#@^A)N>A-J\[#L>*?6+@N]?.>6XWC/&^-
MY/*=OH$=J8C[-9+C+\YPJ"R^I.NYL ! .@Z^-=_;32O&9<V]6UN$*'$^Z/J0
MX%QR'Q?B?8,0L/CT;8\=,>:5*)^LM:BNZEJ.JE&K?;VYG.I8FT<,-X]4G:#E
MO=O@G&>68#'$<WPC"7YF$2;/J;E-H6ZTU?JMEP72GQK7L;D5MB>1O;<VAR7E
MG,?4EWQXGC^T;G;R3C'4KC(S.8>:>80\8PVI+Q= 0TDFRUVO\0L*VTKM5MJU
M0POKFN,.Z\W].B\GZ<87:/!/MNY_!H:FP)3GP-R,BT5+<!)^JEPK6D$^Z]<]
M-[&YELOMYIB.;@>/Y]ZE,5VQ7V)9[;9 SU1G<4SE_(>+[<)XG>.GEJLE10ES
M=;;K71/ES;5JAJK.YIQAZ=],O:*9V=[>-8?,A!Y-E7U9',>4=Z&E*2$-L!?1
M7EI&I_=$VTKE[C=UWX<F_9IIKQ=,YM%DSN&\B@PVE/RY6+G,1V4"ZENN1UI0
ME/O)-A6JOO0VSR>>/1+PCF/!^)<EB\RP<S!R94]A<9F>V65K0AH@E(\0#77W
M5XM,8EHV:36,2P?IV[=\[XWZ@NX/(^0<>F8W!31.$+(R6MC#_G2T+06E7^+<
MD7J[UZSM1$3Q*5F+3*7-]N^>/>M*!S1GCLUSAZ51W%YQ+=X:0F%L5=SP(5\-
MJL7KY.,\4FDZ\M$[AQ.79#U99YKMM&Q?.\Z]$")F)S3*'\?%90RE+D=_S2$)
MV$#:4F^NT^-;*37RN/!JG/F\&X8'OOS_ +.<TPO!.Z/;K!<5PN>6V$.<:0E@
M(#B_*#P2VI:%A*OKI^M6JVU%JZHG+9&Y,6Q,/98W"X.I%K5P\G3+QKZM>VW<
M#F'=K@^6XKQR;F,7%CQVI4N*UYC+*T3BXKS%7^&R=:[MB\5I.9XN;=VYM,3T
M=%]7W:?(]S>WC,OCN/7D>48"1YT2(PG<\_%D6;D-('4GZJQ]%:]B\5MQY,]Z
MDS'!H')5]^,QZ3\5QACB^4;YB9#>!S,5+1&0<Q$>^UU+8LH)6D(;4?8#[:VX
MVXW)X\$M%M.(:+VBY!ZA^R_&WN/<:[)R):Y+YDSLE*C21)D.'1 5L4 $H3\*
M0/?[36>Y7;O_ .37376.3OW'<'GO4AP&9B>_O#'^*JA91#N/B15OPW7$M-Z.
M@K*E6NI23X&N69C;M[,Y;XC5[T.==WO1SP+CO;W,YCMG@\KD^;1PR<=&3+7(
M6K<\@.6:( 40@JTK;M]S:;>TUWV8QP;-Z:NP>-P/;7(3>3X6;B>8\O@2L/R!
MB8HA:8:U+2C:R=$':0:QW]Z;6X<EVMO$<7'."/\ ?STK97D/%H7!'N5XC)OH
M5#F,(?<C+6T"EIUMQD'ZR" M"@#>M]YV]R(F;8EKVZVI,Q$<'4_2SV;YMC.7
M<@[S=T(BL?R//*>3!QSJ=DAM4MSS'WW$ _B]U@A"#K:Y/A6G>M7$5KRALVZ3
M$S,N(=QN*]^>6]W9W->5=M\IRJ!CIKC.-P[C+J<:J#'6?(;065 ^6;!:K'XS
M]:NG;G;BF,\6K<V[6G+O_ .\GJ.R_*\!@.1=H!@^+27T19\]#,EE,2*$VWIW
MJ*$A-A8$5RWVZ17,6S+?2;3'&,/4'33W5RMKR5ZLO3WRCFF7A=SNW+)?Y- :
M0SDL:RKRY3R8ZMS$B.K0%QOZNVX)%K5U[&Y$1,2Y]W;F9B8:EC^_/K!R6.'#
MH/;Y7YT!L1SG9$!]IU*OJAYQ*R&$GVDC;[JR\O:S[S&+[G1N'?7L+W$[@]GN
M(%^5]M]TN)LE>3^-(7-$E(+Z&W" DK;*4[>@58^ZL=G<K6\])9;U)M6'/\MW
M>]2W+.#N]IT=LIS&:E0TXB=F1'D)=+ 2&U*VK ;0I:192BH@=:RFNW%LQ9C>
M;XQAVOMGV7S';/T[\CX>^V)O,<WC\C*FQHWQ@2I$8M-1FU#Z^T )OXJ)K5N;
MFK<B?!MI3%6*]$_"N7\'X1R"'S'"2\',E9)#L=B<V6G%MI82DJ"3X7TO6SN[
MUM,8E-JLUB8:UZ7.W?.^*]Z>XF;Y-QV;B</.;DHA3931;9?4Y.#B?*5?XKIU
MK+N+UFD1$L=NDQ:95/T><['K3'-3QV;^:!NK[<#?^)V^1\O5SV[OAM[:FNOD
MXSQ2*3YFISOU.(Y*OU38%'"U(;Y>8^..#6YMV?.A2O+W;]+$Z:UM[?&B<\FK
M>SKC"3N?DO45ZCIN&[=Y#M](XVWBY'F9%]2'4Q/F5I\OSW7G?A#:$E2D)3<F
M_CI6.WY=)F=65W:WW(B,.D^J/L9R?)]K.!8G@<-W,M\$08TN PDE^0TMAIKS
MDM@_%\39*TC6RC:M?;[D1>9F<9;-W;F:Q$-"[DY'N[WK[5L<6XOV=D\=PF!^
M7?GJ#>Q^3(CI+26H+.Q"BD%14N]R!X^W9336^=64W*VFL5PZOW%X/S+)>CS&
M<-@8.7*Y:S Q:7<*VWNEI6R\A2T[+]4@:BM%;1&YGP;)K,TPZ+Z:\!F^,=EN
M+X7D6/>QF9BH?,B!*1L>;WR'%)W)\"00:U[\Q-YF&S;C%<. \TX)W/[']]\K
MW=X5Q9SF?#^0%Y^="81YCK7S1"WVUI2E2D%*QN:6!M(T/C756];[>F9QASS6
M8OF(=,X-WM[D<\YCAL=C>SDOCW%G7B,SGLJ-ACLI03=JS;8*KZ#K7/.W73[T
M-T6G/)H/J=[:]Q<)W7P??;MUC'<TY"^67,B1VB\XS)@W2"MM/Q*:<;^%2A]4
MUMV;UG;FMIPT[FW.O5#0^\?ZQWJ%XO&SDCM](Q7&\.ZE,+",-K<GRI,D%*I"
M4N!*RV@"U[ ?3K6W9G;I/,O6U_##W7PB)*@<+XW!FLJ8F1<9!9DLN?70ZW'0
ME25>\$6-<-O>ET1R:;ZA>&YGGW9_D_%^/-^=FY##;L*.2$^<N.\AXMW/BI*2
M$^^U9;4Q%HF6.Y&:S#AGI.Y=W6P3F)[09KM_+Q_'<=\\[.Y#+:>CJ84LJ=0V
MH+&PDK.SKJ*W=SHM.JLYEAMZHC$PTI/#^\7I<[KY[DW#>+O<MX3F@\E"HZ%N
MH5%>=#R$.%H%33S2OAU390K9KIN5Q:<->FU;YAD,-P3N[ZD^\&%[A=QN-N\2
MX9@1'4U&>0ILN,Q7"^AID.66M3KA^-9 "4_<%372E,5G)IM>^9C#W.@W)KA=
M;QYZT>W7/.;<DX3+X?QV=G(\1M]J6Y!;\Q+*U/(4G>;_  BPO<UW=O>M:S$R
MYMVDVF)Z/7L1#B8$=MX'S4M(2L'4[@D7O]VN*>;H\'%?5CQ?D/+.S&0P_%<7
M(R^65+B.I@PT>:^IMM?Q%*?&U;MBT1?,M>[6;5Q#G&4[1<\Y'Z-,%P*/CW8G
M-,8A,YW"/@-/N^1+><+)!-@LH6%I!ZD 5NC<BN[,L9K,4Q'-H&$R'=S/]F7^
MQO'NT+V,R4>(Y&S>?FMF,TMEJ[Q*4J0"J4[MV@;S<G3W9YKYFO5$^AC$6T8P
MZGV0[2Y_*>EO+]M.7XZ3Q_*YEW((:8R#?E/-%Q2%,.+2+FV] /MM6G=W/YFJ
M&=:>QAR7MCS'U$>GF!,[;*[92N0,KF.R<<MMMY3:7G $K\IUD*2ZTHI"AJ"+
MFMV[Y=YB=35MZZUQAUSN7VP[G=]/3YBD<LBL0>[,)]67:QB;,-6*G$"*3<A"
ME,J38J_"%CXUII>M-ST-MJ:J\8:KPGOGW7X=QG&\'Y%V4RF3Y-BX[<&-*8CE
ME#S3" AM3B/)4-U@+E*K'K6>Y2EK9B\%9F.&'8<JKGW.O3KG?S@XO]B<URN*
MF('&(=UK0HJ4&D $_P (I(!M[37/2(C<SG@SF9FKS7VKR_J3]/'"TH3V]>S'
M&<VXY+8Q[K;GS>.GBS1+Z&;K"7 A*K*ZV^$C6NS=\N\YU.;;B],QC@Z)Z2>T
MO.<7R7D7=_N/"=@9G.AQ$.'*1Y<E:Y3OG/O+;_ 2=$H!U.I]E:NYW*XB*\6>
MSM8F9EH#7$^\OI9[I9_D7#N+/<NX5FO-2VN.A;J%1GG?.0EPM K:>:4=NJ=J
MATK.;4O2,SAC6EJ6G$99/C_ N[GJ/[RX?N/W)XTOB7#L#Y"FXDA*VRZS%<+R
M&&0Y9:RXX=SBR  .G@*3>E*3%9RFBU[1,P]R6.^]C]/W;UYV9P[?%5K)"@4"
M@@03T-J!;4'Q% L:"-!*02=#:@FH($7&M L==>M L:J.)^ISL_R/O3P2)QGC
M$V'!R46>W-WY#S RM"4+04@M)40KXO96W:OHG+"]=48=([?\<E\2X-QSBTU]
MM^9A\=%@R'V00VMQAI*%*1NL=I(TO6NTYF99Q'!L>T$6]O6H(D7%KU%1H% H
M($&@&]!&@E(.MC:] L;=?VZ"-C>]_N4$:!0*!00UH(T$"+^-  (\;T B_NH!
M!]NE!YN[P>GWEG<+O3Q'N-B<ICXV#P@BIGQI7F_-$17R\?+"$E)W V%R*WUW
M<5PTVV]5LO1Z22I5[V]]:&Y-:XH%C[:"- H%!"UNE %!  B_OH(VUOXT"@C0
M*"!"O ^/]B@C00(/MT]E!&@4"@4$NWH+F@B1>@6.OC01H% H%!*N]@1UH/*G
M,_3%W$Q_<S)]TNRW,V,#E\LMQ^9$R+:E)"WR"XA*DH<2IM1&X)6C0UU5[B-.
M)C+1;;G5F)1XUZ7^><DYYC>X/?SF+/)YN)+;D'%0&U(C[F5EQ"5%24!+85\1
M2A'Q'J:3O1IQ6,)Y>;9EZJ2#J5#6N1T)JH4"@4"@&]! #P.M M[]/901H% H
M%! @WH !MJ2: 1J* 03X_>H(T"@:T$% E) J#S?W#]/G+>6^H3C7=B!E,<QQ
MW$&&J7#?\[YPF&HJ(0$I*#N\+JKIV]W37#3;;S.7I  ^/WJYVX(-!"Q-K]1X
MT$U H($&@6/M^_0"#;0VH !\3>@C00(O0"FXL=:!:@C0*!0*!0#02@*TN;^V
M@FH)0DBXO]% "3>Y-!'6]5$145"VM_&@ 'QH(T$I!]M$344H% H% H% H% H
M% H% H($ T$:!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!02E"3U TH(A(3H*"-
M H% H% H% J8"J% H% H% H% H% H% H% H% H% ZT$-HH 2!TH(T"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4$+"@C0*!0*!0*!4P%4*!0*!0*!0*!0*!0*!0*
M!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*
M!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*
M!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*@50H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H+.?E,=BVC)R<QF%&20"])<2RW<]!N60+U14B3HDYA$N%(;DQ'1=I]
MA0=;4+VT6DD&H*V]/MZ4#>CVT#>F]KZT#>GI>@;T^V@;TVO>@CO3KKTZT$-Z
M?;049<V)!CKES7VXT5L;G'WUI;:2"; J4H@#7VT%1#B5 $*!!UTU!^@^-!,%
MI(N#0-Z;@ W)Z4%E"S6)R:WVL;/C37(QVR41GFWE-J]BPA1*3]-%'\OC(LJ/
M!E3H[$Z6?\5BNNH;==UM\"%$*5]P418.\SXHPXXV]G\:VME1;=2J9'2I"Q^"
MH%8L?<:N!E538K<4S7'VT0PCS3)*TI:#=K[BLFUK>-[5!"%D(61CHF0)+4J(
MX-S<AA:76U#W+02#]PT%QO3TO0-Z?;0"H>W7V4&#Q?,N-9K,9+ 8G*QYN7PY
M"<I%85O5'*OP5D?#<="+W'C09S>GVT$=R?;[J"SA9?&Y);R,=-CS#&7Y<GY=
MU#I:<_<K""=I]QH#&6QTJ7(@1Y;#TZ);YJ,VZA;K6[IO0DE2;^\4!O+8UZ:[
MC6I;#F182%R(:'4*?;2>BE-@[@#[Q07>]/MH&]/MH&].NO3K06D_*8_&LKDY
M"6S#C(L%2)*TLM#=T!6L@?V:"I#R$+(,-RH$AJ5%=!+4AA:76E ::*02#]^@
MK[T^V@CN%KB@MHF0A3VB_"DM2F0I2/-86EU&]!VJ3N22+@Z$4$%3XB98A?,-
M?.%'FIC%8\XM V*PB^XI!TO:@N=Z?;0 M)U!TH&]%MU]*")4D=:"- H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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M)/S@2V TVL".PH)-U7*K_#X5='4U=%^WS7NYS#E6 XKB78O"YF2XJ,]EF\G
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MGH"1XUY^W]/VJ;L[N/:EWW[_ ';;4;,S[,-D M7>X4J_"QL:+#SWF\#R'/\
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M-NBQZ*VGK6J9RV1P<ME=N^:N<%YSBV\,O[0RG<B1GL<PE;8+V+5.CNID WL
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M8&TAXMCP25[K4&4H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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M!0*!0*#P;ZU?3_W"[A\[C\UXE'8GP(^,9AOQ"Z&WTN(<6JZ0=#<*%J#Q!GN
M\WXLYMY'Q^?CDI) 4ZPHH-O]6 4T&MI4@JWI78#\ Z'[E!-=12$*T((UZT$Z
MU;TI!5I<Z >/04%,V4-=$ ?"/ @']F@B%!1VVNDI^('P(\:""7MIL-4*&VY_
M"'OH)B+ %1(T"K"WC007HE25:J&B0#J1[;B@D\P)0;>)L;BY/W:"*@5:J('2
M]O[%!,5$FQ^*X.EM ?IH*>^Z=MK@Z:Z:^^@G&U"0$C=?11]E_902W0E*M0H]
M"/$W]E!MO'>WO+N32D1HF.<C-"RGIDY*H["4GHHE0!5ITVB@[!A^UW%>!XT\
MCS$C[4G0&U.OEQ(2TDIM9#*%=5$ZA2NE!J3V3RW/N0L9S+H::P.,(,/&7^'8
MV"=O^N-_B]]!?9YK!\H?,B-C&XGE-@1]GP;A?4;4@"X]M!K?'\2]CN4P"XE)
M#97):6+[7&TZ&P/X5]"*#%9V0,CEY<Q2-RG'2I2'%:;;VM[P+4&1XYRK/<:D
M,.XR<\&&;),0J*HBF5:["@W'6@]*<?;=Y%BXF;=CNQ4S&R8S(2#N -E6 (L0
M1?Z*"O.PN&RBU./1V<E"%_EP^VEU-W!M-U>ZQH-5RO:+M[)6?,P 00=A,%;C
M&EAJ1<@*]E!J\OT]<4>BJ<AY67!>4X1Y:@'FTI(.T$D)/7K>@U/)>G#G&-4V
MF%)B3GB-R6]Q:!'464JX-Q[Z#3,GVMY[C+^?@GW$ Z.QK/HT/@4$]30:S)A3
ML>2F9$>C*Z6?:4BQOKJ106NX*&T'3P-[6]^G[%!%5E+*K!)-R1;V>R]!%95M
M /2^AZ?L4$$A )V@E>EO !5 *0HE1O<=1[ON4#:G<5$W3T(%R+>S[E!%SRUH
M24I*1:ZE?^7K0?2C_NX_Z,.3C_YU_P##HH/9E H% H% H(*%P10<,]2^)XRC
MC.*Y#DL!Q[(YU&7Q^.@YOE"4B#C4RGB/F'S=*G&FRK^!)VDFY%KT&.[+<>5A
M.7O.Q^1]OY[3T-Q+T+A^.B0LDNRD%*E+8=6HM)_"3:UR*#T+0*#5NYG]&_,/
MY$R7^2.T&I>F?^@/M[_(T?\ 8-".3JU H% H)=Z=VWQI'%,H[A[:+*&\5<)D
MWCVTP9-PI@R;Q3!DWCVTP9-PI@R;A3!DWCVTP91"@:8,HU%*!0*!0*!0*!0*
M!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*
M!0*!0<:[F\U>X_R48YA$5[SXK;KL>1<+("E *!OH-+?30:R.Y."R,/Y7+X9Q
MHK&US:$/("5:%"?-!N".M!I^9[>^G3F:'5SN-(9DM A2TLF/\5OW3>@H.:Y?
MT9]J,RGYOCG)G\4PHC<2ZAU"%'PVK^*@T'*>A[+%*U\5Y='GMH44.-NQW J_
MA\2+@ ^V@T_)^C+OGCPX[&Q4::RV 5*:>"%!*NAVKL;4&IO^F_O;%*A^9\IX
MMDFS"FU7'B>NH]]!B'NRG=^&2V_PS*!RX3\+._172VV_7PH+)[M/W,:+A<XC
ME6PV0ES_ !99(OI[*"U7V^Y['39SC&43\0NHQ'+!/A8[?;04/S#YL5J2KCF3
M*Q;</E'1;_S?&@K*[<\^\P,*XQDPXX2&T_*N:E/6QMK09*/VA[I2R$1.'911
M6+(!CJ3IT_" H-BQ_IM[L2]<ABVL1%1_"O3GD#8!I8I05&_NH-IQ/INQL>QY
M%GR\_P!?E8"+))'@5*Z7%!T/C_ >,X-#9Q6#90H6+3[S8>>4I"K?$I=[&@V;
MD>2P.+BF=G9A:<7=J,E]6BUC\#3Q]EJ#E'=7+M9WBR\FPT6&72Q%2GJ%K!)6
MH>P;0*#4<9COLW$,IDKV2G!YCH_O:G/J_P!@T%W%1'>E)9\P-/G\6E6SX 4>
M(^GVT%#*0T,Q6\^XI99C(=;;VJW*%]>FGB*#05H+X4XXGRPLE6I^JA6NM!D^
M/81C+Y*+BW)8CHD74D@$A6P;@FWM-OA]M!MK/(.1RF'<,B>ZUB<;(VP(Z?P7
M7-2BXL;:Z:Z4&^\2?R?&.)MM\G\V'$#BC%4XG>MM2E@@6'Q*"AX^%!GH/,L/
M*?6J'F&_-"3<R$E*&V[] 2+&Q\30;!$Y#.QUG,I'#L5QLE4ID;T+0K0+-[@6
M]U!E&<YC<HH):DI*PD7:=3\1"1IM3IK[:"[\M2@@1]C0>*0RT2460K0E('4)
MH(-8-,=#Z,K'0^TM)<C.K2A\7)MM(4#8'K08#)=J>#91AQ_+\7:7M6D*=8 :
M>5N%R4E!'3WT&A9#TZ<&?6OY7YV"7 ?*4RZ';$>Y8]E!K^0],,) "X'(7H[@
M64J:FQPOP\"T2*#7,KZ=>80FFVX,W%S%)45!8<4PZI*Q<;BK2U!JT[LSW+QX
M4XY@'7VA>ZHKK;@M[0$JN?N4&&?[=\\;^!7')Z!8';Y*E"Y'73VB@LG>&<N:
M0%N8*>A(^&Y8<(O;Z*#Z*_\ =V1)4+MKRB/,8<COC,@EMU)0JWRZ-;'Z*#V/
M0*!0*!0*!0<D]0KF/'"8>/GXO%Y%.8S./Q<=_/QTS,7CY$Q9;3.?:79*@U<A
M() *E '2@Y+Z>1A<9S'C4=C!\:5F,U@\JN;D\)C(^.R<1[%9)413CWRYVICR
MTI04(MHM.FE!ZUH%!JW<S^CCF'\B9/\ R1R@U+TS_P! 7;W^1H_[!H.K4"@X
MQR3OKR/C_(,C@XO:7F&:8@/%EK+X^&VY#DI !#C*RL72;T&KX3U7R^38T9CC
M?:/F>7Q2ENM(F0HC3K2G6%%#B H.=4J24GWT&5[I>HMSME!XK+D<4EO2>315
MS5P);R8DF$4!!+3R;*^,;['V$5HW-V:\(>?WG>>1,<,Y<Z_7A!T_,=T6_P#S
MZ/R=:?/GT?C_  <,_5IC_P 3]>!/^@[O\?1^3IY\^C\?X']WGX3]>!/^@[O\
M?1^3IY\^C\?X']WGX3]>!/\ H.[_ !]'Y.GGSZ/Q_@?W>?A/UX$_Z#N_Q]'Y
M.GGSZ/Q_@?W>?A/UX$_Z#N_Q]'Y.GGSZ/Q_@?W>?A/UX$_Z#N_Q]'Y.GGSZ/
MQ_@?W>?A/UX$_P"@[O\ 'T?DZ>?/H_'^!_=Y^$_7@3_H.[_'T?DZ>?/H_'^!
M_=Y^% ^N ?Z#NG_]>C\G3SY]'X_P/[M/PNZ=DN[">[_&IG($XI6($68N%\NM
MX/E6Q*5;MP";?6M:M^WN:LO1[3NOF(F<8Q.'3*W.TH% H% H% H% H% H% H
M% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H/(/
MJ6R+4#N1&$Z(IV O&-?CFMP<2OS%VN>AM[*#F3/+TO-J+N3>:U \IU"7!ITM
M;I09IGF>4C MQ3'E..VOY"]JE _ND&VH'NH,BO-0I<B.TXU\H^+%22FQM?V_
M3[:"X;SDB#("H>=<B.R75MJ0PYM*UIZ$V\*"_1S;/@J85R-Y3B+J?3YAWN)(
MV@DZ[DCQ H*B^4<M?C-.#/2%,J;%UEQ)2G:39*#:]M!05&^6<U<!6]FG?(6
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M>26_]I9 (^:\AQW?Y8?"+;A?;MV^Z@V_TTD'L+V^/B<-'O\ >-#P=6H% H.
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M$GFWZ))]MJ"'FW%TH)^B@B'2=0@D:@V]HH!=(_!)5^Y\:"9*PH=+'V&@FH%
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ML]9_;[FB/J._.>7J>F?2_P!RN9]RN/Y^=S&:U/EX^:W'BN-,-Q]K:VMQ!#8
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M9+#2&VI#[D/B>.86ZTM"7YCI\M9&MTZ_65TH+.9S>3BLTWC(O$\89:T':ZE
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MN*4#%@@AE-B;73?K0:WR7LOQ#E&6F9B8B="DY5M#&<1BY[\!C),MZ)3+;:4
MYI\-]%$:7H)\UV8X9E7X4N"Q*X]-@PDXIJ5Q^6YBW58Y'U8SGDZ+;'A<7'A0
M9-WMGQ!WBD+@J<8(_%<>ZP_$A,+4C:Y%>#Z%%=RI1*QN42;D]:#.9_ P>2X7
M(X#,,E[&Y1AR),;2HH*F'DE*@%#4:&@U61V;X++A3L>] =,3)/XV7*3YZP2]
MAFVVHI!O<;4MI!MUH,'S;L=CN49/'3<>\K'(7R!'(\^ZAYUN2Z\Q%5&;5&<;
M-VEIND^R@S^$[3<0X[,P60Q<!Q,_CWSRH,ER0MUUQ[*A(EO2%*)+KKNT74K[
MEA06^)[+\'P7)FN48Z"]\U&>D2\;!=E.N8Z!*F_^T/18JB4-K<N;[>GX-J"O
M&[.]OXF+Y3AFL*V<=S.8YDN0,J6LAZ4[8[D$$%O84A3>RVTZB@H0.S/$8D8,
M2E9+*O"?"ROSV4R#\R5\SB[_ "HWN*T0W<V2!KXWH,@>UG$5>850UW=SZ>7+
M_'*US"+6=_UNGU.E!C,?V2X1C9DB3%9FH@O(F(8PIG/JQD4Y)!1*5'B[MC9<
M"E>Y-_A H+M_M#PF1$QL)Z MR-A\1)X[ ;+R[)QLUI++S9UU)2FP5U%!L_'<
M#'XUA,?@(*WG86-91&CN2G3(>\IL62%N*U40- ?909>@4"@^<?KE=7^F6(VE
M:DE&%C*%AI8O.7H.#,S)#,%+JUJ4+A6GBF^FONH,H,HI#92%7)^*Y5:X(Z&@
MA]NN(8&M@?JW/3WF@RF)Y"ZTTI*W0O<M)1?ZUOVJ#:)7(M_E!PA82@ZG2@HX
MWD 3'DV\% I5NN?N4%Y.Y3*2VP$NKVJ^$7-Q84"0O'F*)K[(4^H*2%BX TN1
MIXT&!R.&8RJ&78,K:X47\MTFQ)]_A067'\-,CY8(FI4B.!N "O@)'4T'0H3&
M/>AK;*PENY)'4D_2=:#6N2<KDX5H-8W<W';(2D@&Q/M-J#+\6Y3(Y/%_Z3W/
M+;!4VZFX0E0%K;NMO;07Z\V]CI")6/+S<Y/P>8I6Y)MIH? 4&18Y;.BL%61*
M)A>)'Q)"O+/TF@L8F19BN..190$5]16XTOXK$]=:#+Q>3M/-(C/RU>0VHE+:
M2"GV@JH+USF;&%C?-8U2$R7;E:T@*<43U)/A]R@T+.<]DS'MT*ZY:B/,6L;E
MWMKUO03XG(\@>AOKDOJ;42C8';W%_$"@VAY>-DPV7YSKDB;'2"F2VX-P5T^*
M]!H3G<+(\=S:V_FW%Q4FR"X3JGV7H,J.[N2R+2FD2RA+1W ^WVB@QV8[K9=*
M1&<E.;$ [;*OU^B@<<[CYYL%*))::6?B*S^$?OWH-RC\WE--E;R_F5K!()/7
MVZ'PH#/.(I6VZ[%\NUQ;;<?3]%!,OES+[B;*(!T".H /L^F@E1RQQQW89!\I
MO1+(-@![Z"*N9N%S8APZ?#\6A^B@HO<N==4E2E!2^A*C[>E!BI')7W2I+8&Z
MY)3>Q%OV10:S-S&0;D)D!=VKFY5<&_M \:"I,Y8^\PECSK[M== ;>T4&,7-B
MQ]SJ'"%@ZIW>)U)%!ALWG([["V@JX42 E9O=*1?X:#V'_P!WQ($GM[RQP&X^
MW%6TM_N*:#U_0*!0*"%Z"- H.1>HA_%1>&8R?D,K]@SH6>QC^"SCK;;T*%E4
M.*$=V:AUQL&-J4ND&Z;[@#:@P?;C[1Y?W#C\PYMS?B6;Y%A\?)@X'C_#9(>:
M;9E*;,F2\IUQ3RU$(0G;;8CKU-!WF@4&K=S/Z..8?R)DO\D<H-1]-*@GL#V^
M)_S-&_8-".3J*I"=R4@C>02$$C<0.MAUH"9"%*6D%.YL@.)"@2FXOJ!TTUUH
M((E-.);<2I)9=MY;H4"A6X73M/C?PM0<)]&_]",3^5\U_P#4'J#F'K>_ZXX5
M_O,__;-UP[_O?<^?^K>]7[)_<\J5RO'*(4"WOHN2WOHN2U#):B%"2B(#I19Y
MO<?HI_HUR_\ ++__ ";==G;\Y^[\GO\ TKW+?\GI6NQ[)0*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!00VB]Z"-A[*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*#YE^O>68_?"$@J(0<)%T_P#7.:?=H//7VM_B*6#8+N-@'30V(M07
MJ,AYD=:74IW#X5B_1/L%!(],'D-^20I)58IUT'OH$?(E*W%%24MKL$$&^T^S
M[M!FG,LXEUM5[_BRC:="1;0_<H*,#D1;AJ"5:$VL?'7P]]!<3,]YIBI\RR22
M%"_3QZT&Q?;?_1E@L"XL3?ZH]]!-!RJ2E!OH$[!8C4^-!6=R:R\5%PZ#9H?&
M@MX&>DM(=.Y0 (23>XN=; 4%4YMAYJT@!T.&R4."Z21020\\U%<VQ+-,D_5;
M^J >N@ZT%TKD3;B0A9W%&N[W$Z7H">0I* WN247TU]]C057LM%UV)*$E("];
MINGQH,5\^T"LI>+:"DE(!-R?N4%9&;NAML.?$G19.FIZ4&;@Y>$PWH$*DC5:
ME ;B3TU%!:Y7/+>7N;=4E5R!K<$Z=?HH+3'9Y;4CR'EDZV5KUTOTH*>=;P68
M94J2E29"2 A2= J_70=;4&!9;Q<(AH.$D:'70I/C07"V,4ZK<?C)%QI?2@SL
M=S%1H+0"=[@  L D"@@,JPE-VW-I1IJ:"V>SJ"=Q42FUTA)U('A:@HKSQ2D%
M*QN)WD>(OX4%J,^0H[OA*CUOKI]%!*O/EQ6TKL2-Q(.I^B@@YR,JL"I0 L4I
M/3Z*"DGD!#VXN7&[12;V%QTO06DW.EP?&NZ6[FY/X1'04&"DYE14 ;I(%SOZ
M@4%W]II0PHLD%9L4J!!*B1T\:#"9+)W;?%RA L%7]A]A\-:#WO\ ]W0=W;3E
M2CU.;)/W6$4'LF@4"@QW(,S"X[@LGR#)$IQ^*BOSI12+J\F,V7%V'B;)TH.(
M<9]46(Y-S'"<2/%\ECV<NS 1)R[ZFU,PLIEHRID2"\E&N];("MPZ$VM0=_1]
M47H(T''_ %'9#'X_MZV,G&PRXD[*P8"LCR6.U,QF-,I9;^><CO?"XIJ_P).E
MSKI>@Y=VO>X)VN[J-8)WDG">0-Y'$/3/SFQD'$8"=C2AUM 8<7#4&W&I!-T)
MW;P4ZC;K0>L 00"#<'4$>R@CTH-4[E*![<\Q -[8/)?Y([0:9Z=)+4/T[<%F
MO%08CX)EUS8"I6QM)4; :DV'2A')Y9P7=_(<I[\SN>)R,F/F<GQ#D+?&^/*C
MR <:80683*FUH"5/.ALR'%6V75MOX4%OV8P$CD,"+Q1+:<5S+NIPR9,B<L@Y
M:7-5*<:EI7)5EXRE%*75J24(=:U0A2F[$C0K?>/Y&!VVY)A\5S!Y^9Q_@,S)
M2&<9@ _*B#/3F%3)##"7E[E0\1!_&K*SN2XX=#:B.H>C-U#_ &,@26CN8?RF
M7>8< MN;<G.J2JQ .H/C0:SZL>WO*><9+BS_ !V.T\B W+1)\UU+5BZI!3;=
MUZ5YO=[E:3QZ/"^J[5[VK-8SC/[GG;] O<RW_L,;^--UP_,4]+R?)W>GXGZ!
M>YO_ #&-_&FZ?,[?I3R=WI^)^@7N9_S&-_&FZ?,T])Y.[TCUH?H%[F?\QC?Q
MINGS.WZ3R=WX8]:/Z!>YG_,8W\:;I\S3TGD[O3\3] O<S_F,;^--T^9IZ3R=
MWX?Q/T"]S?\ F,;^--T^9V_2>3N](]9^@7N9_P QC?QINGS%/2>3N]/Q/T"]
MS/\ F,7^--T^9IZ3R=WX8]:'Z!>YG3Y&-_&FZ?,4])Y.[GE'K>M_2GP[/<*X
M+D\9R%IMF8[E'7T(:<2Z-BFT &Z?HKTNTM%HF8>]]-V[4I;/5WBNYZQ0* 2!
M02+=;;25K4$I&I)Z6J3)X92B3'(!#J"#K]85-4=4S"/S#']]1_="FJ.IF#YB
M/_?4?W0IJCJ9@^8C_P!]1_="FJ.IF#YB/_?4?W0IJCJ9@^8C_P!]1_="FJ.I
MF#YAC^^H_NA35'4S!\Q'_OJ/[H4U1U,P?,1_[ZC^Z%-4=3,'S#']]1_="FJ.
MIF$$R&%K+:'4J6-2D$$TBT3R,\<*@(/0WK)4:!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*#YA>O^R>^<!;@T.$C;+:G<'7/O6H/,H<
M6AO?N2 @&VXZ_%XF@J,2B0I2AH5)W;M 2D?V#[Z"X$Q2FE:A)!L4VO\ "->M
M!/!E#120&RL!=SKH3I<4&5ER6O+;W'X2C:%'0@).OW?8*#&QWPEMSXA?=NN0
M+WM[J":0_9EA1*=B3N2B]S[:#*+F2!CUJ0\"E2=UCJ-WA:@FQN3>;6-RE$J
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M/8 +4$' =#:X'6@\Z]SI'J?.!YHVQ X2>'F#DDMNN/9$3OLXL.:D ;/-\O\
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M@J1O:0E6TD"XO0;30*#5NYG]'',/Y$R7^2.4&I>F?^@+M[_(T?\ 8-".3JU
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M6D?DZ?);W2/6>3N?!;_Y1_60[)W'_P!U)_BTC]Y3Y/=Z)Y6Y\%O4W3A_JP[
MXB \S-Y<E#BWBI($26K2P'5+1%>UV>W:E9BW5Z';5FM9S$QQ\6Q?KC>G:]OS
MP3_$IOY&NYU(?KC^G;_3!/\ $IOY&@C^N-Z=O],$Z?\ Y*;^0H'ZXOIV-O\
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M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!00\:F>(>-3/$1K(*!0*!0*@4"J%
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MA.EP#TKU>TFTUG,YXOS?_)HQW%?^+I/V;CO^:,_\&C]JNU\F?9N._P":,_\
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ME,/YIME32?,0TZI*74W"M01<4'I!/L(Z4$:#5NYG]'',/Y$R7^2.4&I>F?\
MH#[>_P C1_V#0CDZM0*!0#0>,_6\XVWD.';R "S/UUZ[VJ\KO8F;1]C]#_Q6
M]:[6YJX<8_*7E1:F]Q4' 0>FIKS<2^\M>F<YA+O;_=C[YIB6.NG6#>W_ 'P?
M?-,2>93K!O;_ +X/OFF)-=.L&]O^^#[YIB3S*=8-[?\ ?!]\TQ)YE.L&]O\
M=C[YIB3S*=8-[?[L??-,2:Z=8-[?[L??-,2>93K %M6_A!]\TQ)KIUA[E]%9
M0KMQF"@@C[7=O;I?R6J];LHG$Y?FW^53$[VWCX9__J7I2O1?%E H(*Z&B2UC
MN!_V*S7^\?\ I)K1O^Y+U?I?]5M_;#S6GZJ?H%>"_89YHT0H% H% H% H%!O
M':7_ +:M?^[._L"NSM/U'S7^2?T?_:'3NZ_]%'./Y!RO^1NU[3\PGFQOI_\
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M9/%YLS$Q(\Y@7C/SX4,HEJ:6/A7M4I(6I.EZUVS$1$MD3$N3<J<Y&WQCNAW
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MA31*ZXRZ1Q_.XSDV$Q_(,,[YV*R<=N5#=(*2IIU(4FX.H.NHK&5ADJBE H%
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M??\ TY>K]+_JMO[8>:T_53] KPG[#/-&B% HI1$**4"@C00I WGM+_VU:_\
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M:/\ ".G0T'5J!0*!0*!0*!0*!0*!0*!0*!0*!0*""NE$EK'<'_L5FO\ >/\
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M#VXYA_(F3_R1R@U+TS_T!]O?Y&C_ +!H1R=7H% H% H% H% H% H% H% H%
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M>E\?RL</Q,EC\;-;R3$N,I!R;@2Q9LMI7=Y)NTJVP^-!7PO>CMOG,TU@<;G
MO(2')<9CS6'V6%2,:5?,LAY:$ME;025*2%=-:"?CG>7MYR[.,<;X]F!*S,QE
MZ5!CJCR&0_%C*V./M+<;2E;85IN23>@Z".FO6@4"@4"@4'#O6#__ ,V\]_\
M=(O^71Z#X^!PA2U CS%:6]@^F@6NDI'1(WW3U*C[:"IOLG:$$K)LK:;C36@I
MJ 6G^#V?N5*\4_MT$R1IN ^JH%0&@!/0T$JQ\>T#:#J1K:PZF@BI(/U+[3=*
M;Z7'OH(!7EN F_P^/4'V4#<X4DIT;5IKUN?;03)+C0WI(*E?6W>SV6H(:$'0
MN:6N?K#;KI014A.WS%D@*M<6OUUM>@@JQ O<@$;?H\=/"@;DZ!M14V+#;:V@
M]OWZ"!6"L)2;)^K>W6WC]-!$BRE)ZDBX4D"]O830%^:G<A) %@%6_"H()N5?
M&- -=;:@WH(N!2KKM]:VX=>O36@@ !:X!!U%P "1X4$R5;U)( 2G6Q&EC0%B
MXNH@%5AN7U)]H]U!,DD7<'XS:=3H-?H]AH(*LK1(4#;6YT)&OAXT$$E(.@U&
MJ?$"@F0++VIVIO<_%UO[Z"4[K (LD@74E6O3V4$Q"DI2I1VDZ=+DGPN?=00
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M\>B_E*?)[G3\C_9^RZSZI/U7.]G^8F_X[&_*4^3W.GY'^S]GUGU2?JM][/\
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MP2H:4%&;S_C.&0TG*1W6%37#9+?XRP: *2GQ\?"@SD->*RY#^)EB1&;VKCN
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MM3[*!M3[**A9/2U!':GV4#:GV4#:GV40VCV4$-B2+6TH1P1"4IZ"U%1HA0*
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M;>\F@R'Z"N[W]?G(?YOQ_P"]H(_H*[O?U^<A_F_'_O:!^@KN]_7YR'^;\?\
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MUG&O2V49!]*G&8BG$)?<0GJI+9.X@6\!07M H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H%!I?==<1OM[G7)FL9++9<'N\Y%O[-
M!Y-5FLS"D_+85$<XY\E;CB;(4"3JH"^GW*"X;YSW C[\9E@Y*Q#R]K4ELAY
M1[5-JW B@VS'Y2+%B)^V<!!?.\J9<AH5&?=84FQ.]HI 5X64*#68^*[?R>3N
MR2QE8(E'X&%!$UK?<?"0XD$B@VJ;VHXCE'E?*SV&7EE+CD2;#<AJ0F^I*FRH
M#7QVVH,&]Z?\)*<*V5LRE+2I+:8$UES>O<#90="%)T]M!;K]-4L/+<0U.:8*
M 5I#:75;E&P%FUF^GX5!BHGI\S#"6W8ZI;:0M:&4+CNA1-]3N H,+DNRT]EM
MHNY-9<\U7FHD-OM[=J[ _&C4'I04GNS6?6B0Y#F,+0DI6'0L-7"2$ZI5M-Q?
MI085GM7S25FLJF*EN2U'2RIORW I2&S8$I 5<Z^ H+')]J.51[HDXXK2H;D)
M!4I2DDWW)(N+FWC06;O!\[#90I4!UN.NP/FA6I2= ;BP/T4%ARPYS%XR0I$=
M\>04-K22$ A8O8ZT$\+D')Y4.&&6GFO+0DEI*@190MK]R@OQD.4MKC-XUA2!
M(<.YMO:2$(3;6YUOXT&MLP,O*GRW9,,AS<=CGPI^(VZIO_9%!7AX*>,H6Y#1
M9;0P5E:EHUL3H"3[:#+MX:=*2(19*)*CN\U+B -=0"+VT\:"PEX&?'95#::8
M\\J/FNJ<2 I74#4Z:>V@P.-PLW'(D?,LEUV83N99 *0G=<7(/6@G?PF0=FO&
M)&4M*%-I6+A)0#T^L?;UM056,'DVLW$0VRY9Q%R"XDI2JQ^K8^T4%_%XGR"0
MMUQLA)+HW(2LDDW)4?AH+YWBO)75EYU12Q\?XP[M$V^*X '3WT&,1P;/KQ_S
M#YT?<NEM6Y0 %RDC76@P7Y@9)+^\I2VM:4EI:;I4H*)3?4^W2@R;O;F:EQ;B
MO)T82M(NFY*18VNJ@K2>WLIA38^98W/("7!9)^)(N-PW=/ 4%VQPP-RHZ7I*
M?+6D-N(9 6+]2%:'[E!L[?;9YU;*FI#TA:M=C+2R6]QLG<$IT^B@S$#M'D)Z
M'&HN-R+SZW% I:C+\I)%@4G=;P^*@SV-[ \A7(6VUQN2NZ =[ZVVE!5[:[U=
M/?074GT^2V<]@T3(D&,IQ;K3LA^<W9&Q-]I2W< D^/C0;$OLIC(1+<O+X)AM
M:B3*\QYS5/4  #J.E!-^C/@%@RURM@N(6I:1C("G%%9%K76? >V@R'!L#PR%
MW)X^UBIN1R,R(ZV@!33<=MM2+_$\FUS?W&@]:)-P?IH)J!0*!0*!0*!0*!0*
M!0*!0*!0:WW @R\GP3E.-Q[!DY";B,A&BQQ8EUYZ,XA"+'Q4H@4'ECA7:;F_
M;?,]K>69/$9OG.&A8-R.]@,A,7*D<:Y!\MN2_&:4I+:6G=ORY!2?*^L#T%"%
M3@K?=;.Y#D^6Y!Q+D6"[T\Y8D8V+S.;%;5A.-8Y&]4:+%*7BM+:1\2EI2%*=
M.XZZD-0P_8/O)Q0<T:9P4"7C,)F>*YW'P<:A;!S;N$1N?7&7(6J[BDJ6MTNZ
MK>Z&@VMV#WAXQQ'.9[CW")\?EO<3E^2SC+K,9C(97C&'G,M,K=2V5I2)KR$$
M!(6$B_Q'2U!UB%&'#/3M'B</[=Y#*R,=%VXK@^=::>GNS%22H/34W4DGS29+
MA3_L;&U@XWA>*\_;BXGNA(X;R/+\_P /RACD'.F<DQ'AS,J'H3D5(Q3(=6DL
MP@0TTVI0)22=.@#'XWM3W9[>8&#E&N(OY_(<IXGR/BDW$8]]GSL3,Y%E7,A&
M7(*SM+*4+"75)^JH'W4'5>Z?:K/9+LOVL[=IQJL\[@\WQ=KD<>.;H^0A)+4M
MS<2D^6D7%QK:@YWB^Q&5X[R'&9OC_$GL5-@=TI,B)DF+VB<07&<VJ;3OLF*7
M%!12/K'K0AIO8>+C(W=[M!@HN%9C\KQ".2GEG((N18R",N^6%VE_B''"4$FR
M7G0DE1V6^&@^@XH(T"@4"@4"@4'G?N;VPY9SCO\ 8#)8W)YOC'&F.*2X4[DO
M'WD1GOF%34K3$6XH+T4/Q@&WJ :#2>?=FN0\.R;6+[6<35G^-8K@$[#QHN2<
M+C$F9+RJ93[;RDK;4M]:5./[;I#BOAT%!J$+M/W#&#Y.\_Q'(9/BRN6X7D,S
MBCD>-B%YG$1X:D2&F8+#GDME+@23&W?%87-!#GG:?E>6Q?#\KB.V.0Q/;V,U
MFHI[?,*8S4V#*R2]S.0^6D/-MMJ<22D!*R8Q (H+/F?97FQRG(84KM]E>9S\
MMQG 8+BO*9#[#;^.RL5FRI$E:'-"T;;WD7U1MU"R:#-<B[-=S'N7Y&!,XS*S
MG</*9?#9+CO=Y$L(BXK'XYIA+[:CO#C:D^6ZD-!/XW??P%![=0% 64;GQ/2Y
M\303T"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@Y9ZCIQQO93ETU.BFH[!!'OE,I_MT'AB#S+S65$NI2L)(NK4WM07S7,G4L7;
M?*1M(!"CX>%!G\1SV8J*G_&2HI(VCJ![=:#+-<YCRI27L@DK<C$EI;9V67U!
MTH*$7DO(%9M')AERI*ALNZDJ(0HV((O97W:#;CF</+D,9)<G=FQJJ0V4M,D#
M]TTD6.GCUH+R'F9C,[\2_(;QK25!,]B4O>I2[DIU\/V*"I,[VL<81"A3DS77
MT.J6_)=E+"G&U"R4C9IH/&@I9'U(QH[SGV?-FO8YX[XZ)#H6MI5P;%2A\0^F
M@V;$]ZW.3,.):FP!)!"Q&RL=HH6I(UVN('4^TB@QD3N?CX^=F2,IA\,YEY32
M6R$'R&P6Q8)WI/4CQH+E?=7B[2DG*\/^4LA3;:HT@HLE6IV[;A(H+M_N%VYS
MT8!4;*L8]C:7%^>#;8.B L>'NZT&N9_,]JL[&E%C+3-$)3$$YIMR^U5]I!%E
M"@L<9@>U\J @.\E2P%*3\UMB-#X1;X1J-#>U!=N\'[7!R-*_.A"4L+6$H;BI
ML 19(&NOO-!B(?!.WT7+2I*^5E/U T$QOAVJ%[F^AL?"@O,7VU[?-91.4R/.
MO,8?3Y?DF.D#<DGX3J+V!%!G#P/M]'B)>>Y-*:C(5O#C6/\ K*OTN390(H+%
M_A?:2<PX&^29"=);N-K41&X!1O99-^GA?I086-P3LSBY34E?(<BXV%E(0ZP@
MI*0=RD'47/\ JJ#;V,=VHS:_)Q^*ES8^X@.QVFV7E$^TD$6/]B@D8X/P:/FF
MIT+!9<;DA"(RG&F_A0?B"B4Z#WT%=6+X;C<J"GC&3F2'WPK8F9N:2!H+J;%A
M>^M!+F4\-P*#D,MQ%M4=Q9#GDRC(64G0 %)Z4&(8F\2&*6RQV^6\P276I;KC
MET)4+6U-!BF<IPJ1-<<;X=%;4TD$%YQ1OMZ)U)ZGPH*JN48)&^6.&XH("=@+
MEC8@Z[1U!H,OC\JN=$.1Q7&,.X6@M'D[4^:+BX()!N?IH,AA>:<C4 ES"8["
M,C5!=A-/.K4!U*; ]:#+XOG'*9GF(=FG&RFT;?,##;#:M? @7(]U!37R/,/)
MDNO\EF.EO=O3!6&KGPL!T^F@U9/*UY%_Y7+./QT"Q^;6XH.N;3T6;ZW'6@DR
MQXUDIV,5&=/RC:U*><#BBI0%M#<^%!<9CF_',6RVI+3:F0"GR0E/EE*=!HJ^
MI]M!A$<SQS2%Y2&RTS(/Q-(; ;+:CIJ$C6@F[?\ <V5/[I<9Q4U*49";,0T\
MM(2DK20;$V&M![23U)]M!-0*!0*!0*!0*!0*!0*!0*!0*"4IO>]!#RR#?=K0
M0\M7BLD>R@B$$?A'VT#9UL3K002V1U5<^V@%LE05N.G3[M!$-VN0=3UH)?*(
M)(4=:"/E'K>Q]M!B,5P[BN#GR,KAL)C\=DI8M*F0XC,=YVYN=ZVT@FYU.O6@
MS0%J"- H% H% H%!(6R=;VUO0 V1^$:"'EGQ43;6@CY9O?<;T$/+(TOIK?[M
M!$-E(L%'[M!/0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0<6]6JU-^G7G:TDA0B1[$:'_P!L8H/FA$D/-Q]"5V2-RK_%8^)H
M+G[47L2A;A2$I*NI -NM!=8[D7EQ["_QKN-;;$I'4_307C')' ZO\8"E2-+G
M0WH-NPG(D+PUE.I)! !UTL?;05(^?4T^HI-P6U$V.A!/@*#)GE<EEH>6\;_"
M2D'P-!CYZF<XRI>04LNI 2A:%6(W^P=*#7G>-LO14*CS"IQ)4/)>Z$=!8B@F
M@X/+P)4>[RFXJE **' OKX^Z@W^-Q^"J8^\M:GVT)2=5E+O3P-!0S67_ #;:
MW1'O-L-4K&\6(T'Q4$<%W!E<@2B%(92QY=MBFD DGWI M097(35%*1D/)"&"
M%(;:9 4!?I?P'NH+DYS&2([1=QS2X2%66VD!)(MUN-:"X0XAC(1\IC5MKQJ$
M;4Q9=CY=QU2/$4&2A<G@MMNP0IL?,*LXO:%!!O?3=J*"X;=X]#D&>PIEZ0!H
MM[5._P#=$'2]!@>2=S<T4)B1W%-AL_ VWHV??:@Q7'.19A4]<F<HM,DV?  0
ME8ZA5A:YH-IG*Q&4;*4S"&G02^@6U)T^$>%!H_).59/B1CC$SUN1&0=H%T$;
M>EZ"[P_?3,2@VA3X+JQMW$_$+:$T%SD^ZV0Q\8I@RRH/*NM(^&ZE?10:I#[F
MYEG(+DE?F(;-O+)*DI!Z]=*#=HW.<CE&F%R)&QFQ^!!VB_6U!?(Y%C62'#&\
MPJ39Q9_#^F@F/(,*Y>R$,A1"BBWB/&@.<@,-U+N/D^45GXPD6!^Y07XYHM+B
M79#A6Z+%+B^NG@#06\SG4AU:5.%%[W'Q:$'VT&*5RXM..%!(!5^";))H,'FL
M[+E J!*%+^J=U[$#06'MH-:A\JF09+*)*B"V3M!]_M H*F4S3N7"B7@VE7U2
M?;?V4$JLN8+ 3O*TD;BKWT&3[39EB=WXX$DV\W[2;U43<DI5:@^FR>E!&@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4'$?5
M\;>F_GU_^9QQ]^:P*#Y5M9[8BZ+J01MO;H3X7]WMH*C>8*P%K5N;+92I)%U&
M]!=0IBUL)7;>DJVDWN=H!TM04?G@T\XO<H70=B4]4W\#0;'B9ZQB6P2=B2#M
MZ$7.NE!,SF7DJ)024H2K:0;72#[_ &4%RO/?B5;7#M4L*23T]^M!F\=F1\L7
M%.#8X+$$^ _MT%Q%R+:V6TAVZ4K(">O6@JRIX;2AT*(0%: =:"Y9Y*ZVXLK6
M4IL-+ZGZ:"HC/MR7%_-(2^B]MC@W J ]VM!6CYO'PEGY2.(J0;J"-/B/B+T%
M:1R9IQMU+BBHD;5$&_7H:"I$Y+%9C+0D))-@+B@F7FXKC84T=I'UDWT_L4&&
M<R3"7%K#RTDB_7QO;QH)?MIYIQ8><WL6 L3:Q!TO]-!F<7GX3CNZ6/,L!M!%
M[6Z:T%UFL[#>C%#%D*O?X/A]W6@P,7.+C%(;=44_A!76@OLAD,9E(:F)9)2K
M0D==>I^Y0:2N#BX<I/R[I^ 70";:W]WC09=*X#Z6PX_=*-4WU)7X"@N8<?%+
M?<6562 H:WT/_EH+B'.A1P6Q=7Q7.X^(H*[F>0-2?@M9)\;_ $4$GVZQNLI1
M"B#<Z:4%O+Y"H/@^9\('Q:WM;H:"F[R,*%RI2]H^'7Q^B@I+Y&I12-RB1?<-
M-*"V7R10N0Z+E5S8]?HH(2>3++0.X@^V]K >%!K<O.A4@.)45K4"K0V('_BH
M)8V?4X&U>82!<W/3[OT"@C-S >: 0ZDI391!.NWW4&R=@<HZ_P"H7MXT3\+F
M52+=0 E)('TB@^N0%J"- H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H.(>L#_P#YNY]_[I&_RZ/0?) .*.Y1Z)2K1&@3X7-J
M"9+UVEA'UDA/QCXBM/C;WB@NV' TVI2UA"5+O873J1]4&@(6'%$M()%S=S0V
M!_:M09J$\RWCR I018+O8KW#V"@M%.L:%EPA2DJ" 0=1>X303*=*6/+"PDI
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MV'J([>@?YW1_M%4'V9H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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M^#_XR@A^*_P?_&4$?Q7^#_XR@?BO\'_QE _%?X/_ (R@?BO\'_QE _%?X/\
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JPZ>9?IXW\/;0=1],7E_K#=O;>7?[5;^KYE_J+Z7TM[*#[*#I01H%!__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
